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Thesis Abstract 
 
The objective of the work presented in this thesis was to extend our understanding of 
depression aetiology and to identify brain MRI endophenotypes of depression. Our work 
builds on previous research that highlighted the genetic relationships between stress, sex 
and depression. In addition, MRI measurements are heritable and do not relying on self-
report. As such, they represent promising endophenotypes that could help break down 
further the genetics of depression.  
Preliminary work involved reporting depression prevalence in a young adult 
Australian twin sample (N=2,773) as well as comorbidity with affective and substance use 
disorders (Chapter 1). In addition, we demonstrated the good psychometric properties of 
the SPHERE questionnaire, which provides self-reported measures of anxiety-depression 
and chronic fatigue. Properties of the scores include: i) stochastic ordering on the sum score, 
ii) limited sex and age bias through adolescence, iii) high internal consistency, iv) good 3 
months test-retest, v) moderate heritability, vi) significant association with lifetime MDD, 
social anxiety and alcohol dependence diagnoses (Chapter 2).  
In an older sample of Australian twins (N=5,221, Chapter 3), we performed a direct 
test of the diathesis-stress hypothesis in depression, which states that stressors can mediate 
the effect of genetic predisposition (diathesis) on the disease risk.  We used Polygenic Risk 
Scores as a measure of diathesis and report a significant interaction with personal stressful 
life events, supporting the idea that stress and predisposition have a multiplicative effect on 
the depression liability scale. This interaction may be different between sexes as suggested 
by the stratified analysis.  
We then performed 3 analyses of resting-state fMRI from which we showed that:  
1) Head motion (HM) is reliable and heritable in addition to being a major 
confound in fMRI analyses. However, this is unlikely to greatly confound twin studies 
of resting-state functional connectivity (FC). As a by-product of the analysis we 
showed that FC in the Broca’s areas networks exhibited low to moderate test-retest 
and heritability (Chapter 4). 
2) HM is phenotypically and genetically associated with ADHD scores of 
Inattention and Hyperactivity/Impulsivity. This leads to most head motion image 
processing options to reduce power and/or to induce a sampling bias in RS-fMRI 
studies of ADHD. We discussed ways of circumventing this problem, via volume 
pruning or multivariate analysis (Chapter 5). 
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3) Nuisance regression (global signal regression, CompCor and HM 
regression) options in RS-fMRI processing have a moderate impact on the test-retest 
of regional homogeneity. Independently of the processing options, the low to 
moderate intra-class coefficients estimated in our sample may be due to insufficient 
scanning time (5mins 20s) and would impair our statistical power to detect RS-fMRI 
endophenotypes of depression (Chapter 6).   
Rather, we focused on structural brain images and contributed samples (n>300) to 
the ENIGMA-MDD consortium, which resulted in two publications on the subcortical and 
cortical signatures of depression (Chapter 7). The large samples (N>8,900) included in the 
meta-analyses suggested robust candidate endophenotypes not prone to publication bias: 
hippocampus volume, and cortical thickness in adult depression. 
In addition (Chapter 8), we showed a small but significant association between 
anxiety-depression scores (validated in Chapter 2) and the lingual gyrus surface area, in a 
population sample of young adult twins (N=834). We replicated the finding using the Human 
Connectome Project (N=890). However, the small effect limited our power to confirm a 
genetic correlation, required to qualify as an endophenotype. This finding could relate to 
impairments of visual memory, or Stroop task performance observed in adults with 
depression.  
In the last chapter (Chapter 9), we reviewed the GWAS literature on brain 
morphology and described the local analyses performed for the upcoming ENIGMA GWAS 
meta-analysis on cortical thickness and surface area. In addition, we showed that 
multivariate GWAS approach should prove more powerful in the analysis of subcortical 
volumes and hippocampus subfields compared to the current univariate approach. Finally, 
we showed that the effect sizes of SNPs reaching genome-wide significance are greater for 
brain phenotypes than for psychiatric disorders, which is consistent with a hypothesised 
simpler genetic architecture. 
We concluded that MRI phenotypes represent excellent candidate endophenotypes 
for complex psychiatric traits and depression. We hypothesised that larger samples, with 
state-of the art MRI sequences, pedigree and genetic information should allow the 
identification of brain endophenotypes for depression. In addition, large longitudinal genetic 
studies through adolescence will shed light on the early and complex interplay between 
genes, stresses, brain development, cognition and mental health.    
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Introduction 
Depression is a prevalent and disabling disease across the world [1, 2]. It is 
moderately heritable in the general population (h2~0.38) [3, 4], with some sex-specific 
genetics (h2=0.40 in females vs. 0.30 in males, genetic correlation across sex ~0.60 [4, 5]). 
MDD may be even more heterogeneous, with a large twin study identifying at least 3 genetic 
factors to explain the variety of symptomatic profiles [6]. In addition, environmental risk 
factors (e.g. childhood trauma and stressful life events) also contribute to the heterogeneity 
of MDD, and may even define genetic sub-types [7-9]. Furthermore, symptoms of 
depression may also be present in other psychiatric disorders (and conversely), making the 
diagnostic boundaries overlap. This translates into widespread comorbidity and genetic 
correlation with other psychiatric illnesses [10-12].  
Identifying genetic variants associated with depression should provide insight into the 
biological mechanisms of the illness, hence new leads for therapeutics [13]. However, the 
heterogeneity and comorbidity of depression complicates the search for associated SNPs 
and may explain the relative lack of success of the GWAS [13, 14].  This can be overcome 
by studying much larger samples than for other psychiatric disorders [13] or by focussing on 
subtypes of MDD (e.g. female, recurrent), which has shown promising results [15] but is 
limited to the known subtypes of the disease.  
Gottesman and Gould coined the endophenotype concept in psychiatry in 2003 [16] 
while highlighting its promises in the study of complex traits. In short, endophenotypes may 
decompose or deconstruct a complex trait, which could result in more successful genetic 
analyses (due to hypothesised simpler genetic architecture), redefinition of diagnosis, better 
study of the course of illness or even development of pertinent animal models [16]. An 
endophenotype needs to satisfy 4 core criteria: being heritable, but also genetically and 
phenotypically associated with the illness in the population [17] as well a state-independent 
(not a consequence of the disorder). In light of depression genetics, endophenotypes may 
prove very valuable in defining MDD subtypes and providing biomarkers whose genetic 
factors may be more easily identifiable.  
 Brain MRI phenotypes represent ideal candidate endophenotypes for mental health 
disorders, as they do not rely on self-report [16] and are more and more reliably measured 
thanks to methodological and technological improvement [18-25]. In addition, the heritability 
of many MRI brain phenotypes has been established: from structural [26-30], to resting state 
and task fMRI [31-34]. Other promising endophenotypes include biochemical, 
endocrinological or cognitive measurements [16].  
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The work presented in this thesis had the overall objective to identify such 
endophenotypes. It relied mostly on twin data collected as part of the Brisbane Longitudinal 
Twin Sample (BLTS) [35] as well as from the Australian Twin Registry (ATR) [36-43]. Indeed, 
univariate twin models allow decomposing the inter-personal differences into an additive 
genetic (narrow sense heritability) a shared/familial environment and a unique environment 
component. Multivariate models provide estimates of genetic and environmental 
correlations between traits [44-46]. Complementary molecular approaches have been 
developed to estimate heritability and genetic correlations from genetic data [47] or from 
GWAS summary statistics [48, 49] but they require large sample of unrelated participants 
for the first, or access to new meta-analytical results for the second.  
 In chapter 1 we describe the BLTS cohort [35] and report the lifetime prevalence 
and comorbidity of psychopathologies in the population twin sample (MDD, social anxiety, 
panic disorder, agoraphobia, alcohol and cannabis use disorder, but also history of psychotic 
episodes and panic attacks). We put these rates in perspective using previous 
epidemiological reports. We aimed at confirming and evaluating the extent of comorbidity 
between psychiatric disorders using an extensive clinical interview that provides a very 
detailed picture of the psychiatric landscape in the young Australian population. We also 
used the diagnoses in Chapter 7, for our collaboration with the ENIGMA-MDD consortium. 
Chapter 2 focussed on self-reported scores of anxiety-depression and chronic 
fatigue, collected using the SPHERE questionnaire (Somatic and Psychological Health 
REport) [50, 51] in 4 waves of the BLTS. We used non-parametric Item Response Theory 
[52-56] to investigate the scale properties at an item level (monotonicity, sex and age bias). 
In addition, we reported internal consistency, heritability, 3months test-retest and 
association with lifetime diagnoses (from chapter 1). We used these scores in Chapter 8 in 
our search for cortical endophenotypes. 
In Chapter 3, we contributed to the literature on the aetiology of depression with a 
focus on the interplay between genetic predisposition (diathesis) and stress (personal 
stressful life events, network life events and absence of social support) [57]. We estimated 
the diathesis using polygenic risk scores (PRS) [58, 59] based on the largest GWAS for 
depression. We then tested their interaction with self-reported measures of stress and 
investigated sex differences in aetiology. Chapter 3 is the only chapter of the thesis that 
uses the ATR twin data.  
Moving on to the imaging component and using the QTIM cohort, a sub-sample of 
BLTS, we estimated the reliability [60] and heritability of head motion, one of the major 
confounders in resting-state (RS) fMRI studies [61-64]. We then evaluated the bias induced 
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by motion on heritability of resting-state functional connectivities, by considering a well-
described brain network that does not implicate the primary motor cortex (resting-state 
language production network, organised around Broca’s areas) (Chapter 4). As a by-
product of this analysis, we report the heritability of voxel-wise resting-state functional 
connectivities in this network.   
In a second RS-fMRI analysis (Chapter 5), we report the phenotypic and genetic 
correlation between head-motion and ADHD scores [65]. We used this result to illustrate the 
limitations of some image processing approaches when motion is associated with the trait 
of interest.  
We then conducted a comparison of RS-fMRI processing approaches in order to 
measure the influence of processing options on test-retest reliability of Regional 
Homogeneity (ReHo) [66] (Chapter 6). This is of interest as test-retest is often the upper 
bound for heritability estimates [67] and directly relates to statistical power of genetic and 
phenotypic analyses. The overall low reliability of the measurements led us not to pursue 
the search for resting-state endophenotypes.  
Instead, we focused on T1 structural brain images available from the QTIM cohort 
and contributed to the ENIGMA-MDD consortium, whose meta-analytic design proposes 
robust candidate endophenotypes not prone to publication bias. In Chapter 7, we detail the 
steps of sample extraction and data preparation that aimed at harmonise study design 
across groups within the consortium. In addition, we briefly summarise the main findings of 
the two publications on the subcortical and cortical signatures of MDD [68, 69]. 
In Chapter 8 we perform a data-driven analysis in our Brisbane (QTIM) sample to 
identify cortical endophenotypes of anxiety-depression. We use previously validated 
anxiety-depression scores (see Chapter 2) and performed a genetic parcellation of the 
cortical ribbon [70] in order to reduce multiple testing. We used natural splines to allow for 
linear-relationships between cortical phenotypes and anxiety-depression scores, as well as 
twin models to break down phenotypic correlations into their genetic and environmental 
components.  In addition, we sought replication using the freely available data from the 
Human Connectome Project [71-74].  
In the last chapter (Chapter 9), we start by reviewing the GWAS literature on brain 
morphology and by describing the QTIM sample that we contributed to the upcoming 
ENIGMA GWAS on cortical thickness and structure. Next we highlight a statistical limitation 
of the current ENIGMA GWAS approach, which is that the number of brain phenotype 
considered may increase faster than the sample size. We evaluate the statistical power [75] 
resulting in performing multivariate rather than multiple univariate GWAS, using real case 
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scenarios: GWAS of subcortical volumes and hippocampal subfields. Finally we came back 
to the hypothesised simpler genetic architecture of endophenotypes compared to psychiatric 
diagnoses [16]. We contrasted published SNP effect sizes on brain phenotype (ICV, 
hippocampal volume, putamen, nucleus accumbens) [76-78] with those of psychiatric traits 
(depression, schizophrenia) [15, 79] and evaluated if they align with the theory. 
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Abstract / Pocket profile 
 
Keywords: Twin sample, affective disorders, psychotic symptoms, substance use 
disorders, genotype, MRI, prevalence, comorbidity 
Cite this as: The full version of this profile is available at IJE online and should be used 
when citing this profile. 
Cohort purpose: The nineteen and up study (19Up) assessed a range of mental health and 
behavioural problems and associated risk factors in a genetically informative Australian 
cohort of young adult twins and their siblings. As such, 19Up enables detailed investigation 
of the genetic and environmental pathways to mental illness as well as substance use and 
misuse. 
Cohort Basics: Participants are twins and their siblings from Queensland, Australia. Data 
were collected between 2009-2016 on 2,773 participants (mean age=26.1, SD=4.1, range 
18-38, 57.8% female, 369 complete monozygotic pairs, 494 dizygotic pairs). The majority of 
participants are of European ancestry. 
Follow-up and attrition: The 19Up study complements a phenotypically-rich, longitudinal 
collection of environmental and psychological risk factors including personality, psychiatric 
phenotypes and diagnostic outcomes, neurobiological correlates such as brain imaging, and 
genome wide association data (Figure 1). Furthermore, a follow up study at 25+ years is 
currently ongoing.  
Design and Measures: A structured clinical assessment (CIDI) was used to collect lifetime 
DSM-IV and DSM-5 diagnoses of Major Depressive Disorder (MDD), Social Anxiety, 
Cannabis Use Disorder, Alcohol Use Disorder, Panic Disorder/Agoraphobia as well as 
symptoms of mania and psychosis. In addition, the 19Up study assessed general health, 
work activity/occupation, level of education, personality, migraine and headaches, suicidal 
thoughts, ADHD symptomatology, sleep/wake, romantic preferences, friendships, familial 
environment, stress, anorexia bulimia as well as baldness, acne, asthma, endometriosis, 
joint flexibility, and internet use. 
Unique features: The 19Up study is unique by it size (N=2,773), with 84% of participants 
genotyped and 36% imaged using multi-modal MRI.  It combines well-characterised lifetime 
DSM diagnoses with multiple known or hypothesized risk factors. In addition, most of the 
participants have been assessed for mental health risk factors in adolescence, with up to 4 
observations (12, 14, 16 and 21 years, Figure 1). Finally, measures of cognition in 
adolescence are also available for 57% of the sample (100% with parental report of ADHD 
symptomatology, 20% with binocular rivalry, 30% with electroencephalography). 
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Reasons to be cautious: The main limitation of the 19Up is the relatively young age of the 
participants, it is expected that a later assessment will capture additional cases. 
Collaboration and data access: Please contact Professor Nicholas Martin for 
collaborations using 19Up (Nick.Martin@qimrberghofer.edu.au). 
Funding and competing interests: the National Health and Medical Research Council 
(NHMRC) and the National Institute of Health (NIH) funded the study. 
 
Why was the cohort set up?  
Between 2009 and 2016, the Nineteen Up Study (19Up: Mapping neurobiological 
changes across mental health stages [35]) assessed a range of mental health and 
behavioural problems and associated risk factors in a genetically informative Australian 
population sample of young adult twins and their siblings. These individuals are part of the 
ongoing Brisbane Longitudinal Twin Study (BLTS, or Brisbane Adolescent Twin Study: 
BATS [35, 80]), which began in 1992 when twins were recruited from primary and secondary 
schools in the greater Brisbane area via media appeals and by word of mouth. A key strength 
of 19Up is the ability to link twin data with a phenotypically-rich, longitudinal collection of 
environmental and psychological risk factors including personality, psychiatric phenotypes 
and diagnostic outcomes, neurobiological correlates such as brain imaging, and genome 
wide association data (Figure 1). As such, 19Up enables detailed investigation of the genetic 
and environmental pathways to mental illness as well as substance use and misuse.  
The 19Up study complements and extends earlier BLTS and BATS studies of mental 
health and well being in adolescence (Figure 1)[51, 81-89] by providing a detailed 
assessment of mental health and substance use, and misuse from early teenage years 
through to young adulthood. The study was organised for the purpose of collecting lifetime 
diagnoses of substance misuse and common affective disorders, but also includes a range 
of behavioural and non clinical assessments, as well as updates on phenotypes previously 
collected in the BLTS (Figure 1). 
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Figure 1: Summary of the BLTS data collection 
Longitudinal: Vitamin D; Infections (Antibodies); Neuroticism (JEPQ [90], NEO [91]); Psychiatric signs 
(SPHERE [50]) 
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Cross-sectional: Hair Cortisol; Cognition (Verbal, Performance IQ, Working Memory, Information 
Processing); Binocular rivalry (Rivalry rate); Brain imaging (multimodal MRI); Substance use (Alcohol, 
Tobacco, Recreational drugs); Sleep patterns (Actigraphy); Psychiatric diagnoses (CIDI) [92]; Life 
events/social support/relationships (e.g. early home environment, family relationships, traumatic events, 
socioeconomic factors). 
 
Who is in the cohort? 
Data were collected in three waves (NU1, NU2, NU3) between February 2009 and 
June 2016 (Figure 2). Initially, the mental health data were collected via an online survey 
(NU1, N=373), which was replaced in September 2010 by a detailed online questionnaire 
followed by a Computer Assisted Telephone Interview (CATI) of the Composite International 
Diagnostic Interview (CIDI [92]) (NU2, N=665). Beginning July 1st 2012, the online survey 
and CATI instruments were then merged into a more economical online protocol, divided in 
3 sections (NU3, N=2,151;  
 
 
 
 
 
Table 1, Figure 2). Ascertainment began with the oldest BLTS adult twins and their 
siblings in order to limit censoring, and to obtain data from individuals who had passed 
through the median age of onset for substance use disorders, anxiety and mood disorders 
[93-96]. Ethnically, the BLTS cohort should reflect the population structure of families with 
twins in Australia at the time of recruitment, with a majority of participants of European 
ancestry, and minorities of predominantly Asian ancestry [35]. 
Of the 4,156 individuals invited to participate in the study 67% of the twins and siblings 
provided complete data. Overall, females were over-represented among the 19Up 
participants comprising 50.5% (95%CI: 48.9 – 52.1) of the invited population, but 57.8% 
(55.9 – 59.6) of the participants ( 
 
 
 
 
 
Table 1). 
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Across the last 2 waves (NU2&3), N=2,773 twins and siblings completed the 
demographic and CIDI questionnaires, between ages 18–38 (mean age=26.1, SD=4.1, 
57.8% female, 369 complete monozygotic pairs, 494 dizygotic pairs). Due to the 
ascertainment strategy employed, participants who completed the telephone interview 
(NU2) were significantly older than participants who completed the online survey (mean age 
27.4 vs. 25.7, p-value=2.2E-16) but the sex ratio was comparable across the 2 waves: 
58.2% vs. 57.6%, c2 test, p-value=0.80 ( 
 
 
 
 
 
Table 1).  
 
 
 
 
 
Table 1: Demographics of the final sample and detail by wave 
 
Total** NU1 NU2 NU3 
N Invited 4,156♯ 841♯ 2,240♯ 3,374♯ 
% Females [95% CI] 50.5%  
[48.9 – 52.1] 
54.8%  
[51.4 – 58.2] 
50.4%  
[48.3 – 52.4]  
49.7%  
[48.0 – 51.4] 
N Completed (response rate) 2,773 (67%) 373 (44%) 665  (30%) 2151 (64%) 
Mean age (sd) [range] 
26.1 (4.1) 
[18.7 – 38.6] 
24.7 (3.3) 
[18.4 – 30.4] 
27.4 (2.9) 
[20.6 – 38.6] 
25.7 (4.3) 
[18.7 – 38.3] 
% Females [95% CI] 57.8 % 
[55.9 – 59.6] 
62.9%  
[57.7 – 67.8] 
58.2%  
[54.3 – 62.0] 
57.6%  
[55.4 – 60.0] 
Marital status % (n)  
NA⌃ 
  
Married 21.6% (599) 
 
28.1% (187) 19.4% (418) 
Separated 1.0% (28) 
 
0.9% (6) 1.1% (23) 
Divorced 1.0% (28) 
 
1.4% (9) 0.9% (20) 
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** NU1 data is in part reported in [35], but not included in the total sample or used in this analysis as most of 
the participants (345 out of 373: 92%) later completed NU2 or NU3. 
♯: 4,156 unique individuals were invited to participate in the 19Up, but some were invited in several waves. 
Participants invited in NU1 were all re-invited in NU2. They were also invited as part of NU3 if they had not 
completed NU2 and not refused to be recontacted. Forty participants of NU2 also completed NU3. 
⌃ Succinct demographics for NU1 were collected as part of a different study on political views and economical 
games and different questions were used. 
 Participants were asked about their highest level of education (completed or partially completed) at the 
time of questionnaire 
 
 
 
 
 
 
Widowed 0.1% (3) 
 
 0.1% (3) 
Never married 76.3% (2115) 
 
69.6% (463) 78.4% (1687) 
Have children 
% [95% CI] 
18.3%  
[16.9 – 19.8] 
NA⌃ 
22.1%  
[19.0 – 25.5]  
17.3%  
[15.7 – 19.0] 
Highest education level 
 %(n) 
 
 
NA⌃ 
  
No formal education 0.0% (1) 
 
0.0% (0) 0.05% (1) 
Primary school 0.0% (0) 
 
0.0% (0) 0.0% (0) 
Junior Secondary school 1.8% (51) 
 
1.5% (10) 2.1% (45) 
Senior secondary school 16.2% (449) 
 
14.4% (96) 16.9% (364) 
Certificate or diploma 24.3% (675) 
 
29.3% (195) 23.2% (498) 
Degree 44.7% (1239) 
 
39.5% (263) 45.7% (983) 
Post graduate diploma, 
masters, PhD 
12.8% (354) 
 
15.2% (101) 11.9% (256) 
Don’t know / prefer not to 
answer 
0.1%  (4) 
 
0.0% (0) 0.18% (4) 
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Figure 2: Timeline of 19Up data collection 
Because of the changes in protocols, participants from NU1 were all re-approached to complete the following 
NU2 or NU3 waves. The vast majority (92%) then completed NU2 or NU3. Despite an interval of several years, 
these data provide an opportunity to examine test-retest reliability of scores or compare collection methods 
(e.g. self-report online vs. telephone interview). In addition to providing insight into the validity of the measures 
these data are important for twin modelling, as the stability of a phenotype or diagnosis sets an upper limit for 
the heritability [67]. 
 
Informed consent, reimbursement & ethical approval  
Informed consent was obtained from all participants of the 19Up after they were given 
information regarding the study aims, protocols and requirements. Participants who 
completed the questionnaire(s) received an honorarium in appreciation of their time. QIMR 
Human Research and Ethics Committee and the Virginia Commonwealth University 
Institutional Review Board approved the study (see [35] for all details). 
 
How often have they been followed?  
All participants had been invited to complete previous wave(s) of the BLTS [35, 80] 
(Figure 1). Height, weight, personality, psychiatric signs, sleep patterns, migraine and blood 
samples (hematological and immunological measures: e.g. antibodies markers of infections, 
vitamin D) were collected longitudinally in the BLTS, with up to 5 time points for some 
phenotypes (Figure 1). 
In addition, genome-wide SNP genotypes are currently available for 84% (N=2,324) 
of the 19Up participants. These data have been imputed and quality controlled (see [35] for 
details) using the most up to date procedures [97-100], which allow combining data from 
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different arrays, and have been shown to represent a more cost-effective approach to study 
complex human traits than whole genome sequencing (at current prices) [101].  
  Multimodal brain magnetic resonance imaging (MRI) [102] was collected cross-
sectionally and is available for N=987 (36%) of the 19UP respondents. Further assessments 
during adolescence are available for part of 19Up: cognition (available for 56.8% of the 
sample), parental report of ADHD symptomatology (100%), binocular rivalry (19.6%) and 
electroencephalography (30.4%). Finally, a follow up study of those who are 25 years old 
and above has been funded and is currently ongoing. 
 
What has been measured?  
The NU1 wave assessed general health, mental health symptomatology (SPHERE-
12 [50, 103-105], KESSLER-6 [106]), alcohol, nicotine [107], cannabis, and other substance 
use; migraine and headaches, inattention (SWAN) [65] and baldness (Supplementary 
Document 1).  
The following waves (NU2&3) also included structured clinical assessment (CIDI 
[92]), measures of mania [108], suicidal thoughts, sleep/wake (PSQI [109] and ISI [110]) 
and general demographics, where participants were asked about their work 
activity/occupation, level of education, quality of friendships, familial environment (PBI [111]) 
and stress (LTE [112-114]). Finally, sections of the NU2&3 questionnaires also asked about 
participants’ personality (PAI-BOR [115]), acne, asthma, anorexia bulimia, endometriosis, 
joint flexibility, romantic preferences, and internet use (Supplementary Document 1, Figure 1: 
Summary of the BLTS data collection, see also [35]). 
The CIDI (WHO, 1990) was used to collect lifetime DSM-IV diagnoses of Major 
Depressive Disorder (MDD), Social Anxiety, Cannabis Dependence, Alcohol Dependence, 
and Panic Disorder (with and without agoraphobia), as well as symptoms of mania and 
psychosis. Lifetime DSM-5 diagnoses of MDD, social anxiety, panic disorder, agoraphobia 
and substance use disorders could also be computed from the same instrument.  
 
What has been found? Lifetime prevalence and comorbidities of 
psychopathologies in 19Up 
Among the DSM-IV affective disorders, Social Anxiety and MDD were the most 
prevalent diagnoses (17.5 and 16.8%, respectively), followed by Panic Disorder without 
Agoraphobia (1.5%) and Panic Disorder with Agoraphobia (0.9%) (see Supplementary 
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Document 2 for more details). When applying DSM-5 criteria for MDD the prevalence 
increased to 19.6%, however, this could be attributed to the exclusion of bereavement 
criteria in the revised edition. Furthermore, DSM-5 separates Panic Disorder (prevalence 
2.4%) from Agoraphobia (0.9%, Table 2).  
Over half (57.8%) of the sample reported illicit substance use, or the non-medical use 
of a prescribed substance (Table 2). Among the substance use disorders, DSM-IV diagnoses 
of lifetime Alcohol Abuse (Alc-ab) and Dependence (Alc-deb) were the most prevalent at 
33.8% and 28.0%. In comparison, lifetime prevalence of Cannabis Abuse (Can-ab) and 
Dependence (Can-dep) were 11.6% and 6.8% respectively (Supplementary Document 2). For 
each drug class, the DSM-5 merged the previously distinct substance abuse and 
dependence disorders into a single ‘Substance Use Disorder’ with three levels of severity 
(i.e. “mild”, “moderate”, and “severe”). Consequently, clinical criteria for DSM-5 Alcohol Use 
Disorder (AUD) were met by 47.4% of the sample (19.0% mild, 14.8% moderate, and 13.6% 
severe). DSM-5 Cannabis Use Disorder (CUD) was present in only 12.9% of the 
respondents (4.4% mild, 3.3% moderate and 5.2% severe, Table 2). 
Among participants, 7.1% had experienced one or more psychotic symptoms in their 
lifetime (Table 3). Visual hallucinations were the most common, occurring in 3.9% of the 
sample, followed by auditory hallucinations (3.3%) and delusions (Thoughts Insertion and 
Thought Broadcasting: 0.4%, “Made” Feelings and Impulses: 0.3%, Delusions of 
References: 1.1%, and Delusions of Persecution: 0.9%). 
The prevalence for (DSM-IV and 5) affective disorders was higher in females than 
males (Table 2, Supplementary Document 2). For example, females were almost 1.5-fold as 
likely than males to meet the DSM-IV and 5 criteria for MDD (DSM-IV: 19.1%F, 13.6%M, p-
value=1.6E-4, DSM-5: 23.1%F, 15.0%M, p-value=1.4E-7) and social anxiety (20.7%F, 
13.2%M, p-value=3.2E-7). Panic disorders were at least 3 times more prevalent in females 
than males (DSM-IV: with agoraphobia 1.3%F, 0.3%M, p-value=5.9E-3, without 
agoraphobia 2.0%F, 0.7%M, p-value=0.02; DSM-5: panic disorder 3.3%F, 1.1%M, p-
value=2.9E-4, agoraphobia: 1.3%F, 0.3%M, p-value=7.5E-3). Similarly, Panic Attack(s) 
were more common in females than males (18.1%F 9.2%M, p-value=4.5E-11). No 
significant sex differences were observed in the prevalence of manic episode or psychotic 
symptoms (Table 3).  
Among males, the Substance Use Disorders were more common (Can-ab: 17.0%M 
7.7%F, p-value=5.6E-14; Can-dep: 9.8%M, 4.6%F, p-value=1.1E-7; Alc-ab: 40.2%M, 
29.2%F, p-value=2.1E-9; Alc-dep: 35.4%M, 22.6%F, p-value=1.7E-13; AUD 56.8%M, 
41.0%F, p-value2.1E-18; CUD 18.0%M, 9.2%F, p-value=7.4-11). Use of any illegal drug 
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(including misuse of prescription medication) was also significantly higher in males 
compared to females (63.2%M, 53.9%F, p-value=1.0E-6, Table 2, Supplementary Document 
2). For CUD (and Can-ab/Can-dep), or Alc-dep the prevalence was higher in the CATI (NU2) 
compared to online (NU3) participants (Table 2, Supplementary Document 2), which could be 
partly explained by the older age of the NU2 sample compared to the NU3 participants ( 
 
 
 
 
 
Table 1).  
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Table 2: Prevalence of DSM-5 diagnoses in the 19up study 
 Total 
prevalence 
Prevalence Males Prevalence 
Females 
p-value 
males vs. 
females 
Prevalence 
NU2 
NU3 p-value NU2 vs. 
NU3 
Affective Disorders 
MDD 19.7% (545) 
[18.2 21.2] 
15.0% (175) 
 [13.0 17.2] 
23.1% (370) 
[21.1 25.2] 
1.4E-07 17.6% (117) 
[14.8 20.8] 
20.3% (428) 
[18.6 22.1] 
0.14 
Social anxiety 17.5% (486) 
[16.1 19] 
13.2% (154)  
[11.3 15.3] 
20.7% (332) 
[18.8 22.8] 
3.2E-07 16.2% (108) 
[13.6 19.3] 
17.9% (378) 
[16.3 19.7] 
0.35 
Panic Disorder 2.4% (66)  
[1.86 3.04] 
1.1% (13)  
[0.62 1.95] 
3.3% (53) 
 [2.5 4.3] 
2.9E-4 2.7% (18) 
 [1.7 4.3] 
2.3% (48)  
[1.7 3.03] 
0.63 
Agoraphobia 0.9% (25)  
[0.6 1.4] 
0.3% (4)  
[0.1 0.9] 
1.3% (21)  
[0.8 2.0] 
7.5E-3✝▲ 1.2% (8)  
[0.6 2.5] 
0.8% (17)  
[0.5 1.3] 
0.48 
Panic Attack 14.3% (397) 
[13.0 15.7] 
9.2% (107)  
[7.6 11.0] 
18.1% (290) 
[16.3 20.1] 
4.5E-11 15.6% (104) 
[13.0 18.7] 
13.9% (293) 
[12.5 15.5] 
0.29 
Manic episode 0.5% (14)  
[0.3 0.9] 
0.7% (8)  
[0.3 1.4] 
0.4% (6)  
[0.2 0.9] 
0.39 0.6% (4)  
[0.2 1.6] 
0.5% (10) 
 [0.2 0.9] 
0.75✝ 
Substance Use 
Disorders 
       
Cannabis Use Disorder 
“Mild” 
4.4% (123)  
[3.7 5.3] 
5.4% (63) 
 [4.2 6.9] 
3.7% (60) 
 [2.9 4.8] 
7.4E-11 5.4% (36)  
[3.9 7.5] 
4.1% (87) 
 [3.3 5.1] 
1.1E-3 
 
“Moderate” 
3.3% (90) 
 [2.6 4.0] 
5.0% (58)  
[3.8 6.4] 
2.0% (32)  
[1.4 2.8] 
 3.5% (23) 
 [2.3 5.2] 
3.2% (67)  
[2.5 4.0] 
 
 
“Severe” 
5.2% (145)  
[4.4 6.1] 
7.6% (89)  
[6.2 9.3] 
3.5% (56)  
[2.7 4.5] 
 8.0% (53) 
 [6.1 10.4] 
4.36% (92) 
[3.6 5.4] 
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Cells report prevalence%, (N) [95% CI] 
P-values calculated using a Chi Square test unless stated otherwise 
✝: Fisher’s Exact test used 
▲: Would not survive multiple testing correction of 0.05/18=0.0027 
Significant p-value after multiple testing correction are highlighted in bold 
ø : Illicit drug or non-medical use of prescription drug. Participants are asked specifically about: Cocaine, Amphetamine type Stimulants, Inhalants, Sedatives or 
Sleeping Pills, Hallucinogens, Opioids, Party Drugs (Ecstasy, Ketamine, GHB), Over the counter/Prescription Pain killers and Analgesics for non-medical purposes, 
Over the counter/prescription Stimulants for non-medical purposes, or other
Alcohol Use Disorder 
“Mild” 
19.0% (526) 
[17.5 20.5] 
20.7% (242)  
[18.4 23.1] 
17.7% (284) 
[15.9 19.7] 
2.1E-18 21.1% (140) 
[18.1 24.4] 
18.3% (386) 
[16.7 20.0] 
0.031▲ 
 
“Moderate” 
14.8% (411) 
[13.5 16.2] 
17.6% (206)  
[15.5 19.9] 
12.8% (205) 
[11.2 14.5] 
 14.7% (98) 
[12.2 17.7] 
14.8% (313) 
[13.4 16.5] 
 
 
“Severe” 
13.6% (376) 
[12.3 14.9] 
18.5% (217)  
[16.4 20.9] 
9.9% (159)  
[8.5 11.5] 
 15.9% (106) 
[13.3 19.0] 
12.8% (270) 
[11.4 14.3] 
 
Lifetime Use of any drug 
ø 
57.8% (1604) 
[56.0 59.7] 
63.2% (740)  
[60.4 66.0] 
53.9% (864) 
[51.4 56.4] 
1.0E-06 62.3% (414) 
[58.4 65.9] 
56.5% (1190) 
[54.3 58.6] 
9.4E-3▲ 
 48 
Table 3: Prevalence of psychotic symptoms 
 Total 
prevalence 
 
Prevalence 
Males 
 
Prevalence 
Females 
 
p-value 
males vs. 
females 
Prevalence 
NU2 
 
Prevalence 
NU3 
 
p-value NU2 
vs. NU3 
Psychotic symptoms in the 
last 12 months 
2.7% (75)  
[2.2 3.4] 
2.9% (34)  
[2.1 4.1] 
2.6% (41) 
[1.9 3.5] 0.66 
2.4% (16)  
[1.4 4.0] 
2.8% (59) 
[2.2 3.6] 0.68 
Lifetime Presence of any 
psychotic symptoms• 
 
7.1% (196)  
[6.2 8.1] 
7.4% (87)  
[6.0 9.1] 
6.8% (109) 
[5.6 8.2] 
0.57 7.8% (52)  
[6.0 10.2] 
6.8% (144) 
[5.8 8.0] 
0.44 
Visual Hallucinations 3.9% (107)  
[3.2 4.7] 
3.6% (42)  
[2.6 4.9] 
4.1% (65) 
[3.2 5.2] 
0.60 4.2% (28)  
[2.8 6.1] 
3.8% (79)  
[3.0 4.7] 
0.73 
Auditory Hallucinations 3.3% (91)  
[2.7 4.0] 
3.9% (46)  
[2.9 5.3] 
2.8% (45) 
[2.1 3.8] 
0.13 3.3% (22)  
[2.1 5.1] 
3.3% (69) 
[2.6 4.2] 
1.0 
Delusions: Thought insertion 
and Thought Broadcasting 
0.4% (11)  
[0.21 0.73] 
0.6% (7)  
[0.26 1.3] 
0.3% (4)  
[0.1 0.6] 
0.22✝ 0.6% (4)  
[0.2 1.7] 
0.3% (7)  
[0.2 0.7] 
0.30✝ 
Delusions: “Made” feelings 
and impulses 
0.3% (9)  
[0.2 0.6] 
0.3% (4) 
 [0.1 0.9] 
0.3% (5)  
[0.1 0.7] 
1✝ 0.6% (4)  
[0.2 1.6] 
0.2% (5) 
 [0.1 0.6] 
0.23✝ 
Delusions of Reference 1.1% (29)  
[0.7 1.5] 
1.5% (17)  
[0.9 2.4] 
0.7% (12) 
[0.4 1.3] 
0.11 2.0% (13)  
[1.1 3.4] 
0.7% (16) 
[0.5 1.3] 
0.015▲ 
Delusions of Persecution 0.9% (25) 
 [0.6 1.3] 
0.9% (10)  
[0.5 1.7] 
0.9% (15) 
[0.5 1.6] 
0.98 1.1% (7) 
 [0.5 2.3] 
0.9% (18) 
[0.5 1.4] 
0.81 
Cells report prevalence%, (N) [95% CI] 
P-values calculated using a Chi Square test unless stated otherwise. ✝: Fisher’s Exact test used. ▲: Would not survive multiple testing correction of 0.05/16=0.0031 
•: includes any of the psychotic symptoms below 
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Ages of onset were comparable across sexes for all DSM-IV and -5 diagnoses, but 
they varied substantially across disorders (i.e. 11.5 years old for Social Anxiety, 18.5 years 
for Panic Disorder, and around 20 for MDD and Can-dep; Table 4). Age of onset was not 
available for alcohol dependence as only the age at initiation (16.0 years old) was collected. 
The mean ages of onset for manic episode, panic attack and psychotic symptoms were 19.6, 
17.6 and 15.7 respectively.  
Prevalence of MDD (DSM-IV) in 19Up was higher than reported by the 2007 National 
Survey of Mental Health and Wellbeing (NSMHW, 7%) [116] [117] and the WHO World 
Mental Health Surveys (12.8%) [118] while, comparable rates have been reported in New 
Zealand [119, 120] and in a Australian women [121]. These results highlight that if overall, 
MDD is a common condition in high-income countries [119] its observed prevalence 
depends on the age of the respondent. Similarly, the younger age of participants in the 19Up 
likely explains the younger mean age of onset for MDD compared to published research 
[122, 123]. 
   Our prevalence rate for Social Anxiety was higher than previously reported in 
Australia [121, 124], New Zealand [120] and the US [125], but similar to the prevalence 
estimated on Australian twins [126]. Age of onset for social anxiety in the 19Up was similar 
to previous reports [120, 122, 123].  
The prevalence of Panic Disorder without agoraphobia has been reported between 
2.7% and 10.9% [120, 125, 127], higher than our findings (1.5%). Published prevalence of 
Panic Disorder with agoraphobia was also higher than in our study (1.1 to 3.8% [125, 127] 
vs. 0.9%), which could be due to our limited age range. 
Population studies found between 5.4%-6.2% of Australians meet criteria for CUD 
[128, 129]. However, the prevalence has been reported higher (11.4%) within 25-44 years 
old [129], comparable to our finding for CUD (12.9%) or Can-ab/Can-dep (11.6%). In 
addition, we found 28.0% of those in 19Up were alcohol dependent (46.6% with AUD), 
consistent with previous publications [40, 125], despite differences in recruitment and age 
of the respondents. The differences with studies that reported lower rates of alcohol 
dependence in both Australia (3.8%) [129] and New Zealand (4%) [120] could be due to 
differences in data collection (face to face vs. online), recruitment and demographics. 
Finally, prevalence of use of any illegal substance (and misuse of prescription drug) was 
comparable to previously available Australian data (57.8% compared to 51.2% in 20-29 
years old, 59.3% in 30-39) [120, 130].  
Prevalence of psychotic symptoms in the 19Up (7.1%) matched results of the largest 
studies to date [131, 132], while other studies reported prevalence between 5.5% [133] and 
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11.7% [134]. Hallucinations were the most common symptom, as previously reported [131] 
and the prevalence of specific symptoms were very similar to our results [131, 133, 134]. 
However, we found a younger mean age of onset for Psychotic symptoms (15.7 years old) 
than previous studies [135], which could be attributed to the age range of the cohort. 
On the whole, the sex differences matched previous studies. Affective disorders: 
were all more prevalent in women [116, 120, 126, 136, 137] while substance use disorders 
(and abuse or dependence) were more common in men [95, 120, 130]. 
In our sample, comorbidities were widespread across the diagnoses (Table 5, 
Supplementary Document 3) consistent with previous epidemiological results [40, 118, 122, 
124, 129, 138-140] and explained in part by genetic correlations between psychiatric 
diagnoses [10, 11]. Thus, about 65.2% of our sample met the criteria for at least one DSM-
5 diagnosis, with 29.3% of these reporting a second lifetime diagnoses, and 11.5% having 
3 or more comorbid diagnoses. 
Consistent with previous reports [118, 122, 124, 127], most affective disorders were 
significantly comorbid (Table 5, Supplementary Document 3) and the non-significant 
associations may be explained by the low prevalence of manic episodes and agoraphobia 
(yielding low statistical power). In addition, MDD was also associated with presence of 
psychotic symptoms, previously reported in an Australian sample [139] and in a world-wide 
mega-analysis [140]. An association between Social Anxiety and psychotic symptoms had 
also been reported [139, 140] but did not reach significance in our study. Furthermore, we 
replicated the known link between social anxiety and risk of CUD and AUD [141]. Finally, 
panic attacks were associated with higher risk of all affective disorders, CUD, AUD and 
substance initiation, as well as psychotic symptoms, most of which already reported using 
the DSM-IV classification [127]. Panic disorder on the other hand, was only associated with 
increased risk of affective disorders and AUD in the 19Up [127, 137]. 
AUD, CUD and any drug use were, unsurprisingly [129], highly comorbid (Table 5, 
Supplementary Document 3). Furthermore, AUD and CUD were associated with higher rates 
of panic attacks [127] and manic episodes [142]. Finally, AUD was more likely to be reported 
by individuals with social anxiety [141], while CUD was more common in individuals 
reporting psychotic symptoms [140]. 
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Table 4: Differences in the age of onset for males and females 
 Mean age of 
onset (sd) 
Mean age of 
onset Males 
(sd) 
Mean age of 
onset Females 
p-value 
males vs. 
females 
Manic episode (DSM-IV & -5) 19.6 (5.0) 19.2 (5.4) 20 (5.6) 0.87 
First Psychotic symptom 15.7 (6.4) 15 (6.4) 16.2 (6.3) 0.21 
MDD (DSM-IV) 20.6 (5.1) 21.3 (5.4) 20.3 (5.0) 0.038 
MDD (DSM-5) 20.7 (5.2) 21.2 (5.5) 20.4 (5.0) 0.13 
Social Anxiety (DSM-IV & -5) 11.6 (5) 11.3 (4.7) 11.7 (5.1) 0.42 
Cannabis Abuse (DSM-IV) 19.7 (3.1) 19.8 (3.0) 19.6 (3.2) 0.65 
Cannabis Dependence 
(DSM-IV) 
19.8 (3.0) 20 (2.9) 19.6 (3.0) 0.39 
Cannabis Use disorder 
(DSM-5) 
19.5 (3.2) 19.6 (3.1) 19.3 (3.2) 0.49 
Cannabis Initiation 17.7 (4.1) 17.5 (2.8) 17.9 (4.9) 0.05 
Alcohol Initiation 16.0 (1.8) 15.8 (1.8) 16.1 (1.8) 1.20E-05 
Panic Attack 17.6 (5.5) 16.8 (5.9) 17.9 (5.3) 0.11 
Panic disorder with or 
without agoraphobia (DSM-
IV) 
18.7 (5.7) 20.4 (5.0) 18.3 (5.9) 0.22 
Panic Disorder (DSM-5) 18.8 (5.7) 20.4 (5.0) 18.4 (5.9) 0.24 
Agoraphobia (DSM-5) 18.4 (5.0) 18.0 (3.6) 18.4 (5.3) 0.85 
Age of onset was not collected for alcohol abuse, dependence and use disorder. We reported age at first 
drink (initiation), age at first intoxication and age of “regular use” (one drink a month for 6 months) have also 
been collected. 
 
Can I get hold of the data? Where can I find out more? 
Data used in this analysis and described in this article are available to all interested 
researchers through collaboration. Please contact Professor Nicholas Martin 
(Nick.Martin@qimrberghofer.edu.au). 
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Table 5: Proportion of people with one DSM-5 disorder (rows) who also have another disorder (column) 
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88.5%  
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[3.4 5.0] 
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p 4.7E-30 1.1E-28  NA 1.9E-27 6.7E-07 1.8E-7 0.07 0.42 1.2E-07 1.1E-4 0.51 0.31 9.7E-8 0.0032 1.5E-12 
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20.4%  
[15.1 26.9] 
65.3%  
[58.1 71.9] 
 
N
o 18.9% 
[17.4 20.4] 
17.0%  
[15.6 18.6] 
13.0%  
[11.7 14.4] 
2.2%  
[1.7 2.9] 
0.9%  
[0.5 1.3] 
0.5%  
[0.3 0.9] 
87.9%  
[86.6 89.1] 
4.5%  
[3.7 5.4] 
3.1%  
[2.4 3.8] 
4.5%  
[3.8 5.4] 
53%  
[51.1 55.0] 
19.1%  
[17.6 20.6] 
14.9%  
[13.5 16.3] 
13.0%  
[11.8 14.4] 
57.3%  
[55.3 59.2] 
 
p 2.0E-4 0.018 1.5E-12 0.062 0.57 1 8.1E-6 0.67 0.084 9.4E-9 0.15 0.75 0.91 0.0052 0.034  
 Read rows first followed by columns, e.g. of participants with MDD 31.9% also had Social Anxiety. 
Significant p-values after multiple testing correction (Bonferroni corrected, significance threshold: 0.05/45=1.1E-3) appear in bold  
Ñ Illicit drug or non-medical use of prescription drug. Include: Cocaine, Amphetamine type Stimulants, Inhalants, Sedatives or Sleeping Pills, Hallucinogens, Opioids, 
Party Drugs (Ecstasy, Ketamine, GHB), Over the counter/Prescription Pain killers and Analgesics for non-medical purposes, Over the counter/prescription Stimulants 
for non-medical purposes, or other. 
✝: Fisher’s exact test to accommodate the small numbers of cases 
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What are the main strength and weaknesses of 19Up? 
The 19Up study is a major resource to study mental health and substance use in a 
representative Australian sample of young adults. The main strengths of the 19Up within the 
BLTS are: 
(a) Large sample size (N=2,773; 369 monozygotic and 494 dizygotic twin pairs): provides 
significant power (>0.8) to detect heritability above 0.25, shared environment influences 
above 0.2 and a genetic correlation above 0.3 (when heritability for both phenotypes >20%) 
[44, 45]. 
(b) Genotyping: the majority (84%) of the sample has been genotyped allowing GWAS 
studies [143], SNP based heritability  estimation [44, 47] and polygenic risk scores analyses 
[58, 59]. 
 (c) Longitudinal design: most participants have been assessed at 12, 14, 16 and 21 years. 
(d) Well characterised lifetime substance use, DSM-IV abuse and dependence criteria, and 
DSM-5 substance use disorder criteria for a wide variety of licit and illicit substances 
(including non-medical use of prescription medications).  
(e) Rich biological samples: hair sample (cortisol, see [144]) and longitudinal blood samples 
(Vitamin D, antibodies, metabolites, gene expression, GWAS). 
(f) Multi-modal Imaging: 36% of participants underwent structural and functional MRI and 
DTI. 
(g) Repeated observations within 19Up, to study scores and diagnoses stability and 
reliability. 
The main limitation of the 19Up is the relatively young age of the participants. 
However, it is expected that a later assessment will capture additional cases. The next wave 
of the BLTS, currently underway, should provide a further assessment of the twins’ 
psychopathologies in adulthood. 
In addition, twins are not necessarily a random sample of the population as twinning 
is likely heritable [145] and could be associated to some traits of interest. However, we can 
compare twins and non-twins siblings in this study to rule out any confounding effect of 
twinning. 
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Abstract 
Background: The Somatic and Psychological HEalth REport (SPHERE) is a 34-item 
self-report questionnaire that assesses symptoms of mental distress and persistent fatigue. 
As it was developed as a screening instrument for use mainly in primary care-based clinical 
settings, its validity and psychometric properties have not been studied extensively in 
population-based samples.  
Methods: We used non-parametric Item Response Theory to assess scale validity 
and item properties for SPHERE-34 data collected through four waves of the Brisbane 
Longitudinal Twin Study (N=1,707, mean age=12, 51% females; N=1,273, mean age=14, 
50% females; N=1,513, mean age=16, 54% females, N=1,263, mean age=18, 56% 
females). We estimated the heritability of its subscales, their genetic correlation, and in a 
sub-sample (N=1,993) who completed the Composite International Diagnostic Interview, the 
predictive ability of the SPHERE-34.  
Results: After excluding items most responsible for noise, sex or wave bias, the 
SPHERE-34 questionnaire was reduced to 21 items, comprising a 14-item subscale for 
anxiety-depression and a 10-item subscale for chronic fatigue. These new subscales 
showed high internal consistency (alpha>0.78), moderate three months reliability 
(ICC=0.47-0.58) and item scalability (Hi>0.23), and were positively correlated (phenotypic 
correlations r=0.57-0.70; rG=0.77-1.00). Heritability estimates ranged from 0.27 to 0.51.  In 
addition, both subscales were associated with later DSM-IV diagnoses of MDD, social 
anxiety and alcohol dependence (OR in 1.25 - 1.56). Finally, a post-hoc comparison showed 
that several psychometric properties of the SPHERE-21 were similar to those of the Beck 
Depression Inventory. 
Conclusions: The subscales of SPHERE-21 measure valid and comparable 
constructs across sex and age groups (from 9 to 28 years). SPHERE-21 subscales are 
heritable, genetically correlated and show good predictive ability of mental health in an 
Australian-based population sample of young people.  
 
 
Background  
The Somatic and Psychological HEalth REport (SPHERE) provides an assessment 
of common symptoms of mental distress and persistent fatigue by self-report [50]. The 34 
items of the SPHERE (SPHERE-34) were selected from four widely used clinical 
assessments of mental health, based on their predictive ability [50]. Anxiety and depression 
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items were selected from the General Health Questionnaire [148], chronic fatigue from the 
Schedule of Fatigue and Anergia [149], neurasthenia from the Illness, Fatigue and Irritability 
Questionnaire [150], and somatisation items from the Diagnostic Interview Schedule (DSM)-
III-R. Participants respond to each of the 34 items, choosing from one of three fixed options 
(“sometimes/never”, “often”, “most of the time” coded 0, 1 and 2 when calculating sum score) 
to describe the frequency of their symptoms over the “past few weeks”. While three 
subscales can be extracted: anxiety-depression, somatic distress and persistent fatigue 
(Figure 3), these are assumed to represent overlapping constructs that underpin common 
mental disorders.  
Except for an earlier paper from our group, where we showed that the anxiety-
depression and somatic-distress subscales of the SPHERE-34 are moderately heritable 
(~40%) and correlated (phenotypic correlation of 0.42, genetic correlation of 0.87) [51], there 
has been no detailed assessment of the psychometric properties of this questionnaire 
outside clinical settings. This is important, as these properties may not generalise to 
population samples [151]. Here, we used Item Response Theory (IRT) to assess the validity 
and the psychometric properties of SPHERE-34 data collected in a large Australian-based 
population sample of young people [35, 80].  
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Figure 3: Items and subscales of the SPHERE-34 
Items’ short names are used through this manuscript. Some items may be included in several subscales as 
indicated by multiple “x” in some rows. Items from the shorter SPHERE-12 appear in blue. Each subscale of 
the SPHERE-12 comprises six items, which were created to provide a screening tool for common 
psychological and somatic distress in general practice [50, 103-105]. The two dimensional picture of the 
Australian population for the SPHERE-12 showed good psychometric properties and very high sensitivity for 
current and life-time major depression, anxiety and neurasthenia as assessed by DSM-III and DSM-IV [50, 
104]. In addition, it was a good predictor of disability (as measured using the Brief Disability Questionnaire 
[152]), psychiatric morbidity [153] and doctor’s rating of psychological risk [50], which has led to its use in 
research and medical practice in Australia [154]. 
  
IRT origins trace back to the 1940s [155-157] and is a very popular framework for the 
validation of questionnaires, given the simplicity of model formulation and the numerous 
theoretical developments (chronologically: normal ogive, Rasch model, two and three-
parameter logistic models, extensions for polytomous items, non-parametric IRT) [53, 158, 
159]. There are two main advantages of IRT over classical test theory – it explicitly models 
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the items’ properties and uses them to perform maximum likelihood (ML) estimation of the 
latent trait based on the individuals’ responses to the questionnaire. This provides an IRT 
score that takes into account the difficulty and discrimination of each item, often resulting in 
a more accurate estimation of ability, compared to using a sum of the items (sum score) [56, 
160]. That said, the sum score is also a (consistent asymptotically normal) estimate of the 
latent trait [161], and its use may be preferred to communicate test performances, and for 
use outside of a research context for obvious reasons of simplicity in calculation and 
interpretation [162].  
In IRT, a scale of items (or questions) requires three hypotheses to be met: 
Unidimensionality: there is a single latent dimension (or trait) θ underlying a set of items; 
Conditional Independency: items are conditionally independent given the latent trait θ; 
Monotonicity of the Item Response Step Function: the probability of having a symptom, 
knowing the latent trait θ, is a growing function in θ. Conceptually, unidimensionality of a set 
of items is never verified, as several abilities are required to answer even the most simple 
question (e.g. reading ability, memory). Several tests have been proposed to assess 
unidimensionality [163], all testing H0 “Unidimensionality” vs. H1 “multidimensionality”. 
Thus, none of them can conclude that unidimensionality is verified; at best they conclude 
that it cannot not be invalidated. Furthermore, when large samples are considered, one 
would expect such tests to always reject the null hypothesis of unidimensionality. Similar 
criticisms can be formulated about testing for conditional independence (see [164] about 
necessary but not sufficient conditions for conditional independence). Consequently, we 
excluded items that did not satisfy the hypothesis of monotonicity or might be the most 
influenced by secondary abilities (see Material and Methods below). However, we assumed 
that unique psychological dimensions could explain most of the responses to each subscale. 
Finally, we also assumed conditional independence: the answer to one item is not 
dependent on any other answer.  
Nowadays, more than a dozen different IRT models for polytomous items have been 
proposed [165-167] that differ in hypotheses (definition of the IRSF) and properties of the 
final score [165-168]. Models can be classified into parametric (PIRT: IRSF are assumed to 
be logistic) and non-parametric IRT models (NIRT: no constraint on the shape of the IRSF). 
Here we chose to use NIRT models for several reasons. Firstly, in the absence of prior 
information about item properties, NIRT models do not assume the IRSF to be logistic. Items 
with non-logistic IRSF have been reported for depression scales, with NIRT leading to 
improved model fit and fewer items excluded [54]. Secondly, they allow a better diagnosis 
of the item properties by detecting local violations of monotonicity or local variations in item 
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discrimination and bias [52, 169]. Thirdly, they offer user-friendly and straightforward 
diagnostic tools by means of visual inspection [169], and are less computationally 
demanding than PIRT by combining kernel regression and fast Fourier transform [52, 56]. 
Lastly, despite being more general than PIRT models, NIRT models have similar properties 
of stochastic ordering on the sum score [167, 168]. 
For the present study we merged the somatic-distress and fatigue scales into a 
“chronic fatigue” subscale, as they appeared to be driven by the same genetic factors 
(rG>0.97, phenotypic correlation above 0.9 using the SPHERE-34 definition, see 
Supplementary Document 4). This choice is consistent with the definition of the short version 
of the questionnaire (12 items, SPHERE-12), composed of two scales: psychological 
distress and somatic distress. We then excluded items responsible for bias in the score 
distribution and participant ordering (non-monotonic), or poorly contributing items with low 
discrimination. We also tried to improve the scale(s) by including additional items with good 
discrimination. Next, we investigated whether the SPHERE-34 scores measured similar 
constructs across both age and sex, to ensure that any later differences observed across 
groups represent true differences in liability. Then we investigated the impact of the new 
subscale definition on the scores (IRT ML score as well as sum score) reliability (3-months 
test-retest), internal consistency [170] and scalability (Loevinger’s Coefficient [171]). In 
addition, we estimated the heritability of the new subscales for each age group and their 
genetic, environmental and phenotypic correlations. Finally, in a reasonably large 
subsample we assessed the predictive ability of the SPHERE-21 by examining the 
association of age specific SPHERE-21 scores with mental health lifetime diagnoses 
collected in early adulthood, and did a post hoc comparison of the SPHERE-21 with the 
Beck Depression Inventory (BDI). 
Material and Methods 
SPHERE questionnaires in the Brisbane Longitudinal Twin Study  
SPHERE-34 was administered as part of three main projects that make up the 
Brisbane Longitudinal Twin Study (BLTS; also known as the Brisbane Adolescent Twin 
Study (BATS)) [35]. The first two waves of data were collected in the clinic, following an 
assessment of Melanocyte Naevi (moles) around the twelfth (TWin Mole study visit 1: TW1) 
and fourteenth birthday of the twins (TWin Mole study visit 2: TW2) [51, 87-89] with a third 
wave of data, also collected in the clinic, as part of the twin cognition project (Twin Memory, 
attention and problem solving, TM), mostly at age 16 years [51, 81-84]. The final wave of 
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SPHERE-34 data was collected as part of a mailout, which included assessments for 
laterality, personality and reading, as well as smell and taste tests; the study is known as 
the Twin Adolescent (TA) study. Participants who were administered the SPHERE-34, as 
part of the TA study, were on average 18 years old [51, 85, 86]. In total, 3,312 twins or 
siblings (individuals) were included in at least one of the four waves in which the SPHERE-
34 was administered, and at each wave responses were available for >1,200 individuals 
(TW1: 1,707; TW2: 1,273; TM: 1,513 and TA: 1,263). Almost half of the participants (44%) 
answered the questionnaire more than once (19% three times), with 134 individuals (4%) 
being assessed at all four waves (Figure 4). Missingness was overall limited (maximal 
percentage missingness per item ranged from 0% to 0.6%, number of participants with 
missing items ranged from 0% to 4.0%; Supplementary Document 5) and at each wave can 
be assumed to be at random, with exclusions having little impact on results and power 
(Supplementary Document 5).  
 
Figure 4: Venn diagram of the four waves of the BLTS that included the SPHERE-34 
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Selection of unrelated observations for NIRT 
As the sample included twin pairs and siblings, and IRT still lacks methods able to 
model relatedness in samples, we selected unrelated individuals for the IRT analysis. 
Despite a significant reduction of the sample size, the familial pruning ensures unbiased 
confidence intervals of IRSF and facilitates the comparison across sexes and studies, in 
which the relatedness might confound the results. In order to maximise the number of 
observations included, we randomly selected one individual per family in each of the waves. 
To ensure sampling homogeneity of our pruned sample with the full sample, we iterated the 
random selection process 1,000 times, keeping the sample with the most similar age mean, 
variance and sex frequency as the full sample.  
For the across wave comparison (study Differential Item Functioning (DIF), see 
below), we chose to successively compare TM, TW1, and TW2 to TA, which we used as a 
benchmark. This approach maximised the number of observations used in NIRT model 
estimation, hence reducing confidence intervals. For each dataset, we only allowed 
unrelated individuals within and across waves. When multiple observations were available 
for a participant we preferentially selected the observation from the wave that had a smaller 
number of participants in order to obtain a comparable sample size across waves. We 
iterated the familial pruning and observation selection 100 times each, keeping the sample 
that included the most similar number of participants across the four waves. 
In most of the resultant (pruned) samples, there were slightly more females (2-9%; 
Table 6). Mean age in TW1, TW2, TW and TA was 12, 14, 16 and 18 years respectively 
(Table 6). Age had a pseudo-normal distribution in TA but exhibited large peaks in the other 
three waves due to the smaller age dispersion. Pruned samples (to investigate study DIF) 
showed comparable age and sex distributions as the full samples (Table 6). 
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Table 6: Demographics of the full samples and sub-samples pruned for relatedness 
and/or longitudinal observations 
Wave  N  Mean 
age  
SD  Age 
range  
% 
Females  
TW1  1,695  12.64  1.33  9-18  51%  
TW1 pruned for 
relatedness 
651 12.63 1.34 10-19 51% 
TW2  1,265  14.03  0.68  9-18  50%  
TW2 pruned  602 14.02 0.68 10-18 50% 
TM  1,513  16.49  0.84  15-22 54%  
TM pruned  683 16.48 0.83 16-22 53% 
TA  1,213  18.06  3.07  11-28  56%  
TA pruned 592 18.27 3.13 12-26 56% 
TA+TM pruned –
one assessment 
wave/ individual 
1,117    55% 
TA subset 543 18.67 3.02 12-26 56% 
TM subset 574 16.42 0.78 16-22 54% 
TA+TW2 pruned  1,012    52% 
TA subset 506 18.93 2.98 12-26 56% 
TW2 subset 506 14.10 0.52 10-16 47% 
TA+TW1 pruned  1,149    53% 
TA subset 585 18.39 3.12 12-26 55% 
TW1 subset 564 12.50 1.15 10-19 50% 
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Subscale development  
Redefining the SPHERE-34 subscales is an attempt to improve their properties by 
ensuring that the IRT hypothesis of monotonicity is met in practice but also by including, 
when possible, items frequently endorsed that inform on the individuals with low 
proficiency. We first examined its subscales in TA, the oldest cohort (mean age=18 years, 
SD=3.10), where we can assume questions were fully understood by most participants. 
Starting from subscales defined from clinical samples, we estimated the IRSF, excluding 
items not showing monotonic IRSF or specific to a subset of individuals, and included 
additional items (not present in other subscales) that add information to the subscale 
(Figure 5). An item’s relative difficulty and discrimination can be calculated using principal 
component analysis using the evaluation points of the expected item scores [56, 160]. The 
items are projected on the first two principal components. The first principal component 
often corresponds to the difficulty of the items, while the second principal component 
measures the items’ discrimination. Axes are detailed for each figure legend. Plots were 
created using the FactoMineR package [172, 173].  
Then, we studied sex DIF in all waves and excluded items responsible for large 
item bias (Figure 6). Finally we evaluated the wave DIF to identify items behaving 
differently across studies or age groups (Figure 6).  
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Figure 5: Protocol for SPHERE-34 scale development in the TA study 
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Figure 6: Protocol to study and limit DIF across sex groups and waves 
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Nonparametric Item Response Theory model  
We used a non-parametric Graded Response Model [174, 175] that is the most 
general NIRT model for polytomic items [166, 168], while having the simplest and arguably 
the most plausible IRSF definition [176, 177]. Thus, hypothesis three of monotonicity 
becomes for each item j and each response ! ∈ 0,1,2 :  ' () ≥ !	 ,)	./	0	123242325/	323678970/.3:	;5384.23	.3	,		 
With () the random variable of the score on item j. ' () ≥ 1	 ,) and ' () ≥ 2	 ,) are 
respectively the probabilities of reporting symptoms more than often (“often” or “most of the 
time”) or most of the time.    
In NIRT, the absence of interpretable parameters (that define the logistic IRSF) forces 
one to rely on visual inspection of the IRSF or to rely on additional metrics [160, 178, 179] 
in order to describe or compare the functions. We used the “kernSmoothIRT” package [56] 
for NIRT modelling, which is an R equivalent of TestGraf [160]. It allows plotting the IRSF 
from which the hypothesis of monotonicity and the item properties could be visually 
appreciated. In addition, we calculated relative difficulty and discrimination of the items [160]. 
Using visual inspection and item bias summary statistics [160], we studied differential item 
functioning (DIF or item bias), present when individuals from different groups (e.g. sex, 
ethnicity, wave) with the same proficiency have different probabilities to endorse one item 
or one item category. DIF can cause an artificial score difference between groups and 
threatens the internal validity of the scale by causing incorrect ordering of the participants 
on the latent trait [179-181]. If DIF is strongly undesirable in the final score, it can also inform 
on the dimensionality of the scale. Indeed, items presenting DIF can be seen as measuring 
additional dimension(s) for which the groups have different abilities [181]. As a conclusion, 
study of DIF offers a partial check (limited to the groups considered) of the unidimensionality 
hypothesis in IRT.  
In addition, some NIRT models have fewer measurement properties than some of 
their parametric counterparts [166-168]. A central property that allows inferences to be made 
on the latent trait is stochastic ordering of the latent trait (SOL) by the sum score. It states 
that the order of participants, as given by the item sum score, gives a stochastically correct 
ordering on the latent variable [167]. In theory, this property is only verified [166, 167] for 
very simple polytomous parametric models [182, 183] that force the slope of the IRSF to be 
equal across items and categories. However, there is practical evidence that SOL by the 
sum score is often verified [168, 177] when IRT hypotheses are met, enough items are 
present (>5) with a limited number of categories (<5) and similarly shaped IRSFs [168]. 
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Thus, our use of NIRT models maximises goodness of fit to the data while allowing us to 
make inferences on the individual’s proficiency based on their questionnaire score.   
Finally, we preferred the kernel estimation of IRSF, or “TestGraf approach” [52, 56], over 
Mokken Scale Analysis (MSA) [53, 171, 184], another NIRT approach that relies on 
Loevinger’s Coefficient [156, 171] to assess properties of items. Despite a simpler 
framework, through the use of predefined criteria and rules (see Material and Methods 
below), MSA often results in more item exclusions and suffers from the lack of interpretability 
of Loevinger’s Coefficient that are reduced by low correlation to latent trait, redundant items, 
intersecting IRSF, low discrimination or non-monotonicity [53]. We report Loevinger’s 
Coefficients of the final subscales in the psychometric section as a measure of scalability. 
Score description, three months test-retest and psychometric properties 
Using the final subscale definitions, we estimated the ML estimate of the latent trait, 
which is an efficient estimate of the individuals’ proficiency [160] and calculated the sum 
score (items scored 0, 1 or 2 for “sometimes/never”, “often”, “most of the time”) as a 
benchmark of score performance. We report the mean IRT and sum scores by sex for the 
four waves. To accommodate related individuals in the sample, the sex difference was 
tested using the “hglm” R package (fixed effect, Student’s t-test) [185]. A matrix of genetic 
relatedness was used to model the variance covariance structure of the sample. Such matrix 
was created using the “kinship2” package [186].   
For test-retest evaluation, we included all unrelated participants with a test-retest 
period shorter than four months. This resulted in 52 participants with a median test-retest 
interval of 1.9 months (range 1 day-3.8 months), 27 (50%) of the participants were females. 
Median age was 14 years (range 12-18). Test-retest was calculated using intra-class 
correlations (ICC) from the R package “irr” (two-way consistency ICC) [187].  
Two widely used metrics in questionnaire validation include Cronbach’s alpha [170] 
and Loevinger’s Coefficient [156]. Cronbach’s alpha, often known as internal consistency, 
measures the proportion of the variance in the scale attributable to a common factor [188]. 
Despite being reported in almost every scale description, many parameters (e.g. number of 
items, items inter-correlation, dimensionality) have been shown to influence the coefficient 
[188], making its interpretation difficult [188, 189]. However, it is commonly considered that 
alpha > 0.7 suggests an acceptable consistency while alpha > 0.9 may indicate presence of 
redundant items [189]. The use of Loevinger’s Coefficient (H), or “scalability” coefficient, was 
popularised in Mokken Scale Analysis [53, 171, 184], a NIRT approach, which relies on a 
set of metrics to investigate the items or scale properties. Leovinger’s Coefficient can be 
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calculated between two items (Hij), between an item i and a scale (Hi), of for a whole scale 
(H). Under the assumption of monotonicity of the IRSF, it has been shown that Hij>0 for all 
(i,j), and Hi>0 [190], however the reciprocal does not hold, thus Loevinger’s Coefficient 
cannot be used to confirm monotonicity of the IRSF. In addition, Loevinger’s Coefficient is 
sensitive to population variance, item difficulty, discrimination and presence of redundant 
items in the scale making their interpretation also difficult [191, 192]. However, it is 
commonly accepted that items satisfying Hij>0 for all (i,j), i ≠j,and 0.3<Hi<0.4 form a “weak 
Mokken scale”. When 0.4<Hi<0.5 the scale is defined as “medium”, and when 0.5<Hi the 
items form a “strong Mokken scale” [171, 190]. Internal consistency was calculated in R 
using the “psy” package [193], Loevinger’s Coefficients were calculated using the package 
“Mokken” [184]. For all scores in all studies, we report Cronbach’s alpha, number of Hij<0, 
min(Hi).  
Twin sample description for heritability, genetic and environmental 
correlations 
To facilitate interpretation of age specific heritability and correlations across ages, we 
binned the observations by age, creating four age bins (9 to <13 years, 13 to <15 years, 15 
to <17 years and 17 to <28 years), which were centred around the mean age for each wave. 
For those individuals where two SPHERE-34 assessments occurred close together, which 
resulted in two assessments for an individual in an age bin, we randomly selected one 
SPHERE-34 assessment (Table 7). Next, we restricted the family size to a maximum of three 
siblings (one twin pair and one sibling or non-identical trio), which led to the exclusion of 161 
participants (additional siblings or identical trio). Thus the final sample for genetic analyses 
comprised 1,382 individuals with a mean age of 12 years, 1,371 individuals with a mean age 
of 14 years, 1,508 with a mean age of 16 years and 887 with a mean age of 19 years. See 
Table 7 for number of complete trios, monozygotic (MZ) and dizygotic (DZ) twin pairs, twin-
sibling pairs and singletons. The two younger age bins had an equivalent proportion of males 
and females (50%), while there were slightly more females in the two older age bins (15 to 
16 years (54%); 17 to 28 years (58%)) (Table 8). 
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Table 7: Sample size and demographics for genetic analyses  
Age Bins: 8 to 12 
years 
13 to 14 
years 
15 to 16 
years 
17 to 28 
years 
Total number of 
observations 
1,492 1,552 1,683 959 
Number of repeated 
observations excluded 
(same participant with two 
questionnaires in age bin) 
53 154 108 25 
Number of observations 
from identical triplet or 
extra siblings (excluded) 
57 27 67 47 
Final sample size 
(individuals) for genetic 
analyses 
1,382 1,371 1,508 887 
Incl. N complete twin 
pairs 
634 603 670 242 
 Incl. N MZ pairs 226 209 230 96 
  N DZ pairs 408 394 440 146 
  N extra 
sibling 
84 114 89 62 
 N twin-sibling pair 1 1 0 23 
 N singletons 28 49 79 295 
 Incl. N twins 8 8 15 96 
  N siblings 20 41 64 199 
Mean age (SD)  
[range] 
12.09 
(0.41)  
[9-12] 
14.15 (0.31)  
[13-14] 
16.16 (0.37) 
[15-16] 
19.69 (1.92) 
[17-25] 
% Females 50% 50% 54% 58% 
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Heritability, genetic and environmental correlation of the subscale scores 
We used a twin and sibling design to partition the variance into additive genetic “A”, 
unique environment components “E” and either familial (common) environment “C” or 
dominant genetic “D” [44, 46, 194, 195]. Heritability is defined as the proportion of trait 
variance explained by the additive genetic factor. The twin design relies on the fact that, for 
a heritable trait, the twin-pair correlation increases with the degree of genetic relatedness, 
resulting in higher twin correlations in the MZ group compared to the DZ group. Here, we 
included an additional sibling when available, which provides an increase in power for 
detecting A and C/D [196]. Finally, we included singletons (in studies TA and TM) that do 
not contribute to power for detecting A or C/D, but improve the stability of the estimates of 
means and variance. Analyses were performed in OpenMx 2.2.6 [46, 197] using full 
information maximum likelihood (FIML) to accommodate singletons and incomplete trios. 
We compared the fit of ACE vs. ADE models using the Akaike Information Criterion [198], 
and tested the significance of A, C/D and E fraction of variance using log-likelihood ratio test 
on nested models. 
  Prior to variance component modelling, we tested the comparability of means, and 
variances across zygosity groups and siblings, to identify sampling issues and outliers that 
may bias the results [199]. In order to limit the number of tests and improve readability, we 
performed an omnibus test (likelihood ratio test, 20 degrees of freedom) that tests whether 
equating all means and variance results in a significant reduction of the model fit. In addition, 
we tested the effect of sex, age and study on the score means, and also whether the twin 
covariances suggested sex-specific heritability [200]. All significant covariates were included 
in subsequent analysis. For each age group, we reported the heritability of the subscale 
scores (IRT and sum scores). Then, we fitted a bivariate model to estimate the genetic and 
environmental correlations across subscales. 
DSM-IV clinical assessment 
 A later wave of the BLTS (“19up: the study mapping neurobiological changes across 
mental health stages”) [35] collected Composite International Diagnostic Interviews (CIDI) 
[92] that we used to compute DSM-IV diagnoses of major depressive disorder (MDD), social 
anxiety, alcohol and marijuana dependence (i.e. substance dependence), and panic 
disorder [35]. As of April 2016, a total of 2,753 twins and siblings had completed the study, 
of which 1,993 had previously answered at least one SPHERE-34 questionnaire. 660 
participants had a SPHERE-34 score collected between 8 and 12 years (mean age at 
CIDI=22, SD=1.7, 58% females), 878 with SPHERE-34 between 13 and 14 years (mean 
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age at CIDI=22, SD=2.4, 57% females), 1,010 with SPHERE-34 between 15 and 16 years 
(mean age at CIDI=23, SD=2.5, 60% females) and 749 who answered the questionnaire 
between 17 and 28 years (mean age at CIDI=28, SD=3.1, 62% females). Despite a later 
age at CIDI for individuals who completed the SPHERE-34 questionnaire after age 17 years, 
the prevalence of MDD, social anxiety and substance dependence were comparable to the 
other SPHERE-34 age bins (Table 8). This should prevent the association between 
SPHERE-34 and the DSM-IV diagnoses being confounded by censoring. Thus, different 
predictive abilities of age-specific SPHERE-34 scores can be attributed mostly to differences 
in age at questionnaire, rather than to age at CIDI. Age of onset is not available for substance 
dependence and only the age at initiation was collected.  
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Table 8: Sample size, demographics and prevalence of individuals with SPHERE-34 
and CIDI 
 8 to 12 
years 
13 to 14 
years 
15 to 16 
years 
17 to 28 
years 
N stratified by age at SPHERE-34 
assessment 
660 877 1,010 748 
Demographics 
 Mean age at CIDI 
(SD) 
22 (1.7) 22 (2.4) 23 (2.5) 28 (3.1) 
 N (%) Females 380 (58%) 501 (57%) 608 (60%) 461 
(62%) 
Prevalence 
MDD N (%)  93 (14%) 119 (14%) 137 (14%) 109 
(15%) 
 Mean age onset 
(SD) 
17 (3.3) 18 (3.8) 18 (3.5) 22 (5.5) 
Social 
anxiety 
N (%)  124 (19%) 150 (17%) 176 (17%) 119 
(16%) 
 Mean age onset 
(SD) 
12 (4.4) 12 (4.8) 11 (5.1) 12 (5.5) 
Alcohol 
dependence 
N (%)  78 (12%) 132 (15%) 155 (15%) 112 
(15%) 
Marijuana 
dependence 
N (%)  25 (4%) 43 (5%) 44 (4%) 28 (4%) 
Panic 
disorder 
N (%) (with 
agoraphobia)   
4 (0.6%) 6 (0.7%) 11 (1.1%) 3 (0.4%) 
 Mean age onset 
(SD) 
17 (2.7) 16 (2.7) 15 (4.5) 22 (3.6) 
 N (%) (without 
agoraphobia)   
12 (1.8%) 11 (1.3%) 9 (0.9%) 12 (1.6%) 
 Mean age onset 
(SD) 
16 (3.3) 16 (3.8) 18 (4.5) 21 (4.0) 
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Association of SPHERE-34 scores with DSM-IV diagnoses  
We estimated the increased risk of DSM-IV diagnoses (MDD, social anxiety, alcohol 
and marijuana dependence) associated with an increased SPHERE-34 score. We do not 
report results of association with panic disorder as low numbers made estimation of 
parameters impossible. Results are presented in the form of odds ratio, which are equivalent 
to relative risk estimates as disease prevalences in our sample match those of the general 
population. To accommodate related individuals in the sample, the model parameters were 
estimated using quasi-likelihood implemented in the “hglm” R package (fixed effects, 
Student’s t-tests) [185]. A matrix of genetic relatedness, created using the “kinship2” 
package [186], was used to model the variance-covariance structure of the sample. This 
approach provides unbiased estimates of the variance of the estimates, which prevents 
underestimating p-values. Sex, ages at SPHERE-34, age at CIDI and dummy variables for 
the SPHERE-34 study waves were included as covariates in the model. Finally, we 
estimated the number of independent SPHERE-34 scores across all age bins (np) using the 
eigenvalues of the correlation matrix [201, 202]. We then used a Bonferonni significance 
threshold of 0.05/(np*4), four being the number of diagnoses tested, to avoid enforcing a too 
stringent significance threshold.  
Results and discussion 
Development of the subscales in a young adult sample (TA study)  
Anxiety-depression subscale: All items of the anxiety-depression subscale 
showed monotonic IRSF in the normal range of the latent trait distribution. Item 5 
(“Nervous/ tense”) presented the most obvious decrease of IRSF (Figure 7), but this was 
limited to the top 2.5% of the distribution, which did not justify its exclusion. Additional 
items showed monotonous IRSF in the presence of the other 14 items and could be 
considered pertinent for the assessment of anxiety-depression: item 1 (“Headaches”), 7 
(“Waking up tired”), 16 (“Longer sleep”), 17 (“Tired after activity”), 29 (“Tired after rest”), 
and item 31 (“Tired after activity”). However, these were all items from the somatic-distress 
or fatigue subscale and we did not include them in the anxiety-depression subscale to 
avoid artificially inflating the correlation across subscales. Item 3 (“Poor memory”) was the 
least discriminant (Figure 8) 
 having the flattest IRSF, while item 2 (“Irritable/ cranky”) was the most discriminant 
(steepest IRSF). Items 26 (“Annoyed easily”) and 23 (“Frustrated”) were the least difficult 
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(Figure 8) being endorsed by individuals with low proficiency (early elevation of IRSF, see 
Figure 7), while item 28 (“Dizziness”) was the most difficult. 
 
 
Figure 7: Response Step Functions of the 14 items proposed to measure anxiety-
depression 
For each item, two IRSF are calculated that correspond to the probability of having the symptom more than 
often (dark blue line) and the probability of having the symptom most of the time (light blue line). Dotted lines 
correspond to the 95% confidence interval of the IRSF. Using NIRT estimation, we do not constrain the IRSF 
to be logistic. 
 
 
 78 
 
 
Figure 8: Difficulty and discrimination of the items for each scale 
A) The 20 items considered for Anxiety-depression scale. The first principal component corresponds to the 
difficulty of the items, the easiest items being on the right (items 26 and 23). The second principal component 
measures the items’ discrimination (item 2 being the most discriminant). 
B) The 11 items considered for the chronic fatigue scale. The first principal component corresponds to 
the difficulty of the items, the easiest items being on the left (items 22 and 32). The second principal 
component measures the items’ discrimination (item 29 being the most discriminant, 1 the least 
discriminant). Added items appear in red. 
 
Chronic fatigue subscale: We started with the 15 items present in either the 
somatic-distress or fatigue scales (items 1, 3, 6, 7, 10, 13, 14, 16, 17, 24, 25, 29, 30, 31 
and 32) and estimated the IRSF. Several items exhibited small local decreases in their 
IRSF (Supplementary Document 6). However, this could be a consequence of the presence 
of items poorly correlated to the scale, leading to biased estimation of the latent trait. 
Indeed, items 14 (“Fevers”) and 24 (“Diarrhoea/ constipation”) were not often endorsed, 
even for individuals with very high latency (Supplementary Document 6). For example, the 
estimated probability of reporting fevers “more than often” was below 0.4, and no 
participants reported fevers “most of the time” (Supplementary Figure 8). Thus, we 
excluded items 14 and 24 as they showed the lowest probability of endorsement with 95% 
confidence intervals not reaching 1 (Supplementary Document 6). We further excluded items 
6, 10 and 16 for non-monotonicity and item 13 for its low endorsement. These exclusions 
resulted in smoother and monotonous IRSF for the nine remaining items (Supplementary 
Document 7). Then, we considered relevant items not included in the anxiety-depression 
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subscale: items 15 (“Back pain”) and 22 (“Weak muscles”). After inclusion of these 
additional items, the IRSF remained monotonous (Figure 9). Overall, item 1 (“Headaches”) 
was the least discriminant (Figure 8) having the flattest IRSF, while items 17 (“Tired after 
acivity”) and 29 (“Tired after rest”) exhibited the steepest IRSF (Figure 8, Figure 9). Newly 
included items 15 and 22 were moderately discriminant, with item 22 being the most 
difficult in the scale, hence adding information on the individuals with extreme somatic-
distress. These two items were included in the chronic fatigue subscale. 
 
 
Figure 9: Response Step Functions of the 11 items suitable for the chronic fatigue 
subscale 
 
Differential item functioning across sex and study wave  
Anxiety-depression subscale: Sex DIF was moderate to low in all study waves and 
items, even if item bias might be slightly more pronounced in the TM study that shows a 
median DIF statistic of 0.13 (vs. 0.11 in TA, 0.065 in TW2 and 0.080 in TW1). Maximum sex 
DIF was found for item 33 (“Losing confidence”; DIF=0.23) and item 27 (“Everything on top 
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of you”; DIF=0.22) in study TM. However, we kept these items in the subscale as they did 
not show consistent DIF across studies, and their impact on the TM score would remain 
small (DIF<0.25 and mostly overlapping 95% CIs, Supplementary Document 8, Supplementary 
Document 9, Supplementary Document 10, Supplementary Document 11).  
We observed a very limited DIF between waves (Supplementary Document 12, 
Supplementary Document 13, Supplementary Document 14) suggesting that the anxiety-
depression subscale measures the same latent construct across waves, hence age groups. 
Median item DIF was 0.087 for TM vs. TA, 0.10 for TW2 vs. TA and 0.088 in TW1 vs. TA. 
Items 12 (“Unhappy/ depressed”), 20 (“Under strain”) and 23 (“Frustrated”) consistently 
showed item bias above the median, TA participants being more likely to report the 
symptoms “more than often”, knowing the latent trait. However, these levels of DIF (0.13-
0.24), which would have moderate impact on the scores, did not justify exclusion of these 
items. 
Chronic fatigue subscale: Monotonicity of the IRSF was observed for all items and 
waves, in the normal range of the chronic fatigue continuum (Additional Files 12-15). The 
median sex DIF of the scale was 0.11 in the TA study, 0.12 in TM, 0.10 in TW2 and 0.092 
in TW1, suggesting overall minor artificial sex differences in chronic fatigue scores 
(Supplementary Document 15, Supplementary Document 16, Supplementary Document 17, 
Supplementary Document 18). However, we excluded item 1 (“Headaches”) which showed a 
high item bias (DIF=0.26 in TA and 0.24 in TM, non-overlapping CIs: Supplementary Figures 
12-13), with females more likely to report headaches when compared with males with the 
same latent score.  
We observed very limited DIF between TM, TW2, TW1 and TA (Supplementary 
Document 19, Supplementary Document 20, Supplementary Document 21). Median DIF across 
items was 0.084 for TM vs. TA comparison, 0.090 for TW2 vs. TA and 0.069 in TW1 vs. TA. 
Item 15 (“Back pain”) was more frequently reported by participants of the TA study and 
showed the highest DIF in TW1 vs. TA and TW2 vs. TA (DIF=0.21) but not in TM vs. TA 
(DIF=0.084). However, the item did not meet the DIF exclusion criteria and we maintained 
it in the scale.  
Summary of NIRT analysis 
NIRT analysis showed that IRSF of the SPHERE-34 items were roughly logistic, 
varying in difficulty and discrimination (Figure 8), sometimes exhibiting right asymptotes 
below 1 and local plateaus (Figure 7, Figure 9, Supplementary Document 6, Supplementary 
Document 7). The latter would cause even the most complex PIRT model (four parameters 
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logistic, with parameters measuring difficulty, discrimination, left and right asymptotes) to fit 
the data poorly. Using common PIRT model (e.g. two parameters logistic – modelling 
difficulty and discrimination only) would have resulted in poorer fit to the data, likely resulting 
in exclusion of more items. Overall, such exclusions would have led to smaller scales that 
tend to be less reliable and precise [192]. Finally, the IRSF left asymptotes were all 0, which 
suggests absence of guessing (i.e. no participants answering the questions at random). 
Thus we can infer that participants in all waves understood the questions (or answered by 
the negative when they did not understand).  
The anxiety-depression subscale was left unchanged after NIRT analysis. Across all 
four waves the anxiety-depression items met the IRT hypothesis of monotonicity. In addition, 
no item showed substantial DIF by sex or study wave suggesting the scale measures a 
consistent construct across groups and that sex or study wave differences observed arise 
mostly from true differences in latent trait.  
On the other hand, we excluded six items from the chronic fatigue scale that were only 
endorsed by a fraction of the participants or did not satisfy the requirement of monotonicity 
of the IRSF. Two additional items, not present in the anxiety-depression subscale, were 
added to improve the stability of the scale and/or the score distribution, as these provide 
information about individuals with low chronic fatigue scores. Finally, we excluded item 1 
(“Headaches”) that showed large sex DIF (in studies TA and TM), being more frequently 
reported by females, compared to males with the same proficiency. All other items of the 
chronic fatigue subscale met DIF inclusion criteria. Overall low DIF suggests that the 
subscales measure comparable constructs across sex and waves, hence age groups. 
The final version of the SPHERE-21, which measures anxiety-depression (14 items) 
and chronic fatigue (10 items) is available in Supplementary Document 22 (questionnaire) and 
Figure 10 (scale definition). Three items are present in both subscales (items 3 “Poor 
memory”, 30 “Poor concentration” and 32 “Feeling lost for words”).  
We computed the IRT and sum scores of the two subscales of SPHERE-21. As the 
subscales satisfy IRT hypotheses, contain enough items (>5), with a limited number of 
categories (<5) and similarly shaped Item Response Step Functions, stochastic ordering on 
the sum score can be assumed [168]. This allows inferring the ordering of the participants’ 
true abilities from the ordering of the SPHERE-21 sum score. 
 
 82 
 
Figure 10: Summary of NIRT item validation and selection 
Items from the original scales are indicated by an x. Items included in the new version of the scales are 
indicated by a rectangle of colour. Items not present in any scale after the reduction to 21 items appear in light 
grey. 
 
SPHERE-21 mean scores, reliability and psychometric properties 
Using all observations available we tested for sex differences, after correcting for 
familial relatedness. Females had significantly higher anxiety-depression scores compared 
with males in study TM and TA (+0.4 and +0.5 for sum scores, p-values<8.8E-4), but the 
difference was not significant at younger ages in TW2 and TW1 (after correction for multiple 
testing, Bonferroni correction). In addition, female’s reported lower chronic fatigue in study 
TW1 (-0.2 pt. in sum score p-value<9.7E-5) but no significant differences survived multiple 
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testing correction in the older waves (Table 9). Up to a quarter of the participants answered 
“never or sometimes” to all questions (22% in TA, 23% in TM, 25% in TW2 and 21% in TW1) 
yielding a sum score of 0 and an IRT score of -3. This proportion was lower for chronic 
fatigue (15% in TA, 14% in TM, 17% in TW2 and 19% in TW1). 
The IRT SPHERE-21 scores are moderately reliable: ICC=0.47 [0.23, 0.66] for 
anxiety-depression and ICC=0.57 [0.35, 0.73] for chronic fatigue. Reliability of chronic 
fatigue aligns with those of somatic-distress (ICC=0.57 [0.37, 0.73]) or fatigue (ICC=0.62 
[0.42, 0.76]). Reliabilities of the IRT scores were higher (albeit non-significantly) than those 
of the sum scores (0.25 [-0.025, 0.49] for anxiety-depression, 0.49 [0.26, 0.67] for chronic 
fatigue). In addition, the internal consistency, as measured by Cronbach’s alpha, was 
greater than 0.7 for all scores (Table 10). Anxiety-depression has the highest internal 
consistency (alpha in 0.86-0.88), versus 0.78-0.79 for chronic fatigue.  
Similarly, the pairwise Loevinger’s Coefficients (Hij) were all positive, indicating 
positive item correlation in each scale (Table 10). In addition, the Hi were also positive, which 
is expected when the hypothesis of monotonicity of the IRSF is met [190]. However, we note 
that the minimal Hi were all below 0.3 (items with Hi<0.3, Table 10) and that items with low 
discrimination (e.g. items 3, 15, 31 in chronic fatigue, item 3 in anxiety-depression, see Figure 
7 and Figure 9) would be excluded in Mokken Scale Analysis (MSA) [53]. Items 32 in chronic 
fatigue and 28 in anxiety-depression would also be excluded in MSA despite their good 
discrimination. Thus, one may prefer to use MSA for its simplicity, or when trying to reduce 
the length of a questionnaire. The counterpart being that MSA relies on rather arbitrary 
criteria (see [191] for further discussion on the interpretation of Loevinger’s coefficients) and, 
like PIRT, may reduce reliability and precision of the instrument [192].  
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Table 9: Mean SPHERE-21 IRT and sum score for each subscale, wave and sex 
group 
 
 
 Mean 
(SD) 
Mean 
Females 
(SD) 
Mean 
Males 
(SD) 
Sex 
difference 
p-value  
TA       
Anxiety-
depression 
IRT score -0.39 (1.6) -0.27 (1.6) -0.56 (1.7) 7.6E-4 
 Sum score 4.6 (4.8) 5.0 (4.9) 4.2 (4.6) 8.8E-4 
Chronic fatigue IRT score -0.24 (1.5) -0.19 (1.4) -0.30 (1.5) 0.087 
 Sum score 3.9 (3.4) 3.9 (3.4) 3.8 (3.5) 0.37 
TM       
Anxiety-
depression 
IRT score -0.44 (1.7) -0.25 (1.7) -0.67 (1.6) 2.5E-6 
 Sum score 4.1 (4.5) 4.7 (5.0) 3.3 (3.7) 9.3E-10 
Chronic fatigue IRT score -0.22 (1.5) -0.15 (1.5) -0.31 (1.4) 0.042 
 Sum score 4.0 (3.4) 4.2 (3.6) 3.7 (3.2) 0.018 
TW2      
Anxiety-
depression 
IRT score -0.47 (1.7) -0.47 (1.7) -0.46 (1.7) 0.88 
 Sum score 3.7 (4.3) 3.7 (4.2) 3.7 (4.4) 0.96 
Chronic fatigue IRT score -0.28 (1.5) -0.38 (1.5) -0.18 (1.5) 0.031 
 Sum score 3.6 (3.3) 3.4 (3.3) 3.8 (3.3) 0.079 
TW1      
Anxiety-
depression 
IRT score -0.4 (1.6) -0.48 (1.7) -0.30 (1.6) 0.026 
 Sum score 4.1 (4.4) 3.9 (4.3) 4.4 (4.5) 0.023 
Chronic fatigue IRT score -0.33 (1.6) -0.48 (1.6) -0.18 (1.5) 2.5E-6 
 Sum score 3.5 (3.3) 3.3 (3.3) 3.8 (3.4) 9.7E-5 
Here, we performed eight tests yielding a (conservative) Bonferonni-corrected significance threshold of 0.0063. 
Significant p-values after multiple testing correction appear in bold. All participants were used to produce this 
table. Relatedness was accounted for using mixed models when testing sex-differences.  
 
 
  
 85 
Table 10: Cronbach's alpha and Loevinger's Coefficients of the SPHERE-21 anxiety-
depression and chronic fatigue subscales 
  TW1 TW2 TM TA 
Anxiety-
depression 
alpha 0.88 0.87 0.87 0.86 
# Hij<0 0 0 0 0 
Min(Hi) 0.29 0.24 0.28 0.24 
Items Hi<0.3 3 3, 28 28 3 
Chronic 
fatigue 
alpha 0.79 0.79 0.78 0.79 
 # Hij<0 0 0 0 0 
 Min(Hi) 0.24 0.26 0.25 0.23 
 Items with 
Hi<0.3 
3, 15 3, 15, 31 3, 15 3, 15, 32 
Alpha corresponds to Cronbach’s alpha; #Hij<0 to the number of pairwise Loevinger’s Coefficient below 0 for 
(i,j) items; Min(Hi) is the minimal Loevinger’s Coefficient between an item i and the scale; Items Hi<0.3 lists 
the item number corresponding to Hi<0.3. 
 
Heritability, genetic and environmental correlations of the SPHERE-21 
subscales 
Covariate effect, twin-pair correlations and homogeneity of sampling across twin 
zygosity groups and siblings were investigated for IRT and sum scores in each age bin. 
Detailed results are available in Supplementary Document 23. In summary, sex was nominally 
significant (p-value<0.05) for most bins and scores, except for the anxiety-depression scores 
of the 13 and 14-year age group (p-values=0.78 and 0.91). Females had lower anxiety-
depression (-0.85 sum score, p-value=4.8E-4) and chronic fatigue scores (-0.79 sum score, 
p-value=4.5E-6) at age 8 to 12 years. At older ages, females had higher anxiety-depression 
(+1.52 sum score at 15 to 16 years, p-value=3.9E-10; +1.37 sum score at 17 to 28 years, p-
value=2.0E-5) and chronic fatigue scores (+0.38 sum score at 15 to 16 years, p-
value=0.036; +0.54 sum score at 17 to 28 years, p-value=0.021). Age at assessment was 
significant for chronic fatigue sum score (-0.55 in sum score per year of age, p-value=0.033) 
in age group 15 to 16 years, and both the anxiety-depression (-0.17 in sum score per year 
of age, p-value=0.041) and chronic fatigue sum scores (-0.20 in sum score per year, p-
value=0.021) for those aged 17 years and older.  
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For all the IRT scores, the omnibus test did not reject the null hypothesis of equality 
of means and variance across groups (Supplementary Document 23). On the other hand, the 
test returned significant p-values (between 0.015 and 3.2E-7) for all but one sum score 
(chronic fatigue within 15 to 17 age range, p-value=0.59). We winsorised the sum scores to 
three standard deviations from the mean, in order to limit the influence of extreme values. 
However, most sum score means and variance were still significantly different across groups 
(p-values in 0.72-4.7E-5, Supplementary Document 23). In addition, two tests suggested 
presence of sex limitation, however only on sum scores, and we also attributed these 
rejections to the skewed distribution. Tests of familial aggregation and presence of genetic 
effect were significant for all the IRT scores. Non-significant results observed for sum scores 
in the 17 years and older age group could be attributed to lower power (smallest sample 
size). Finally, the MZ twin pair correlations were always greater than the DZ correlations 
suggesting presence of heritability (Supplementary Document 23, Table 11). These results 
highlight that sum scores are not normally distributed, with overly frequent scores of 0 and 
a heavy right tail. Winsorisation reduced the weight of extreme observations but did not 
remove completely the false positives in assumption testing induced by the score 
distributions.  
We fitted ACE and ADE models for IRT and (Winsorised) sum scores in all age groups 
(see Supplementary Document 23 for summary of model fit). We did not have the power to 
detect A and C/D simultaneously; due to the modest number of twin-sibling pairs and 
considering the magnitude of the effects (Supplementary Document 23). In Table 11 and Figure 
11 we report the heritability estimates from an AE model, however, we cannot exclude that 
a shared environment source of variance may be present for some age groups 
(Supplementary Document 23). Heritability estimates for anxiety-depression IRT scores were 
consistent across age groups (h29-12years=0.41 [0.32,0.49], h213-14years=0.42 [0.33,0.50], h215-
17years=0.29 [0.20,0.38] and h217-28years=0.37 [0.21,0.51]) as indicated by overlapping 95% 
confidence intervals (Table 11, Figure 11). In each age group, heritability of the sum score 
(h29-12years=0.46 [0.37,0.54], h213-14years=0.40 [0.31,0.49], h215-16years=0.27 [0.17,0.37] and h217-
28years=0.20 [0.028,0.36]) was comparable to those of the IRT score (Supplementary Document 
23). 
Heritability of chronic fatigue IRT score was also similar across age group (h29-
12years=0.42 [0.33,0.51], h213-14years=0.51 [0.43,0.59], h215-16years=0.35 [0.25,0.44], h217-
28years=0.27 [0.11,0.41]) and consistent with results on sum scores (h29-12years=0.45 
[0.36,0.53], h213-14years=0.50 [0.41,0.57], h215-16years=0.36 [0.26,0.45], h217-28years=0.18 
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[0.016,0.35]) (Table 11, Figure 11). Differences between IRT and sum scores could be 
partially explained by outliers present in the sum score distribution.  
 
Table 11: Summary of variance component analysis (AE models and twin pair 
correlations) 
 Parameter Estimates Twin pair 
correlations 
 A E rMZ rDZ 
Anxiety depression  
8-12 years 0.41 [0.32,0.49] 0.59 [0.51,0.68] 0.43 0.22 
13-14 years 0.42 [0.33,0.5] 0.58 [0.5,0.67] 0.38 0.32 
15-16 years 0.29 [0.2,0.38] 0.71 [0.62,0.8] 0.28 0.20 
17-28 years 0.37 [0.21,0.51] 0.63 [0.49,0.79] 0.39 0.18 
Chronic fatigue   
8-12 years 0.42 [0.33,0.51] 0.58 [0.49,0.67] 0.42 0.25 
13-14 years 0.51 [0.43,0.59] 0.49 [0.41,0.57] 0.53 0.29 
15-16 years 0.35 [0.25,0.44] 0.65 [0.56,0.75] 0.38 0.15 
17-28 years 0.27 [0.11,0.41] 0.73 [0.59,0.89] 0.27 0.07 
Estimates of proportion of variance explained by additive genetics (A) and unique environment (E) calculated 
from AE models. When AE was the “best model” (i.e. most parsimonious model with no significant difference 
of fit with full model) the parameters appear in bold. Full tables that include ACE, ADE estimates and model fit 
comparison are available in Supplementary Document 23. 
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Figure 11: Heritability of anxiety-depression and chronic fatigue scores across age 
Bars indicate 95% confidence intervals. Estimates and confidence intervals correspond to the ones from AE 
models. 
 
The anxiety-depression and chronic fatigue IRT scores were positively correlated 
(Supplementary Document 23), consistently across age groups (r9-12years=0.62 [0.58,0.65], r13-
14years=0.67 [0.64,0.70], r15-16years=0.68 [0.65,0.70] and r17-28years=0.63 [0.58,0.68]). The 
phenotypic correlation was mostly driven by the genetic correlation: rG9-12years=0.87 
[0.77,0.98], rG13-14years=0.85 [0.77,0.98], rG15-16years=0.88 [0.77,0.90] and rG17-28years=1.00 
[0.88,1.00]. Environmental correlations between anxiety-depression and chronic fatigue 
were comparatively lower (rE9-12years=0.44 [0.35,0.52], rE13-14years=0.52 [0.43,0.59], rE5-
16years=0.58 [0.51,0.64] and rE17-28years=0.43 [0.31,0.54]). All correlations were significantly 
different from 0, even after multiple testing correction (p-values<5.2E-7, significance 
threshold set to 3.0E-4 based on 16 independent tests, Supplementary Document 23). 
Phenotypic and environmental correlations were also significantly different from 1 (p-
value<1.5E-6), suggesting that anxiety-depression and chronic fatigue only share a fraction 
of their environmental sources of variance. Correlations between the sum scores differed 
little in strength and supported the same conclusions (Supplementary Document 23). Finally, 
the genetic correlations were only significantly different from 1 at ages 15 to 16 years for the 
IRT score (p-value=7.0E-4) and before age 15 for sum scores (p-values<3.1E-6) suggesting 
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that most of the genetic sources of variance are common to the two SPHERE-21 subscales 
(Supplementary Document 23). We investigated the impact on the correlations of the three 
items common to both subscales, by removing them from the anxiety-depression score. 
Their exclusion had little impact on the genetic correlations (rG9-12years=0.83 [0.71,0.95], rG13-
14years=0.87 [0.77,0.99], rG15-16years=0.91 [0.75,1.00] and rG17-28years=0.97 [0.75,1.00]) and did 
not change the conclusions reported above (see for all correlations and p-values). 
Previous results on the total sample (1,168 complete pairs aged 12 to 25 years, [51]) 
reported similar heritabilities around 0.40 as well as correlations (r=0.60, rG=0.87 and 
rE=0.41) between anxiety-depression and somatisation sum scores. Here, we expanded 
these results by showing consistent heritability and correlation between SPHERE-21 
subscales in different age groups. Results can be compared across publications as we used 
the same definition for the anxiety-depression subscale, and combined the somatisation and 
fatigue scales that showed almost perfect genetic correlations (Supplementary Document 4). 
 
SPHERE-21 association with some psychiatric DSM-IV diagnoses 
We tested the association of SPHERE-21 scores from earlier ages with DSM-IV 
diagnoses (MDD, social anxiety, alcohol and marijuana dependence) assessed with the 
CIDI after age 19 (mean age 22). We estimated the number of independent SPHERE-21 
scores to be six [201], yielding a significance threshold of 2.1E-3 corresponding to an 
estimated 24 independent tests. The anxiety-depression IRT scores were associated with 
increased MDD risk (OR15-16=1.30 [1.13,1.47], p=1.4E-4; OR17-28=1.27 [1.09,1.48], p=2.0E-
3), as well as increased risk of social anxiety (OR13-14=1.39 [1.21,1.59], p=1.9E-6; OR15-
16=1.40 [1.24,1.59], p=1.2E-7 and OR17-28=1.41 [1.21,1.64], p=1.1E-5) and alcohol 
dependence (OR15-16=1.25 [1.11,1.42], p=3.7E-4; OR17-28=1.38 [1.18,1.62], p=6.3E-5). All 
other odds ratios were greater than 1 but did not reach significance (Figure 12). 
Chronic fatigue IRT scores were also associated with increased risk of MDD (OR15-
16=1.31 [1.13, 1.52], p=3.5E-4), social anxiety (OR13-14=1.41 [1.22, 1.63], p=2.9E-6; OR15-
16=1.41 [1.19, 1.68], p=4.1E-7 and OR17-28=1.41 [1.19, 1.68], p=9.0E-5) and alcohol 
dependence (OR13-14=1.35 [1.16, 1.58], p=1.4E-4; OR15-16=1.29 [1.12, 1.48], p=4.4E-4 and 
OR17-28=1.56 [1.29, 1.87], p=6.4E-6) (Figure 13). Such odds ratios (1.09 to 1.87 from the 
confidence intervals) translate to a 0.6 to 6 fold increased risk between individuals with 
minimal (-3) and maximal (+3) IRT score. 
Sum scores showed the same pattern of association, except for anxiety-depression 
in those aged 17 to 28 years, which did not reach significance (p=7.3E-3, Supplementary 
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Document 24, Supplementary Document 25). Effect sizes were comparable, taking into account 
the difference in range between IRT and sum scores (Supplementary Document 24, 
Supplementary Document 25). 
 
 
Figure 12: Risks of MDD, social anxiety and substance dependence increases with 
anxiety-depression IRT scores  
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p-values are indicated above 95% confidence intervals. The stars correspond to significance after correcting 
for multiple testing (Bonferonni correction). * corresponds to pcorrected<0.05, ** pcorrected <0.01 and *** pcorrected 
<0.001. 
 
 
Figure 13: Risks of MDD, social anxiety and substance dependence increases with 
chronic fatigue IRT scores  
p-values are indicated above 95% confidence intervals. The stars correspond to significance after correcting 
for multiple testing (Bonferonni correction). * corresponds to pcorrected<0.05, ** pcorrected <0.01 and *** pcorrected 
<0.001. 
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Comparison of SPHERE-21 and BDI psychometrics 
Compared with the psychometric properties of the “gold standard” Beck Depression 
Inventory (BDI-II) [203, 204], the SPHERE-21 is considerably shorter for measuring anxiety-
depression (14 vs. 21 items) and provides an additional measurement of chronic fatigue. 
While studies on the latent structure of the BDI consistently identify two dimensions: 
cognitive-affective and somatic-vegetative [204], more sophisticated modelling showed that 
much of the variance of the BDI could be explained by a general construct, and BDI 
subscales are rarely used in practice [204]. Furthermore, combining cognitive-affective and 
somatic-vegetative symptoms may be appealing as it matches the DSM-IV (and DSM-5) 
definition of MDD. Based on our results, the high genetic correlation between anxiety-
depression and chronic fatigue could justify combining the two subscales, as the same 
genetic factors would contribute to both traits. However, anxiety-depression and chronic 
fatigue shared less than half of their environmental sources of variance and separating them 
in analyses could help identify specific environmental contributors [3].  
Psychometric properties of the BDI have been studied for more than 50 years [203, 
204]. However, most of the early studies suffered from lack of powerful statistical methods 
(such as IRT). Based on omnibus measures of test-retest and internal consistency, the BDI 
shows very good psychometric properties, comparable to SPHERE-21 (Table 12). However, 
more in depth assessments [179] revealed that two items of the BDI (9 “Suicidal wishes” 
and 10 “Crying”) failed to meet IRT requirements of monotonicity of IRSF in depressed 
outpatients and non-patient college students [179], potentially leading to bias in score and 
misordering of the participants on the sum score. In addition, item 19 (“Weight loss”) 
correlated poorly with the latent trait, thus not contributing to the scale and potentially 
breaching unidimensionality [179]. Finally, item 14 (“Distortion of image body”) showed large 
sex DIF (DIF=0.32), being endorsed more often by women [179]. These do not invalidate 
the BDI, as it has also been shown to effectively measure depression in both clinical and 
non-clinical settings, and across different languages and populations [204]. However, one 
can question what impact score bias, sex differential functioning, and participants’ 
misordering have on a study’s power and predictive ability.  
Heritability of the BDI score has been reported from large family data (N=200 from 12 
families) [205] or broken down into subscales (343 twin pairs) [206]. The first study reported 
heritabilities between 0.45 and 0.87, while the second could not conclude regarding the 
presence of heritability or common environment factors, explaining 2 to 30% of the score 
variance. Larger twin studies are required to provide more accurate heritability estimates of 
the BDI across ages. 
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Finally, the BDI has been evaluated many times as a prediction tool for MDD in clinical 
settings [204]. A few studies have focused on non-clinical samples but suffered several 
limitations: a) small samples; b) samples with greater prevalence than in general population; 
c) non-DSM-based diagnoses; and mostly, d) use of score cut-off criteria which defeats the 
purpose of using a continuous score but also makes comparison of specificity and sensitivity 
impossible across studies when different cut-offs are used (see [204] for a review of these 
studies). We could not find a publication reporting the association between the BDI score 
and disease risk in the general population, and much testing remains to be done on the BDI 
to validate its use in population samples and non-clinical research. Comparison of SPHERE-
21 and BDI qualities is summarised in Table 12. 
 
Table 12: Comparative psychometric properties of the SPHERE-21 and BDI 
 SPHERE-21  BDI 
Number of items  14 (for anxiety-depression) 21  
Short form for 
clinical use 
SPHERE-12 (six items for 
anxiety-depression)  
BDI-11  
IRT 
requirements 
Monotonicity verified 
Good correlation of 
items with the latent trait 
Monotonicity breached for items 
9 and 10  
Poor correlation of item 19 with 
the latent trait [179] 
Sex DIF Limited (DIF<0.25) Large DIF for item 14 (DIF=0.32) 
Limited otherwise (DIF<0.25) 
[179] 
Age group DIF Limited (DIF<0.25); 
comparable construct from 
age 9 to 28 years 
Not tested at item level (IRT) 
Not investigated in a population 
sample 
Comparable structure and internal 
consistency (Cronbach’s alpha) 
for adolescent inpatients [207] 
Language(s) Arabic, Cantonese, 
Croatian, Dutch, English, 
Greek, Italian, Japanese, 
Mandarin, Portuguese, 
Arabic, Chinese, English, Farsi, 
Finnish, French, German, 
Japanese, Korean, Norwegian, 
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Serbian, Spanish, Turkish, 
Vietnamese * 
Portuguese, Spanish, Swedish, 
Turkish 
Test-retest 0.47 [0.23,0.66] at three 
months 
0.48-0.86 [203] depending on the 
sample and test-retest interval  
Cronbach’s 
alpha 
0.87 0.81 [203, 204] 
Heritability 0.41 [0.32,0.49] between 
ages nine and 12 years, 
0.42 [0.33,0.50] at 13 to 14 
years, 0.29 [0.20,0.38] at 
15 to 16 years and 0.37 
[0.21,0.51] between ages 
17 and 28 years 
(AE models, anxiety-
depression subscale) 
0.18 [0.05,0.31]  
(AE model, mean age 31 years, 
range 16-71) [206] 
Association with 
DSM-IV 
diagnoses 
Significant from age 15 
years with MDD and 
alcohol dependence; and 
from age 13 years for 
social anxiety (anxiety-
depression subscale). 
Not evaluated in general 
population 
Price Free Around 2 USD per questionnaire 
[208] 
* Questionnaires in non-English languages available on demand. Please contact Pr. Ian 
Hickie (ian.hickie@sydney.edu.au)  
 
There are several limitations to the SPHERE-21 that are worth mentioning – it has 
only been tested in an Australian-based population sample of young people, and previously 
on clinical participants [50, 103-105, 152, 153]. Thus, more testing and DIF investigation is 
required on older participants, patients with specific pathologies or different cultures and 
ethnic groups. Use of the SPHERE-21 in other English-speaking countries may require 
some items to be reworded. For example, for item 2, the word “cranky”, not frequently used 
in the United States, could be replaced by “easily irritated”. The scalability of the BDI across 
countries and languages led to its world-wide popularity [204], though only recently was IRT 
used [209-213], and little has been done to assess cross-cultural comparability of the BDI 
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scale [204] (e.g. DIF by culture or ethnicity). In addition, unlike the BDI [204], correlations 
between the SPHERE-21 scores with other measures of anxiety, depression or fatigue 
remains to be investigated. The only published research showed a positive correlation (and 
significant genetic relationship) of the anxiety-depression sum scores with neuroticism [51]. 
SPHERE-34 was also shown to have some value in screening for psychiatric morbidity 
[153]. Finally, the SPHERE-21 lacks positive item results in a skewed distribution, but this 
limitation also applies to the BDI [204]. A simple way to improve the score distribution may 
be to separate options “never” and “sometimes” during SPHERE-21 questionnaire 
collection, as it may provide more information about individuals with low anxiety-depression 
and fatigue. 
Conclusions 
Here, we examined the use of the SPHERE-34 for assessment of anxiety, depression 
and fatigue in a large Australian-based population sample of young people. Using an NIRT 
analysis we showed that the questionnaire could be reduced to 21 items (SPHERE-21), 
providing a measure of anxiety-depression (14 items) and chronic fatigue (10 items). We 
showed that these two subscales of the SPHERE-21 measured valid and comparable 
constructs across sexes and age groups (from age 9 to 28 years), and that both showed 
moderate reliability, high internal consistency and good item scalability. We also showed 
that the SPHERE-21 subscales were moderately heritable and genetically correlated across 
adolescence, correlation that was not due to the items common to both subscales. In 
addition, we showed that anxiety-depression and chronic fatigue were, from an early age 
(13 or 15 years) significantly associated with a later risk of MDD, social anxiety and alcohol 
dependence. This further validates the SPHERE-21 by demonstrating its predictive ability in 
the general population and its relevance to measure anxiety-depression and chronic fatigue 
across adolescence and into adulthood. Finally, in a post-hoc evaluation, we suggest that 
the psychometric properties of the SPHERE-21 are at least equivalent to those of the Beck 
Depression Inventory, in an Australian-based population sample of young people. 
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 Abstract 
The diathesis-stress theory for depression states that the effects of stress on the 
depression risk are dependent on the diathesis or vulnerability, implying multiplicative 
interactive effects on the liability scale. We used polygenic risk scores for major depressive 
disorder calculated from the results of the most recent analysis from the Psychiatric 
Genomics Consortium as a direct measure of the vulnerability for depression in a sample of 
5,221 individuals from 3,083 families. In the same we also had measures of stressful life 
events and social support and a depression symptom score, as well as DSM-IV MDD 
diagnoses for most individuals.  In order to estimate the variance in depression explained 
by the genetic vulnerability, the stressors and their interactions, we fitted linear mixed 
models controlling for relatedness for the whole sample as well as stratified by sex. We show 
a significant interaction of the polygenic risk scores with personal life events (0.12% of 
variance explained, p-value=0.0076) contributing positively to the risk of depression. 
Additionally, our results suggest possible differences in the aetiology of depression between 
women and men. In conclusion, our findings point to an extra risk for individuals with 
combined vulnerability and high number of reported personal life events beyond what would 
be expected from the additive contributions of these factors to the liability for depression, 
supporting the multiplicative diathesis-stress model for this disease. 
 
Introduction 
A popular explanation for the aetiology of depression is the diathesis-stress model 
[214-219]. Initially developed to explain the origins of schizophrenia in the 1960s [218, 219] 
and adapted for the study of depression in the 1980s [214-217], this model states that stress 
may activate a diathesis or vulnerability, transforming the potential of predisposition into the 
actuality of psychopathology [57]. The model proposes that there is a synergism between 
the diathesis and stress that yields an effect beyond their combined separate effects into 
depressive symptomatology and thus, the effects of stress on the depression risk are 
dependent on the diathesis. Implicit in this theory is that there will be not only additive but 
multiplicative interactive effects on the liability scale [57].  
Over fifty years ago David Rosenthal [219] described the diathesis-stress theories as 
“the ones in which genuine meaning attaches to the commonly repeated statement that 
heredity and environment interact”. However, he criticised the vague formulations for the 
predispositions and stressors that these theories propose. This criticism has been 
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highlighted by others like Monroe [57], who call for more research and more precise 
measures on the “conceptual essence” of the diathesis-stress premise, i.e. “the nature of 
the interaction between elements in the etiologic process over time”. The diathesis-stress 
theory and research have been criticised for being “unproductive, either theoretically or 
empirically” [220].  
The genetically driven sensitivity to environments proposed by the diathesis-stress 
model can be operationalised as a gene by environment interaction (GXE). GXE studies 
have commonly focused on single loci in candidate genes, such as the length polymorphism 
(5HTTLPR) in the serotonin transporter gene (SLC6A4), with mostly inconsistent or negative 
results [221-225]. This approach has limitations related to poor quality genotyping, 
inconsistent types of interactions, inconsistent grouping of genotypes, selective presentation 
of results, interactions arising from the scale of measurement, and publication bias [221]. 
Moreover, MDD is a polygenic trait, arising from the effect of multiple risk variants, each with 
small effect sizes [14, 226]. Therefore, MDD is influenced by many genetic variants of small 
effect, and it is more likely that affected individuals carry a polygenic burden of risk alleles 
rather than any single genotype of large effect. However, the progress from a candidate 
gene to an hypothesis-free genome-wide approach is hampered by the need for extremely 
large samples due to expected small effect sizes as well as necessarily imperfect 
assessment of environmental stressors across large cohorts [227, 228]. 
Polygenic risk scores (PRS) provide a novel opportunity to test the diathesis-stress 
model, since PRS can be conceptualised as an indicator of the diathesis and will likely prove 
a much stronger instrument than any single risk gene. PRS estimation uses Genome-Wide 
Association Study (GWAS) results to predict the genetic risk of each individual in an 
independent genotyped sample; PRS are estimated as the sum of risk alleles weighted by 
their respective independently estimated effect sizes [229].  
The first ones to use PRS for MDD to test for GXE interaction in MDD were Peyrot et 
al. [228]. Using a sample of 1,645 participants with a DSM-IV diagnosis for MDD and 340 
screened controls from the Netherlands Study of Depression and Anxiety, they showed 
increased effects of PRS on MDD in the presence of childhood trauma, with evidence for 
interaction. Musliner et al [230] studied the association between PRS-MDD, Stressful Life 
Events (SLEs) and depressive symptoms in a sample of 8,761 participants from the Health 
and Retirement Study in the United States. SLEs were operationalised as a dichotomous 
variable indicating whether participants had experienced at least one stressful event in the 
previous two years. Depressive symptoms were measured using an 8-item Center for 
Epidemiological Studies Depression subscale and operationalised as both a dichotomous 
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and a continuous variable. They found that both SLEs and PRS were significantly and 
independently associated with depressive symptoms, but found no evidence that SLEs 
moderated the association between PRS-MDD and depressive symptoms. Instead, their 
results were compatible with an additive model. Most recently, Mullins et al. [231] examined 
the idea using 1,605 cases with recurrent MDD and 1 064 controls all with SLE data, and a 
subset of 240 cases and 272 controls with childhood trauma data from in the RADIANT UK 
study. Both PRS and SLEs were significant predictors of case/control status but no 
interactions were found between PRS for MDD and SLEs, in agreement with previous 
findings by Musliner et al. [230]. Significant interactions were found between PRS and 
childhood trauma but, contrary to Peyrot et al. [228], there was an inverse association with 
depression status. In summary, these studies do not present consistent results. Studies to 
date have used the first wave of GWAS data (MDD1) from the Psychiatric Genomics 
Consortium (PGC) MDD working group (PGC-MDD), based on 9,240 cases and 9,519 
controls [14], and so are likely underpowered. 
We report here a direct test of the diathesis-stress model for depression using PRS 
for MDD and measures of Stressful Life Events (SLEs) and Social Support (SS; lack of SS 
being considered a stressor); we predict diathesis using an updated version of PGC-MDD 
GWAS results (N total=159,601, after excluding QIMR data). Given the higher lifetime risk 
of MDD in women [232], we also tested the hypothesis in sexes separately. 
 
Materials and Methods 
Phenotypic data 
Phenotypic data were collected as part of a general Health and Lifestyle 
questionnaire (HLQ) mailed to adult twins enrolled in the Australian Twin Registry between 
1988 and 1992 [36-38]. It included self-report questions about depression, recent personal 
or network stressful life events (PSLE, NSLE) and SS. The content and details of data 
collection have been previously described [36-38]. Data used in this analysis were collected 
in 3 waves. The first wave ran between 1988 and 1992 (N=5,843) and targeted adult twins 
(mean age 41.2, SD=12.8, range 24-86, 61.0% females) [36]. The second wave (N=3,646, 
collected between 1990 and 1992) focused on younger twins (mean age 23.2, SD=2.2, 
range 16-31, 65.6% females) and the questionnaire was slightly adapted to cover some of 
the more common issues of that age group [36, 37].  Finally, the last wave (N=236) targeted 
twin pairs whose information was partially missing from the original 1980 survey, using the 
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same questionnaire (collection between 1990-1992, mean age 42.0, SD=9.9, range 27-73, 
58.5% females).   
Depression scores were calculated by combining the 7 depression items from the 
Delusions-Symptoms-States Inventory (DSSI) [233, 234] with 5 depression items from the 
Symptom CheckList (SCL-90) [235]. The factor structure of the scale has been reported 
previously in the younger dataset [37] and the score has been used in several publications 
[36, 37, 39, 221, 236].  
The HLQ also assessed Personal Stressful Life Events (PSLE) and Network Stressful 
Life Events (NSLE), adapted from the List of Threatening Experiences [112]. For PSLE, 
participants were asked to report adverse events (divorce, marital separation, broken 
engagement or steady relationship, separation from other loved one or close friend, serious 
illness or injury, serious accident, burgled or robbed, laid off or sacked from job, other serious 
difficulties at work, major financial problems, legal troubles or involvement with police, living 
in unpleasant surroundings) that happened in the last 12 months. In addition, they were 
asked if they had had serious problems getting along with their close network (spouse, 
someone living with you e.g. child/elderly parent, other family member, co-twin, a close 
friend, neighbour or workmate) in the past 12 months. These 19 yes/no items were summed 
to calculate the PSLE score.  
NSLE was calculated from 21 yes/no questions, in which the participants could report 
death, injury or crisis that their close network (spouse, child, mother/father, co-twin, other 
brother/sister, other relative, someone else close to them) experienced in the last 12 months.  
Perceived Social Support (PSS) was measured using the Kessler Perceived Social 
Support (KPSS) Measure [237]. Several publications from our group have made use of 
these data [36, 221, 236, 238-240].  
We used Item Response Theory [52, 241], which weights the item responses by their 
difficulty and discrimination, to calculate individuals’ scores of depression, PSLE, NSLE and 
SS. First, we performed an exploratory non-parametric IRT analysis the KernSmoothIRT 
package in R [56]. It allows estimation of the probability of endorsing each option of each 
item as a function of the latent underlying trait (known as Item Response Step Functions: 
IRSF), without any constraint on the shape of the fitted curve [52]. We used it to confirm the 
monotonicity of IRSF necessary to ensure the property of stochastic ordering on the sum 
score [168]. It further allows choosing the most appropriate parametric IRT models based 
on the shapes of the non-parametric IRSF. 
IRSF plotted in Supplementary Document 26 show, for all scales and items, monotonic 
IRSF in the normal range of the latent trait continuum (-2 2). Small breaches of monotonicity 
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were observed for extreme values of the latent trait and can be attributed to small numbers 
of participants that lead to unstable non-parametric kernel estimation (as indicated by 
widening 95% CIs). Consequently, we estimated the IRT scores using a 2-parameter logistic 
model in WinBUGS v. 1.4.3 [242] that constrains all left asymptotes to be 0 and all right 
asymptotes to be 1. In such a model, the IRSF only differ in term of difficulty and 
discrimination [176, 241]. Such IRT scores are maximum likelihood estimates of the latent 
trait and carry the same information as a sum score while presenting more normal 
distributions, thus reducing the influence of extreme values in later analyses.  
Missingness in the depression items was limited to less than 2% of the respondents 
and most of the missing answers (88 or 60%) were found in the item “recently, I have lost 
interest in sex or have found not found sex pleasurable”. The 1.6% of the respondents who 
omitted this item tended to be females (p-value=4.2e-04), 4 months older on average (p-
value=9.7e-06), and with a slightly higher DSSI score (+0.1 pts, p-value=3.6e-05). 
Missingness not at random (i.e. potentially dependent on depression level) implies that 
excluding participants may create a sampling bias. Thus, we chose to impute the missing 
observations using WinBUGS (described in [240, 243]) using age, sex and the depression 
items as predictors. Overall, due the low missingness rate imputation should have little 
influence on the results. 
Lifetime DSM-IV depression diagnoses were obtained in most of the cohort in two 
telephone interview follow-up studies using the clinical Semi-Structured Assessment for the 
Genetics of Alcoholism (SSAGA [244, 245] in 1992-1993 and 1996-2000 (see Supplementary 
Document 27 for a summary of the phenotypic data collection). Details of data collection are 
described elsewhere [39-43]. The depression score significantly predicted lifetime DSM-IV 
MDD status assessed 4 to 7 years later [40, 41] (OR=1.96, 95%CI 1.85-2.08, p-value=3.0e-
108, N=8 607), which translates to a 6.1 fold increased odds of MDD between participants 
in the top and bottom deciles of depression IRT scores (Figure 14a), so demonstrating the 
utility of the score. For our analysis we used the continuous IRT score rather than the binary 
diagnosis as continuous models provide greater statistical power than logistic regressions 
(>99.9% vs. 88.0%, N= 5 221, O.R.= 1.1, beta = 0.095, with α= 0.05, proportion of cases 
and SD of outcome and predictor measured in our sample) and is available for larger sample 
size (5 179 vs. 5 221 with IRT score). 
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Polygenic Risk Scores calculation 
DNA collected from blood was genotyped using commercial arrays (Illumina 317K, 
370K, 610K, ‘1st generation’, or Core Exome plus Omni-family, ‘2nd generation’ [246-248].) 
and imputed from a common SNP set to the 1000 Genomes (Phase 3 Release 5) reference 
panel [97-99], a strategy that allows genotype data from different arrays to be combined. 
Observed genotypes were cleaned (by batch) for call rate (≥95%); MAF (>=1%); Hardy-
Weinberg equilibrium (p≥10-3; PLINK1. 9 [249]), GenCall score (≥0.15 per genotype; mean 
≥0.7) and standard Illumina filters, before integrating batches and re-running the quality 
control and Mendelian checks. We imputed the genotype data via the University of Michigan 
Imputation Server [250] or in-house (chr. X only) using the 1000 genomes Phase 3 Release 
5 ‘mixed population’ reference panel) [97-99], with phasing by SHAPEIT [251, 252] followed 
by imputation using minimac3 [253]. ‘1st generation’ and ‘2nd generation’ were imputed 
separately due to poor overlap between observed markers. Imputation was based on 277 
690 (‘1st generation’) and 240 297 (‘2nd generation’) observed markers; and the two 
combined after imputation to maximise sample size. This resulted in 9 411 304 SNPs 
available for analysis, after QC. 
PRS [58, 59] were calculated from the imputed genotype dosages, using GWAS 
summary statistics from the most recent PGC-MDD release [July 9th 2016], with the 
exclusion of the contribution of QIMR, for a final sample of 49,524 cases and 110,074 
controls (see Supplementary Document 28 for cohort contributions). For comparison, we also 
calculated the PRS using the first wave GWAS summary statistics published by the PGC-
MDD [14]. From our data, we excluded SNPs with low imputation quality (r2<0.6) and MAF 
below 1%. We selected the most significant independent SNPs using PLINK1.9 [249] in 
order to correct for signal inflation due to Linkage Disequilibrium (LD) (criteria LD r2<0.1 
within windows of 10MBp). We calculated 8 different PRS using different p-value 
thresholding of the GWAS summary statistics (see Supplementary Document 29 for number 
of SNPs included in each threshold). Histograms of PRS for MDD (1000G imputation, 
GWAS results from July 2016), together with the histograms of the IRT scores for 
depression, PSLE, NSLE and SS scores are reported in Supplementary Document 30. 
Our final sample comprised 5,221 individuals (from 3,083 twin families) of European 
ancestry with available phenotypic and genetic data (mean age at questionnaire 35.7, 
SD=12.2, range 17-85, 65.6% females). Covariates (age, age2, sex, age*sex and age2*sex 
interactions, and the first four genetic principal components) were regressed from the PRS 
and the stress scores before inclusion in the models to guard against confounding influences 
on the PRS-stress interactions [254].  
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Statistical Analysis 
In order to estimate the variance explained by the PRS, the stressors and their 
interactions in the depression score, we then fitted linear mixed models that controlled for 
relatedness for the whole sample as well as stratified by sex). The parameters of the model 
were estimated using GCTA 1.26.0 (student test to test the significance of the fixed effects) 
that accounts for twin relatedness using a Genetic Relatedness Matrix (GRM). The linear 
model used is as follows: 
Depression = intercept + b*Covariates + c*PRS_z + d*PSLE_z + e*NSLE_z + f*SS_z 
+ g*PRS_z*PSLE_z + h*PRS_z*NSLE_z + i*PRS_z*SS_z + j*G 
With b,c,d,e,f,g,h,i the vectors of fixed effects 
Covariates used in this analyses were age, sex, age2, sex*age, sex*age2, GWAS 
array, wave, and first 4 genetic principal components. Note that sex and its interaction were 
not included when stratifying the analyses by sex. 
PSLE_z, SS_z, NSLE_z and PRS_z are the residuals of the scores after regressing 
out the covariates listed above 
G is the random effect that models the sample relatedness G~ N(0, GRM), with GRM 
the NxN matrix of relatedness estimated from SNPs 
We used OpenMx [197] to calculate the heritability and correlations (likelihood-ratio 
test, using a kinship matrix to account for familial relatedness) of the depression score and 
the stressors, correcting for age, sex, age2, sex*age, sex*age2, and wave. Following the 
significant genetic correlations estimated from twin models, we investigated how much of 
the variance in stress scores could be accounted for by the MDD-PRS. We controlled for 
age, age2, sex (and their interactions), study, imputation batch and 4 genetic principal 
components. Model parameters were estimated using GCTA 1.26.0 [47] that accounts from 
twin relatedness. 
 
Results and Discussion 
PRS for MDD significantly predicted the depression score (maximum variance 
explained=0.46%. p-value=5.01e-08, Figure 14b, right panel), which represents a substantial 
improvement compared to PRS predictions based on earlier GWAS [14] (Figure 14b, left 
panel, variance explained=0.08%, p=0.018), reflecting the increased sample size of the 
GWAS discovery samples [255, 256]. The main effects of PSLE, NSLE, and lack of SS were 
also significant, explaining respectively 12.9%, 0.3% and 3% of the depression score 
variance (Figure 14c), with effects in the expected directions. Lack of SS predicted more of 
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the depression score in women than it did in men (between sex differences, p-value= 4.7e-
03) but there were no other differences between sexes that reached significance.  
The significance of main effects allowed testing the significance of the interaction 
between each stress type (PSLE, NSLE, lack of SS) and the most predictive PRS (using all 
SNPs: p<1). The interaction with PSLE was significant (0.12% of variance explained, p-
value=0.0076) and contributed positively to the risk of depression, predominantly in women 
(Figure 14d). Overall, the variance explained by PRS main effect plus the interaction was 
comparable in men (0.73%) and women (0.60%). The interaction was not significant in men 
while explaining almost as much variance as the main effect in women. However, there was 
no significant difference when comparing the size of the interaction across sexes (p-
value=0.21).  For completeness, interactions between each stressor and all PRS are also 
reported in Supplementary Document 31. 
Our finding of a significant diathesis-PSLE interaction points to an extra risk for 
individuals with combined vulnerability and high number of reported PSLE beyond what 
would be expected from their additive contributions to liability (Figure 14d, e). In the full 
sample 0.58% of the depression score variance was explained by the PRS and interaction, 
of which ~80% corresponds to the main effects and ~20% to the interaction. As the power 
of the PRS increases with larger GWAS [255], and if these proportions are maintained, the 
interaction explaining about 20% of the heritability would be typical of the size of GXE 
estimates for other traits in other species[257]. We cannot dismiss the possibility of diathetic 
interactions with NSLE or SS, as the power of our study is still limited by the PRS instrument 
[255] and our sample size. This is evidenced by our measure of genetic predisposition still 
only explaining a small fraction of the depression score variance (Figure 14b) and heritability 
(Supplementary Document 33).  
We confirmed using a twin analysis of the dataset (1,110 MZ pairs, 1,032 DZ pairs, 
961 singletons) that our measure of depression and all 3 stress measures are moderately 
heritable (30-40%, p-value<2.1e-25; Supplementary Document 33), as reported previously [7, 
258]. AE models showed the best fit to the data and shared environment could not explain 
the association (p-value<1.7e-03).  We also replicated that self-reported measures of stress 
are genetically correlated with the depression score (Supplementary Document 33) [8, 9].  
PRS for MDD predicted PSLE and SS (p-value<0.001), no significant association was 
observed with NSLE (Supplementary Document 34). This is consistent with heritability and 
genetic correlation results reported from twin models.  
On the scale of measurement for depression that we have used, our results support 
the multiplicative diathesis-stress model for depression proposed in the 1980s. In addition, 
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our results suggest possible differences in the aetiology of depression between women and 
men, which may have implications for the tailoring of treatments. However, we must caution 
that the presence and size of interaction are completely dependent on the scale of 
measurement and more perfectly normal scales for depression and stressors may have 
produced a different result [257, 259]. For example, using a simple sum score for 
depression, with an extreme reverse-J distribution yields an even larger and more significant 
estimate of interaction (0.39% variance explained; p-value=6.8e-07) whereas using logistic 
regression to analyse the binary DSM-IV diagnosis, predicated on an underlying normal 
liability, produces a smaller and only marginally significant estimate (0.06% variance 
explained; p-value=0.059), although this analysis has much lower power than using a 
continuous variable.  
Notwithstanding the above caveat, more work is needed to evaluate different 
mechanisms of interaction, including a bi-causal relationship between PSLE and depression 
or molecular interaction (e.g. through methylation changes). We are aware of potential 
confounds of interaction analyses: in addition to sensitivity of the analyses to the properties 
of the scale [260] and unavoidable departures from normality in the outcome and predictors 
as discussed above (Supplementary Document 30, Supplementary Document 32) problems may 
also arise from the stress and depression measures being self-reported in the same 
questionnaire, and the fact that the stress measures are genetically correlated with the 
outcome variable. Replication of our findings in independent cohorts and improvement of 
PRS via larger GWAS and larger samples with both depression and risk factors evaluated 
will allow us further to refine our understanding of the aetiology of depression.  
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Figure 14: Depression diathesis interaction with personal stressful life event 
(a) Increased odds of DSM IV MDD diagnosis per decile of depression IRT score assessed 4-7 years 
previously. (b) Association between MDD-PRS and depression scores (main effects, one-sided tests, results 
expressed in % of variance explained). Full sample analyses using the two versions of the PRS were run in 
the same target dataset with the exact same covariates. Red bars indicate positive correlation with the 
depression score. PRS were calculated using different p-value thresholds from the GWAS summary statistics. 
The most conservative only includes independent loci with genome wide significant SNPs (P-value<5e-8), 
while the least conservative include the most significant SNP of each haplotype (P-value<1). (c) Association 
between self-reported stress (PSLE, NSLE, lack of SS) and depression IRT score (main effect, one-sided 
tests, results expressed in % of variance explained). Blue bars indicate negative correlations and red bars 
indicate positive correlation with the depression score. Dashed bars indicate sex specific effects. (d) Variance 
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of the depression score explained by the interaction between PRS and PSLE (2-sided tests). Dashed bars 
indicate sex specific effects. We focused on the association with the PRS comprising all haplotypes but the 
other associations are also reported for completeness. Blue bars indicate negative correlations and red bars 
indicate positive correlation with the depression score. (e) Increase in depression score (fitted values, vertical 
axis) as a function of PSLE and MDD-PRS. For example, the effect of the PSLE-diathesis interaction is visible 
when comparing the bottom (minimal PSLE) and top (maximal PSLE) edges of the surface. The difference in 
slopes indicates that PSLE mediates the effect of the genetic predisposition on the depression score. From 
right to left, results for the whole sample, females and males.  
In all analyses, we accounted for familial relatedness using a kinship matrix (a) or a genetic relatedness matrix 
calculated from SNPs (b-d). For (a) we used R package “hglm” [261] to estimate the odds ratios (student test 
to test the significance of the fixed effects). For panels (b-d) the parameters of the model were estimated using 
GCTA 1.26.0 (student test to test the significance of the fixed effects) [47]. All analyses controlled for age, 
age2, sex, age*sex and age2*sex interactions, study, array, and the first four genetic principal components in 
the outcome variable and predictors [254]. 
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Abstract 
Head motion (HM) is a critical confounding factor in functional MRI. Here we 
investigate whether HM during resting state functional MRI (RS-fMRI) is influenced by 
genetic factors in a sample of 462 twins (65% female; 101 MZ (monozygotic) and 130 DZ 
(dizygotic) twin pairs; mean age: 21 (SD=3.16), range 16-29). Heritability estimates for three 
HM components—mean translation (MT), maximum translation (MAXT) and mean rotation 
(MR)—ranged from 37 to 51%. We detected a significant common genetic influence on HM 
variability, with about two-thirds (genetic correlations range 0.76-1.00) of the variance 
shared between MR, MT and MAXT. A composite metric (HM-PC1), which aggregated these 
three, was also moderately heritable (h2=42%). Using a sub-sample (N=35) of the twins we 
confirmed that mean and maximum translational and rotational motions were consistent 
“traits” over repeated scans (r=0.53-0.59); reliability was even higher for the composite 
metric (r=0.66). In addition, phenotypic and cross-trait cross-twin correlations between HM 
and resting state functional connectivities (RS-FCs) with Brodmann areas (BA) 44 and 45, 
in which RS-FCs were found to be moderately heritable (BA44: h==0.23 (sd=0.041), BA45: h==0.26 (sd=0.061)), indicated that HM might not represent a major bias in genetic studies 
using FCs. Even so, the HM effect on FC was not completely eliminated after regression. 
HM may be a valuable endophenotype whose relationship with brain disorders remains to 
be elucidated.  
 
Introduction 
Head motion (HM), defined as small head movements (from µm to a few mm), can 
be detected in every individual, despite the restraint of the head during magnetic resonance 
imaging (MRI). HM is routinely computed and analysed in resting state functional MRI (RS-
fMRI) studies, where it is known to be a confounding factor in the measurement of brain 
connectivity. Participants with excessive HM are often excluded, and spurious sources of 
variance caused by HM are removed using linear regression. However, it has been shown 
that these steps do not remove all the bias introduced by HM in functional connectivity (FC) 
analyses [61-63, 263-267]. For example, in young adults with greater head motion, FC 
measures in long-range networks were reduced and local FC between nearby voxels 
increased. This suggests that HM may weaken the long-range signal and create false 
positive local correlations, at least in those with relatively high HM [61, 62]. Similar results 
have been reported in adolescents using various FC analysis methods (seed based, 
amplitude of low-frequency fluctuation (ALFF & fALFF) or Independent Component 
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Analysis: ICA) [265]. In addition, motion has been associated with long term (up to 10s) 
BOLD signal changes in grey matter, white matter and cerebrospinal fluid, drawing a more 
complex picture of the spurious effect of motion [263]. This translates into RS-FC, with a 
manifest motion bias up to 10s after motion [263], longer than previously reported [264] and 
a lowering of the reliability of the FC estimates [62].  
HM is fairly consistent across RS-fMRI sessions, with reliability estimates in the 
moderate range (rMT=0.66) [61]. This suggests that HM is a trait that is consistent enough to 
study. In addition, an association of HM with age has been reported. HM is higher in younger 
individuals (8-23 years old) [265] and increases with age in older individuals aged 61 years 
and over [268]. Furthermore, males tend to exhibit more head movement than females [61]. 
So far, only a few studies have investigated HM in neurological or psychiatric 
diseases associated with motor control difficulties. Patients recovering from stroke with a 
hemiparesis exhibit greater task-related HM, perhaps because they may need to recruit 
more proximal muscles to respond to a stimulus [268]. In a more general way, task-related 
fMRI is likely to provoke more motion when individuals (both cases and controls) know they 
have made a mistake (“whoops” phenomenon), complicating analyses of error-monitoring 
and related processes [269]. This limitation can be even more important in schizophrenia or 
ADHD, in which impulsiveness on Go-NoGo tasks is increased [270]. In addition, the 
proportion of ADHD and autism subjects excluded because of excessive (gross) head 
movements is significantly higher than for controls [269, 271-273]. In schizophrenia, head 
rotation in particular appears to be significantly higher among patients than healthy controls 
[274]. 
Here we investigated the “trait” aspect of HM during RS-fMRI, by analysing a sample 
of 462 healthy adolescent and young adult twins (mean age: 21 years). In the twin design, 
we included both monozygotic (MZ) and dizygotic (DZ) twins. This enables the familial 
similarities in a trait to be decomposed into genetic (heritability) and environmental sources 
[44, 46]. We estimated the heritability of three translational and rotational HM measures [61]. 
Phenotypic correlations between HM parameters were decomposed into common (shared) 
and specific (non-shared) sources of genetic and environmental variance. In a post-hoc 
analysis we then examined how strongly genetic influences on HM affect FC, by focusing 
on the language production networks, organised around Broca’s area [275], which 
comprises Brodmann areas (BA) 44 and 45. These resting state (RS) networks have been 
characterised previously using seed-based approach [276, 277] and parallel ICA [278].  In 
addition, we examined the reliability of the HM measures in a sub-sample of the twins who 
were scanned twice. 
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Materials and methods 
Participants 
Data were collected as part of the Queensland Twin Imaging Study (QTIMS), which 
has acquired MRI scans on more than a thousand individuals, including twins and their non-
twin siblings [102]. For the present study, we included all twin pairs aged between 16 and 
30 (years) for which RS-fMRI scans were available. We excluded individuals (n=30) with 
very large overall HM (i.e., maximal rigid body parameter [279] greater than 3mm or 2 
degrees, the centre of rotation being the centre of the FOV) prior to any analyses. This 
censoring was performed on absolute motion (measured from a volume of reference) as 
available in Statistical Parametric Mapping SPM8 [280]1. In Chapter 5, we used a more 
accurate and restricted definition of gross motion, leading to fewer exclusions. Our final 
sample comprised 101 (73 female and 28 male) monozygotic (MZ) and 130 (49 female, 26 
male and 55 opposite-sex) dizygotic (DZ) twin pairs (65% females, mean age = 21, 
SD=3.16, range 16-29). Sixteen percent of the twins were aged 16 (38 pairs, 15 MZ, 23 DZ). 
In addition, a sub-sample (35 twin individuals (7 MZ and 3 DZ pairs) and 15 siblings; mean 
age=22.5, SD=2.5, 58% females) of the participants were scanned twice for RS-fMRI in 
order to assess the reliability of the measurements. The median interval between the two 
scans was ~3months (median=96 days, range 35-203). 
Zygosity was established objectively by typing nine independent microsatellite 
polymorphisms (PIC>0.7) in the ProfilerPlus™ set using standard methods, and was later 
confirmed for >80% of the sample genotyped on the 610K Illumina SNP chip [281]. 
Participants were screened (by self-report) for significant medical, psychiatric or neurological 
conditions, including head injuries, a current or past diagnosis of substance abuse, and for 
current use of medication that was likely to affect cognition. Written informed consent was 
obtained from all participants. The study was approved by the ethics review boards of the 
Queensland Institute of Medical Research, the University of Queensland, and Uniting Health 
Care, Wesley Hospital, Brisbane. Participants received an honorarium, in appreciation of 
their time. 
                                                
 
1 Using absolute (versus frame to frame) rigid body parameters for “gross motion’ exclusion is not the most 
pertinent approach in fMRI as this may lead to more individuals being excluded and does not guarantee that the motion 
occurring during a repetition time is smaller to the voxel size. In our case, using frame to frame parameters, we would 
have excluded only 9 individuals, and these were all excluded using absolute motion parameters. We therefore believe 
that our use of absolute motion should have a limited impact on the results and the statistical power. 
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Image collection 
The images were acquired on a 4 Tesla Bruker Medspec whole-body scanner in 
Brisbane, Australia. RS-fMRI was performed with a repetition time TR=2100 ms, echo time 
TE=30 ms, flip angle=90°, field of view FOV=230 mm, and total acquisition length of 5 min:19 
s. Thirty-six 3 mm-thick transverse slices, with 0.6 mm gap, were acquired per volume, 
yielding a voxel size of 3.6x3.6x3.0 mm. In total, 150 volumes were collected, with the first 
5 volumes discarded from the analysis to allow time for steady state to occur.  During the 
scan participants were asked to close their eyes, empty their minds, and to try not to fall 
asleep. Participants who reported having fallen asleep were excluded, to ensure a 
consistent experimental procedure. The RS scan was part of a larger protocol lasting 
approximately 60 minutes, including a 3D T1-weighted scan to which the functional scans 
were coregistered. Structural scans were acquired with TR=1500 ms, TE=3.35 ms, TI=700 
ms, flip angle=8°, 256 or 240 (coronal or sagittal) slices, FOV=240 mm, 256 × 256 × 256 (or 
256 × 256 × 240) matrix, slice thickness=0.9 mm and voxel size 0.9 mm3. 
Head motion measurement 
Six head motion parameters were obtained from rigid body transformation [279] of 
fMRI volumes with Statistical Parametric Mapping SPM8 [280]. Three translation (sagittal or 
left-right, coronal or front-back, and axial or up-down directions) and three rotation 
parameters (pitch, roll and yaw) were extracted by comparing each of the remaining 145 
volumes of the time series to the first. For each participant, 4 aggregated measures of the 
HM time series were then computed, adapted from the description by [61]: mean 
translational head motion (MT), maximum translational motion (MAXT), number of 
movements greater than 0.1mm (NUMO) and mean rotation (MR).  
We calculated the motion from frame to frame (i.e. relative transformation 
parameters), and not the absolute parameters that measure the displacement from a 
reference frame. This approach accounts for most of the movement that is responsible for 
the bias in RS-FC. While absolute motion parameters that capture the position of the head 
are responsible for shifts in the intensity of the BOLD signal, these have little effect on RS-
FC (Power et al., 2014). Calculating the motion metrics from the differenced time series of 
rigid body parameters also has the added advantage of stabilising the mean and variance 
over time (1st order integration often results in enhancing processes stationarity). MT and 
MAXT were calculated for each participant using the following formulas: 
MT = 1N xC − xCEF = + yC − yCEF = + zC − zCEF =JCKF  
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 MAXT = maxC( xC − xCEF = + yC − yCEF = + zC − zCEF =)		MR	was	defined	similarly	with	∆θ	, ∆φ	and	∆ϕ the differenced rotation angles (∆θC = 	θC −	θCEF) and N=144 the number of frames. 
 
MR = 1N 	 cosEF cos ∆θC cos ∆φC + 	cos ∆θC cos ∆ϕC + cos ∆ϕC cos ∆φC + sin ∆θC sin ∆φC sin ∆ϕC − 12JCKF  
 
 Variables were log-transformed to ensure normality of the distribution. In the 
following MR, MT, MAXT and NUMO refer to the log-transformed variables, if not stated 
otherwise. NUMO did not reach normality but was strongly correlated with MT (r=0.92) and 
therefore was not analysed further. Out of the 462 individuals, five observations (1 for MT, 
4 for MAXT) were classified as outliers (>3 SD from the mean) and Winsorised (by imputing 
their values to ±3SD). None of the outliers were from the same participant or the same twin 
pair. Using the same criterion, we checked the data for twin-pair outliers by considering the 
mean value of the pair. We identified 2 outlying twin pairs, one for MT and one for MAXT. 
For MT, the pair of DZ opposite sex twins, aged 20 years, additionally showed high rotational 
movements (top 10% of the distribution). For MAXT, the outlying MZ female pair, aged 16 
years, had normal MT and MR (just above average). In addition, both of these twin pairs 
were identified as outliers in their zygosity group. Thus, for these pairs, MT and MAXT 
respectively were set to missing, due to their possible strong impact on variance and mean 
estimation. 
Using a principal component analysis (PCA) we then showed the first principal 
component (PC) of the PCA (HM-PC1) represented a “size effect”, keeping most of the 
information carried by MR, MT and MAXT, and defined a composite metric of motion 
(accounting for both rotational and translational motion). The second PC (HM-PC2) 
differentiated rotation from translation, where individuals exhibited asymmetric motion 
(rotation without translation and conversely) with the third PC capturing the residual variance 
and extreme motion (MAXT vs MR and MT). 
Several composite HM metrics have been proposed to summarise the information 
from the rigid body parameters [61-63, 282]. A recent comparison [62] showed very good 
performance of Jenkinson et al. ‘s composite metric against Yan et al’s metric of reference. 
Mathematically, the 2 approaches are very similar: they consist of averaging, over all the 
voxels of the brain, the displacement occurring between two frames. Their only difference is 
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that Yan et al. average the displacement of each voxel while Jenkinson et al. assume that 
the brain is a sphere of radius 80mm. Thus, the very strong agreement between metrics [62] 
suggests that the simplification of the brain into a sphere or radius 80mm is valid, at least 
for young adults. Here, we use a sample very close in age to Yan et al. (2013), and can 
therefore reasonably assume the equivalence of the Yan et al. and Jenkinson et al. metrics. 
We chose to use the Jenkinson et al. metric, which is the faster of the two to compute, as 
the motion measurement of reference, to expand on prior work that compared the metrics 
[62]. We showed that the Power et al. metric (aka. FD: “framewise displacement”), HM-PC1 
as well as MT were highly correlated with the metric of reference (rPearson >0.90, τKendall>0.80) 
and that all metrics showed similar reliability and heritability. We suggest that residual 
differences between MT, HM-PC1, Power et al. and Jenkinson et al. arise from the weight 
given to rotation over translation, since all the metrics are built upon equivalent norms (2-
norm (Euclidian) for Jenkinson et al., Yan et al., MT, MR and HM-PC1; 1-norm (“taxicab”) 
for Power et al. metric). As previously found, we also show that there is poor agreement 
between Yan et al.’s metric and their definition of mean translation, and we attribute this to 
their choice of parameterisation (Inline Supplementary Table 1). Thus, using the Jenkinson 
et al. metric as a reference, we found only very small differences in the correlations between 
metrics. We attribute this to the different weight given to rotation over translation, which 
depends on the brain radius for Power et al. and on the PCA decomposition for HM-PC1. 
Ultimately, and despite these small differences, we show very similar estimates, reliability 
and heritability for the metrics (Inline Supplementary Table 1).  Further, even if validity and 
comparability still remain to be assessed in adolescents and younger children, the 
robustness shown here for young adults suggests that all composite metrics (and MT) might 
also be a good proxy for HM in younger subjects. (Detailed results are presented in 
Supplementary Document 35 and Supplementary Document 36). 
 
Resting-state functional image processing 
Resting state fMRI images were processed using the DPARSF-A [283] toolbox for 
SPM8 [284]. The first 5 images were removed and slice-timing correction was applied. 
Functional volumes were realigned and coregistered with the structural scans using 
DARTEL [285]. Then, using General Linear Model (GLM), we regressed out sources of 
physiological (white matter, cerebrospinal fluid) and non-physiological noise (trend, HM rigid 
body parameters, global mean signal) from the BOLD signal and band pass filtered ([0.01-
0.08Hz]) after linear regression [286].  
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Functional connectivity maps were computed in a seed-based analysis using BA44 and 
BA45, as the seed regions. The seeds were defined using cytoarchitectonic maximum 
probability maps (MPMs) as masks (from SPM8’s Anatomy toolbox [287]) merged with the 
grey matter mask created from structural scans (inclusive masking). The average time 
course in each seed region was calculated and the correlations were estimated with all the 
voxels of the brain (r-map). Fisher’s z transformation (z = arctanh(r)) was applied to the 
correlation map to centre and normalise the distribution (z-map). 
We performed a one-sample t-test voxel-wise among the participants’ z-maps to 
discard the voxels showing non-significant z-correlations, correcting for multiple testing 
using a topological estimate of the Family Wise Error (FWE) rate: the Euler characteristic 
[288], which takes into account the volume tested and the smoothness (i.e., local correlation) 
of the image [289]. Outlier detection and deletion was performed voxel-wise. For each 
observation a chi-squared test (chi-squared distance, 1 degree of freedom) was performed 
with a risk alpha set at 0.001 and outlier values set to missing. 
We further masked the FC results according to their reliability using the sub-sample 
of participants scanned twice, adopting an Intra-Class Correlation (ICC), threshold of >0.4, 
with random effect on subjects. Analyses were performed using the R package “irr” [187]. 
This step aimed to limit the number of false positive in our analysis by ensuring that the 
observed FC was corresponding to a robust co-activation with the seed. In doing so, we 
assume that RS-FC must be fairly consistent across a short period of time (3 months in 
median between test and retest MRI), even in presence of brain plasticity or brain 
maturation. This strong assumption may partially explain why the overall reliability of the RS-
FC was never strong (<0.8 across the brain) and why it can be justified to set a “low” 
reliability threshold (ICC>0.4 is, at best, described as “fairly reliable” in the literature). It is 
true that this approach may exclude from the analysis the regions of BA44 and BA45’s 
networks that evolve the most (or the faster) with age, but we think it is a fair price to pay 
considering the gain in power that the pruning of voxels represents.  
For BA45, 31,671 voxels (67% of the 47,279 grey matter voxels) showed a significant 
correlation with the seed, 2,902 of which reliably (ICC>0.4) defined BA45’s network. The 10 
largest clusters (size greater than 50 voxels) comprised 64% of BA45’s reliable network 
(1,855 voxels out of 2,902) and allowed a good description of the network.  From these 10 
clusters we identified 8 brain regions using SMP8’s Anatomy toolbox [290]: Inferior Frontal 
cortex (IFC; BA44, BA45 and pars Orbitalis), Middle Frontal cortex (MFC), Supplementary 
Motor Areas (SMA; BA6); Inferior Parietal (IPC: PGa, PF, PFm, hIP1-3), Superior Parietal 
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(SPC: BA7a, BA7pc), Inferior Temporal (ITC) and Middle Temporal cortex (MTC); 
Occipital/Visual cortex (OC; BA17, 18, hOC5).  
For BA44, 32,775 voxels passed the significance threshold, of which only 4,422 
reliably defined BA44’s network. Again, the 10 largest clusters (size>50) comprised most 
(73%) of the network that covered 9 brain regions: Inferior Frontal cortex (IFC; BA44, BA45 
and right pars Orbitalis), Middle Frontal cortex (MFC), Supplementary Motor Area (SMA; 
BA6); Inferior Parietal (IPC: PGa, PF, PFm,PFcm, PFt), Superior Parietal (SPC: BA7M, 5M, 
5Ci, 5L); Inferior Temporal (ITC) and Middle Temporal cortex (MTC); Occipital/Visual cortex 
(OC; BA17, 18, hOC5) and Cerebellum (Lobule VIIa, crus 1-2). 
Similar areas were activated in the left and right hemispheres, except for the 
Cerebellum Lobule where only the right side of the cerebellum was correlated with BA44. 
However, the extent of the activation was greater in the left hemisphere. Furthermore, all 
the clusters, except for the occipital cortex and superior parietal areas, were positively 
correlated with the seeds. 
These findings replicate those of resting-state FC studies on Broca’s language area, 
with similar positive correlation of Broca’s area with the IFC (pars opercularis, triangularis 
and orbitalis) [276-278], the MFC [276, 278], the SMA (pre-SMA and BA6 [277]); the IPC 
(supramarginal and angular gyrus) [276-278], the ITC [276, 278] and the MTC [277]. 
Significant FC between Broca’s area and the cerebellum (crus) has been reported [276], 
however the authors used a 3.4cm3seed centred in BA45 while we only observed an 
association with BA44. We did not replicate findings of positive association with the superior 
frontal cortex (medial frontal gyrus with BA8, 9, 32 [277], BA8 [276]). Kelly et al. reported 
positive correlation with the caudal part of the superior temporal gyrus and sulcus while 
Tomasi and Volkow reported non-significant correlation, coherent with our observations. 
Anti-correlations replicated previous results showing anti-activation in the SPC (BA7 [278], 
BA7 and BA5 [276]) and with the OC [276]. 
Genetic analyses of head motion 
Saturated models were fitted to compare HM means, variances and covariances for 
the five zygosity groups (MZ males, MZ females, DZ males, DZ females and DZ opposite-
sex), with age, age2 and sex included as covariates. Model fit was assessed based on the 
difference in the -2 log likelihood between the full model (ACE or ADE) and any nested 
model (AE, CE or DE and E), which follows a chi-squared distribution under the null 
hypothesis (of no difference of fit). At the univariate level, using two zygosity groups (i.e., 
MZ and DZ, after ensuring the homogeneity of each of these groups in the saturated model), 
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we decomposed the variance of each of the HM measures (MR, MT, MAXT and HM-PC1) 
into additive genetic (A), common environmental (C), and unique environmental (E) sources 
of variance. We also estimated a dominant genetic (D) effect (instead of the shared 
environment) when the MZ and DZ correlation indicated a possible non-additive effect 
(rDZ<0.5×rMZ). The dominant effect models the alleles’ interaction at one locus (dominance) 
or at different loci (epistasis). 
We then examined the covariation among MT, MAXT, and MR using a Cholesky 
decomposition followed by independent and common pathway modelling [44, 46]. Cholesky 
decomposition is the standard general approach to decompose variance into genetic and 
environmental sources, so we used this model to test the significance of shared A and C 
influences and to estimate the genetic correlations. In our Cholesky decomposition, the three 
dimensional genetic and environmental variance/covariance matrices are decomposed into 
the product of a lower triangular matrix and its transpose. This decomposition involves a first 
factor that influences all variables, a second factor (independent of the first) that influences 
the second and third variables, and a third factor (independent of the two first) that influences 
only the third variable.  
Common and Independent pathway models represent a different approach from the 
Cholesky decomposition in that they distinguish, for each variable, the shared sources of 
variance from the specific. However, the Independent pathway model contains the same 
number of parameters than the Cholesky and is equivalent in term of fit. The common 
pathway model is different from the Independent pathway model, in that the co-variation 
between the HM measures is determined by a latent variable: a global HM factor. This latent 
HM factor has genetic and environmental sources of variance, which account for a 
proportion of the MR, MT and MAXT variance [291]. The Bayesian Information Criterion 
(BIC) was used to compare model fit between these two models, taking into account the 
number of parameters to estimate2. All genetic modelling was performed in OpenMx [197] 
using a full information maximum likelihood (FIML) estimator, under the R 3.1.0 distribution 
[292]. 
Reliability of the four HM metrics was assessed using the ICC, which corresponds to 
a mixed effect model (random effect of subjects, fixed effect of experiment). Since ICC 
coefficients are highly sensitive to outliers, extreme values in the series were identified, 
based on visually inspecting the test-retest scatter plots. All the identified outliers were 
                                                
 
2 The BIC often leads to select more parsimonious models (than the AIC) as it penalises more heavily the model 
complexity (number of parameters).  
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excluded from the reliability analysis if their value was greater than ±3SD from the mean. 
Two unrelated individuals were excluded for MR and HM-PC1, none for MT and MAXT.  
 
Genetic multivariate modelling of head motion and heritable functional 
connectivity 
Using FC measures extracted from the same dataset as HM we ran a voxel-wise 
heritability analysis in OpenMx [197], fitting univariate ACE models with HM, age and sex 
as covariates, for each voxel of BA45 and BA44’s networks.  
Homogeneity of sampling across groups (female-male, MZ-DZ), covariate effects and 
significance of the heritability estimates were tested voxel-wise (likelihood ratio test) and 
corrected for multiple testing, controlling the FWER. We used the Monte-Carlo simulation 
protocol of 3DClustSim (AFNI) [293], to estimate the volume threshold such that the chance 
of larger clusters of contiguously significant voxels (individual level α=5%; i.e., “discovery 
clusters”) occurring at random is smaller than 5%. The FWHM, as an estimate of spatial 
correlation, was calculated from the square root of the network residual map from the GLM 
regression using 3dFWHMx (AFNI) [293] and used as a 3DClustSim input. The significance 
volume threshold was 47 voxels for BA45’s network, and 58 voxels for BA44.  
In each network, to explore common sources of variance between HM and all heritable 
FC measures, we estimated cross-trait (phenotypic) and cross-trait cross-twin (ct-ct) 
correlations. At first, we used HM-PC1 as a composite measure of HM. Then, we made the 
distinction between rotational and translational confound by calculating the correlations with 
MR and MT separately. Thus, for each FC and HM measurement (HM-PC1, MR and MT), 
we tested, using a likelihood ratio test whether: a) the MZ and DZ phenotypic correlations 
are equal and null, and b) the MZ and DZ ct-ct correlations are equal. The ct-ct correlations 
can shed light on the genetic and environmental contributions to the phenotypic correlations 
and represent a simple way of assessing the presence of genetic correlation. Indeed, where 
phenotypic correlation is observed, a MZ ct-ct correlation greater than DZ indicates a genetic 
effect, a DZ ct-ct correlation greater than half the MZ suggests a significant effect of the 
shared environment. Finally, if the traits are driven by independent individual environmental 
factors the ct-ct correlations should be null. Phenotypic and ct-ct correlations, as well as the 
p-values, were estimated using OpenMx [197], which takes into account the relatedness in 
the sample.  We used the same previous multiple testing approach to identify regions of 
significant correlation. The significance threshold and smoothness were re-estimated on the 
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sub-maps of significant heritability, with a resulting threshold of 29 voxels for BA45’s 
connectivity map and 24 voxels for BA44.  
 
Results 
 Head motion characteristics of the sample 
Table 13 shows the motion characteristics for the sample. The HM means and 
variance were similar to those reported in a previous study [61] and exhibited similar 
magnitude with a mean MT=0.064 (SD=0.025). Assumption testing supported homogeneity 
of means and variances, across zygosity and sex. For MR there was a subtle significant 
negative effect of age (-0.013 [-0.014,-0.012]; p-values=0.02) and age2 (-0.00027 [-
0.00028,-0.00026]; p-values=0.03) but no difference between males and females. Age, age2 
and sex were not significant for either MAXT, MT and HM-PC1. HM measures were 
moderately to highly correlated (Table 13). Test-retest ICCs for all four HM measures 
indicated moderately good reliability, improved by the exclusion of outliers on MR 
(ICCMR=0.46, ICCHM-PC1=0.65, in the overall sample, ICCMR = 0.53 and ICCHM-PC1=0.66 when 
excluding outliers) (Table 13).   
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Table 13: Motion characteristics of the twin sample 
 MT (mm) MAXT (mm) MR (degrees) HM-PC1 
Descriptive statistics     
Raw Mean (SD) 0.06 (0.02) 0.27 (0.22) 0.04 (0.01)  
Range [0.03,0.28] [0.06,1.35] [0.02,0.10]  
Log-transformed Mean(SD) -2.83 (0.35) -1.54 (0.65) -7.32 (0.32) 0.00 (1.50) 
Range [-3.63,-1.89] [-2.75,0.30] [-8.24,-6.39] [-3.63,4.46] 
Covariate effects     
P-valueAge  0.61 0.54 0.02*  0.18 
P-valueAge²  0.67 0.57 0.03* 0.22 
P-valueSex  1 1 1 1 
Reliability     
ICC [95% CI] 0.59 
[0.32,0.77] 
0.53 
[0.24,0.73] 
0.53 [0.24, 
0.74] 
0.66 
[0.42,0.82] 
Phenotypic correlations 
[95% CI] 
    
MT - 0.71 
[0.66,0.75] 
0.58 
[0.52,0.64] 
0.88 
[0.86,0.90] 
MAXT  - 0.60 
[0.54,0.66] 
0.89 
[0.87,0.91] 
MR   - 0.83 
[0.80,0.86] 
Twin correlations     
rMZ [95% CI] 0.50 
[0.39,0.60] 
0.33 
[0.20,0.45] 
0.29 
[0.16,0.41] 
0.38 
[0.20,0.54] 
rDZ [95% CI] 0.25 
[0.13,0.36] 
0.19 
[0.07,0.30] 
0.14 
[0.02,0.26] 
0.18 [0.01, 
0.34] 
Means, standard deviations, and ranges of the HM measurements (raw and log-transformed), as well as sex, 
age² and age effects, repeatability coefficients (ICC), Phenotypic correlations (Pearson) and ML twin 
correlations are presented. Exclusion of 2 outliers improved the reliability of MR and HM-PC1 (ICCMR=0.46 
[0.15, 0.68] and ICCHM-PC1=0.65 [0.40, 0.80] in the overall sample). No outlier was identified in test-retest MT 
and MAXT distributions. Our sample exhibited similar amount of motion to that reported previously [61]. 
*= p-value<0.05 
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Genetic modelling of head motion 
Univariate modelling indicated neither a significant common environmental (C), nor a 
dominant genetic effect (D) on the HM measures (ACE vs AE model for MT: p=1, for MAXT: 
p=0.71; ADE vs AE model for MR: p=0.82, for HM-PC1: p=0.46) (Table 14). Similarly, using 
Cholesky decomposition of MR, MT and MAXT, common environmental effects were not 
significant. Therefore, all subsequent modelling included A and E components only, knowing 
that we may slightly overestimate the additive genetic effect, as it would include the non-
significant C or D variance. 
 
 
Table 14: Model fit and parameter estimates of the univariate genetic models for HM 
Variable Model Parameter estimates Model fit 
  A C/D E df -2LL AIC P-
values 
 
MT 
ACE 0.54 [0.21,0.65] 0.00 [0.00,0.24] 0.46 [0.35,0.61] 4 302.06 -609.9  
AE 0.54 [0.39,0.65]  0.46 [0.35,0.61] 3 302.06 -611.9 p=1 
CE  0.35 [0.23,0.46] 0.65 [0.54,0.77] 3 310.51 -603.5 p=0.003 
E    2 340.25 -575.7 p<0.001 
 
MAXT 
ACE 0.26 [0.00,0.48] 0.07 [0.00,0.35] 0.67 [0.51,0.85] 4 886.35 -25.7  
AE 0.34 [0.19,0.48]  0.66 [0.52,0.81] 3 886.48 -27.5 p=0.71 
CE  0.26 [0.13,0.37] 0.74 [0.63,0.87] 3 887.54 -26.5 p=0.27 
E    2 903.26 -12.7 p<0.001 
 
MR 
ADE 0.19 [0.00,0.42] 0.09 [0.00,0.44] 0.72 [0.56,0.89] 4 236.14 -679.9  
AE 0.27 [0.10,0.42]  0.73 [0.58,0.90] 3 236.19 -681.8 p=0.82 
E    2 246.22 -673.8 p=0.006 
ACE 0.28 [0.00,0.42] 0.00 [0.00,028] 0.72 [0.58,0.90] 4 234.46 -677.5  
HM-PC1 
ADE 0.32 [0.01,0.55] 0.08 [0.00,0.29] 0.60 [0.45,0.78] 4 1653.1 745.1  
AE 0.42 [0.25,0.56]  0.58 [0.44,0.75] 3 1653.6 743.7 p=0.46 
E    2 1673.0 761.4 p<0.001 
ACE 0.39 [0.00,0.53] 0.00 [0.00,0.00] 0.61 [0.47,0.78] 4 1653.3 745.3  
The parameter estimates are followed by the 95% CI between brackets .All the estimates are standardised 
(percentage of variance). df gives the degree of freedom i.e. the number of estimates in the model. -2LL is -2 
times the log-likelihood of the model, AIC the Akaike criterion for each model. The P-value corresponds to 
the likelihood ratio test of the full model versus any nested model. For each HM variable, the best model (P-
value>0.05 and AIC minimal) appears in bold.  
 
Additive genetic estimates in the AE Cholesky model were highly significant 
(p<0.001). High genetic correlations (rg) (rgMT-MAXT=0.99 [0.65,1.00]; rgMR-MAXT=0.77[-0.32, 
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1.00] and rgMT-MR=0.82 [0.18,1.00]), indicated that the three HM measures shared, to a large 
extent, common additive genetic factor(s). The environmental correlations (re) were lower 
(reMT-MAXT=0.64 [0.55, 0.74], reMR-MAXT=0.56 [0.45, 0.66] and reMT-MR=0.61 [0.50, 0.70]). Thus, 
the environmental factors influencing MT head motion were mostly common to the 3 
measures.  
A common pathway model provided a similar overall goodness-of-fit to the 
independent pathway decomposition (AICIndependent=2891.8 and AICCommon=2891.9). 
However, with only 14 parameters to estimate (versus 15) the common pathway model was 
the simplest for a similar fit, and minimised the BIC criterion (BICIndependent=-1730.7 versus -
1724.0). Therefore, we used the more parsimonious AE common pathway model to examine 
the covariation between the HM measures, and to test the significance of common (Ac) and 
specific additive genetic sources of variance (As). Both specific and shared A and E 
estimates were significant in the model (p<0.001).  Estimates are presented in Figure 15.  
 
 
Figure 15: The common pathway model showing parameter estimates and 
covariation between MT, MAXT and MR 
In the path diagram, the square boxes represent the observed variables (phenotypes), and the circles the 
latent variables (A, C, E). Ac and Ec are the Additive genetic and Environmental effects common to the 3 HM 
measures through the latent HM factor (oval). As and Es are, for each HM variable the specific additive genetic 
and environment effects. Path coefficients (standardized) are presented in bold. Below each is the percentage 
 125 
of variance for the HM measurement and the latent variable, followed by its 95% confidence interval. 
Heritability estimates for each HM measure are shown below each HM variable name.  
 
The latent HM factor explained a high proportion of the observed variance: 70% for 
MT, 72% for MAXT and 50% for MR. This result confirms that a substantial amount of the 
variance in MT, MAXT and MR is due to a common source.  Forty-six percent of the variance 
in this latent HM factor was due to an additive genetic factor (A) and 54% due to non-shared 
environmental (E) variance, some of which is correlated measurement error. The variance 
explained by specific factors was as low as 30% (19% As and 11% Es) for MT and 28% (2% 
As and 26% Es) for MAXT. Specific variance was slightly higher for MR (50% [14% As and 
36% Es]). 
Following this evidence for large common underlying genetics (and environmental) 
factors in rotational and translational movement we investigated the heritability difference 
between MT (h2=0.51) and MR (h2=0.37) by coming back to the distributions of frame-to-
frame rigid body parameters. It became clear that the extent (amplitude) of movement during 
an MRI session is not the same in all directions: translation along the X axis (left-right 
translation) and rotation around the Y (“maybe” rotation) and Z axis (“no” rotation) exhibited 
reduced variance. These differences in variance are likely due, at least in part, to the head 
coil restraining rotation more than translation. In addition, heritability of MAXT (h2=0.35) was 
also lower than for MT, likely arising from MAXT being (by construct) more sensitive than 
the mean to the presence of rare and extreme movement, which results in greater within-
pair variability. 
 
Genetic modelling of Broca’s functional connectivity 
Saturated univariate models estimated on each voxel indicated no mean or variance 
differences for either sex or zygosity groups. Common or shared environment (C) had no 
significant influence across the brain and was dropped from the models. There was a 
significant effect of age and sex in 3 regions of BA45’s network (see Supplementary Document 
36, Supplementary Document 37, Supplementary Document 38). The principal components of 
HM were not significant across the brain (the biggest cluster of significant voxels for HM-
PC1 effect was of size k=32 voxels, the discovery clusters were even smaller for HM-PC2: 
k≤28 and HM-PC3: k≤24, none of them reaching the significance threshold). Fitting AE 
models we identified 3 regions of BA45’s network with significant heritability: left IPC (k=254 
voxels, h==0.27 (sd=0.069)), left SMA (k=133, h==0.23 (0.048) ), right IPC (k=82, h==0.25 
(0.043) ) and right IFC (k=53, h==0.22 (0.034) ) (see Figure 16, Supplementary Document 37).      
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In BA44’s network, age, sex and the first PC of HM were kept as covariates. 5 regions 
showed a significant effect of age or sex on FC (see Supplementary Document 39, 
Supplementary Document 40). In one region there was a significant effect of the first principal 
component of HM (HM-PC1) that corresponds to HM effect size and therefore can be 
interpreted as the global amount of motion. The region was located in left/right SPC (k=98, β =0.025 (0.0069)). We identified three regions of the BA44 network that showed significant 
heritability, and contained 4 significant clusters: left SMA (k=123, h==0.23 (sd=0.043)), IPC 
(k=90, h==0.23 (0.036); k=69, h==0.23 (0.042)) and left/right OC (k=62, h==0.21 (0.045) ) 
(see Figure 3 and Supplementary Document 39).  
 
 
Figure 16: Heritability map of BA45’s network and effect of head motion on the 
network’s FC 
 127 
(A) Heritability map of the BA45’s network (heat-map) and corresponding –log(p-values) map (purple) 
(B) HM-PC1 effect on BA45’s FC with beta maps and corresponding –log(p-values) 
The negative betas are shown in cold colours (with strongest effect corresponding to green), positive betas 
are plotted with warm colours (the strongest effect being white). Therefore, all the colorbars rank 
effect/significance from low to high (i.e. left to right). Effect size and significance are plotted voxel-wise.  
Heritability and HM effects are projected onto brain maps after averaging the signal (using 12 voxels depth 
resolution) using MRIcron (Rorden and Brett, 2000). We plotted the top 80% of voxels for heritability and 
motion effect to facilitate the reading of the image. No thresholding was applied on the p-values maps and 
significance of all the voxels considered is presented. 
 
 
Figure 17: Heritability map of BA44’s network and effect of head motion on the 
network’s FC 
(A) Heritability map of the BA44’s network (heat-map) and corresponding –log(p-values) map (purple) 
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(B) HM-PC1 effect on BA44’s FC with beta maps and corresponding –log(p-values) 
The negative betas are shown in cold colours (with strongest effect corresponding to green), positive betas 
are plotted with warm colours (the strongest effect being white). Therefore, all the colorbars rank 
effect/significance from low to high (i.e. left to right). Effect size and significance are plotted voxel-wise.  
Heritability and HM effects are projected onto brain maps after averaging the signal (using 12 voxels depth 
resolution) using MRIcron (Rorden and Brett, 2000). We plotted the top 80% of voxels for heritability and 
motion effect to facilitate the reading of the image. No thresholding was applied on the p-values maps and 
significance of all the voxels considered is presented. 
 
Sources of covariation between head motion and functional connectivity 
No clusters of phenotypic correlation between FC and HM-PC1 passed the 
significance threshold for BA44 (24 voxels) and BA45 (29 voxels). In BA44’s heritable 
network, the significant correlations were positioned randomly in the network (k≤2 voxels 
for the discovery clusters of phenotypic correlation, k≤7 for the ct-ct correlation, k≤2 for the 
genetic correlations). We also examined the correlation between FC with both MR and MT, 
and again, no significant correlations were observed.  
In BA45’s heritable network, the size of the discovery clusters for phenotypic 
correlation reached k=24 voxels, k≤17 for the ct-ct correlations but only isolated genetic 
correlations were observed (k≤2). Therefore, we could not reject the null hypothesis of no 
correlation between FC and HM across the brain. The histograms of p-values may have 
suggested a significant phenotypic correlation; however no area passed the significance 
threshold (that accounts for multiple testing).  
We broke down the HM into rotational and translational components by considering 
the correlations of FC with MT and MR. MT showed no significant correlation with the FC 
in heritable voxels. However, we identified an area, in the left IPC, showing significant 
differences in MZ and DZ phenotypic correlation between FC and MR (k=42 voxels, rMZ =0.090	 sd = 0.061 , rDZ = −0.16	 sd = 0.039 ). The sign difference between MZ and DZ 
correlations suggested a false positive, which was confirmed by the low ct-ct and non-
significant genetic correlations (on k=42 voxels, ctctMZ = 0.056	 sd = 0.050 , ctctDZ =−0.033	 sd = 0.042  and only 3 voxels were significantly correlated with MR).  
 
Discussion 
Here, we show for the first time that individual differences in small movements of the 
head during RS-fMRI are influenced by genetic factors. Using a healthy population sample, 
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comprising 462 largely young adult twins, we demonstrated significant low to moderate 
heritability of three HM measures: mean translation, mean rotation, and maximum 
translation. The strong covariation across MR, MR and MAXT was captured by a latent head 
motion factor for which half of the variance was found to be due to genes. Heritability of HM-
PC1 (0.42) was very similar to the latent Head Motion factor (0.46) from the Common 
Pathway model, suggesting HM-PC1 captured well the genetic dimension of head motion. 
We confirmed that HM measurements are reliable, and showed that there was little effect of 
age or sex on small head movements. 
Our finding that each of the three HM measures is significantly heritable (MT=54%, 
MAXT=35%, MR=37%) is consistent with the proposal that small movements of the head 
are stable traits [61]. Interestingly, we found that a large proportion of translational and 
rotational HM is under the control of the same genetic factors (genetic correlations ranging 
0.76 to 1.00). Common variability, represented by a latent HM factor, was equally explained 
by the genes and the environment (h²=46% [0.27, 0.61]). Thus, variation in HM in the 
population can be partially explained by an additive effect of several genetic loci common to 
the 3 HM measures.  In contrast, specific genetic influences explained only a small 
proportion of the variance in HM (19% for MT; 2% for MAXT and 14% for MR). In addition 
to a common genetic influence, we also showed that both translation and rotation head 
movements were significantly influenced by the same environmental factors (environmental 
correlations about 0.6) some of which may reflect correlated measurement error. Specific 
environmental factors explained a minor proportion of the variance in MT (11%) but a greater 
amount of the extreme and rotational displacements (26% for MAXT, 36% for MR). This was 
likely to be the case for MAXT since it may capture some voluntary movement. One must 
keep in mind that all these results were obtained for HM constrained by the head coil; a 
study of unconstrained HM might reveal a slightly different pattern of genetic and 
environmental factors. Similarly, gross motion exclusion may remove part of the HM 
variation in the population, and may impact the heritability estimates. However, the sample 
motion reported in Table 13 shows that HM and gross motion are different, at least in scale 
(e.g. MT=0.06mm, MR=0.04 degrees, vs. 3mm and 2 degrees movement in gross motion), 
thus potentially in nature (e.g. voluntary vs. involuntary). Here, we lack information about 
scanning events that could help confirm this difference or identify factors influencing HM 
and/or gross motion (e.g. comfort, sneezing or shivering).  
  Our heritability estimates for HM are consistent with those for another non-voluntary 
movement such as eye blink startle reflex suppression, which has a heritability of 50% [294]. 
However, our estimates for HM are somewhat less than those reported for resting tremor 
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(i.e., 93-99%) [295], which is caused by contraction of opposing muscle groups [296], or eye 
blink startle magnitude (i.e., 70%) [294]. Eye blink startle reflex suppression and resting 
tremor are frequently associated with Parkinson’s disease [294, 295]. Furthermore, eye blink 
startle reflex suppression is implicated in the biological bases of schizophrenia and has been 
proposed as a possible endophenotype for genetic studies [294]. Both types of non-
voluntary movement are associated with impaired cerebellum connectivity [296, 297]. 
Moderate test-retest reliability for all HM metrics (range 0.53-0.66) confirmed the 
results of a prior study [61]. Higher test-retest reliability (ICC=0.73) has been reported for 
the Yan et al. metric of HM [62]. However, the reliability of the concurrent metrics on the 
same sample was not reported and thus could also be higher (e.g. due to better controlled 
experimental parameters across sessions or longer RS scans). We also found similar 
magnitude of HM in the twins to those previously reported [61], despite having possibly 
made different choices for the centre of rotation and the motion used (absolute or frame-
wise). However, contrary to their study, we found little indication of any sex difference in HM. 
Similarly, and only for rotational motion did we find a subtle decrease with age. This may 
reflect the fact that the twins in our sample were largely young adults, with the youngest 
participants aged 16 (i.e. mean age = 21, SD=3.16, range 16-29). A prior study that reported 
significant linear and quadratic effects of age [265] had a much younger sample (8-23 years 
old). Further studies are needed to investigate the effects of age and sex on HM, but our 
findings suggest that at least in healthy young adults, variability in HM due to age and sex 
are likely to be small.  
HM is a known confound for RS-fMRI. Linear regression of HM is insufficient in 
removing all bias [61, 62, 263, 264, 266, 267] so the real effect of motion on FC is still 
unknown and is likely to be expressed differently according to the FC metric used [61, 62]. 
Here, in a post-hoc analysis we investigated the extent that heritable HM could confound 
seed-based FC heritability studies by creating a bias related to sample zygosity. Overall, we 
found that the FC and HM correlations indicated  little common genetic sources of variance 
between those traits, indicating no major motion induced bias in the genetic estimates of 
FC. However, some sparse residual associations were found in BA44’s network (HM-PC1 
was a significant covariate in SPC). While these results require confirmation on a larger 
sample (greater power) and at a larger scale (we focussed on seed-based resting-state FC 
and did not investigate more complex [non-linear] relationships), our findings should 
encourage controlling for and minimising HM influences on FC estimates. Thus, including 
HM measures as covariates (in pre-processing and further analyses) can reduce the 
confound with fMRI measurements [62, 63, 263, 264, 266, 267, 298, 299], and even more 
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when slice-wise motion is used [298], but knowing the complex and wide spread effect of 
HM on brain signal [263] and its association with other regressors [263, 300], a complete 
removal of the spurious effect of motion through regression only is illusory. To this effect, a 
new approach, based on post-hoc deletion (censoring) of highly noisy volumes, has been 
developed to reduce the residual effect of HM on FC and shows significant promise [63, 
263].  
As a consequence, we can interpret our findings of a significant genetic influence on 
FC for both BA44 and BA45’s network with greater confidence. In previous MRI studies, a 
similar level of heritability has been reported on RS-FC based graph theory metrics [301]  
and group-ICA FC [302-304]. This is the first genetic study of seed based RS-FC and we 
provided heritability maps of the Broca’s networks at rest. They showed that several regions 
across Broca’s resting state networks were heritable with the genetic influence on FC for 
BA45 and BA44 distributed differently. It would be of interest for other studies to replicate 
these findings as would heritability studies of additional RS brain network. In addition, it 
could be worthwhile investigating the extent of any genetic covariation between RS-FC and 
cognitive ability scores, such as vocabulary or language skills [305, 306]. This could shed 
light on the network’s organisation and performance.  
Besides, the moderate heritability of HM and FC has to be considered in light of the 
(moderate) reliability of these traits. Reliability (or repeatability) represents, in most cases, 
an upper bound for heritability estimates [67]. Here, for both type of measures the similarity 
of MZ correlation and reliability estimates suggests that most of the reliable signal is 
heritable and it would be of interest to see how the heritability estimates evolve when the 
reliability of the measurement is increased (by acquiring longer RS fMRI for instance, or by 
using a more reliable metric if available).  
Finally, together with the work showing an association between gross HM level and 
case status for diseases such as schizophrenia [274], autism [272] and ADHD [269, 271, 
273], we suggest that HM may be considered a possible endophenotype for brain disorders, 
especially if the diseases are known or suspected to impact motor functions. 
 
Conclusion 
We estimated, for the first time, the heritability of HM measured during RS-fMRI. HM 
was found to be a trait rather than a state, with good reliability and a significant genetic 
influence. Most of the variance in the three HM measures (mean translation, rotation and 
maximum translation) was due to common genetic and environmental influences, through a 
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latent HM factor. Genetic and environmental influences specific to each HM measure were 
significant, but could be biased upwards in our experimental protocol. No clear sex or age 
effects on movement amplitude were observed in our largely young adult sample. Further, 
while post-hoc analyses showed that FC in multiple areas of Broca’s network is heritable, 
there was little evidence of shared genetic influences between HM and FC of this network.  
HM could help to describe and characterise heritable brain disorders, and therefore 
may be a valuable endophenotype in future fMRI studies. 
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Abstract  
Head motion (HM) is a well known confound in analyses of functional MRI (fMRI) 
data. Neuroimaging researchers therefore typically treat HM as a nuisance covariate in their 
analyses.  Even so, it is possible that HM shares a common genetic influence with the trait 
of interest. Here we investigate the extent to which this relationship is due to shared genetic 
factors, using HM extracted from resting-state fMRI and maternal and self report measures 
of Inattention and Hyperactivity-Impulsivity from the Strengths and Weaknesses of ADHD 
Symptoms and Normal Behaviour (SWAN) scales. Our sample consisted of healthy young 
adult twins (N=627 (63% females) including 95 MZ and 144 DZ twin pairs, mean age 22, 
who had mother-reported SWAN; N=725 (58% females) including 101 MZ and 156 DZ pairs, 
mean age 25, with self reported SWAN). This design enabled us to distinguish genetic from 
environmental factors in the association between head movement and ADHD scales. HM 
was moderately correlated with maternal reports of Inattention (r=0.17, p-value=7.4E-5) and 
Hyperactivity-Impulsivity (r=0.16, p-value=2.9E-4), and these associations were mainly due 
to pleiotropic genetic factors with genetic correlations [95% CIs] of rg=0.24 [0.02, 0.43] and 
rg=0.23 [0.07, 0.39]. Correlations between self-reports and HM were not significant, due 
largely to increased measurement error. These results indicate that treating HM as a 
nuisance covariate in neuroimaging studies of ADHD will likely reduce power to detect 
between-group effects, as the implicit assumption of independence between HM and 
Inattention or Hyperactivity-Impulsivity is not warranted. The implications of this finding are 
problematic for fMRI studies of ADHD, as failing to apply HM correction is known to increase 
the likelihood of false positives. We discuss two ways to circumvent this problem: censoring 
the motion contaminated frames of the RS-fMRI scan or explicitly modeling the relationship 
between HM and Inattention or Hyperactivity-Impulsivity. 
 
Introduction 
Head motion (HM) is a well known confound for functional and structural 
neuroimaging studies [61, 63, 265, 266, 308-312]. Movement during functional MRI (fMRI) 
is responsible for greater error in the measurement of the Blood Oxygen Level Dependent 
(BOLD) signal (also in white matter and cerebrospinal fluid), for up to 10 seconds after the 
movement occurs [263, 264]. Motion during functional imaging tends to create spurious local 
functional connectivity (FC) and to weaken long range FC [61-63, 265, 313]. Similarly, HM 
can positively bias Fractional Anisotropy (FA) and mean Diffusivity (MD) measures 
computed from Diffusion Tensor Imaging (DTI) images [310, 311].  
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In fMRI analyses, several strategies are used to control or account for the effect of 
HM. A common approach is to regress out HM in the image processing [314] but also in 
downstream analyses [61]; this is the ‘nuisance covariate’ approach [61, 264, 267, 286, 299, 
300, 314]. Even so, the effect of HM on FC may be too complex and dynamic to be 
completely removed by regression [61, 62, 263, 264, 266, 267]. A more recent approach, 
based on censoring of the highly noisy images [63], outperforms the regression based 
methods [263] (but see [315]) by reducing the number of false positive results. Importantly, 
both these methods assume that HM is independent of the trait of interest (e.g., case-control 
status, or a cognitive or personality measure); thus the HM contribution to the fMRI signal is 
considered to be solely noise. However, in groups of patients with diseases such as multiple 
sclerosis or stroke there is increased HM compared to healthy controls [268, 316, 317], 
although the evidence is somewhat contradictory for schizophrenia [274, 318-320]. 
Recently, HM (in both fMRI and DTI) was shown to be greater in impulsive individuals, in 
line with the findings from externalising disorders such as Attention Deficit Hyperactivity 
Disorder (ADHD) and conduct disorders [321]. In many studies the frequency of exclusions 
for gross motion was greater in ADHD [269, 271, 273] and autism cases [272, 322] 
compared to controls. This suggests a possible relationship between HM and the trait of 
interest that is yet to be investigated rigorously. 
Many of these relationships with HM need to be replicated but, if confirmed, image 
processing pipelines will need to take such relationships into account to avoid a significant 
power loss and inflation of the false positive rate, as well as possible misinterpretations of 
the genetics of traits examined. An association between HM and the trait of interest during 
fMRI can potentially contribute to false positive discoveries and reduced power to detect 
effects at many levels. First is the exclusion criterion: common practice is to discard scans 
exhibiting motion greater than the voxel size [316]. Under dependency, such exclusion 
would introduce a sampling bias, as the exclusion would depend on the trait of interest. 
Second, HM association with the trait of interest might also contribute to false positive (and 
negative) results when groups are compared. False positive findings can arise from spurious 
(often short range) functional connectivities (FC) in the group with excess motion. False 
negative results are caused by the increased BOLD and FC variance in the motion group, 
which reduce statistical power. Thirdly, HM bias can be introduced by the experimental 
design: the nature and difficulty of a task can, for example, influence the frequency and 
intensity of stimulus correlated motion [269, 323]. Finally, there might be combinations of 
case/control status and experimental conditions that interact to induce even more motion as 
recently reported [316, 320].  
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In the resting-state literature, some functional brain differences in ADHD are 
consistently reported, such as reduced connectivity in the Default Mode Network [324, 325] 
and altered connectivity with visual, ventral attention and frontoparietal networks [325, 326] 
or with the partially overlapping cognitive control network [324]. These may explain 
attentional lapses in ADHD, where mind wandering controlled by the DMN might interfere 
with sustained attention [324, 325]. However, many other findings have not been replicated, 
for example the reduced connectivity between DMN and putamen [324, 327], reduced 
regional homogeneity in the DMN [328], inferior frontal gyrus and dorsal caudate [324, 329], 
together with aberrant brain activation or network properties [324, 330, 331]. Investigating 
the relationship between HM and ADHD symptoms such as inattention or hyperactivity-
impulsivity might indicate whether inconsistent findings from prior resting-state studies could 
reflect a potential confound.  
Here, we chose to focus on the relationship of HM with ADHD, following a recent 
study showing an association between HM and impulsivity [321]. We used the twin design 
to investigate how much of the association between these traits is due to environmental or 
genetic factors. Impulsivity-Hyperactivity and Inattention were measured by self and 
maternal report using the SWAN (Strengths and Weaknesses of ADHD Symptoms and 
Normal Behaviour) questionnaire [65]. We used the Jenkinson et al., metric [282] to 
summarise the 6 motion time series and compute the level of motion of each participant. 
This provides a computationally fast and direct measurement of the mean displacement over 
all brain voxels [62, 262, 282].  
 
Material and methods 
Measures of ADHD were collected in the context of the Brisbane Longitudinal Twin 
Study [80] in which twins are assessed at average ages 12, 14, 16 and 18 on a range of 
measures. During the in-person visits or during follow up online assessment, the mothers of 
the twins completed the SWAN questionnaire (detailed below) with ~65% asked to rate the 
twins’ current ADHD symptoms, where the mean age of the twins was 22 (years) (see 
Supplementary Document 41 for a detailed explanation of the various waves and protocols). 
As young adults (mean age 26, range 18-32 years) the twins also completed a self-report 
version of the SWAN [35], where the majority were asked to provide ratings of any current 
ADHD symptoms (see Supplementary Document 41). In addition, at age 21-28 many of the 
same twins were invited to participate in the Queensland Twin Imaging (QTIM) study [102], 
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involving structural [332] and functional MRI (both resting-state and during a working 
memory task [31, 32, 262, 333]) as well as DTI [334, 335].   
Participants 
We included all twins/siblings for whom head motion and at least one SWAN score 
were available (N=892). For simplicity, we selected one pair of twins (or sibling pair) from 
each family resulting in the exclusion of 27 individuals. Eight additional participants were 
excluded for gross motion that occurred during resting-state fMRI (described in 
Supplementary Document 42). The final sample included 857 individuals from two overlapping 
sub-samples (Figure 18). See [336] for a description of the resting state sample, [337] for the 
mother-reported SWAN sample and for a partial description of the self-reported sample 
(ongoing study). We also describe the currently available sample with self-reported SWAN 
data in Supplementary Document 41.  
Fifty-seven (57) non-twin singletons remained in the final sample and provided 22 
sibling pairs that were pooled with the dizygotic (DZ) twin pairs in the genetic analyses. 
Mother reported SWAN scores and HM were available for 627 participants (95 monozygotic 
(MZ) twin pairs, 144 DZ pairs, 149 singletons) and self reported SWAN scores and HM on 
725 individuals (101 MZ pairs, 156 DZ pairs and 211 non-paired singletons). Our combined 
final sample included slightly more females (64%) with a mean age of 22 years for the 
resting-state scan (Supplementary Document 41). On average, there was 1.2 years (range 3 
days-3.9 years) between the MRI scan and the SWAN rating from the mother, with 54% of 
the participants completing the scanning first. The interval between the MRI scan and 
collection of the self report SWAN scale was 3.1 years on average (range 6 days-7.1 years); 
98% of participants were scanned first.  
Zygosity was established objectively by typing nine independent microsatellite 
polymorphisms (PIC N 0.7) in the ProfilerPlus™ set using standard methods, and was later 
confirmed for 80% of the sample genotyped on the 610 K Illumina SNP chip [281]. Prior to 
imaging, participants were screened (by self-report) for being right-handed and for 
significant medical, psychiatric or neurological conditions, including head injuries, a current 
or past diagnosis of substance abuse, and for current use of medication likely to affect 
cognition.  
Written informed consent was obtained from all participants including a parent or 
guardian for those aged less than 18 years. QIMR Human Research and Ethics Committee 
(HREC) approved SWAN data collection. Data collection for SWAN self report was also 
approved by the Virginia Commonwealth University Institutional Review Board (IRB). The 
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QTIM study was approved by the ethics review boards of the Queensland Institute of 
Medical Research, the University of Queensland, and Uniting Health Care, Wesley Hospital, 
Brisbane. QTIM participants received an honorarium in appreciation of their time. 
 
 
Figure 18: Overlap between SWAN scores and Resting-State functional MRI samples  
This figure shows the sample size of the ADHD and QTIM studies. Individuals who exhibited gross motion 
during resting-state fMRI (N=8), and siblings of a complete twin pair (n=27) are not included. The sample used 
in the current study included those with both a SWAN score and HM measures, comprising two overlapping 
sub-samples (N= 725 and N=627) as presented in the grey boxes. Number of monozygotic (MZ) and dizygotic 
(DZ) twin pairs (which include sib-pairs), and number of singletons are shown for each sub-sample.  
 
Head motion Measurement 
We extracted Head motion from a 5m 19s resting state fMRI recording [102]. Rigid 
body registration [279] was performed using SPM8 [280] and the DPARSFA toolbox [283], 
to realign the 150 images acquired during the scanning session. This processing step is 
unchanged in the new software version: SPM12 [338]. Three translational and three 
rotational parameters were calculated for each image to fully describe its position from the 
first, and reference, image. Using the standard exclusion criteria for 3-4T fMRI studies, we 
identified 8 outliers with translation (in one of the directions x,y or z) greater than 3mm, or 
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rotation (around one of the axes) greater than 2 degrees. These individuals with gross 
motion were excluded from the analysis due to their possible large influence on the results. 
Characteristics of these individuals and comparison to the rest of the sample are reported 
in Supplementary Document 42. 
For the final sample comprising 857 participants (see Figure 18) we summarised the 
6 motion time series by computing the Jenkinson et al., metric of HM [282, 339] which offers 
the advantages of being comparable across studies (independent of centre of rotation), 
highly correlated with the metric of reference (average voxel-wise displacement) but is much 
faster to compute [62]. It can be calculated using the formula: Fk R=trace AlA + (t + Axm)l(t + Axm) where T=TFEF − I = A t0 0 , xm being the centre of the 
volume (software specific), TF and T= the transformation from volumes of interest (frames at 
time d and d+1) to reference volume (usually the first frame). A is therefore the 3x3 matrix 
of rotation and t the vector of translations of the affine transformation between volumes of 
interest. R is the arbitrarily chosen radius of the brain, here 80 mm [282]. Hence, the 
Jenkinson et al. metric aggregates translation and rotation movements that we showed to 
be genetically homogeneous [262]. We log-transformed the HM metric to enhance normality 
of the residuals in the linear models. One outlier, with a composite HM greater than 4sd from 
the mean (5.4 standard deviations from mean), was identified but included considering the 
minimal impact of a single observation on the result. The average level of motion observed 
in the sample, as well as the MZ and DZ twin pair correlations aligned with our previous 
report of heritability of HM [262] and is reported in Table 15. The description of excluded 
participants for excessive motion (greater than voxel size) is available in Supplementary 
Document 42 but the comparison with included participants is limited by the small number of 
excluded participants (N=8).  
 
ADHD measurement 
Dimensions of ADHD (Inattention and Hyperactivity-Impulsivity) were assessed using 
18 items from the SWAN questionnaire [65]. This includes 9 items for the Inattention 
dimension and 6+3 for Hyperactivity and Impulsivity. The items correspond to the symptoms 
defined in the DSM-5 (and DSM-IV) and each of them is rated on a Likert-type scale. Raters 
are instructed to use average individual (of a specified age) as a reference. Mothers were 
provided 7 rating possibilities for their children: far below average, below, slightly below, 
average, slightly above, above and far above average. For self-rating a five-point Likert-type 
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scale was used: far below average, below, average, above and far above average. In both 
cases, “average” was rated 0 and “far below average” was given the maximum score. For 
each dimension symptom ratings are averaged to create a continuous score, a higher score 
indicating higher levels of ADHD. This instrument has high reliability (r=0.82) and internal 
consistency (α = 0.88), as well as good agreement with the Disruptive Behaviour Rating 
Scale [340] or ADHD diagnosis [341]. In addition, the SWAN scale may more precisely 
describe the individuals at the left end of the distribution (low Inattention and Hyperactivity-
Impulsivity) [341-343], which better suits the study of population samples and estimation of 
twin correlations [342, 343].  
In the previous version of the DSM (DSM-IV), ADHD was only defined for children 
and adolescents, but the new edition (DSM 5) raises the age when the symptoms can be 
documented, allowing diagnoses to be made on adults. Thus, the SWAN scores based on 
the DSM symptoms can be safely used in young adults and jointly analysed together with 
the observations at earlier age providing that age and sex are used in the analyses to 
remove their confounding effects [333, 344, 345].  Indeed, results from a large community-
based sample in the US indicate persistent sex differences across all age groups, as well 
as a steady decrease of mean scores from childhood to adulthood [344]. 
Here, SWAN scores were, on average, greater for males than females, consistent 
with previous observations of the same data [337] and with independent analyses of 
impulsivity and inattention [333, 344, 345]. In addition, mean and variance differences in 
Inattention and Hyperactivity-Impulsivity between waves (see Table 15), led us to consider 
wave and design (prospective vs. retrospective) as covariates, in addition to sex and age. 
Previous research on this dataset showed similar variance decomposition in each of the 
waves or design samples, suggesting that after accounting for the effects of age and wave 
the maternal and self-report data may be jointly analysed [337]. Finally, a negative contrast 
effect has been previously found in ADHD scores [337, 346-352], whereby a high rating of 
one twin is associated with a lower rating of the co-twin. This contrast effect can arise from 
phenotypic interaction (the behaviour of the hyperactive twin might impact the co-twin’s 
behaviour, and vice versa) or more likely from a rater effect (the more hyperactive a twin is 
perceived, the less so is the co-twin perceived) [347]. Negative contrast is usually suggested 
by reduced twin pair correlations for some raters (e.g. parent report in ADHD), which can 
sometimes yield negative DZ correlations. Using the full twin sample (N=3,223), a significant 
contrast effect was found for maternal report of Hyperactivity-Impulsivity and self reported 
Inattention [337]. Here, we tested the effect of the number of siblings in a family on SWAN 
scores, which could attenuate (up to a third) the rater effect as mother of large families tend 
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to judge more accurately how their twins compare to average [350]. In our sample, families 
comprised 3 children on average (sd=1.0, range=2-7), which despite being the best measure 
available may be under-declared and dated. 
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 Mother reported (N= 627) 
 
Self reported (N= 725) All (N=857) 
 Inattention Hyperactivity- 
Impulsivity 
Inattention Hyperactivity-
Impulsivity 
Head Motion 
(log-
transformed) 
Head Motion 
(mm) 
 Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd) 
All individuals -1.04 (1.14) -1.06 (1.10) -0.51 (0.59) -0.50 (0.62) -2.59 (0.35) 0.080 (0.032) 
Sex                  
F 
-1.24 (1.08) -1.21 (1.07) -0.57 (0.58) -0.57 (0.60) -2.62 (0.34) 0.078 (0.031) 
M -0.70 (1.17) -0.81 (1.10) -0.40 (0.62) -0.36 (0.64) -2.53 (0.35) 0.085 (0.032) 
Wave            
1st 
-1.04 (1.14) -1.07 (1.09) -0.64 (0.33) -0.28 (0.55) NA  NA 
2nd -0.64 (0.94) -0.70 (1.36) -0.61 (0.66) -0.62 (0.68) NA NA 
3rd NA NA -0.48 (0.58) -0.47 (0.60) NA NA 
 Pair correlation Pair correlation Pair correlation Pair correlation Pair correlation  
MZ 0.72 0.86 0.47 0.31 0.41 0.43 
DZ 0.15 0.51 -0.069 -0.046 0.16 0.15 
Table 15: Levels of Inattention, Hyperactivity-Impulsivity and Head Motion in the final sample 
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Statistical analyses 
Analyses were performed in R 3.1.0 [292] using OpenMx [197], which allows the use 
of family data when estimating the correlation between HM and the SWAN scores, the effect 
of covariates (age, sex, wave, design, number of siblings, time difference between scoring 
and scanning), heritability (univariate variance component ACE/ADE modelling), as well as 
the estimation of genetic correlations (bivariate ACE or ADE models, with Cholesky 
decomposition). Additional packages were used to facilitate plots and data handling [353-
355]. ACE or ADE models decompose the variance of a trait into an “additive genetic” (A) 
component that estimates the additive contribution of the genetic factors to individual 
differences; “shared environment” (C) that captures the effect of a common 
environment/household factor on a sib pair; “dominant genetic” (D) for the non-additive 
genetic contribution, and “unique environment” (E) that corresponds to the effect of person-
specific environmental factors or measurement errors on the trait variance. When several 
traits are modeled together (bi- and multivariate analyses), sources of variances are further 
decomposed into sources common between several traits and specific to each trait. This 
methodology is well known and well described [44, 199, 356]; see [46, 200] for a user-
friendly description. MZ and DZ twin pair correlations (Table 15) suggested the presence of 
genetic factors for all traits (rMZ>rDZ), with possible dominant genetic effects for the SWAN 
scores (rMZ>2rDZ). To estimate genetic and environmental correlations between the SWAN 
scores and HM, we used an AE decomposition of variance, to maximize power in our limited 
sample. In such model, the A factor would gather most of the D contribution to variance 
(when present) and genetic correlation can be interpreted as mostly additive or mostly 
dominant depending on the SWAN score considered. Correlations were corrected for 
covariates that reached significance in the univariate models, as well as time difference 
between scoring and scanning, which could mediate or confound the relationship between 
motion and ADHD levels. Significance of the correlations, covariates and model fit 
comparison were tested using likelihood ration test (nested models). We reported estimates, 
p-value and degrees of freedom of the test statistic law.  
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Results 
Preliminary tests – covariate effects, homogeneity of sampling, and genetic 
effects 
Overall, covariate effects were small or non-significant. For all SWAN scores males 
scored on average 0.18 to 0.56 points higher than females (Δdf=1, p-value < 4.7E-4). Age 
at MRI had a small effect on HM with an average reduction of 0.6% in HM per year of age 
(Δdf=1, p-value=4.0E-4) Supplementary Document 43. HM for males was greater than for 
females (Δdf=1, +3.2% on average, p-value=1.4E-3). Significant covariates were regressed 
out in subsequent analyses. 
Two tests suggested variance heterogeneity between zygosity groups (Supplementary 
Document 43) but only the variance differences in HM between groups corresponded to a 
true difference: the variance differences in self reported Inattention being driven by one 
outlier (Supplementary Document 44).  
Finally, test for “quantitative sex limitation” was significant for mother reported 
Hyperactivity- Impulsivity, suggesting different levels of heritability between sexes. 
Covariances for female pairs (0.97 in MZ, 0.74 in DZ) were higher compared with males 
(0.64 for MZ, 0.27 for DZ, Δdf=2, p-value=0.024, see S3 Table) pointing to a higher shared 
environment effect in the female group. Presence of genetic factors (MZ covariance > DZ 
covariance) was significant for all variables tested (Δdf=1, p-value<2.2E-4, S3 Table). As a 
consequence, in estimating heritability we fitted a general sex limitation model for mother-
reported hyperactivity-impulsivity (allowing the A, C/D and E components to be different 
between males and females) and standard “2-zygosity groups” ACE or ADE models for the 
3 other SWAN scores. In HM univariate modelling, we allowed the variance to be different 
between female same sex and opposite sex pairs. 
Heritability of Inattention was between 0 and 43% for maternal report with a dominant 
genetic effect explaining another 32 to 83% of the variance. For mother reported 
Hyperactivity-Impulsivity we found the additive sources to explain between 88 and 94% of 
the variance in females. The A component was only explaining 63 to 87% in males. The 
general sex limitation model outperformed standard ACE confirming tests from the 
hypothesis testing (Supplementary Document 45). Genetic correlation (rg=1) between males 
and females suggested that genes influencing Hyperactivity-Impulsivity are the same, even 
if they explain different proportion of variance within sexes. Variance of self-reported 
inattention was also attributed to additive (0-22%) and dominant (16-60%) factors, while 
additive sources of variances explained less that 34% of the self rated Hyperactivity-
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Impulsivity variance. Heritability of HM was estimated to be h2HM =0.40 [0.26,0.53] 
(Supplementary Document 45).  
 
Genetic and environmental correlations of HM and ADHD 
The phenotypic correlation between HM and the SWAN scores was fairly 
homogeneous, with correlation coefficients ranging from 0.09 to 0.20 (Table 16). All 
phenotypic correlations were significant, as suggested by the 95% CI (Δdf=1, p-values: 
7.4E-5, 2.9E-4, 0.017 and 2.0E-3). 
Most of this correlation arose from common genetic factors, with the genetic 
correlation (0.19 to 0.40) being greater than the environmental correlation (0.03 to 0.12). 
Genetic correlation coefficients with HM were significantly different from 0 for maternal 
scoring (Δdf=1, p-value=3.0E-2 for Inattention, 3.9E-3 for Hyperactivity-Impulsivity). The 
correlation of HM with self-report Inattention or Hyperactivity-Impulsivity did not reach 
significance as indicated by the CI (p-value=0.29 and 0.074). Correction for age and age 
difference between ADHD scoring and MRI scanning did not significantly improve the fit of 
the models (Δdf=4, p-value=0.23 for mother reported inattention, p-value=0.30 for 
Hyperactivity-Impulsivity, 0.30 for self scoring Inattention and 0.17 for Hyperactivity-
Impulsivity), and left the correlation estimates unchanged.  
 
Table 16: Phenotypic, genetic and environmental correlations [95% CI] between HM 
and the four SWAN scores 
 Maternal report scores Self report scores 
 Inattention Hyperactivity / 
Impulsivity 
Inattention Hyperactivity / 
Impulsivity 
Phenotypic correlations            
Head Motion 0.17 [0.09,0.25] 
p-value=7.4E-5 
0.16 [0.07,0.24] 
p-value=2.9E-4 
0.09 [0.02,0.17]  
p-value=0.017 
0.12 [0.04,0.19] 
p-value=2.0E-3 
Genetic correlations                  
Head Motion 0.24 [0.02, 0.43] 0.23 [0.07,0.39] 0.19 [-0.20,0.56] 0.40 [-0.05,1.00] 
 p-value=0.030 p-value=3.9E-3 p-value=0.30 p-value=0.074 
Environmental correlations     
Head Motion 0.12 [-0.07,0.31] 0.05 [-0.14,0.24] 0.07 [-0.10,0.25] 0.03 [-0.13,0.20] 
Correlations were calculated using OpenMx [197] to take into account the relatedness in our sample when 
computing p-values or confidence intervals. Genetic correlations were estimated using a bivariate AE model, 
correcting for sex, age and age difference between scoring and scanning. 
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Discussion 
Here, we investigated the relationship between head movement during RS-fMRI and 
SWAN scores of ADHD in a young, non-clinical population sample. We found head motion 
to be significantly correlated with self and maternal reports of Inattention and Hyperactivity-
Impulsivity. When breaking down this association into its genetic and environmental 
components, we detected pleiotropy (shared genetic effects) between HM and the SWAN 
sub-scales. Therefore, treating HM as a nuisance covariate in an RS-fMRI study of ADHD 
would likely remove some of the signal of interest.  
Our findings align with the (phenotypic) association of HM with (self reported) impulsivity in 
a similar age group (r=0.10) and in children (r=0.34) [321].  We also found a significant 
phenotypic correlation between HM and inattention, which has not been reported before 
[321]. We expanded prior findings [321] by showing that the association was driven by 
genetic factors common to HM and ADHD rather than by experimental conditions 
(environmental). Indeed, the genetic correlation coefficients were around 0.2 between HM 
and the SWAN scores. Correlations were significant between HM and the maternal report 
scores. However, they did not reach significance for the less reliable self-report scores. 
Environmental correlation estimates, on the other hand, were much lower and remained 
non-significant. This suggests that most of the phenotypic correlation between HM and 
Inattention or Hyperactivity-Impulsivity arises from pleiotropy between these traits. In other 
words, the association between in-scanner motion and Hyperactivity-Impulsivity or 
Inattention can be attributed to genetic factors shared between the traits.  
The genetic nature of the association between HM and maternal reports of 
Hyperactivity-Impulsivity raises concerns about the way HM is handled during the image 
processing pipeline and to a lesser extent during downstream analyses of neuroimaging 
studies. Indeed, our results indicate HM appears to contain meaningful information for the 
study of hyperactivity-impulsivity. Regressing out HM when studying ADHD (or Inattention 
or Hyperactivity-Impulsivity) using neuroimaging would result in a loss of information in the 
analysis, with a direct increase of the false negative rate. For example, in an analysis of 
brain changes associated with ADHD, factors contributing to ADHD, brain phenotype and 
HM would suffer from diminished power. For example in Figure 19, HM regression would 
limit the detection of common factors (common to HM, brain phenotype and ADHD: in blue) 
that we estimated to represent about a quarter of the ADHD genetic factors. HM regression 
could also reduce heritability of processed brain phenotypes that are genetically correlated 
with HM. A similar criticism can be made about HM regression in downstream analyses that 
typically include HM as a covariate in across subjects analysis [61]). However, this may have 
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little effect on the results as it is usually performed after HM regression in image processing, 
when most of the HM effects on the phenotype have already been removed. Thus, if it is 
accepted that head motion needs to be addressed to avoid false positives [61, 63, 265, 266, 
308, 309], we might have to consider approaches that do not rely on HM regression in rs-
fMRI studies of ADHD. As a consequence, the RS-fMRI studies of ADHD [324, 330, 331, 
357, 358] that performed HM regression might have suffered from reduced power, leading 
to some of the inconsistent results reported. Conversely, the recent study of neurobiological 
changes associated with HM [359] might have been partially confounded by trait Inattention 
or Hyperactivity-Impulsivity. Overall, our results could explain some of the network structure 
observed within the variance removed by HM regression [360]. Indeed, the ‘nuisance 
covariate’ approach would likely remove highly structured signal corresponding to brain 
networks of Inattention/Hyperactivity, as well as noise [360].  
A similar limitation may apply to Global Signal Regression (GRS) whose 
independence of the trait/disease of interest has been debated. Factors influencing the 
global signal in RS-fMRI are only partially known: cardiac pulsation and breathing [361, 362], 
head motion [263], intrinsic spontaneous physiological low frequency oscillations [362], 
cerebro-spinal fluid [363]. In addition, their impact on the global signal might not be uniform 
across the brain [362, 363]. For example, cardiac pulsation is more prominent in the base 
of the brain, and respiration affects mostly prefrontal and occipital lobes [362]. As a result, 
GSR regresses out physiological noise [361] and increases specificity in positive functional 
connectivity [286], but changes the distribution of FC across the brain [361, 364] and may 
exacerbate motion distance-dependent bias [313], which could lead to false positives or 
even negative FC [361]. This suggests that, similar to HM, an assessment of the association 
between global signal and trait of interest is required to understand how GSR impacts the 
results. Preliminary results suggest that global signal could be heritable, with GSR reducing 
heritability estimates of graph metrics calculated from RS-fMRI images [336].  
In addition, we presented only weak evidence that the exclusion of scans based on 
motion could cause a sampling bias (Supplementary Document 42). We were limited by a very 
small sample (8 individuals with gross motion, and only 4 with self reported scores for 
Inattention and Hyperactivity/Impulsivity; Supplementary Document 42). However, if 
exclusions were found to be associated with levels of Inattention of Hyperactivity-Impulsivity, 
researchers would have to reconsider gross motion exclusion in rs-fMRI processing.  
Some already available preprocessing methods might be employed to avoid gross 
motion exclusion and regression of HM (or other confounds), such as within-subject image 
volume censoring [63, 263]. This approach, however, does not guarantee comparability of 
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HM between groups, as only the noisiest volumes are excluded [263]. Similarly, it might not 
completely prevent sampling bias as individuals with high numbers of noisy volumes are still 
recommended to be excluded [263]. Nevertheless, censoring could still be considered a 
valid approach, if it can be shown that both exclusion and remaining estimates of motion 
between frames are independent of the trait of interest (e.g. ADHD). If motion scrubbing 
were to prove insufficient in removing HM, or if GSR had to be avoided, structural equation 
modelling (SEM i.e. a multivariate approach) could be employed as an alternative to prevent 
researchers having to choose between increased false positives or power loss in RS-fMRI 
studies. For example, SEM could allow decomposing the variance of the MRI phenotype 
into motion specific, Hyperactivity-Impulsivity specific and that which is common to HM and 
Hyperactivity-Impulsivity. Therefore, one could identify brain changes specific to ADHD but 
also brain differences driven by the combination of HM and hyperactive-impulsive profile 
(see Figure 19 for a path model with impulsivity as example). SEM more generally applies to 
all study RS-fMRI data in the presence of dependency between a confounding factor (HM, 
or global signal) and a trait of interest. It is also compatible with twin and family data for 
which the variance can be further decomposed into genetic and environmental factors [44]. 
Finally, it can accommodate phenotypes of high dimension; such as voxel-wise brain maps 
while modeling the local correlation of the voxels.  
Another alternative to motion regression or censoring could be regression of principal 
components of the voxel-wise nuisance signals from WM and CSF (aCompCor) [365]. 
Indeed, such correction appeared to make censoring redundant in a healthy adolescent 
sample, while also accounting for some of the global signal [315]. However, the 
interpretation of the principal components remains unclear and they may also be associated 
with the trait of interest, hence removing some meaningful signal. 
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Figure 19: Structural Equation Model that can disentangle the effects of HM and 
psychological trait (here impulsivity) on RS-fMRI phenotype 
The RS-fMRI phenotype variance is decomposed into 4 factors (or latent traits). The first one influences HM 
and the brain phenotype and captures false positive findings induced by HM. The second factor is common 
to HM, Impulsivity and the MRI phenotype. This source of variance can be regressed out by HM regression 
thus reducing power of detecting some brain changes associated with Impulsivity. The third factor influences 
Impulsivity and the RS-fMRI phenotype, it is conserved after HM regression. Finally the last latent factor is 
unique to the imaging phenotype and gathers the sources of variance not accounted by the 3 others. The 
use of twin and family data allows breaking down each of these factors into genetic and environmental 
components, thus showing light on the genetic structure of the associations.  
 
Finally, beyond considerations of RS-fMRI image processing, the genetic correlations 
measured here suggest that HM could be a valuable endophenotype [16] and a risk/trait 
biomarker [366] in RS-fMRI studies of Hyperactivity-Impulsivity, Inattention and, by 
extension, for ADHD. A similar trait biomarker for ADHD is activity levels (measured using 
accelerometers), which has also been genetically associated with ADHD [367, 368]. 
However, despite being two widely used measures of movement, the extent to which activity 
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level (large voluntary movement) and HM at rest (microscopic and involuntary) are caused 
by the same genes and environment factors is still unknown.  
We showed some of the correlations to be reliable across scores (self or maternal 
report), despite observations acquired at different ages. Even so, the association between 
self report scores and HM was weaker, which could be explained by noisier measurement 
[337] and perhaps by the longer time difference between self report collection and scanning. 
However, in our sample, age and time difference between scoring and scanning were not 
associated with mean phenotypes and left the correlations unchanged. This might be due 
to observations made mostly at adult age when we can expect greater stability of personality 
and ADHD traits, as shown by higher SWAN scores test-retest coefficients [341]. 
Nevertheless, we cannot exclude that the effect of time difference may be non-linear and so 
undetected. Another limitation of our study was that we could not separate hyperactivity from 
impulsivity in the analysis, nor could we investigate subtypes of impulsivity that might not 
contribute to the HM increase [321]. In addition, RS-fMRI was acquired last in the ~50 
minutes scanning session, which could potentially accentuate the strength of the 
relationship between HM and Impulsivity or Hyperactivity by increasing movement in the 
impulsive or hyperactive group. Finally, we have used a healthy population based sample 
and the correlation between HM and Inattention or Hyperactivity-Impulsivity (thus the 
influence of HM regression on the results) might be larger in a clinical sample where the 
contrasts between participants are increased, as suggested by correlations in a case-control 
sample [321]. Finally, sampling could also be a limitation as we only included imaged 
participants, who were screened for past diagnoses of mental illness and prescription 
medicine [102]. Hence, the sample used here might no be representative of the unselected 
cohorts studied for ADHD. However, heritability of SWAN scores (including higher 
contribution of environmental sources on the variance of the maternal report of 
hyperactivity/impulsivity) aligned with prior findings from full datasets [262, 337] and from 
independent cohorts that used the SWAN instrument [343, 351, 369, 370] (see S3 Appendix 
and S4 Table). In addition, we observed higher SWAN scores and head motion in males 
compared to females, consistent with previous reports on the full cohorts [262, 337] and 
results from independent studies [61, 333, 344, 345], including meta-analysis on case 
control status [345], continuous performance test [333] for ADHD. As a consequence, we 
can be confident that the results reported here are unlikely to be due to sampling bias. Sex 
differences in ADHD have been attributed to lesser inhibitory control in males and higher 
internalizing of struggle in females [333]. On the other hand, very little is known about causes 
of higher motion in men but we can hypothesise that it might be partially influenced by the 
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same factors, considering the association between the traits. Differences in heritability 
between maternal and self report scores are ubiquitous in ADHD [351, 371] and may be 
partially due to increased measurement error in self report, as suggested by the test-retest 
reliabilities that often sets the upper bound of the heritability estimates [67] (test-retest is 
around 0.45 for self report and 0.80 for mother report [337]). Lower reliability of psychiatric 
self-reports has been attributed to lower self-awareness, perspective taking, recall, 
reasoning ability, and expressive skills in adolescents/young adults [345]. However, there is 
evidence that, despite the differences in reliability, heritability of maternal report of 
hyperactivity might also well be overestimated as twins perceived as identical tend to be 
given more similar scores (expectancy effect) [348].  
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Chapter 6: Evaluation of Regional Homogeneity 
processing options on test-retest correlation 
 
 
Introduction 
For the analysis of RS-fMRI images, several metrics are available that aim to solve 
different research questions but share most of the image processing steps. The most 
common include functional connectivity (FC), Amplitude of Low Frequency Fluctuations 
(ALFF), fractional ALFF and ReHo (Regional Homogeneity). (ReHo) measures the local 
synchronisation of the neurons/voxels BOLD signal e.g. the localised neural connectivity 
[66]. ReHo is commonly calculated over brain maps by taking the KCC (Kendal Coefficient 
of Concordance) of each voxel of interest with its neighbouring voxels [66]. Refinements 
include coherence ReHo [372] and Integrated Local Correlation [373] that may be less 
sensitive to physiological noise or tissue class [372, 373] but are less often used.  
Test-retest is measured using intra-class correlations (ICC) on repeated observations. It 
captures the reliability or stability of the measurement within individuals over an (often short) 
period of time. Test-retest quantifies the signal to noise ratio of the MRI measurements and 
often sets up an upper limit for heritability estimates [67]. Thus, test-retest analysis can 
inform us on measurement quality, which is correlated with statistical power of phenotypic 
and variance component analyses. Large measurement error (low ICC) can lead to the 
following problems in the analysis of the variables:  
• Assuming the measurement error is independent from the trait of interest (e.g. 
depression), the statistical power is reduced as the observed effect size is scaled by the 
test-retest reliability. 
• A large measurement error associated with the trait of interest could cause spurious 
association and inflate the false positive rate. 
Studies have reported that test-retest reliability of ReHo measurements increases with 
scan duration [18, 22]. We could expect a moderate to high test retest (mean ICC=0.8) after 
10minutes RS-fMRI [18], while 50 minutes scans may be required to ensure an ICC greater 
than 0.7 for all voxels [22]. ReHo test-retest is also improved by using a short test-retest 
interval [22], higher number of voxels [374], smoothing [18], regression of noise (WM, CSF, 
HM) [18], fast sampling rate [18]. However, many of the factors that influence test-retest 
encompass several processing options whose effects have not been individually studied. 
 155 
Here, we used a subsample (N=59) from the Queensland Twin Imaging (QTIM) study [102] 
who were imaged on two occasions. We varied the image processing options in SPM12 
[283, 284] (Global Signal Regression (GSR) / CompCor [365], head motion regression, 
smoothing and number of voxels in KCC) in order to quantify their effect on the test-retest 
reliability. Overall, we expected a low to moderate ICC due to our relatively short imaging 
time (5min 19s). 
 
Material and methods 
Sample details and data collection 
We included 59 participants (from 37 families) from the QTIM study who were imaged 
twice (mean test-retest time: 101 days, SD=33, range 35 – 203). Participants were 22.5 
years old on average at first scan (SD=2.2, range 20 - 28), 69.5% were females. 
The RS fMRI scans were acquired on a 4 Tesla Bruker Medspec whole-body scanner 
in Brisbane, Australia. RS-fMRI was performed with a repetition time TR=2100 ms, echo 
time TE=30 ms, flip angle=90°, field of view FOV=230 mm, and total acquisition length of 
5min 19s. Thirty-six 3 mm-thick transverse slices, with 0.6 mm gap, were acquired per 
volume, yielding a voxel size of 3.6x3.6x3.0 mm. In total, 150 volumes were collected.  
During the scan participants were asked to close their eyes, empty their minds, and to try 
not to fall asleep. In addition, we also collected 3D T1-weighted scan to which the functional 
scans were coregistered. Structural scans were acquired with TR=1500 ms, TE=3.35 ms, 
TI=700 ms, flip angle=8°, 256 or 240 (coronal or sagittal), phase encoding in the second 
dimension, resulting in a FOV of either 240x240x240 or 240x240x216mm, and voxel size 
0.9 mm3. 
 
Image processing  
Images were processed in SPM12 [375] using the DPARSF toolbox [283]. We 
processed several times the images varying some of the processing options (Figure 20). 
Some steps were common to all processed versions: DICOM Images were converted in the 
NIFTI format, the first 5 volumes were discarded from the analysis to allow time for steady 
state to occur, slice-timing correction, realignment, coregistration of the T1 images to the 
functional scans, normalisation and band pass filtering (0.01-0.08 Hz) (Figure 20).  
We performed 4 sets of processing in order to study the individual effect of 
GSR/CompCor, head motion regression, smoothing and number of voxels (Figure 20). In 
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each set, only one step of the processing was altered to allow comparison of test-retest 
(Figure 20). 
In the first set (Figure 20) we processed the sample varying GRS and CompCor [365] 
(GSR vs. GSR and CompCor vs. CompCor vs. only regression of physiological noise: WM 
and CSF). CompCor regresses the principal components of the physiological signal 
estimated from the images and may better preserve the FC from the physiological [365] and 
motion confounds than competing approaches [315, 365].  
In the second step we considered 4 main techniques for head motion regression [64]:  
1) Rigid body regression that regresses the 6 motion parameters (3 for rotation and 
3 for translation) measured during realignment. 
2) “Friston 12” that regresses the 6 motion parameters and their derivatives [314].  
3) “Friston 24”, which regresses the 6 motion parameters, the 6 parameters from 
previous time point (auto-regressive effect) and their derivatives [314].  
4) Voxel-wise motion regression [264]. We did not consider motion-pruning the BOLD 
time series [263] as we already had a limited frame number. 
Then, we varied the level of smoothing (none, FWHM of 1.5, 4.5 and 6mm) as we 
expected a more reliable signal when artificially increasing the local correlation of the brain 
volumes [18].   
Similarly, we changed the number of voxels used in KCC calculation: 7 (voxels 
sharing a face), 19 (voxels sharing a vertice), 27 (voxels sharing and edge) [66]. We 
expected a signal averaged over a greater number of voxels to be more reliable [374]. 
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Figure 20: Processing pipeline for RS-fMRI data 
a) General steps of RS-fMRI processing. The steps in bold allow several options and led to multiple processing. 
b) Processing pipelines that vary GSR and CompCor  
c) Processing pipelines that vary motion regression options 
d) Processing pipelines that vary smoothing level 
e) Processing pipelines that vary the number of voxels  
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Statistical Analyses 
We used the packages oro.nifti [250] and fslr [376] to import and manipulate the ReHo 
brain maps in R [292]. We calculated test-retest intra-class correlations from the R package 
“irr” (two-way consistency ICC) [187]. We also used the matrixStats package to facilitate 
data handling [377] and vioplot for plotting the ICC distributions [378]. 
 
Results 
Test-retest reliability of ReHo was overall small to moderate in our sample, across all 
processing options (Figure 21). Thus, mean ICC ranged from 0.17 (“7 voxels”) to 0.30 
(“Smoothing 6mm”) but the voxel-wise ICC was smaller than 0.8 (Figure 21). 
GSR led to a reduced mean ICC (mean 0.22 vs. 0.25, Figure 21, Figure 22). The highly 
significant t-test reflects that and ICC was available for more than 65,000 voxels of the 
cortex, thus leading to very significant but not necessary meaningful differences. Similarly, 
CompCor improved the ICC in all scenarios considered (with or without GSR, see Figure 21). 
CompCor without GSR was the processing that maximised the mean ICC out of the first set 
of processing (Figure 21, Figure 22). In addition, we observed from the xy plots (Figure 22) 
that the most reliable voxels tend to be the most reliable across all processing.  
The options of HM processing had very little impact on the general ICC in our sample 
(Figure 21, Figure 23), with mean test-retest ranging between 0.211 (“Friston 24”) and 0.223 
(“No HM correction”). In addition, all approaches agreed on the most reliable voxels as 
indicated by a high correlation of ICC in xy plots (Figure 23).  
Finally, larger smoothing or number of voxels was associated with increased ICC 
(Figure 21, Figure 24, Figure 25). For smoothing, mean ICC increased from 0.22 (“no 
smoothing”) to 0.30 (“6mm smoothing”). In addition, smoothing may impact the distribution 
of ICC as indicated by less strongly correlated test-retest across processing versions (see 
xy plots in Figure 24). Number of voxels impacted the mean ICC (0.17 “7 voxels” to 0.22 “27 
voxels”) but the most reliable voxels were consistent across processing (Figure 25).   
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Figure 21: Violin plot showing the distribution of voxel-wise ICC for each processing 
Processing options had a small effect on test-retest distributions of voxel-wise ReHo. 
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Figure 22: Histograms of voxel-wise ICC and xy plots between processing, varying 
GSR and CompCor options 
The highly correlated ICC distributions suggest that the same voxels are reliable across processing options. 
The red line is the identity line. The red dot has for coordinates the mean of each distribution. The p-value 
corresponds to a t-test of differences in mean ICC. P=0 indicate numerical problems (p-value<1e-300).  
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Figure 23: Histograms of voxel-wise ICC and xy plots between processing, varying 
the head motion regression options 
 
The highly correlated ICC distributions suggest that the same voxels are reliable across processing options. 
The red line is the identity line. The red dot has for coordinates the mean of each distribution. The p-value 
corresponds to a t-test of differences in mean ICC. P=0 indicate numerical problems (p-value<1e-300).  
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Figure 24: Histograms of voxel-wise ICC and xy plots between processing, varying 
the smoothing options 
 
Highly correlated ICC distributions suggest that the same voxels are reliable across processing options. Here, 
some levels of smoothing appear to change the ICC distribution as indicated by a greater variance around the 
diagonal (lower correlation). 
The red line is the identity line. The red dot has for coordinates the mean of each distribution. The p-value 
corresponds to a t-test of differences in mean ICC. P=0 indicate numerical problems (p-value<1e-300).  
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Figure 25: Histograms of voxel-wise ICC and xy plots between processing, varying 
the number of voxels options 
 
The highly correlated ICC distributions suggest that the same voxels are reliable across processing options. 
The red line is the identity line. The red dot has for coordinates the mean of each distribution. The p-value 
corresponds to a t-test of differences in mean ICC. P=0 indicate numerical problems (p-value<1e-300).  
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Discussion 
Here, we calculated the test-retest or voxel-wise ReHo from a sample of 59 
participants imaged twice within the QTIM study. We built on previous work that studied the 
effect of scan duration and test-retest interval on test-retest [18, 22] or showed that 
performing nuisance regression, smoothing, an fast sampling rates could increase voxel-
wise ICC [18]. Here, we varied image-processing options to study how best to regress 
nuisance factors (e.g. GSR, CompCor, head motion) in order to maximise the reliability of 
the ReHo measurements. In addition, we described the effect of smoothing options and 
number of voxels on the test-retest. Overall, we showed that the voxel-wise ICCs were 
moderate to small (mean ICC around 0.2) across the brain and that the various processing 
options had a limited impact on the reliability (Figure 21). Low test-retest can be partially 
attributed to short scan length [18, 22], even if our estimates are lower than reported 
elsewhere (mean ICC~0.5 after a 5 min scan [18]). Such difference may be attributable to 
scanner, acquisition options or test-retest interval [18, 22].  
Our study suggested that CompCor and no GSR may slightly improve the ReHo test-
retest, each of about 10% on average. Reduction of ICC after GSR has been reported before 
[18] but the effect of CompCor on test-retest had never been studied. This result is of interest 
as GSR remains controversial in the RS-fMRI field [361, 379-384] and CompCor may 
represent a valid alternative [315, 365], which does not seem to translate into a loss of 
reliability. 
 Head-motion regression options had smaller effects on the test-retest distributions 
(5% differences in mean, see Figure 23). Voxel-wise HM regression and no HM regression 
led the greater mean ICC (0.22, see Figure 23). “Rigid body 6”, “Friston 12” and “Friston 24” 
approaches led to a small reduction in mean ICC, which could be explained by head motion 
being also moderately reliable as we have shown in this sample [262] and has also been 
reported in an independent sample [61].  
Unsurprisingly, increasing the number of voxels used in ReHo calculation or the local 
correlation (smoothing) resulted in higher test-retest, which is consistent with previous 
reports [18, 374]. This illustrates that averaging more signals typically produces more stable 
measurements. However, smoothing is often seen as artificially increasing the local 
correlations [18] and is somewhat redundant with calculating KCC over more voxels [66]. 
Furthermore, smoothing had the most effect on the ICC distribution, as indicated by the low 
correlations of voxel-wise ICC between processing (Figure 24). Thus, using 27 voxels but no 
smoothing may be the safest approach to ensure the highest ReHo test-retest while limiting 
artificial local correlation. 
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As a conclusion, our results suggest that processing options in SPM12 may have a 
small effect on the reliability of ReHo. In order to maximise test-retest we suggest applying 
CompCor to remove physiological noise, and include 27 voxels in the KCC calculation. HM 
regression options likely have a lesser impact on the test-retest and one could prefer to 
apply voxel-wise HM correction for a marginal improvement of ICC, despite a significant 
increase in processing time [62, 264]. Smoothing also increases average test-retest but 
likely introduces artificial local correlations [18]. In addition, our approach could have been 
extended to other RS-fMRI modalities (e.g. ALFF, fALFF or FC, see Chapter 4 for ICC of 
FC in the language network). 
Here, we limited our analysis to most options available in SPM12 and did not 
investigate the test-retest obtained using alternative software packages (e.g. AFNI [293]). 
We did not consider pruning frame with high levels of motion [263], which represents a 
promising approach (see [64] for review and limitations). Finally, the results may be specific 
to our scanner and replication is needed to draw strong conclusions on best ReHo 
processing options.  
Considering the low reliability of ReHo in our sample, we chose not to pursue the 
search for ReHo endophenotypes of depression as we could expect a statistical power more 
than halved for most of the voxels. In addition, noisy measurements can lead to spurious 
associations if the noise happens to be associated with depression. Our results highlight 
that a RS-fMRI scan of 10 min or more may be needed, considering the current MRI 
technology, to allow stable and reliable measurements that translate into maximal statistical 
power.  
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7 
Collaborations with the ENIGMA-MDD consortium 
to propose robust endophenotypes for depression 
 
 
 
 
 
 
 
 
 
Two meta-analyses published in Molecular Psychiatry [385] [68]  
One meta-analysis (secondary project) on subcortical brain changes in suicidal depression in 
review at Translational Psychiatry 
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Chapter 7: Collaborations with the ENIGMA-MDD 
consortium to propose robust endophenotypes for 
depression 
Introduction 
The MDD working group of the ENIGMA consortium (ENIGMA-MDD) is one of the 
30+ ENIGMA working groups [386]. ENIGMA-MDD was established to identify robust brain 
signatures of depression [385] following the lack of confirmed findings due to the use of 
inadequate sample sizes, as well as the criticisms of poor reproducibility of neuroscience 
results in general [387, 388]. To overcome this issue ENIGMA-MDD conducts large case-
control meta-analyses of brain measures, extracted using common processing pipelines 
(http://enigma.ini.usc.edu/protocols/).  
The first publication focused on subcortical volumes and included 18 groups 
worldwide, totalling 10,242 scans (2,188 MDD cases) [385]. The second publication studied 
cortical differences between cases and controls in a combined sample from 20 sites (10,105 
scans, 2,148 MDD cases) [68]. The slightly smaller sample size can be attributed to more 
scan exclusions in the cortical analysis, which is a consequence of the greater number of 
MRI artefacts around the edge of the field of view. Finally, a mega-analysis of the cortical 
and subcortical data is underway to examine how sex and age may mediate the reported 
associations. This new study may include up to 28 groups (see Figure 26). In addition to the 
case-control analyses a few secondary projects making use of the large dataset available 
have been proposed by members of the consortium (see [386] and 
http://enigma.ini.usc.edu/ongoing/enigma-mdd-working-group/ for latest details). Such 
secondary projects will focus on different brain phenotypes (e.g. DTI, shape, asymetry), 
specific aspects of depression (e.g. suicidality) or new methods (e.g. penalised regression 
to select features for MDD prediction). 
Here, we describe the nested case-control samples that we contributed to the 
ENIGMA-MDD analyses. In particular, we describe the selection and screening of cases 
and controls from the BLTS and QTIM studies. Such selection ensures comparability of 
case-control samples across groups and designs (e.g. population samples and clinical 
samples). Structural imaging was collected as part of the QTIM study (see Chapters 4-6, 8 
and 9 for details of imaging parameters and data collection). Clinical interviews were 
collected as part of the 19Up study (see Chapter 1). 
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Figure 26: ENIGMA-MDD contributing groups in 2016 
Figure available on the ENIGMA website (http://enigma.ini.usc.edu/ongoing/enigma-mdd-working-group/) 
 
Sample contributed to ENIGMA-MDD subcortical analysis 
 As per December 2013, 620 participants had completed the 19Up clinical 
questionnaire (89 DSM-IV lifetime MDD cases) and had subcortical volumes available 
(Figure 27). First, we excluded participants with DSM-IV lifetime alcohol and 
cannabis/marijuana dependence (Figure 27). We further excluded the cases that were (MRI) 
scanned before the onset of depression. This ensured that our sample could be compared 
to the clinical samples, in which cases are scanned during or following a depressive episode. 
These clinical samples compose most of the ENIMGA-MDD sample, and our exclusion 
reflects the absence of prior knowledge about the possible brain changes occurring during 
or after a depressive episode. In addition, we pruned the sample to only include unrelated 
participants. To maximise the number of cases we proceeded sequentially: first, where both 
co-twins were cases, we excluded the case with lowest number of depressive symptoms. 
Next, we excluded controls related to cases and then controls related to other controls 
(keeping the control with the least depressive symptoms). Finally, we excluded controls who 
reported having used anti-depressants (Figure 27). These steps of screening and selection 
should maximise the contrast between cases and controls and avoid the results being 
confounded by comorbid disorders. As a result, we contributed 39 cases and 285 controls 
to the ENIGMA-MDD subcortical analysis [385]. 
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Figure 27: Selection of the nested case-control sample for the ENIGMA-MDD 
subcortical analysis (December 2013) 
 
Sample contributed to ENIGMA-MDD cortical analysis 
Due to ongoing recruitment in the 19Up study (See Chapter 1), we updated the case-
control sample in October 2015 for the cortical analysis (Figure 28). A total of 2,260 
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participants (vs. 1,589 one year before) from the BLTS had completed the clinical 
assessment included in the 19Up questionnaires. On the other hand, usable cortical 
measurements were only available for 1,062 participants (vs. 1,113 for the subcortical), due 
to more artefacts impacting cortical processing. Overall, clinical and cortical variables were 
available for 821 participants (vs. 620 the year before) (Figure 27, Figure 28).  
As done previously, we excluded participants with alcohol or cannabis dependence, 
as well as those cases who were (MRI) scanned before any major depressive episode 
(Figure 28). In addition, we performed a more severe screening of cases and controls, which 
followed a concern raised by the reviewers of the subcortical paper about potential 
confounding effect of psychiatric morbidities. This concern was supported by the 
publications from the ENIGMA-SCZ [389], ENIGMA-BD [390] and ENIGMA-OCD [391] 
working groups, which all reported a reduction of hippocampal volume in cases vs. controls. 
It is still unclear whether hippocampal volume is truly decreased in most psychiatric 
disorders or whether unscreened comorbidities were at play. To overcome this problem in 
the cortical analysis, we therefore excluded participants with manic episode, lifetime DSM-
IV diagnoses of panic disorders (Figure 28). In addition, we excluded those who reported 
having been diagnosed with autism, obsessive-compulsive disorder, schizophrenia, 
anorexia, bulimia, post-traumatic stress disorder, ADHD or post-natal depression. This led 
to a handful of exclusions due to the low prevalence of these disorders in the general 
population (Figure 28).  
We further excluded controls who reported having been diagnosed with anxiety or 
depression, or who had been using anti-depressants. We also excluded controls who 
reported more than 2 depressive symptoms or met the DSM-IV diagnosis of social anxiety, 
in order to further increase the contrast with the cases (see Chapter 1 about MDD - social 
anxiety comorbidity). Finally, we pruned the sample for relatedness as described above 
(Figure 28). Consequently, we contributed 54 cases and 304 controls to the cortical analysis.  
 
Final update of the sample contributed to ENIGMA-MDD  
 We performed a 3rd and last update of the case-control sample following the 
completion of the 19Up study in June 2016 (see Chapter 1). A total of 896 individuals from 
the 19Up had available cortical measurements, and we applied the exact same exclusion 
criteria as in the 2015 update (Figure 29). As a consequence, we are contributing 57 cases 
and 239 controls to the ENIGMA-MDD mega-analysis and subsequent secondary projects 
(Figure 29). 
 171 
 
Figure 28: Selection of the nested case-control sample for the ENIGMA-MDD cortical 
analysis (October 2015) 
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Figure 29: Final update of the nested case-control sample for the ENIGMA-MDD 
analyses (November 2016) 
 173 
8 
Lingual Gyrus surface area associated with 
anxiety-depression score in young adults: a 
genetically data driven approach 
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Abstract  
  Here we aimed to identify cortical endophenotypes for anxiety/depression. Our data-
driven approach used vertex-wise genetic correlations (estimated from twin sample: 124 
monozygotic and 188 dizygotic twin pairs) to parcellate the thickness and surface area 
cortical maps into genetically homogeneous regions [70]. In an overlapping twin and sibling 
sample (N=834; aged 15-29, 66% female), in those with anxiety-depression SPHERE 
scores [50] above median we found a reduction of surface area in an occipito-temporal 
cluster, which comprised part of the right lingual, fusiform and parahippocampal gyrii. A 
similar reduction was observed in the Human Connectome Project sample (N=890, age 22-
37, 56.5% female) in those with Adult Self Report DSM-oriented scores [392] in the 25-95% 
quantiles. A post-hoc vertex-wise analysis identified the right lingual and, to a lesser extent 
the fusiform gyrus. Overall, the surface reduction explained by the anxiety-depression 
scores was modest (r=-0.10 and r=-0.040 in the HCP). The discordant results in the top 5% 
of the anxiety-depression scores may be explained by differences in recruitment between 
the studies and especially medication screening as anti-depressants have been shown to 
increase the lingual gyrus volume [393]. However, we could not conclude whether this 
cortical region was an endophenotype for anxiety-depression, as the genetic correlations 
did not reach significance, which we attribute to the modest effect size (post-hoc statistical 
power<10%).  
 
Significance Statement  
Endophenotypes may help shed light on the aetiology, cognitive impairment and 
genetics of psychiatric disorders. Here, we report a non-linear negative association between 
anxiety-depression and surface area of the occipito-temporal region, which comprises most 
of the right lingual and fusiform gyrii (N=834). This cluster was defined by applying a fuzzy 
clustering algorithm to the matrix of vertex-wise genetic correlations. We replicated this 
association using an independent sample from the Human Connectome Project (N=890). 
We could not confirm the presence of a genetic correlation due to the modest effect size of 
the association (r=-0.10) resulting in low statistical power. Our results may relate to impaired 
visual memory and deficits of attention observed in depression. 
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Introduction  
The promises of endophenotypes arise from their hypothesised ability to decompose 
or deconstruct a psychiatric disorder, which should result in more successful genetic 
analyses, redefinition of diagnosis, better study of the course of illness and development of 
pertinent animal models [16]. An endophenotype needs to satisfy 4 core criteria [16]: being 
heritable, but also genetically and phenotypically associated with the illness in the 
population, as well as state-independent (not a consequence of the disorder). The remaining 
criterion from the definition derive from the presence of genetic correlation: that family 
members of affected individuals also exhibit the endophenotype, having, on average, a 
higher disease genetic load than relatives of unaffected. Reliability of the endophenotype is 
sometimes included as part of the definition [394] and is implied by the trait heritability [67]. 
The concept has known a great popularity [395], however only a few endophenotypes 
have been identified for affective disorders [394, 396, 397]. These include: neuroticism 
[394], personal life events [9] and perceived social support [7, 8]. MRI brain measurements 
represent promising endophenotypes, being objective (not self reported), reliable [398] and 
heritable [27, 399]. There has been an explosion of proposed brain endophenotypes for 
depression, with most publications reporting unreplicated phenotypic associations based on 
small sample sizes (see [400-402] for reviews). To overcome publication bias and propose 
robust candidate endophenotypes, the Major Depressive Disorder (MDD) group of the 
ENIGMA consortium [386] has conducted large-scale exploratory case-control 
comparisons, which reported several structural brain phenotypes associated with MDD [68, 
385], but somewhat conflicting cortical signatures of depression when stratifying the analysis 
by age (cut-off 21 yrs.). In addition, another large voxel-wise meta-analysis of cortical density 
reported several volume changes associated with MDD [403]. However, more work is 
required to determine the genetic relationships between depression and structural brain 
phenotype and to replicate the reported associations.  
Here, we aimed to identify cortical thickness (CT) or surface area (SA) 
endophenotypes for depression and anxiety, which share the majority of their genetic risk 
[404, 405]. Our approach consisted of an exploratory data driven analysis in a large, 
genetically informative young adult twin sample, followed by a replication in an independent 
cohort of similar age. We used twin modelling [44, 356] to perform a genetic parcellation of 
the cortex [70], aiming at reducing of the data dimension, while ensuring genetic 
homogeneity of the brain phenotypes studied. We controlled for mean SA/CT in order to 
fully remove the confounding effect of brain or body size. In the exploratory analysis, we 
used validated continuous measure of anxiety-depression (SPHERE: Somatic and 
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Psychological Health Report) [50] (Chapter 2) collected before imaging, rather than a 
lifetime diagnostic criterion with onsets not always preceding the MRI acquisition. This 
allowed dismissing the question of state-independence but also maximised the statistical 
power by providing a larger sample with greater variance through the population. In the 
replication sample we used validated Achenbach scales [392, 406] collected at the time of 
imaging. Furthermore, we aimed to characterise the sources of covariation between anxiety-
depression and cortical measures using twin modelling. 
 
Materials and Methods 
Exploratory Sample 
Participants 
This analysis included a total of 834 twins and siblings from the Brisbane Longitudinal 
Twin Study (BLTS), also referred to as the Brisbane Adolescent Twin Study [35, 80] who 
were assessed for symptoms of anxiety-depression and who had undergone brain imaging. 
Anxiety-Depression was assessed at mean age 17 (SD=2.2, range 10-24) with imaging 
completed 4.4 years (SD 2.1) later, at a mean age of 21 (SD=3.2, range 15-29). The sample 
(66% female) comprised 23 twin-sibling trios (9MZ, 14DZ), 275 complete pairs (101MZ, 
142DZ and 32 pairs of sibling treated as DZ) and 214 singletons (Table 17). Zygosity of twin 
pairs was determined from DNA using a commercial kit (AmpFISTR Profiler Plus 
Amplification Kit, ABI) and was later confirmed by genome-wide single nucleotide 
polymorphism genotyping (Illumina 610K chip). 
Brain Imaging acquisition parameters  
Imaging was conducted using a 4T Bruker Medspec whole-body MRI on 1,161 twins 
and their siblings aged 15 to 30 (62% female), as part of the QTIM study of brain structures 
and function [33, 102, 332]. Participants were all right-handed and, screened for previous 
mental health diagnoses and anti-depressant use, as well neurological disorders and loss 
of consciousness. Structural T1-weighted 3D images were acquired with TR=1500ms, 
TE=3.35ms, TI=700ms, 240mm FOV, 0.9mm slice thickness, 256 or 240 slices depending 
on acquisition orientation: 86% of acquisition coronal (256 slices), 14% sagittal (240 slices). 
The raw T1-weighted images were corrected for intensity inhomogeneity with SPM8 [284, 
375].  Then, SA and CT measurements were extracted voxel-wise (2,384 voxels per 
hemisphere) as well as summed across the whole brain using FreeSurfer (v5.3) [407, 408]. 
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From the total imaging sample (N=1,161), we excluded 11% of participants due to 
neuroanatomical abnormalities (n=48), excessive head motion during scanning (n=16), or 
poor quality Freesurfer cortical surface reconstructions (n=57, ENIGMA quality checking 
procedure (enigma.ini.usc.edu)).  
 
Assessment of anxiety-depression 
The anxiety-depression score was calculated using the SPHERE questionnaire [50], 
which has been administered to 3,312 twins and siblings across 1 to 4 waves of the BLTS.  
When several SPHERE scores were available, we selected the closest to the time of scan. 
We previously showed that the score is moderately heritable [51] (Chapter 2) and has good 
psychometrics properties (stochastic ordering on the sum score, 3 months test-retest, 
internal consistency, limited sex bias) (Chapter 2). In addition, we have shown that the 
anxiety-depression score from the SPHERE collected in adolescence significantly predicts 
lifetime DSM-IV MDD diagnoses in young adulthood in the BLTS sample (Chapter 2).  
Informed consent was obtained from all participants, including a parent or guardian 
for those aged less than 18 years. Participants received an honorarium for each study. The 
studies were approved by the Human Research Ethics Committees of the QIMR Berghofer 
Medical Research Institute, The University of Queensland and Uniting Health Care. 
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Table 17: Detailed family structure of the QTIM and HCP sample 
 BLTS HCP 
Total sample size (Individuals) for phenotypic analysis 834 890 
Final sample size (individuals) for twin modeling 833* 853** § 
Incl. N complete trios  23 184 
 Incl. N MZ pairs + sibling 9 75 
  N DZ pairs + sibling 14 71 
  N sibling trios 0 38 
 N complete pairs  275 109 
 Incl. N MZ pairs 101 14 
  N DZ pairs 142 19 
  N twin-sib pairs 32 38 
  N sibling pairs 0 38 
 N Singletons (214 individuals) 214 83 
 Incl. N twins 181 33 
  N siblings 33 50 
* 1 individual from a family of 4 was excluded for twin modelling 
** We excluded 37 extra siblings (from families of 4+ members) with no effect on the sample characteristics 
(mean age 28, sd=3.7, range 22-37, 56.5% females after exclusion) 
§ A maximum of 12 half-siblings have been included in the sample (categorised as siblings in twin analysis) 
and this low number should have no impact on the estimates from twin modelling. 
 
Genetic parcellation of the cortex 
Twin modelling contrasts MZ twins (who share the same genetic information and 
familial environment) with DZ twins (who have the same familial environment but share on 
average half of their genetic information) and unrelated pairs (independent familial 
environment and genetic information). It allows the estimation of the proportion of inter-
individual differences attributable to the genetic variability in the population (narrow sense 
heritability or additive genetic: A), the individuals’ unique environment (E) and either the 
familial environment (C) or genetic dominance (D) [44, 46, 356]. Multivariate models allow 
the sources of variances to be further broken down into common and trait specific, providing 
an estimate of genetic and environmental correlations [44, 356]. 
Following prior work (Chen et al. 2013), and to reduce the number of brain 
phenotypes tested (hence the burden of multiple testing correction), we estimated the 
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matrices of genetic correlations between the 2,562 vertices (fsaverage4 in FreeSurfer) 
within each hemisphere using bivariate AE models [44] using OpenMx [197], which 
implements Full Information Maximum Likelihood (FIML) that allows some missingness in 
the outcome variables.  Omitting C/D in the models may result in a slight overestimation of 
the genetic correlation, as only moderate shared environmental sources of variance have 
been detected throughout the cortex [409-411]. We included a maximum of 3 individuals (1 
twin pair and a sibling) per family, which increases power for detecting A and C/D compared 
to the standard twin design [196]. 
Before estimating the genetic correlations we residualised the CT and SA measures 
to remove the effects of sex, age, acquisition orientation and intra-cranial volume on the 
correlations. We used a fuzzy clustering algorithm to identify clusters of genetically 
correlated voxels [70, 412] implemented in the R package “cluster” [292, 413] and  
determined the optimal number of clusters using silhouette coefficients [70, 412] (Figure 30). 
Such coefficients combine cluster cohesion (intra cluster differences) and separation (inter 
cluster differences) with a high coefficient indicating better-separated clusters [70]. The 
silhouette coefficients plateaued after 10 to 14 clusters, for each hemisphere and 
measurement (Figure 30). We restricted our analyses to 12 clusters, which results in a 
relatively parsimonious parcellation, to facilitate both comparisons across hemisphere and 
with previous work [70]. For each cluster we calculated the mean thickness and surface 
area, reducing the cortex to a total of 48 phenotypes. See Figure 31 for cluster visualisation 
and labelling. 
Our clusters matched the ones previously described [70] with most of the vertices 
being consistently clustered together (Figure 32), despite large differences in sample 
demographics [70].  
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Figure 30: Silhouette coefficients of the clustering scenarios 
Vertical dashed line corresponds to 12 clusters per hemisphere and measurement, which we used to 
parcellate the cortex.
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Figure 31: Summary of genetic parcellation of the cortical thickness and surface area 
Clusters are labelled 1L to 12L for the left hemisphere and 1R to 12R for the right one. 
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Figure 32: River plots that compare the QTIM clusters (left) to the VETSA clusters (right) 
 
a) Comparison of clustering for cortical thickness brain maps between QTIM and VETSA 
b) Comparison of clustering for surface area brain maps between QTIM and VETSA 
Cluster names on the left hand side of the plots correspond to the QTIM clusters (see Figure 31 for labels). In addition, the colours should match those of Figure 31. 
Cluster names on the right hand side of plots correspond to the names given in the VETSA paper [70]. Percentages represent the proportion of vertices that are 
clustered together across samples. All bands representing more than 25% of the vertices of each cluster are labelled.  
Large bands gathering most of the vertices suggest for almost all hemispheres and modalities a 1 to 1 mapping of the QTIM clusters onto the VETSA clusters.  
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Association between cortical measurements and anxiety-depression 
First, we tested the phenotypic association between the anxiety-depression SPHERE 
score and both SA and CT for each of the genetic clusters. In order to capture complex 
associations, we modelled linear, quadratic and cubic relationships using natural splines, 
implemented in R [292]. This approach allows the detection of both linear and U-shaped 
(quadratic) relationships, as well as changes limited to the extreme of the anxiety-depression 
continuum (cubic), or even a mixture of these. To limit the effect of outlier scores on the 
results, we winsorised four observations with SPHERE sum scores greater than 20 (more 
than 4SD away from the mean, heavy right tail). 
 In order to control for sample relatedness, we used a mixed model that integrates 
the variance-covariance of observations via a 834x834 kinship matrix (calculated with R 
package “kinship2” [186]). To estimate the parameters of the models, we used the “hglm” 
package [261] that relies on extended quasi-likelihood [414-416]. The significance of the 
anxiety-depression score (and all fixed effects) was tested using Student tests (test statistic: 
b/SD(b) ). We included as covariates the linear and non-linear effects of age (at 
questionnaire and age at scan), sex and waves, as well as total SA or CT in order to fully 
remove the effect of sex and age, strongly associated with head/body size. 
In order to avoid an overly stringent multiple testing correction, we estimated the 
effective number of independent brain phenotypes from the eigenvalues of the correlation 
matrix [201]. This method provides an accurate and fast alternative to permutation tests 
[201].  We estimated the effective number of genetic clusters to be 33 (out of a total of 48) 
[201], after regressing out the covariates (age, sex, acquisition, wave, meant CT or SA) that 
tend to inflate the coefficients of the correlation matrix. This translates into about 99 
independent tests (as we are testing 3 effects: linear, quadratic and cubic), which yields a 
significance threshold of 5.2E-4 [417] corresponding to a FWER (Family Wise Error Rate) 
smaller or equal to 5%.  
Then, we used bivariate (AE) twin models to estimate the genetic and environmental 
correlations between cluster measurements and anxiety-depression. Covariates used in the 
phenotypic analysis were regressed from the brain measurement and the residuals were 
used in the twin analysis (see Table 17 for sample composition). We tested the significance 
of the heritability estimates as well as the genetic and environmental correlations using 
likelihood ratio test on nested models (1 degree of freedom tests), and corrected for the 
number of tests performed. Twin analyses were performed in OpenMx [197]. We also 
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conducted a post-hoc analysis to highlight which voxels from significantly associated genetic 
clusters were driving the phenotypic association with anxiety-depression.  
 
Replication Analysis 
Participants 
We used MRI and Achenbach Adult Self Report (ASR) questionnaire [406] data for 
890 participants (mean age 28 SD 3.7 range 22-37, 56.5% female) from the Human 
Connectome Project (HCP) [73, 74] to replicate our results.  In twin modelling, a maximum 
of 3 participants per family were included, resulting in 184 complete trios, 109 pairs and 83 
singletons (See Table 17 for detailed breakdown).  
 We downloaded the pre-processed T1 structural scans from the HCP sample [72]. 
Minimal processing of the structural images by the HCP team consists in removing spatial 
artefacts and T1 alignment [71, 418], using FSL [282, 419] and Freesurfer [408].  We then 
used Freesurfer (v5.3) to extract the voxel level and genetic cluster measures of SA and CT 
in the same space as the QTIM scans. 
We used the two ASR scores that were available: the anxiety-depression syndrome 
scale [406] and a DSM-oriented scale that we constructed by summing the DSM-oriented 
scales for both anxiety and depression [420]. The correlation between the DSM-oriented 
anxiety and depression scales was 0.66 (95%CI 0.62-0.70) and mostly driven by common 
genetic sources of variance: rG=0.87 (95%CI 0.70 1.00), rE=0.54 (95%CI 0.42 0.64). The 
high phenotypic and genetic correlations suggest that combining the 2 DSM-oriented scales 
is a valid approach. Participants reported an average syndrome score of 5.7 (SD=5.2, range 
0-33) and an average DSM-oriented score of 8.0 (SD=5.6, range 0-35). The phenotypic 
correlation between the DSM-oriented and syndrome anxiety-depression score was 0.90 
(95%CI 0.89 - 0.91), with comparable genetic and environmental correlations (rG=0.91, 
95%CI 0.84 0.95, rE=0.89, 95%CI 0.85 0.92). Notably, the genetic correlation between the 
2 scores was significantly different from 1 (p-value=1.2E-4), suggesting that they may have 
some unique genetic sources of variance. All ASR scales have previously shown good test-
retest and internal consistency [392]. In addition, the ASR syndrome scale is heritable 
through adolescence [421] and captures a stable construct across age and sex [422]. DSM-
oriented and syndrome based scales appear to comparably predict affective disorder 
diagnoses [423-425].  
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Analysis 
We considered for replication all significant associations with genetic clusters 
identified in the exploratory analysis. As previously, we tested for linear, quadratic and cubic 
association with the brain phenotypes. We also corrected for sex, acquisition variables, total 
hemispherical SA or CT, linear and non-linear effects of age as well as familial relatedness 
using a kinship matrix [186].  We controlled for multiple testing in the replication analysis by 
estimating the effective number of independent phenotypes carried in the replication step 
[201]. We further corrected for testing linear, quadratic and cubic relationships and for 
considering the 2 ASR anxiety-depression scores. ASR scores more than 4 standard 
deviations from the mean were Winsorised to limit the influence of outliers (heavy right tail) 
on the results. 
We then explored the voxel-wise associations within replicating clusters and further 
decomposed the associations into their genetic and environmental components using 
bivariate AE twin models in OpenMx [197]. As previously, we regressed out the covariates 
before twin modelling. 
 
Results 
Exploratory Analysis 
Across the 48 brain clusters only one (cluster 6R for SA), comprising the lower part 
of the occipital cortex, was associated with the anxiety-depression score from the SPHERE, 
after correcting for multiple testing (third order spline: β=-0.037, SD= 8.6E-3, rP=-0.10, p-
value=2.4E-05, Table 18). Surface area in this cluster appeared to peak for participants with 
a median SPHERE score (score=2.8) and to be substantially decreased (up to 1 SD lower) 
in those with a high-anxiety depression score (Figure 33a). Fitting AE models, heritability was 
estimated to be 0.55 (95%CI: 0.32 0.73) for the 6R cluster for SA and 0.28 (95%CI: 0.14 
0.41) for anxiety-depression (SPHERE), but neither the genetic nor environmental 
correlations between these traits reached significance (cubic correlations: rG=-0.068, p-
value=0.35 and rE=-0.084, p-value=0.11; linear correlations: rG=-0.20, pvalue=0.35 and 
rE=0.0091, p-value=0.91). 
The 6R cluster for SA consists of a total of 94 vertices and is located in the occipital 
cortex. It comprises most of the fusiform gyrus (56.6% or 43 vertices) and the 
parahippocampal gyrus (56.5% or 13 vertices) as well as the lower part of the lingual gyrus 
(33.8% of the gyrus or 22 vertices) and the medial part of the lateral occipital cortex (12.6% 
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or 12 vertices). To identify if a specific or multiple regions of the 6R cluster were driving the 
non-linear association between SA and the anxiety-depression SPHERE score we restricted 
our analysis to the 94 voxels in the 6R cluster. Using a significance threshold that accounts 
for the extra number of tests performed (p-value<4.2E.4), 61 voxels were found to be driving 
the cubic association between SA of the cluster 6R and the anxiety-depression SPHERE 
score (p-value range: 5.9E-06 3.8E-04, correlation range: -0.13 -0.091, Figure 34a). When 
decomposing the phenotypic association using an AE model, none of the genetic or 
environmental correlations were significantly different from zero.  
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Table 18: Summary of discovery and replication analysis 
  
First order spline 
(linear) 
Second order spline 
(quadratic) 
Third order spline 
(cubic) 
  
Beta (se) 
r 
p-value 
Beta (se) 
r 
p-value 
Beta (se) 
r 
p-value 
B
LT
S SPHERE 
scale 
0.010 (6.0E-3) 
r=0.030 
0.094 
-0.021 (6.5E-3) 
r=-0.69 
1.6E-3 
-0.037 (8.6E-3) 
r=-0.10 
2.4E-5 
H
C
P 
ASR DSM-
oriented scale 
-0.18 (0.060) 
r=-0.040 
3.2E-3 
0.015 (0.12) 
r=0.0022 
0.89 
0.15 (0.120) 
r=0.022 
0.13 
ASR 
syndrome 
scale 
-0.032 (0.076) 
r=-0.0064 
0.68 
-0.044 (0.10) 
r=-0.0088 
0.67 
0.079 (0.15) 
r=0.012 
0.61 
Significant associations (after multiple testing correction) are reported in bold 
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Figure 33: Non-linear associations between anxiety-depression and surface area of the genetic cluster 6R 
The solid line represent the regression effect of the significant spline order. The dashed line combines the association for the linear, quadratic and cubic splines and 
the anxiety-depression SPHERE score and the SA of the 6R cluster. The y-axis corresponds to SA after removing the effect of the intercept and all other covariates. 
The vertical dashed bars indicate the 5, 25, 50, 75 and 95% quantiles of the scores distributions 
a) Association between SA and cluster 6R SA and the SPHERE anxiety-depression score (QTIM sample). The reduction of surface area is observed in participants 
with SPHERE score greater than 2.9 (median score, see plain line: 3rd order natural spline).   
b) Association between SA for cluster 6R and the ASR DSM-oriented (left panel) and syndrome based (right panel) anxiety-depression scores. A consistent reduction 
of surface area was observed in participants with ASR DSM-oriented scores between 4 and 19 (25% - 95% centiles; see plain line: 1st order natural spline). No 
significant association was found with the ASR syndrome based scale. 
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Figure 34: Voxel-wise phenotypic association of surface area with anxiety-
depression scores within cluster 6R 
Bottom view (top) and medial view (bottom) of the right hemisphere. The left panels show the cubic effect sizes 
(correlations) for each voxel of the 6R cluster for SA (94 voxels). The right panels show the significance (p-
value) of the association in –log10 scale. Voxels are represented as square edges; the mesh represents the 
Freesurfer tessellation of the cortex. 
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a) Vertex-wise association between SA and anxiety-depression (SPHERE score) in the QTIM sample (N=833). 
The significance threshold of 4.2E-4 is reached for p-values greater than 3.4 in the log scale. 
b) Vertex-wise association between SA and anxiety-depression (DSM-oriented score) in the HCP sample (N= 
890). 
 
Replication Analysis 
We found a significant (first order spline) association between the DSM-oriented 
score for anxiety-depression and SA of the 6R cluster (Table 18), using a significance 
threshold of 8.5E-3, which corresponds to a FWER<5% considering 6 independent tests (3 
tests of association for 2 anxiety-depression scores).  This association supports our finding 
in the QTIM data set, of a reduction of SA (r=-0.040, p-value=3.2E-3) in participants with 
moderate anxiety-depression score (25-95 centile) (Figure 33b), which we reported above.  
In the HCP dataset, we also showed that SA of the 6R cluster was moderately 
heritable (0.63; 95%CI 0.52 - 0.72) after regressing mean SA and the other covariates, as 
well as the anxiety-depression scores: 0.36 for the DSM oriented ASR (95%CI: 0.20 - 0.51) 
and 0.41 for the syndrome based ASR (95%CI 0.24 - 0.56). When breaking down the 
phenotypic association between DSM-oriented scale and 6R SA, neither genetic nor 
environmental components reached significance (linear correlations: rG=-0.090, p-
value=0.37 and rE=-0.032, p-value=0.59). Likewise when using the ASR syndrome scale 
(rG=-0.078, p-value=0.56 and rE=-0.059, p-value=0.49).   
We then tested the association between each voxel of the cluster with the DSM-
oriented scale. We estimated the number of effective independent voxels to be 7 [201] after 
regressing out the covariates’ effect on the vertex-wise measurements. Thus, we used a 
significance threshold of 3.6E-3, which accounts for 13 independent tests (6 previously and 
7 for the voxel-wise testing). Nineteen (out of 94) voxels located in the medial posterior part 
of the cluster survived multiple testing correction (-log(p-value)>2.4, r in -0.040 -0.068, Figure 
34b). Thirteen of these were located in the lingual gyrus and were also associated with the 
anxiety-depression scores in QTIM. A further 3 neighbouring vertices from the fusiform gyrus 
were also consistently associated to anxiety-depression across the 2 samples (Table 19). As 
previously, vertex-wise genetic and environmental correlations did not reach significance. 
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Table 19: Summary of post-hoc vertex-wise association testing for SA of the 6R 
cluster 
 N total 
vertices 
in each 
gyrus 
N vertices for 
cluster 6R 
N vertices 
associated 
in vertex-
wise 
analysis- 
QTIM 
N vertices 
associated 
in vertex-
wise 
replication 
analysis - 
HCP 
  N MNI 
coordinates 
  
Parahippocampal 23 13 x in 14 33 
y in -64 -50 
z in -19 -6 
13 0 
Lingual 65 22 x in 7 32 
y in -107 -68 
z in -4 6  
22 13 # 
Fusiform 76 43 x in 24 43 
y in -102 -58 
z in -19 3 
22 3• 
Lateral Occipital 95 12 x in 21 45 
y in -109 -91  
z in -8 0  
0 2 
# All vertices associated in QTIM. Vertices correspond to numbers 144, 570, 573, 2220, 2244, 2252, 2253, 
2258, 2262, 2264, 2265, 2266, 2269 of the FreeSurfer fsaverage4 parcellation (MNI coordinates: x in 7 20, y 
in -107 -82 and z in -3 6). 
• All vertices associated in QTIM. Vertices correspond to number 2263, 2267 and 2270 of the FreeSurfer 
fsaverage4 parcellation (MNI coordinates: x in 24 27, y in -98 -92, z in 0 3). 
 
Discussion  
Here, we used twin modelling to derive a genetic parcellation of the cortical thickness 
and surface area ribbons, reducing each hemisphere to 12 measurements. The surface area 
of one region (cluster 6R) comprising part of the lingual, fusiform, parahippocampal and 
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lateral occipital gyrii showed a significant association with the anxiety-depression score from 
the SPHERE in the QTIM sample.  We replicated this association in an independent sample 
of similar age, using data from the HCP, in which we found an association between the 
DSM-oriented score and surface area in the 6R cluster. Both associations suggested a 
decrease of surface area in participants with anxiety-depression scores above average (50-
95% quantiles). A post-hoc vertex-wise analysis suggested that the lingual vertices (and to 
a lesser extent fusiform) might drive the association. We cannot conclude whether the 
observed association is specific to the right hemisphere due to differences in the cortical 
parcellation between hemispheres (Figure 31, in the left hemisphere the occipital cortex is 
composed of a unique cluster).  
Interestingly, a meta-analysis (472 cases, 680 controls, from 12 published studies, 
mean age 43, partially medicated) identified significant reductions of GM density [426] (often 
considered as a proxy for volume) in right lingual, fusiform and parahipocampal gyri [403]. 
The authors found little evidence for publication bias and the voxel-based morphometry 
approach cannot be confounded by head/body size. This echoes results from the meta-
analysis by the ENIGMA-MDD group, which reported a significant reduction of right lingual 
gyrus surface area in adolescent depression (237 cases, 294 controls) [68] (non-significant 
association with fusiform or parahippocampal).  Though the meta-analysis by ENIGMA did 
not correct for mean SA and included medicated cases, it is also not totally independent 
from the present study as it included QTIM participants (26 cases, 140 controls).  Even so, 
in other work, right lingual GM density has been identified as a predictor of anti-depressant 
response, with higher density predicting better response to first treatment [393]. The non-
respondent group showed lower performance in 3 aspects of the Stroop test (neutral word, 
colour word and error control), and a post-hoc analysis in cases showed right lingual density 
to be associated with better error control (Stroop), and non-verbal memory (Rey-Kim 
memory test). This is coherent with neurological case reports that highlight the crucial role 
of the lingual gyrus in visual memory [427]. Furthermore, impaired visual memory has been 
associated with 1st episode MDD [428] and with adolescent MDD [429]; lower Stroop 
accuracy has also been reported in adult MDD [430], while more research is needed in 
pediatric depression [431]. Finally, reduced right lingual volume was also reported in adult 
MDD cases (partially medicated) [432], following traumatic brain injury [433].  
Our results suggest that the reported right lingual gyrus volume (or density) reduction 
in depression could be driven by reduced surface area, at least in early adulthood, which 
may be associated with visual memory and attention deficits in depression. In addition, the 
right lingual surface area may be associated with anti-depressant response, which could 
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explain why the findings are not consistent across samples partially medicated. This could 
also explain the difference between the QTIM and HCP results that pointed to a 
normalisation of 6R cluster area in HCP participants with the top 5% anxiety-depression 
scores. HCP participants were not screened for previous or current use of anti-depressant 
medication, so it is possible that some of the participants with the highest DSM-oriented 
scores may have been medicated. Conversely, screening in QTIM may have excluded 
individuals with extreme levels of anxiety-depression and we may be only observing part of 
the association. 
Reduction of right fusiform gyrus volume has also been reported in off-medication 
adult patients [434], but several large studies of older (medicated) participants attributed this 
reduction to reduced cortical thickness [68, 435]. In addition, cortical thickness of the right 
fusiform in MDD cases with comorbid generalised anxiety was even more reduced [435]. 
The central role of the right fusiform gyrus in face perception is suggested by a wealth of 
evidence [436], from neurological case reports of prosopagnosis (face blindness) [437-439], 
behavioural studies [440] and imaging studies [436, 441]. Decrease of the right fusiform grey 
matter density was observed in developmental prosopagnosis [442] and in congenital 
prosopagnosia [443]. In addition, both studies reported an association between right 
fusiform volume and performance in face identification [442, 443]. Reviews on adult 
depression suggest a general reduced accuracy of face expression evaluation, coupled to 
increased attention and response bias in expression evaluation toward sadness [444].  
In adolescent depression, more research is needed to confirm the mixed evidence of 
impairment in face (and face expression) processing [431]. The observed reduction of 
fusiform gyrus surface in young adults might relate to the poorer face recognition and 
processing of face expressions reported in adult depression but we did not have the 
cognition data to test such hypothesis. However, our results only weakly point to the fusiform 
gyrus and do not align with previous studies that only reported a reduced fusiform thickness 
associated with MDD [68, 435]. Overall, we cannot rule out that medication or sample age 
explaining some of these differences, as well as the hypothesis of delayed cortical 
development in depressed participants, implying a normalisation of cortical surface in mid-
adulthood that leaves a more permanent decrease in thickness [68]. 
In line with previous publications [70, 445] that reported significant heritability of 
cortical thickness and surface, we confirmed that the SA of the 6R cluster is significantly 
heritable (h2QTIM=0.55, h2HCP=0.63), even after correcting for total SA, suggesting that this 
region is influenced by specific genetic sources of variance, that do not contribute to global 
SA. In addition, all anxiety-depression scores were comparably heritable (h2SPHERE=0.28, 
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h2DSM-ASR=0.36, h2ASR=0.41), in line with the known heritability of depression from twin and 
family studies [3, 4, 446].  In the bivariate analysis, because of the modest phenotypic 
association, we had limited statistical power to determine whether common genetic or 
environmental factors were driving the observed phenotypic association. Indeed, a post hoc 
power analysis indicates that we had, at best, 10% power to detect the observed genetic 
correlation in QTIM and HCP (taking into account observed heritability and effect sizes, 
assuming an AE model and a risk a=5%). A combined analysis of the 2 samples would not 
confer a statistical power greater than 22%. The limited power can also explain the instability 
of the correlations estimated in both samples, even if differences in anxiety-depression 
questionnaire, sample composition or recruitment could also be at play. 
Our study has several limitations. Firstly, we did not perform a strict replication as the 
anxiety-depression scores differed across studies, and the shape of the relationship differed, 
which we attributed to differences in sample recruitment. In addition, the association 
between 6R SA and anxiety-depression scores in the HCP was only observed using the 
DSM-oriented score, which we attribute to differences in scores distribution, which can 
impair detecting non-linear associations. Indeed, despite high (phenotypic and genetic) 
correlations between the scores (r=0.90, rG=0.91), the correlation between spline orders 
was lower (r=0.79 between first order splines of the 2 anxiety-depression scores, 0.56 
between second order and 0.73 between third order), which reflects differences of scale and 
distribution. Differences in genetic sources of variances (genetic correlation different from 
1) are unlikely to completely explain the result differences, as the correlation remained high.  
Further limitations include our clustering approach, which can impair detecting 
localised structural changes associated with anxiety-depression, as the thickness and 
surface are averaged over large cortical regions. In addition, we did not investigate sex or 
age specific changes that may reflect depression subtypes with different aetiology [5, 447]. 
However larger samples would be required to overcome the multiple testing correction 
burden from a vertex-wise analysis or the loss of power resulting from study stratification. 
Finally, the interpretation of our results is limited by the scarcity of robust research on 
cognitive and imaging aspect of pediatric depression and of normal neuro-development. The 
Research Domain Criteria (RDoC) is, in that sense, a great initiative that will assist making 
connections between cognition, imaging, genetics and psychiatric illnesses. 
In summary, we identified another candidate endophenotype for depression, which 
is heritable, and shows a replicable phenotypic association with anxiety-depression scores. 
The vertex-wise post-hoc analysis suggested that a reduction of SA in the ventral part of the 
lingual gyrus could drive the observed association. Longitudinal studies beginning in 
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adolescence would be needed to precise the temporal and causal relationships between 
brain development, cognition and mental health.  
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GWAS and the genetics of brain phenotypes? 
 
 
 
 
 
 
 
 
 
The Review of GWAS on brain morphology has been published in NeuroPsychological Review [27] 
 I presented the work on power of multivariate GWAS at the 2016 Behavioural Genetic Association 
meeting (Brisbane).  
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Chapter 9: GWAS and the genetics of brain phenotypes 
Abstract 
 This chapter is divided into 3 sections. First, we review the GWAS of brain 
morphology, which was included in a published review [27].  Because this article was 
published at the beginning of 2015, we also provide an update of the literature in the last 
paragraph.  
In the second section, we highlight the power limitation arising from performing 
GWAS on more and more brain phenotypes without substantial increase in sample sizes. 
We hypothesise that a multivariate approach would overcome this issue and provide greater 
statistical power than a univariate approach. We describe a method to calculate the 
statistical power of a multivariate GWAS, based on the path coefficients of ACE/AE 
multivariate twin models (Cholesky decomposition). We calculate the power of 2 real-case 
scenarios: multivariate GWAS of subcortical volumes and hippocampal subfield volumes. In 
both scenarios we showed a substantial power increase arising from a multivariate approach 
compared to the univariate approach.  
The last section focuses on the hypothesised simpler genetic architecture of 
endophenotypes that justifies using endophenotypes to break down the genetics of complex 
traits. We compare effect sizes of genome-wide significant SNPs from GWAS on 
depression, schizophrenia, Alzheimer’s disorder, rheumatoid arthritis, ICV, putamen and 
hippocampus volume and show that they are consistent with brain phenotypes being less 
complex than psychiatric/neurological disorders. We conclude that brain phenotypes 
represent great candidate endophenotypes for such disorders. 
 
Review of GWAS on brain morphology 
GWAS: A decade of publications 
The past decade has seen a number of milestones for GWAS, beginning with the first 
report of genome-wide association (found for age-related macular degeneration in a modest 
sample of 96 cases and 50 controls [448]). Just two years later, the first large-scale GWAS 
was conducted (for common familial diseases; ~2,000 cases per disease and 3,000 shared 
controls; total N=16,179; [449]). Modest effect sizes were observed, with significant loci 
explaining only a small proportion of trait heritability. This study was followed by more than 
1,900 GWAS [450, 451], in which hundreds of SNPs, all with small effect sizes, were 
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associated with Mendelian and complex disorders [452-454]. More recently, imaging 
phenotypes have been the target of GWAS in order to identify specific genes responsible 
for the moderate to high heritability found for brain morphology. The largest study thus far is 
for subcortical volumes (N>30,000, Hibar, Stein [455]). 
 
A well-described methodology 
Several excellent reviews have described the main steps in a GWAS [456, 457], 
including meta-analysis methods [458, 459] and software [458, 460-462], as well as specific 
issues such as imputation [460] and genome-wide significance levels [463-467]. An 
overview of GWAS and GWAS meta-analysis methods is given in Figure 35 (summarising 
the GWAS processing and analyses undertaken at each site, with an emphasis on the 
further methods and requirements of a meta-analysis, as well as key references). 
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Figure 35: Flowchart of genome-wide association study meta-analysis 
 
First, at each site the phenotype is extracted from the MRI image(s), using a rigorous 
processing pipeline that maximises signal to noise ratio and reliability of the measurement. 
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In a meta-analysis it is essential to establish a common protocol that can be used across 
sites (participant inclusion and exclusion criteria, software for extracting the brain phenotype, 
software version and quality control (QC) checks, inclusion of covariates) to ensure 
harmonization of the phenotype [458, 468]. Similarly, at each site the same QC checks (e.g. 
call rate, minor allele frequency, Hardy–Weinberg outliers, technical artefacts, cryptic 
relatedness, and population outliers) of the genotypes are essential and can prevent false 
positives [468, 469]. Each site then imputes their genotype data from the same reference 
panel [470, 471]. Imputation allows the same set of SNPs to be analysed across sites, 
despite the use of different SNP chips with distinct SNP content [468]. Once both the 
phenotypic and genetic data have been extracted the sites use standard software [462, 472, 
473] to test the association of every SNP with the phenotype. For a quantitative trait such 
as a brain volume this is the difference in mean score associated with the probability of 
having the alternate SNP allele. Sites with twin or family data control for individual 
relatedness in the regression [462, 474, 475].  
In a meta-analysis, each site uploads the regression summary statistics (sample size, 
strength of the association and p-value for every SNP) to a central site. The data are then 
quality controlled to remove results from SNPs with low MAF (e.g. less than 1%) and poor 
imputation, as well as checking for evidence of population substructure, which is a major 
confound when correlated with the trait/disease studied [465, 466, 476, 477]. Because 
different ethnic groups can have different SNP allele frequencies, even if geographically 
close [465, 466], random sampling within a heterogeneous population can create false 
positive association or reduce the power of detection [476, 477]. Population heterogeneity 
is assessed by calculating the ratio of the median test statistic to that of the expected 
(lambda) and by plotting the expected and observed distribution of p-values (quantile-
quantile or QQ plot), see Figure 4. A greater frequency of “high” p-values (e.g. >10-4) than 
expected by chance and a lambda different to 1 suggest an unaccounted population 
structure. These spurious effects can be reduced by excluding genetic outliers, regressing 
out principal genetic components [454, 478], using Genomic Control [479], mixed models 
[480], population stratification [480] or family data [462]. 
The threshold for declaring genome wide significance of an association test is a p-
value <5.0x10-8. This corresponds to a Bonferroni correction from an estimated 1 million 
independent loci (0.05/1,000,000) in a European genome [464]. The GWAS results can be 
summarised in a Manhattan plot in which the significance level is represented (Y-axis) for 
all SNPs tested (X-axis). Several meta-analysis approaches allow aggregating the results 
[458, 459] with more or less power and sensitivity to heterogeneity [458]. Remaining 
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differences between sites (e.g. MRI field strength, population differences) can be included 
as covariates. Ultimately, a meta effect size and p-value summarise the SNP association 
across sites, and heterogeneity metrics (Q and I2) used to assess the remaining between-
study variance and heterogeneity not due to chance [458].  
Replication of the results in an independent sample is important in GWAS in order to 
validate findings and eliminate false positives [454]. Often only a set of significant SNPs 
from the discovery stage are carried on to the replication phase, which reduces the burden 
of multiple testing correction. To provide a more accurate estimate of the effect size, 
discovery and replication samples are often meta-analysed. 
 
GWAS for brain morphology 
We conducted an extensive search in PubMed for GWAS using brain morphology 
phenotypes. The search terms “GWAS AND brain AND (MRI or DTI)” returned 168 articles, 
among which 27 were GWAS of brain morphology, including one GWAS of head 
circumference [481]. An additional 6 articles used fMRI or magnetic resonance spectroscopy 
(MRS) [482-487] (described in Supplementary Document 46). We confirmed that our PubMed 
search was exhaustive by crosschecking with the GWAS catalogues [450, 451, 488], and 
identified no additional studies. We omitted two studies that selected SNPs based on a 
round of penalised regression [489, 490], which limits their comparison with standard 
GWAS. Table 20 lists the 25 GWAS for brain morphology, as well as the most recent GWAS 
on brain and subcortical volumes [455] – a total of 26 GWAS. The number of publications 
over the last decade is presented in Figure 36.  
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Figure 36: Number of published GWAS for brain morphology per year  
Studies with replicated results appear in gray. The GWAS that focused on brain phenotypes were identified 
in PubMed using search terms “GWAS AND brain AND (MRI OR DTI)” and manually filtered to select 
GWAS. We ensured that our list was exhaustive by running PheGenI (Phenotype-Genotype Integrator [451]) 
and genome.gov [450] searches for each phenotype previously identified. The second ENIGMA paper [455] 
was not included for 2015. 
204 
 
Table 20:Published GWAS for brain morphology 
Authors Phenotype Discovery sample size Replication sample Number of 
sites  
(if meta-
analysis) 
Samples Ethnicity 
Discovery / 
Replication  
Genome –Wide 
significant 
associationa 
Replicationa 
Seshadri, 
DeStefano [491] 
TBV, lobe volume (frontal, parietal, 
occipital, temporal), hippocampal 
volume, lateral ventricle volume, 
temporal horn volume, WMHI 
Framingham: 705 stroke and 
dementia free controls 
NA NA European No NA 
Baranzini, Wang 
[492] 
T2 lesion load, 
Total brain volume 
1677 (794 MS, 883 HC) NA NA European No NA 
Potkin, Guffanti 
[493] 
Hippocampal volume ADNI: 381 (172 AD, 209 HC) NA NA European No NA 
Debette, Bis [17] Subclinical brain infarcts CHARGE: 9,401 participants CHARGE: 1,822 
Caucasian and 644 
African-American 
7 and 2 
(replication) 
European / European 
and African 
No No 
Shen, Kim [494] 142 measures of GM density, 
volume and cortical thickness 
ADNI: 733 (175 AD, 354 MCI, 
204 HC) 
NA NA European No NA 
Stein, Hua [495] Temporal lobe volume, Hippocampal 
volume 
ADNI: 742 (173 AD, 361 MCI, 
208 HC) 
NA NA European No NA 
Bakken, Bloss 
[496] 
Mean cortical thickness TOP: 94 SCZ TOP: 327 (181 HC, 
97 BD, 49 P&AD)1 
NA European / European 2 SNP in perfect LD No 
Fornage, Debette 
[497] 
WMHI CHARGE: 9,361 CHARGE:3,024 
ARIC: 807 African-
American 
7 and 2 
(replication) 
European / European 
and African 
6 SNP in high LD 
(r2>0.8) 
2 SNP in CHARGE, 
No replication in 
ARIC 
Furney, Simmons 
[498] 
Hippocampal volume, entorhinal 
cortical volume, whole brain volume, 
ventricular volume, entorhinal 
cortical thickness 
AddNeuroMed and ADNI: 939 
(236 AD, 424 MCI, 279 HC) 
NA NA European No NA 
Hibar, Stein [499] Voxel-wise regional brain volume 
differences (vs template) 
ADNI: 731 (413 MCI, 237 HC) NA NA European No No 
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Stein, Hibar [500] Left and right caudate volume ADNI: 734 (172 AD, 205 HC, 
357 MCI) 
QTIM: 464 twins and siblings 
NA 2 European No NA 
Bakken, Roddey 
[501] 
Visual cortical surface TOP: 421 [496] 
ADNI : 482 (180 HC, 302 MCI)2  
PING: 278 
NA 3 All European  2 SNP in LD 
(r2=0.88) 
NA 
Bis, DeCarli [502] Hippocampal volume CHARGE: 9,232  CHARGE: 2,318 12 and 2 
(replication) 
European / European 3 SNP All replicated 
Ikram, Fornage 
[503] 
Brain volume, intracranial volume CHARGE: 8,175 CHARGE: 1,752 7 and 2 
(replication) 
European / European 2 SNP for IV All replicated 
Melville, Buros 
[504] 
Hippocampal volume, total brain 
volume, WMHI 
MIRAGE: 981 (454 AD and 537 
HC) 
ADNI: 692 (168 AD, 336 MCI, 
188 HC) 
MIRAGE: 319 (188 
AD, 231 HC) 
2 and 1 
(replication) 
European / African-
American 
1 SNP and APOE ε4 
for HV 
1 SNP for HV c 
APOE ε4 for TBV 
  
Only APOE ε4 
replicated 
NA 
 
No 
Paus, Bernard 
[505]b 
Total brain volume interaction with 
cigarette exposure during pregnancy 
SYS: 599 (290 females, 309 
males) 
ALSPAC: 2,601 
females 
NA European / European 8 SNP in high LD 
(r2>0.7) in females 
No 
Stein, Medland 
[506] 
Total brain volume  ENIGMA1: 6,500 
 
NA 20 European & Hispanic No NA 
 Intracranial volume ENIGMA1: 7,607 CHARGE: 8,175 22 and 1 
(replication) 
European & mixed / 
European 
1 SNP d Yes 
 Hippocampal volume ENIGMA1: 10,372  
CHARGE: 10,779 
NA 23 European & mixed  1 SNP d NA 
Taal, St Pourcain 
[481] 
Head circumference EGG EAGLE CHARGE:19,089 NA 7 and 6 
(replication) 
European  2 SNP NA 
Hibar, Stein [507] Lentiform Nucleus volume (bilateral) ADNI: 706 (162 AD, 246 MCI, 
198 HC) 
QTIM: 639 (364 families) 
NA 2 European 1 SNP NA 
Hibar, Medland 
[508] 
Regional hippocampal volume ADNI:511 (323 MCI) 
QTIM: 571 (335 families) 
TOP: 172 
NA 3 European 1 SNP NA 
Jahanshad, 
Rajagopalan [335] 
59 measures of brain fibre 
connectivity 
QTIM:169 twins and siblings 
 
QTIM:162 twins and 
siblings 
NA European 1 SNP Yes 
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Hass, Walton [509] Hippocampal volume MCIC: 328 ENIGMA: 7,795 
(5,775 HC, 2,020 
cases) 
IMAGEN: 1,663 HC 
NA All European No No 
Sprooten, Fleming 
[510] 
Fractional anisotropy  BFS: 150 (70 at risk for BD, 80 
HC) 
NA NA European No NA 
Wang, Xiang [511] Grey matter volume reduction in 4 
regions associated with SCZ 
125: (74 SCZ, 54 HC) NA NA Chinese No NA 
Hohman, Koran 
[512] 
Left Inferior lateral ventricle dilation ADNI: 700 (197 HC, 388 MCI, 
115 AD) 
 
NA NA European  No NA 
Hibar, Stein [455] Intracranial volume, 
subcortical volume (hippocampus  
putamen, pallidium, amygdala, 
thalamus, nucleus accumbens, 
caudate nucleus) 
ENIGMA2: 13,163 
 
 
 
 
ENIGMA2: 15,031 
ENIGMA2: 1,878 
ENIGMA2: 3,046 
ENIGMA2: 13,113 
 
 
 
 
28 and 22 
(replication) 
European / European 
& Mixed 
 
 
 
 
 
1 SNP for ICV 
2 SNPs for HV d 
 3 SNPs for PV d 
  
 
1 SNPs for CNV c 
1 for PV c 
All but the SNP 
associated with ICV 
 
 
 
NA 
 
 
a At the discovery stage the Genome-Wide (GW) significance threshold for one phenotype = 5.10-8. When several traits are tested a correction for multiple testing is required. When this step had been 
ignored we calculated and used a threshold of 5.10-8/Ntrait (Bonferroni correction). A similar correction for multiple testing has been applied at the replication stage to control for the number of tests 
performed. Thus in Melville, Buros [504] the SNP rs2298948 associated with hippocampus volume was reported to be genome-wide significant (p-value=4.98 x 10-8) but after correction for multiple 
phenotype testing the association did not survive. Likewise, the SNP rs1970546 association with total brain volume [491] is considered non-significant after correction for testing of multiple phenotypes.  
b Paus, Bernard [505] study differs from the other GWAS on head size in that it aimed to identify SNP effects increased by cigarette exposure during pregnancy, thus measuring a GxE (genetic-
environmental) interaction effect [513]. 
c GW significance using discovery and replication samples 
d SNP significant overall, but heterogeneous effect across ethnicity groups suggests the SNP might have an effect only in individuals of European ethnicity 
AD Alzheimer’s disease; BD bipolar disorder; CSF cerebral spinal fluid; GM grey matter; HC healthy controls; ICV intracranial volume; MD major depressive disorder; MCI mild cognitive impairment, MS 
multiple sclerosis cases; P&AD psychotic and affective disorder cases; SCZ schizophrenic cases; WMHI white matter hyperintensities.  
AddNeuroMed a European collaboration for the discovery of novel biomarkers for Alzheimer's disease [514]; ADNI Alzheimer’s Disease Neuroimaging Initiative; ALSPAC Avon Longitudinal Study of Parents 
And Children; ARIC The Atherosclerosis Risk in Communities Study; BFS Bipolar Family Study; CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology; DNS Duke Neurogenetics Study; 
EGG Early Growth Genetics consortium; ENIGMA Enhancing NeuroImaging Genetics through Meta-Analysis (1 and 2 refer to study phases; Thompson, Stein [386]); FBIRN Functional Biomedical 
Informatics Research Network consortium; MCIC Mind Clinical Imaging Consortium; QTIM Queensland Twin Imaging Study [102]; SYS Saquenay Youth Study; TOP Thematically Organized Psychosis 
study. 
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Volumetric phenotypes are the most widely studied (19 out of 26 publications). A 
main reason being that brain volumes are more straightforward to extract from the images. 
The most common is hippocampal volume with 10 studies [455, 491, 493, 495, 498, 502, 
504, 506, 508, 509] followed by global head size (i.e. total brain volume, intracranial volume, 
head circumference) with 8 publications [455, 491, 492, 498, 503-506]. Hippocampal volume 
has been a main focus as it is commonly associated with early Alzheimer’s disease [515, 
516], schizophrenia [517], depression [518] and memory ability [519]. Other volumetric 
phenotypes include lobe volumes [491, 495], ventricle [491, 498], caudate [455, 500], 
lentiform nucleus [507] and temporal horn volume [491]; grey matter (GM) volumes [494, 
511], tensor based morphometry [499], and most recently nucleus accumbens, putamen, 
palladium, thalamus and amygdala volumes [455]. There are also three GWAS for white 
matter hyperintensity [491, 497, 504] and one for subclinical brain infarcts [17]. White matter 
lesions are frequently associated with ageing [520] , mood disorders [521] stroke [520, 522], 
and with decreases in cognitive functions [523]. More recently, with DTI becoming acquired 
in larger samples, two studies focused on fractional anisotropy [510] and brain fibre 
connectivity [335].  
Of the 26 GWAS, 12 are meta-analyses, of which 11 (92%) report a genome-wide 
significant result. In contrast, for single site studies only three (out of 14, or 21%) found an 
association that was genome-wide significant (Table 20). The higher rate of genome-wide 
associations in meta-analyses is due to the larger sample sizes, hence power. For example, 
the mean sample size in the meta-analyses discovery stage was 6,891, range [1,181-
19,089], while in the single site or single centre studies the mean was 577, range [94-1,677]. 
The largest (and most recent) meta-analysis included >13,000 individuals from 28 sites in 
the discovery sample, and >17,000 scans from 22 sites for the replications [455]. This 
illustrates the trend towards larger samples through the formation of consortia (e.g. 
CHARGE [524, 525] or ENIGMA [386]). ENIGMA has seen its discovery sample size almost 
double in three years [455, 506] with an additional six groups (sites) joining, and the 
availability of larger samples at many of the participating sites. This increase in statistical 
power resulted in more genome-wide significant associations (e.g. for hippocampal volume 
from one SNP to two) and allowed more phenotypes to be studied (e.g. from three to eight 
traits). Ultimately, increased power leads to greater precision in estimating SNP effect sizes, 
as well as enhancing the probability of detecting rare variants with small effects [459, 473, 
526, 527]. 
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Eleven of the 26 GWAS included a replication sample [17, 335, 455, 496, 497, 502-
506, 509], though two [17, 509] used a more lenient significance threshold, which increases 
the probability of reporting false positives in the discovery phase as well as limiting the 
confidence in the replication because it is based on a weak prior [528, 529]. Debette, Bis 
[17] did not replicate their association and the results from Hass, Walton [509] were 
suggestive. Among the other nine publications that identified genome wide significant 
results, seven replicated their findings, at least partially [335, 455, 497, 502-504, 506]. 
Replication samples were smaller than the discovery sample in about half of the studies 
[335, 497, 502-504]. However, due to the smaller number of tests at replication compared 
to discovery, most replication samples were well-powered. Failure to replicate can arise from 
a false positive result at the discovery stage [530] or insufficient statistical power in the 
replication phase [530].  
At a SNP level, the 26 GWAS identified 29 genome-wide significant associations 
(excluding loci in strong linkage disequilibrium) with one of the brain morphological 
phenotypes (Table 21). Of these, 21 findings (73%) replicated, five (17%) were only 
suggestive (no replication) and three (10%) did not replicate. One study used head 
circumference as a replication proxy for brain volume and found suggestive support [505]. 
In addition, some results were replicated in European populations only [455, 497, 506] 
suggesting a different SNP effect across ethnicities, while others replicated in ethnically 
diverse populations [504].  
As can be seen in Table 21 and Figure 37, the associated SNPs are scattered over 13 
different chromosomes, with Chromosome 12 having the largest number of variants (5) 
associated with hippocampal volume [455, 502, 506], intracranial volume [506] or head 
circumference [481]. On several chromosomes, including the sex chromosomes (X and Y), 
which are often excluded from an analysis, no genome-wide associations have been 
identified. Multiple variants were reported across independent studies at locations: 12q14.3 
(rs17178006, rs6581612, rs61921502) and 12q24.22 (rs7294919, rs77956314) for 
hippocampal volume [455, 502, 506] and 17q21.31 (rs9303525, rs17689882) for intracranial 
volume [455, 503]. For some of the regions there were several SNPs in linkage 
disequilibrium that passed the genome-wide threshold [486, 497, 501, 503, 505]. Though it 
is not possible to identify the causal variant(s) from a set of variants in linkage disequilibrium 
using p-values [452], together with expression quantitative trait loci (eQTL), and regulatory 
information they can provide suggestive evidence [531-534].  
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Table 21: Genome-Wide significant associations reported in the GWAS literature of brain morphology 
Phenotype SNP  Chr Minor 
allele / 
Other 
MAF Intronic (gene)/ 
intergenic 
p-valuea % Change in 
structureb 
(% Variance 
Explainedb) 
Replicated Combined 
Sample 
Sizea 
 Study  
Hippocampal 
volume (dorsal 
region only) 
rs6703865  1 A/G 0.08 
(European) / 
0.17 
Intronic (F5/SELP) 1.14x10-9  NA (1.67) Yes 2,102  Melville, Buros [504] 
rs14521252
7  
3 G/T 0.04 Intronic (FBLN2) 1.25 x 10-8  NA (2.26) NA 1,345  Hibar, Stein [455] 
rs17178006  12 G/T 0.10 Intronic (MSRB3) 5.3 × 10−11  
 
-2.4 (0.66) Yes 6,252  Bis, DeCarli [502] 
rs6581612  12 C/A 0.27 Intergenic 7.1 × 10−11  
 
-1.2 (0.36) Yes 11,501  Bis, DeCarli [502] 
rs61921502  12 G/T 0.16 Intronic (MSRB3) 6.87x10-11 -1.01 (0.26) Yes 16,209  Hibar, Stein [455] 
rs7294919 
 
12 C/T 0.09 Intergenic 2.9 × 10−11 
 
+2.1 (0.32) Yes 9,662  Bis, DeCarli [502] 
rs77956314  12 C/T 0.09 Intergenic 2.82x10-15 -1.40 (0.36) Yes 17,190  Hibar, Stein [455] 
rs7294919  12 C/T 0.099 Intergenic 6.70 x 10-16  +2.1 (0.27) Yes 21,151  Stein, Medland [506] 
rs9315702  13 A/C 0.44 / 0.22 Intronic (LHFP) 1.52x10-08  NA (1.44) Yes 2,102  Melville, Buros [504] 
- 19 ε4 0.19 APOE 1.58 x 10-33  NA (6.43) Yes 2,102  Melville, Buros [504] 
Total brain volume rs716890c 4 G/C 0.24 Intronic (KCTD8) 5.4 x 10-09 -5.2 (5.57) (different 
phenotype
) 
557  Paus, Bernard [505] 
- 19 ε4 0.19 APOE 4.25 x 10-10 NA (2.19) Yes 
(Caucasia
n) 
1,683  Melville, Buros [504] 
Intracranial volume rs4273712 6 G/A 0.27 Intergenic 1.8 x 10-13  +1.0 (0.64) Yes 8,175  Ikram, Fornage 
[503] 
rs10784502 12 C /T 0.49 Intronic (HMGA2) 1.12 x 10-12  +0.60 (0.17) Yes 15,782  Stein, Medland [506] 
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rs9303525 17 G/A 0.22 Intronic (KANSL1) 7.6x10-15  -1.1 (0.72) Yes 8,175  Ikram, Fornage 
[503] 
 rs17689882 17 A/G 0.22 Intronic (CRHR1) 7.72x10-9 -0.96 (0.26) No 12,822  Hibar, Stein [455] 
Head circumference rs1042725 12 C/T 0.48 Intronic (HMGA2) 2.8×10−10 -0.14 (0.20) NA 19,089  Taal, St Pourcain 
[481] 
rs7980687 12 A/G 0.20 Intronic (SBNO1) 8.1×10−9  +0.16 (0.24) NA 
 
13,134  Taal, St Pourcain 
[481] 
Putamen Volume rs945270 14 G/C 0.42 Intergenic 1.08x10-33 -0.94 (0.52) Yes 28,275  Hibar, Stein [455] 
 rs62097986 18 A/C 0.44 Intronic (DCC) 1.01x10-13 +0.58 (0.20) Yes 28,036  Hibar, Stein [455] 
 rs6087771 20 C/T 0.29 Intronic (BCL2L1) 1.28x10-12 -0.64 (0.20) Yes 25,540  Hibar, Stein [455] 
 rs683250 11 G/A 0.37 Intonic (DLG2) 3.94x10-11 +0.51 (0.17) Yes 26,258  Hibar, Stein [455] 
Caudate Nucleus 
Volume 
rs1318862 11 C/T 0.42 Intergenic 6.17x10-9 -0.74 (0.22) Yes 15,031  Hibar, Stein [455] 
White matter 
hyperintensity 
rs3744028c 17 C/A 0.18 Intronic (TRIM65) 4.0×10-15  +3.4 (0.46) Yes (in 
Europeans
) 
13,084  Fornage, Debette 
[497] 
rs1055129 17 G/C 0.30 Intronic (TRIM47) 2.3×10-11  +2.0 (0.33) Yes (in 
Europeans
) 
13,084  Fornage, Debette 
[497] 
Average Cortical 
Thickness 
rs4906844c  15 A/G 0.47 Intronic 
(LOC100128714) 
1.08 × 10−8 -3.0 (2.90) No 1,054  Bakken, Bloss [496] 
Visual Cortical 
Surface 
rs238295c 2 T/G 0.36 Intronic (GPCPD1) 6.5 × 10−9  +0.6 (2.4) Yes  1,181  Bakken, Roddey 
[501] 
Left PCC - left SPC 
brain fibre 
connectivity 
rs2618516 11 T/C 0.36 Intronic (SPON1) 3.23 x 10-9 +0.2 (10.4) No 331  Jahanshad, 
Rajagopalan [335] 
Lentiform Nucleus 
volume (bilateral) 
rs1795240 1 A/G 0.43 Intergenic 4.79 x 10-08  -1.7 (2.08) NA 1,345  Hibar, Stein [507] 
a Reported for combined discovery and replication samples. 
b Percentage change in volume per effect allele was based on the absolute value of the final combined effect (discovery + replication) divided by a weighted average of the brain structure across all sites in 
the discovery sample and then multiplied by 100. Percentage variance explained was based on the combined discovery and replication samples using the following equation (t2/((n-k-1)+t2) where the t-
statistic is the beta-coefficient from the regression model (controlling for covariates) divided by the standard error of the beta estimate, where n is the total number of subjects, and where k is the total number 
of covariates (given as 2 for all studies) [455] 
c Several SNPs in LD also passed the Genome-Wide significance threshold 
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NOTE: SNPs are ordered by phenotype and location on the genome. Multiple significant hits within a haplotype are reported together, effect allele, MAF, effect size, and p-values are reported for the most 
significant SNP that appears in bold. The reference SNP cluster ID, starting with “rs”, corresponds to a unique SNP in the dbSNP database [535]. The genomic region contains the chromosome number 
followed by letters “p” (short arm of the chromosome) or “q” (long arm) and the SNP position from the centromere (e.g. 12q24 for chromosome 12, position 22 off the long arm).  
Chr chromosome; NA not available; NR+ not reported, but positive result; NR- not reported, but negative result; PCC posterior cingulate cortex; SPC superior parietal cortex. 
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Figure 37: Karyotype of the genome-wide significant hits of the GWAS on brain morphology 
 
DTI diffusion tensor imaging; PCG posterior cingulate gyrus; SPL superior parietal lobe; VBM voxel-based morphometry. For an interactive karyotype of all GWAS 
findings, see the GWAS diagram browser of the NHGRI GWAS Catalog [451, 488].  
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  In Table 21, we also report the minor and major alleles, the MAF, and the nature 
(intronic, intergenic) of the published SNPs. Most (83%) are common SNPs with a 
MAF>10%, ranging from 4% [508] to 49% [506]. In addition, 19 of the reported SNPs are 
intronic (within gene sequence), with the other 10 being intergenic (between genes). This 
overrepresentation of intronic SNPs aligns with the global trend observed across all 
published GWAS [536], though, as already noted above, the causal variants could be 
different from the reported ones or located in different genetic regions [452, 536]. Even so, 
the finding of a large number of causal variants in intergenic regions suggests the need for 
a better understanding of gene expression regulation in non-coding regions [537]. Several 
techniques, such as eQTL or chromosome conformation capture (3C) are now being used 
to characterise non-coding regulatory variants [537]. In addition, epigenome-wide 
association studies (EWAS), where traits are associated with methylated sites [538, 539], 
can help characterise the effect of non-coding epigenetic variants. However, as recent 
studies suggest methylation of some CpG sites could have a genetic origin [540], a better 
integration of EWAS and GWAS [541] may be necessary to disentangle the genetic and 
epigenetic components of a trait. 
Also shown in Table 21 are p-values and effect sizes. We show effect sizes as both 
percentage change in structure size (e.g. from mL or mm3), and as percentage of variance 
explained, to allow comparisons across studies. Percentage change in structure was not 
possible where means and variances were not reported. Most of the SNPs had small effects 
on structure size, that is, they accounted for less than a 1% change in size per effect allele. 
The largest percentage change in size (-5.2%) was identified in a relatively small sample 
(N=599) and did not replicate [505], and therefore is likely to be overestimated [542]. 
Percentage of variance explained was also small, being less than 1% in the larger studies. 
Much larger estimates of variance explained were found in smaller studies. This 
phenomenon is well known in genome-wide association studies and reflects a combination 
of imprecision due to poor power and “winner’s curse”, where the effect within discovery 
samples is affected by bias away from the null. The combination of evidence from multiple 
studies via meta-analysis has been shown to produce more accurate estimates. 
It is common for variants to have small effects on complex traits, leaving the total 
variance explained by all the GWAS hits (genome-wide significant heritability or h2GWS) often 
far below the heritability measured from twin studies [543, 544]. For example, genome-wide 
significant variants currently explain only 7% of variance for schizophrenia (from 108 
genome-wide significant SNPs) [545]. This gap, often referred to as missing heritability 
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[546], remains substantial for complex traits, even though the percentage of variance 
explained by genome-wide associations has risen, as the power of studies has increased 
[452].  
As we indicated earlier, a greater proportion of variance can be explained by 
considering all SNPs in aggregate (SNP heritability) using tools such as GCTA [47, 547]. 
Assuming brain structure phenotypes are similar to other complex traits, SNP heritability 
estimates will likely be about half that estimated from twin studies [548, 549]. Of the first 
SNP heritability estimates reported for brain structure [550, 551], the best powered study is 
consistent with this assumption. This study found a SNP heritability of 23% for white matter 
hyperintensity, which was considered conservative due to limited SNP coverage (N=2,336; 
<500,000 SNPs [550], compared to estimates of 55-80% from twin and family studies [552-
554]. As GCTA requires thousands of unrelated individuals, the earlier study of SNP 
heritability for multiple GM and WM volumes was considerably underpowered (N=747), with 
confidence intervals covering almost the entire range of possibilities [551]. Even so, as larger 
samples are amassed, it is likely that common SNPs from current genotyping will account 
for more of the missing heritability in brain morphology.  
Accumulating evidence shows that most of the missing heritability is “hidden” [555]: 
due to low power, and in causal SNPs neither tagged nor imputed [452, 536, 555]. These 
include unknown causal SNPs in LD with identified hits, unobserved structural variations 
(insertions, deletions, inversions and translocations) as well as less common (rare (< 0.1%)) 
SNPs [546], which could be identified in the future using Whole-Genome Sequencing, (i.e. 
the entire genome is sequenced) [556, 557]. In addition, non-additive genetic variance could 
also explain some of the missing heritability [558].  
 
Challenges for future GWAS in neuroimaging and emerging approaches 
A major challenge for genome-wide studies in neuroimaging is to work out how best 
to handle the high dimensional imaging and genetic data without generating too many false 
positives or false negatives. Voxel-wise brain maps are an example of high dimensional 
phenotypes that, when combined with genotype data can cause the number of tests to 
skyrocket in GWAS. Several multivariate approaches have been tried, for example, parallel 
independent component analysis (ParaICA) [559, 560], sparse-reduced rank regression 
(sRRR) [561], or reduction of the brain map based on its genetic structure [334, 508]. 
Though sample sizes were limited (less than 500 individuals), these exploratory analyses 
reported a handful of SNP associations with parietal lobe activation [559] or a gene network 
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associated with brain wiring [334]. These methods are not easily adapted to meta-analysis 
and ideally require the sharing of scans and genotypes across studies [559, 561]. 
Gene-based analyses can also be used to reduce dimensionality by aggregating SNP 
effects across genes and excluding intergenic loci [e.g. 490]. While the number of tests 
performed per phenotype is reduced (there are only around 18,000 genes in the human 
genome), the number of phenotypes across a voxel-wise brain map is considerable and 
thus the burden of correcting for these multiple tests remains. As GWAS have become better 
powered gene-based analyses are often used to complement GWAS, as illustrated in [455]. 
In addition, pathway association analyses, which groups genes in terms of their biological 
interactions can reduce the multiple testing [562].  
Ultimately, the reduction of dimension, as well as the prioritisation of SNPs or voxels, 
leads to a (over)simplification of the relations between phenotype and genotype and does 
not make complete use of the data collected. Thus, the optimal solution is not to reduce the 
number of tests performed, but rather to correct for multiple testing while taking into account 
the correlated structure of genotype and brain maps. For example, imaging specialists can 
evaluate the significance of a signal peak, or that of a cluster of voxels within a brain map 
[563], using results from random field theory (RFT) [289]. A concurrent approach derived 
from genome-wide significance threshold calculation, has proposed a genome-wide brain-
wide significance threshold of 5.0x10-12, based on the empirical evaluation of correlational 
structure of voxel level data from two independent cohorts of only 10,000 independent tests 
brain wide [467]. Further development of these and new methods should arise from conjoint 
methodological efforts and the cross-fertilization of ideas between the fields of neuroimaging 
and genetics.  
Lastly, with GWAS findings for brain volumes starting to emerge, it is now possible to 
construct a polygenic score from an individual’s SNP data [59]. These scores are created 
by summing an individual’s effect (risk) alleles for a given phenotype, each weighted by the 
effect size identified in an independent discovery sample. The set of loci is limited to those 
with a p-value below a defined threshold in the discovery sample, though in principal, all loci 
can be included. Polygenic scores provide an estimate of the genetic liability for a trait (or 
disease) and can be used to test associations or to predict a complex trait, even if larger 
GWAS samples are required to achieve useful levels of prediction [255]. Ultimately, the 
quality of a polygenic score depends on the precision of the SNP effect estimates, which 
requires large(r) GWAS samples [255]. As yet, no polygenic scores have been computed 
for measures of brain morphology, mainly due to the small number of genome-wide 
significant hits and small discovery sample sizes, which would contribute to noise in the 
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score. However, a polygenic risk score based on 26 SNPs that have shown replicated 
associations with Alzheimer’s disease (AD) identified an association between cortical 
thickness and genetic liability for AD [564].  
 
Literature review update 
Since the sections above were published, the ENIGMA and CHARGE consortium 
[386] reported new variants associated with ICV [78] and hippocampal volume using 
>30,000 brain scans [76]. Another CHARGE paper focused on white matter lesion [565]. In 
addition to reporting new associated variants, these larger studies also confirmed the 
previously identified associations [76, 78]. In addition, a new manuscript is in preparation 
that focuses on cortical thickness and surface area. Furthermore, a publication investigated 
the relationship between polygenic risk scores of structural brain phenotypes and cognitive 
traits [566].  
 
Upcoming ENIGMA GWAS of cortical thickness and surface area 
For this new analysis we contributed 996 participants with available T1 structural scan 
(see Chapter 8-9 for scanning details) and GWAS data. As previously, the T1 images were 
processed using the ENIGMA pipeline (http://enigma.usc.edu/) that ensures identical 
processing options across groups and involves manual quality control (QC) to remove 
observations or subject with incorrect cortical parcellation. Cortical measurement were 
extracted for each region of the freesurfer anatomical atlas (34 regions) [567] and averaged 
between left and right hemisphere. Participants were on average 22.4 years at imaging 
(sd=3.3, range 15-30), 65% were females.  GWAS data QC steps and imputation are 
described in Chapter 3. Here, we used the 1000genomes phase1 imputation reference 
panel and included several covariates in the analyses: age, age2, sex, age*sex, age2*sex, 
4 genetic principal components, acquisition direction, GWAS chip and average thickness or 
surface areas. GWAS were run in RareMetalWorker 4.13.7 [568], controlling for genetic 
relatedness of the participants via a genetic relatedness matrix. Summary statistics have 
been shared with the consortium for further SNP QC and meta-analysis. 
 
Consideration about the statistical power of ENIGMA GWAS 
 The ENIGMA initiative has been outstanding in merging resources from all over the 
world to perform large scale GWAS and identify variants contributing to ICV, and subcortical 
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volumes. The sample size reached over the years makes ENIGMA one of the most powerful 
meta-analytic sample to study the genetics of the brain (the other being the CHARGE 
consortium). For example, the ENIGMA sample grew from ~8k scans in the first GWAS [506] 
on ICV and hippocampal volume, to ~30k in the most recent analyses (with CHARGE) [76, 
78] and we can expect the sample size to increase again for the cortical analysis. However, 
the number of phenotypes considered has increased even faster (from 2 to 8 subcortical 
volumes to 68 cortical measurements) and we can expect even more phenotypes to be 
included in future projects (e.g. DTI or voxel-wise cortical morphology).  
 This raises the question of statistical power of brain GWAS analyses as the number 
of tests increases faster than the sample size. This led us to compare the statistical power 
of univariate and multivariate GWAS using realistic scenarios, in order to illustrate the 
potential and limitations of each approach.  
 
Multivariate GWAS to study MRI phenotypes  
Review of multivariate GWAS methods 
Multivariate GWAS analyses often consist of a series of MANOVAs, which results in 
only 1 test of association per SNP over all outcome variables considered. Such tests have 
been implemented in popular GWAS software such as PLINK [249, 569]. Another 
approaches worth mentioning include MultiPhen [570] that tests if the vectors of effect size 
of the SNP on the outcomes is different from 0 (likelihood ratio test), or GEMMA, which 
further allows to model relatedness of the participants [571]. These two tests have been 
shown to perform similarly when using continuous traits and common variants (MAF>5%) 
[472, 570, 572]. In addition, Bayesian methods are also available [573, 574], but controlling 
for familial or cryptic relatedness in these models may not be straightforward. Finally, 
Medland et al., [575] proposed an integrated model that allows testing SNP effects on the 
common factor as well as on variable-specific factors, but it remains unclear which factors 
to test and how to handle the correction for multiple testing. 
For completeness, we should mention methods that rely on univariate GWAS but 
also aim at limiting the multiple testing arising from sequential univariate analyses. One 
option is to run a GWAS on the first principal component calculated from the outcome 
variables [576]. Unsurprisingly, this approach is the most powerful when a common factor 
explains all of the genetic variance of the phenotype [572, 577]. On another hand, TATES 
and competing approaches, aim at performing a multivariate association test using 
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univariate GWAS summary statistics and a matrix of correlation of the outcome variables 
[572, 578]. It is unclear how these perform compared to the direct multivariate approaches 
as conflicting results have been reported [472, 572]. Galesloot et al., [472] reported a greater 
power of all multivariate approaches over univariate and TATES, but limited their simulations 
to up to 3 phenotypes and arbitrary heritabilities, effect sizes and genetic or environmental 
correlations. In addition, the power increase was greater when the SNP induced correlation 
was in the opposite direction as the residual correlation [472]. Conversely, van der Sluis et 
al. [572], reported a greater power of TATES over MANOVA in almost all scenarios 
considered. Their simulations varied in term of correlation structure, number of variables 
and correlation strength [572], and one wonders how these options were selected and if 
they are really pertinent in the study of brain phenotypes. These discrepancies reinforce the 
view that the statistical power of concurrent approaches depends on the covariance 
structure of the phenotypes [472, 572, 577, 579], as nicely summarised by Zhou et al., [571]: 
 
“[…] in a GWAS setting no single test will be the most powerful in detecting the many 
different types of genetic effects that could occur. It is possible to manufacture 
simulations so that any given test is most powerful” 
 
To overcome this, we aimed to calculate the statistical power of real-case multivariate 
GWAS of brain phenotypes. We chose a MANOVA model to test the SNP association with 
brain covariates, as it is the direct multivariate equivalent of the univariate GWAS approach 
and does not require time-consuming simulations to estimate power [75]. The comparison 
between TATES-like methods and MANOVA is of interest but is outside the scope of this 
analysis.  
 
MANOVA power calculation 
 Power calculation of multivariate linear models such as MANOVA can be seen as an 
extension of the power calculation in the univariate case [75]. However, unlike the univariate 
case, we can choose between 4 test statistics: Roy’s largest root (RLR), Hotelling-Lawley 
trace (HLT), Wilk’s lambda (WL) (implemented in PLINK [569]) and Pillai-Bartlett trace (PB). 
We focused on the last three as they show the highest sensitivity [580-585] and can be well 
approximated by an F-distribution [75, 586-588]. Multivariate power calculations require 
specification of the sample size (N), design (X, SNP and covariates), the vector of effect 
sizes (b, effects of SNP on phenotypes) and a matrix of residual correlations (S, “residual” 
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means here that the SNP effect has been removed) [75]. From there, power can be 
estimated using non-central F-approximation whose degrees of freedom depend on the 
choice of test-statistic [75]. 
 To obtain realistic b and S for the set of brain phenotypes considered, we used a 
Cholesky decomposition of a multivariate twin model (Figure 38). This is arguably one of the 
most general multivariate models and allows as many independent genetic or environmental 
factors as phenotypes, while minimising the number of paths. In this model all the genetic 
variance is accounted for by the p additive genetic latent factors and the SNP can only affect 
one of the independent genetic factor (e.g. Figure 38). Using a twin sample we can estimate 
the matrices of path coefficients a and e that describe the relationship between latent 
variables and phenotypes: P = aA + eE.  
In the example below (Figure 38), the SNP affects the latent factor A2: A2= b*SNP + 
e. Thus, our vector of effect size can be written as: 
   
 β = 0, %. '((, %. '(), … , %. '(+  
 with '(( … '(+ the path coefficients of the factor A2, estimated from the twin model, SNP 
the categorical variable of the observed genotype at a particular locus (e.g. 1: genotype aa, 
2: aA, 3: AA). We can then choose b based on the maximum path coefficient and the SNP 
MAF so that the SNP explains at most ,( of a phenotype variance. For example if a23 is 
the largest path coefficient (in absolute value) and we enforce that the SNP explains at most ,(	of the variance of one trait, we can use: 
  
  b = /012 134 ∗607 
With 89 8:; = 2=>?(1 −=>?), and '() the standardised path coefficient. Specifying 
the SNP effect size in terms of ,( (variance explained) simplifies the analysis as it 
integrates the effect size b and the SNP MAF. Finally, we can calculate the residual 
correlation matrix S, using the path coefficients from which we have subtracted the SNP 
effect.  
The estimated b and S being specific to the genetic additive factor on which the SNP 
loads (Figure 38), we have to calculate the statistical power for with each genetic factor. We 
aggregated the factor-specific power by taking the mean or the weighted mean (using the 
% of variance explained by each genetic factor as weights).  
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Figure 38: General Cholesky decomposition of the genetic and environmental 
variance of the brain phenotypes.  
The p phenotypes are labels P1…Pp 
Additive genetic (A) and environmental (E) sources of variance: latent variables A1.. Ap, E1…E2 
In this model all the genetic variance is accounted for by the p additive genetic latent factors and the SNP 
can only affect one of the independent genetic factors (here A2). All the genetic and environmental factors 
are independent. 
 
Real case scenarios: subcortical volumes and hippocampal subfields 
First, we considered 7 subcortical volumes (summed over left and right) processed 
using Freesurfer 5.3. Then, we used the 12 hippocampal subfields processed using 
Freesurfer 6.0 [589].  
  We fit 2 multivariate twin models with Cholesky decomposition in OpenMx [197] and 
extracted the standardised path coefficients to calculate the multivariate power. We 
calculated the power varying the sample size (up to N=60,000) and the maximal SNP effect 
size (0.05 to 1% of variance explained).  
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 We compared the results to power calculated using univariate approaches. As a 
benchmark, we used the brain-wide genome-wide significance threshold of 1e-12 [281]. 
More realistically, we used a significance threshold of 5e-8/neff for univariate GWAS, with 
neff being the number of effectively independent phenotypes [201, 590]. A similar approach 
is used by the ENIGMA consortium [463] to ensure a FWER<5% without over correcting 
when performing tests over correlated variables. We estimated neff to be 6 for the 7 
subortical volumes and 7 for the 12 hippocampus subfields, after regressing out all the 
covariates (including ICV). 
 
Summary of multivariate twin modelling 
 
We included 424 complete twin pairs (178 MZ, 246 DZ) with available volumes for 
the subcortical structures and hippocampal subfields. Participants were mostly females 
(63.0%) and on average 21.9 years old at scanning (SD=3.3, range 15 - 29). T1 structural 
scans were collected as part of the QTIM study [102], acquisition parameters have been 
described previously (see Chapter 7 and 8). 
Prior to twin modelling, age, age2, age3, sex, acquisition direction and ICV were 
regressed from the subcortical volumes and hippocampus subfields, and we used the 
residuals in following analyses. Multivariate twin models were run in OpenMx [197] using 
Full Information Maximum Likelihood that allows some of the observations to be missing.  
Table 22 and Table 23 report the estimated standardised path coefficients used in the 
power calculation. From them, one can calculate genetic and environmental correlations 
between the subcortical volumes or hippocampal subfields reported in Figure 39 and Figure 
40. The subcortical volumes and hippocampus subfield appear genetically correlated (rG in 
0.10 0.54 for subcortical volumes, -0.22 0.86 for hippocampus subfields), which justifies 
considering them in multivariate GWAS. In addition, the path coefficients also indicate 
multiple genetic components between the variables (large path coefficients outside of the 
first genetic factor), which suggest that a GWAS of the fist PC would not capture all the 
information. Our results are consistent with the positive genetic correlations previously 
reported [332], even if our estimates are systematically lower, which we attribute to 
controlling for ICV. 
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Table 22: Standardised path coefficient from the multivariate twin model (Cholesky 
decomposition) on subcortical volumes 
 A1 A2 A3 A4 A5 A6 A7 
Thalamus -0.823       
Caudate -0.10 0.93      
Putamen -0.23 0.29 0.84     
Palladium -0.28 0.26 0.31 -0.63    
Hippocampus -0.24 0.098 0.14 -0.084 -0.83   
Amygdala -0.27 0.11 0.18 -0.050 -0.30 0.62  
Nucleus Accumbens -0.15 0.24 0.21 -0.030 -0.032 0.12 -0.62 
 E1 E2 E3 E4 E5 E6 E7 
Thalamus 0.56       
Caudate 0.066 -0.35      
Putamen 0.076 -0.048 0.39     
Palladium 0.061 -0.14 0.18 0.55    
Hippocampus 0.14 -0.023 0.082 0.015 -0.43   
Amygdala -0.0083 -0.0073 0.14 -0.066 -0.065 0.61  
Nucleus Accumbens 0.076 -0.076 0.12 0.073 -0.063 0.11 0.66 
A1-A7 and E1-E7 correspond to the additive genetic and environmental factors. The first column indicates the 
variable they load on.  
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Figure 39: Genetic (above diagonal) and environmental (below) correlations between 
subcortical volumes 
Colour and size of the coloured square indicate the strength of the correlations. No thresholding was applied 
to the matrix based on significance or correlation strength.  
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Table 23: Standardised path coefficients from the multivariate twin model (Cholesky decomposition) for volumes of the 
hippocampal subfields 
 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
presubiculum 0.83            
parasubiculum 0.39 0.64           
Molecular layer HP 0.61 -0.094 0.54          
Granule cells of Dentate gyrus 0.49 -0.18 0.53 -0.26         
CA1 0.54 -0.061 0.58 0.043 -0.21        
CA2/3 0.19 -0.18 0.54 -0.21 -0.07 -0.41       
CA4 / Dentate Gyrus 0.44 -0.18 0.55 -0.26 0.035 -0.0084 -0.073      
fimbria 0.32 -0.0044 4.4E-05 0.09 -0.18 0.14 0.29 -0.56     
Hippocampal fissure 0.34 -0.11 0.21 0.13 -0.091 -0.084 -0.085 0.059 -0.51    
Hippocampal tail 0.28 0.068 0.39 0.22 0.071 0.0082 0.012 0.096 0.12 0.67   
subiculum 0.61 0.0031 0.32 0.15 0.2 0.26 -0.074 -0.076 -0.095 -0.052 -0.23  
HATA 0.39 0.079 0.28 -0.11 -0.41 -0.11 0.12 -0.12 0.13 0.028 -0.061 -0.38 
 E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
presubiculum -0.55            
parasubiculum -0.25 0.61           
Molecular layer HP -0.32 -0.037 0.48          
Granule cells of Dentate gyrus -0.25 -0.032 0.48 0.29         
CA1 -0.23 -0.038 0.44 -0.082 0.28        
CA2/3 -0.15 0.027 0.49 0.245 -0.040 0.33       
CA4 / Dentate Gyrus -0.24 -0.0364 0.49 0.30 -0.054 0.025 0.10      
fimbria -0.13 0.024 5.4E-05 -0.062 0.16 -0.16 -0.049 0.61     
Hippocampal fissure -0.25 -0.058 0.081 -0.019 0.086 0.019 0.040 -0.24 0.62    
Hippocampal tail -0.18 -0.019 0.13 0.023 0.029 0.12 0.039 -0.018 0.046 0.42   
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subiculum -0.31 -0.042 0.26 -0.13 -0.17 -0.18 -0.046 0.0045 0.033 -0.0054 0.26  
HATA -0.23 0.11 0.21 0.085 0.17 0.15 -0.098 0.020 0.052 -0.016 0.034 0.44 
A1-A12 and E1-E12 correspond to the additive genetic and environmental factors. The first column indicates the variable they load on.  
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Figure 40: Genetic (above diagonal) and environmental (below) correlations between 
hippocampus subfield 
 
Colour and size of the coloured square indicate the strength of the correlations. No thresholding was applied 
to the matrix based on significance or correlation strength.  
GC_ML_DG: Granule Cells of the Molecular Layer of the Dentate Gyrus. CA1-4: Cornu Ammonis areas 1-4. 
CA2 is merge with CA3 as the version of Freesurfer used does not allow to differentiate them [589]. HATA: 
Hippocampus-amygdala-transition-area. 
 
 
Multivariate vs. univariate power 
 
Statistical power of subcortical GWAS approaches is summarised in Figure 41. 
Multivariate approach should prove more powerful in identifying genome-wide significant 
variants. For example, the current ENIGMA sample (N~30,000) would detect an association 
227 
 
4 out of 10 times (power=0.38) power with the univariate approach (for a SNP explaining 
0.1% of the variance on any subcortical volume). For the same parameters, a multivariate 
approach would detect the association 8 out of 10 times (power=0.78). The other way 
around, 80% statistical power would be achieved for a sample size of 31,000 in the 
multivariate analysis compared with 42,000 in the univariate case.  
Similarly, multivariate GWAS should lead to greater statistical power than the 
univariate approach using hippocampus subfields (Figure 42). For a SNP explaining 0.1% of 
the variance in the volume of one of the subfields, 80% power can be achieved with a sample 
of 23,000 using multivariate GWAS, against 44,000 in the univariate. 
In both cases, the different weighting of factor-wise power in the multivariate 
calculation resulted in very similar results (see Supplementary Document 47 for factor-wise 
power and effect of weighting). 
The choice of test statistic (HLT, WL or PB) had no effect on the power calculation, 
consistent with previous research highlighting their equivalence in large samples (for 
N>10*p, with p the number of dependent variables) [75].  
 
Discussion and conclusion 
Here, we describe a method to calculate multivariate power of GWAS of real-case 
scenarios using the outputs from a multivariate twin modelling. Our approach is fast (a few 
seconds) and computationally savvy, as it does not rely on simulation but on analytical 
power calculation using the F-approximation [75]. The longest step in this analysis was the 
multivariate twin modelling in OpenMx [197]. Our method provides a power estimate that 
corresponds to the multivariate test implemented in PLINK [249, 569] and which is 
equivalent to the one used in GEMMA [571] (when working on related participants) [472, 
570, 572]. 
Using this method, we showed that performing a multivariate GWAS of the volumes 
for both the subcortical structures and hippocampal subfields confers substantially greater 
power than the standard univariate approach. For the hippocampal subfields, multivariate 
GWAS may even result in a doubling of power, which should lead to the discovery of many 
more variants. This likely arises from the stronger genetic correlations between the volumes 
for the hippocampal subfields compared to subcortical structures [579]. It would be very 
interesting to extend our analyses to multivariate modelling of left and right volumes (instead 
of left and right average), as well as to cortical, or voxel wise measurements. 
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There are some limitations to this study, the first one being that measurement of the 
volume of hippocampal subfields (using Freesurfer 5.3) may not be as accurate as that for 
the subcortical structures. A new version of Freesurfer (6.0) has just been released that aims 
at correcting this issue. We are anticipating that this noise should not inflate the estimate of 
additive genetic factor loadings but rather increase the environmental components. Thus we 
can expect a conservative estimate of power [579] due to noisy subfield measurement. 
Another limitation is that the power calculation relies on estimated parameters (standardised 
path coefficients from twin modelling) and it would be of interest to see how stable our results 
are when using a different twin sample.  
More generally, there are a few limitations in performing multivariate GWAS. Firstly, 
the effect of the SNP is not specific to one variable but rather the set of variables considered. 
Thus, the discovery analysis would identify SNPs associated with hippocampal volume in 
general, without telling us which subfields or set of subfields the SNP has an effect on. This 
could be overcome by performing univariate GWAS replication of the multivariate hits to 
more accurately identify the location of the SNP effect. Another potential concern is the 
computing time of multivariate models, compared to univariate ones. However, simulation 
suggests that this is hardly a problem as the computing time for subcortical volumes should 
be about 1.9 times (3.1 times for hippocampus subfilelds) that of a single univariate GWAS. 
This increase is reasonable, and multivariate GWAS is even faster if the univariate GWAS 
are not run in parallel.  
To conclude, using multivariate GWAS within the ENIGMA consortium should lead to 
the identification of new SNPs associated with volumes of both the subcortical structures 
and hippocampal subfields. This would complement the univariate analyses already 
performed, as well as proving useful for GWAS of DTI (see [591] for genetic correlations 
and multivariate analysis plans) or voxel-wise measurements, which are currently underway. 
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Figure 41:Statistical power as a function of sample size for multivariate (solid lines) and univariate (dashed/dotted lines) GWAS 
on subcortical volumes. 
For all effect sizes and sample sizes, the multivariate approach confers greater statistical power than univariate approach. Multivariate power presented here 
corresponds to the mean power for each genetic factor. Weighting the factors by their proportion of variance explained did not change the conclusions (Supplementary 
Document 2).  
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Figure 42: Statistical power as a function of sample size for multivariate (plain lines) and univariate  (dashed lines) GWAS on 
hippocampus subfields  
For all effect sizes and sample sizes, the multivariate approach confers greater statistical power than univariate approach. Multivariate power presented here 
corresponds to the mean power for each genetic factor. Weighting the factors by their proportion of variance explained did not change the conclusions (Supplementary 
Document 2).  
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What can GWAS tell us about the genetic complexity of brain traits? 
Background 
The genetic architecture of a trait can be conceptualised in terms of the distribution 
of SNP effect sizes: how many SNPs contribute to the phenotype and with what effect size? 
Knowing the genetic architecture allows us to compare the genetic complexity of traits, with 
more complex phenotypes being influenced by more SNPs each having a smaller effect.  
 The question of genetic architecture and trait complexity is one of the foundations of 
the endophenotype theory [16]. Endophenotypes are thought to be closer than a diagnosis 
to the biological mechanisms, hence should have a simpler genetic architecture. This should 
translate into fewer causal variants, each with larger effect sizes, hence more powerful 
GWAS and the promise to breakdown the genetics of a (more) complex trait by studying its 
endophenotypes [16].  
Some Bayesian methods [592, 593] can provide rough estimates of the number of 
causal SNPs but they require access to individual level genetic data from large samples, 
extensive computer resources, and still lack precision. For example the number of 
independent causal SNPs has been estimated to be 2,231 for Rheumatoid Arthritis (95% 
credible regions: 800-6,000) [592] and 8,300 (6,300-10,200) [594] for schizophrenia. To our 
knowledge this has not been reported for depression or any brain phenotypes and we did 
not have the sample size to perform such analysis.  
On the other hand GWAS give us a partial but direct insight into the SNP effect sizes 
and distribution (under the form of OR or betas of genome wide significant SNP) but do not 
tell us about how many SNPs are causal. Here, we aimed to examine if the GWAS results 
align with the endophenotype theory. If indeed brain imaging phenotypes have a simpler 
architecture than psychiatric diagnoses, we should observe larger effect sizes from the 
GWAS results. In addition, we performed an exploratory modelling of the effect size 
distribution using non-parametric kernel density estimation. Such non-parametric approach 
allows modelling the distribution of effect sizes without requiring a hypothesis on the shape 
of the distribution.  
Method 
In order to compare effect sizes across traits and SNPs with different MAF, we 
expressed the effect sizes in term of the percentage (%) of variance explained (!") that we 
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can calculate from a chi-square (chi2) statistic (itself calculated from the reported p-value), 
and the sample size (N) reported by GWAS publications [76]:  
 !" = $"% − ' − 1 + $" ×100	 
With q the number of parameters in the model. When N is large, q has little effect on the !" 
and we set it to 2 for all traits.  
For disorders we applied a further correction to the !" that takes into account that the 
case/control ratio in the GWAS may not reflect the prevalence in the general population 
[595]. This correction converts the variance explained in the sample into the variance 
explained on the liability scale [595]. 
 !-.//01203" = !"× (5 1 − 5 )"7"	×8(1 − 8) 
With K the population prevalence, P the proportion of cases in the GWAS and z the height 
of the standard normal probability density function (liability) at the quantile 1-K [595]. In the 
following, we used prevalence of 20% for MDD, 4% for Alzheimer’s disease and Rheumatoid 
Arthritis, and 1% for schizophrenia. 
We included SNPs from the largest GWAS reporting significant associations with 
MDD (female only, recurrent) [15], schizophrenia [79], Alzheimer’s disease [596], volumes 
of the subcortical structures: putamen, caudate nucleus, and hippocampus, as well as [76], 
ICV and hippocampal volume [77], We also included SNPs from the GWAS for rheumatoid 
arthritis [597] to check if our results align with the conclusions from the Bayesian approach 
[592, 594, 598]. SNPs used and estimated !" are reported in Supplementary Document 48. 
We used results from the combined discovery and replication sample (when available) to 
calculate the !". For each trait/disorder we provide a non-parametric kernel density estimate 
of the distribution of effect sizes that does not require making assumptions on the shape of 
the distribution. We used R for the analysis and plotting [292].  
Results and discussion 
For recurrent depression in females the 2 genome wide significant SNPs each 
explained 0.10% of the liability variance. The 10 additional SNPs reported in the paper [15] 
did not reach GW significance (p-values1.4E-5 – 6.0E-7) and individually explained between 
0.051 and 0.077% of the liability variance. In schizophrenia, the 114 SNPs reported 
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(significant in discovery + replication) explained between 0.014 and 0.064% of the liability 
variance [79]. In Rheumatoid Arthritis one SNP in the HLA region explained 22.98% of the 
variance, another one (rs2476601) on chromosome 1 explained an additional 2.02%. The 
remaining 12 SNPs accounted for 0.025 to 0.14% of the variance [597]. For Alzheimer’s 
disease, the 21 SNPs explained between 0.016 and 0.32% of the liability variance. The 
variance explained by APOE has been estimated at about 6% [599]. Here, we do not report 
its effect size as APOE was indirectly tagged in the GWAS using variants in LD [596].  
In comparison, the 8 ICV SNPs explained 0.099 to 0.27% of the variance [78], the 6 
hippocampus SNPs 0.092 to 0.32% [77], the 4 putamen SNPs 0.14 to 0.32, while the 1 SNP 
associated with caudate explained 0.11% of the trait variance [76]. These results are 
summarised in Figure 43, with the superimposed density showing a clear shift in the 
distribution lift offs.  
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Figure 43: Distribution of Genome Wide significant SNP effect sizes for 
Schizophrenia, MDD, Rheumatoid Arthritis, Alzheimer’s disease, ICV, Hippocampus 
and Putamen volume 
The effect sizes are expressed in % variance explained. The lines correspond to the non-parametric kernel 
estimate of density for each trait. Thus, they can be interpreted as the relative likelihood of a SNP as a 
function of the variance explained: the highest the density the most likely that a SNP with corresponding 
effect size has been identified (and exist). Shifts in density over the !"	range suggest differences in genetic 
complexity. 
 
Our results align with the hypothesis of a simpler genetic architecture of brain 
structural phenotypes compared to psychiatric diagnoses. In addition, Rheumatoid Arthritis 
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appears simpler than schizophrenia, consistent with previous report from Bayesian 
modelling [592, 594, 598]. The simpler architecture of MDD, compared to schizophrenia 
likely comes from the specificity of the CONVERGE GWAS, which focused on female 
recurrent MDD [15]. One explanation may be that this subtype has a simpler genetic 
architecture than general-population MDD or that the recruitment design and careful 
screening of controls may lead to a reduced “noise” in the phenotype (consistently defined 
cases and no misclassification of controls). We confirmed this explanation using embargoed 
data from the PGC-MDD working group (data not shown). Indeed, using general population 
MDD GWAS suggested that MDD is more complex than schizophrenia (not shown).  
There are several limitations to our study that do not allow us to make strong 
conclusions from Figure 43. Firstly, only a handful of variants are known for the brain traits 
and these may well be variants with outstanding effect, thus not informative of the true 
distribution of effect sizes. There are many examples of such loci with large(r) effects: APOE 
in Alzheimer’s disease, or HLA SNPs in Rheumatoid Arthritis for instance. In addition, the 
bi/multi modal distributions observed in Figure 43 may also suggest that the effect size 
distribution contain outliers. Statistically, the small number of SNPs leads to instability in the 
non-parametric estimation of density and it would be interesting to see if the clear differences 
seen in Figure 43 persist when including more genome wide significant SNPs.  Secondly, the 
GWAS have different statistical power, thus different abilities to detect SNPs with similar 
effect sizes. However, considering the very large sample used in the schizophrenia GWAS, 
the analysis is very well powered to detect a SNP with an effect greater than 0.1%, 
suggesting that such SNPs do not exist. It is therefore unlikely that we are overestimating 
the genetic complexity of the disorder. Though, this limitation still holds for brain phenotypes 
(we are potentially underestimating the complexity) and better powered GWAS will help 
shed lights on the traits true complexity. Thirdly, differences in test-retest could explain the 
differences in effect size, as SNPs would only explain percentages of the reliable variance. 
This relates to previous considerations about the scaling effect of test-retest on strength of 
associations (see Chapter 6). This effect may be at play for general-population depression 
due to the self-report and subjective nature of symptoms. However, there is evidence of 
reasonable test-retest of MDD symptoms and diagnosis across instruments, or between 
clinician [600-603]. Reliability of diagnosis is even higher for schizophrenia [604], while ICV 
putamen and hippocampus volume show very good test-retest [332] and agreement 
between processing software [76]. Consequently, differences in measurement error are 
unlikely to completely cause the differences observed in Figure 43 [592].  
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Our analysis relates to a concern raised by Iacono et al., [605] about the usefulness 
of endophenotype search for genetic analyses, which is that brain endophenotypes may not 
exhibit a simpler architecture. However, the authors completely ignored the possibility of 
complexity differences within complex traits. In light of our analysis and published GWAS 
we can confirm that brain endophenotypes are indeed complex traits but also that they 
require a much smaller GWAS sample than in psychiatry for SNPs to reach genome-wide 
significance. Besides, only a small fraction of brain phenotypes has been studied in GWAS 
and there may be much simpler endophenotypes out there (e.g. regional measurements), 
for which, even their small sample of <5,000 participants would lead to identify significant 
variants.  
Another interesting conclusion from our analysis is that heritability cannot be safely 
used as a proxy for genetic complexity. Here, schizophrenia, rheumatoid arthritis, 
Alzheimer’s disease, ICV and hippocampal volume all exhibit comparable heritability (0.81 
(0.73-0.90) for schizophrenia [606], 0.65 (0.50-0.77) for Rheumatoid Arthritis [607], 0.79 
(0.67-0.88) for Alzheimer’s [608], 0.82 (0.73-0.90) for ICV and 0.68 (0.50-0.83) for 
hippocampal volume [27]) but may have very different genetic architecture. Thus, if 
prioritising endophenotypes based on test-retest would make sense, prioritising them based 
on heritability [397] may not be a sensible approach. Indeed, higher heritability does confer 
greater power to estimate a significant genetic correlation with the disorder but such 
endophenotypes may not turn out to be the most useful to break down the genetics of 
complex traits. On the other hand, greater test-retest confers a greater power across all type 
of analyses. 
To conclude, brain-imaging phenotypes may have a simpler architecture than 
depression or schizophrenia, which makes them of great use to break down their genetics. 
Indeed, the larger effect sizes should translate in more successful GWAS (sample sizes 
being equal). In addition, GWAS for imaging endophenotypes could grow faster than 
psychiatry GWAS, considering the increased difficulty in recruiting patients, especially for a 
lowly prevalent disease such as schizophrenia. Understanding the genetics of brain 
endophenotypes will help shed light on the biological mechanisms that underlie brain 
structure and function as well as related psychiatric disorders.  
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Discussion / General conclusion 
 
 
The main aim of this thesis was to identify brain endophenotypes of depression in 
order to shed light on the brain structures and functions associated with the disorder. Further 
down the track, endophenotypes could help identify biological pathways involved in 
depression by providing insights into the genetics of the disease. For this purpose, we used 
twin and sibling data collected as part of the Brisbane Longitudinal Twin Study (a.k.a. BATS) 
that consists of multimodal MRI imaging from the Queensland Twin IMaging (QTIM) study 
as well as clinical and subclinical assessments of mental health. In addition, we used the 
publically available Human Connectome Project dataset that also collected multimodal MRI 
and clinical questionnaires on twins and siblings.  
Seemingly unrelated, we presented some methodological work on resting-state fMRI 
(RS-fMRI) processing, which reflects the relative immaturity of this field compared to the one 
of structural MRI processing. These chapters aimed at ensuring the feasibility and 
pertinence of the search for RS-fMRI endophenotypes of depression in our dataset. 
Together with the chapter focussing on the quality of the anxiety-depression measures, 
these sections provide a good starting point to discuss the relationships between data 
quality, study design and statistical power in the search for endophenotypes.   
In addition, we studied the interaction between the genetic predisposition to 
depression and individuals’ sources of stress, which aimed at providing new insights into the 
subtypes of depression and the sex differences observed in MDD prevalence and 
heritability. We will discuss below how this could enhance the detection of depression 
endophenotypes and the understanding of the genetics of the disorder. 
Finally, anticipating the discovery of brain markers for depression we proposed how 
they could be used efficiently to break down the genetics of depression. In addition we 
compared the genetic complexity of brain structures compared to those of psychiatric traits, 
which responds to recent criticisms of the endophenotype theory.    
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Overview of chapters’ aims and findings 
Table 24: Overview of thesis aims and results by chapter 
Chapter Aim(s) Findings 
(1) Cohort Profile: The 
nineteen and up study, 
mapping 
neurobiological 
changes across mental 
health stages 
• Describe the BLTS cohort used in most of the 
analyses (i.e. Chapters 2,4,5,6,7,8 and 9) 
• Special focus on the latest study of the cohort (19Up) 
that focuses on mental health clinical assessment 
• Large overlap between QTIM (MRI imaging), 19Up and 
subclinical assessment in adolescence (TW1, TW2, TM 
and TA) 
• Prevalence rate in early adulthood consistent with the 
one previously reported in Australia 
• Known widespread comorbidity between psychiatric 
disorders observed in the twin cohort 
(2) Validation and 
psychometric properties 
of the Somatic and 
Psychological Health 
REport (SPHERE) in a 
young Australian-based 
population sample 
using nonparametric 
Item Response Theory 
Describe psychometric properties of the anxiety-
depression score used in endophenotype search 
(Chapter  8). Such properties include:  
• Individual items’ properties derived from IRT analysis 
• Stability of construct across sex and through 
adolescence 
• 3 months test-retest 
• Heritability across adolescence / early adulthood 
• Association between scores in adolescence and 
lifetime DSM-IV diagnoses collected in early 
adulthood 
• Internal consistency 
 
• Items of the anxiety-depression scale all meet item level 
IRT requirements necessary to ensure the property of 
stochastic ordering on the sum score (i.e. ordering of 
participants on the sum score reflects the true ordering 
on the liability scale) 
• The items compose a stable construct across sex and 
adolescence allowing longitudinal modelling and sex 
comparison 
• ICC3months=0.47 [0.23,0.66] 
• h2 9-12years=0.41 [0.32,0.49], h2 13-14years=0.42 [0.33,0.50], 
h215-16years=0.29 [0.20,0.38], h2 17-28years=0.37 [0.21,0.51] 
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• Significant association from age 15 with lifetime MDD 
and alcohol dependence; and from age 13 years with 
social anxiety  
• aCronbach=0.87 
(3) A direct test of the 
diathesis-stress 
hypothesis in 
depression 
• Test the presence of interaction between genetic risk 
of depression (polygenic risk score) and self-reported 
measures of stress (personal stress, network stress 
and social support) in order to explain depression risk 
• Significant interaction between personal stressful life 
event and genetic predisposition to depression 
• Interaction confirmed in females but not in males 
• Self reported levels of stress are endophenotypes of 
depression and define genetic subtypes of the disorder 
(4) Heritability of head 
motion during resting 
state functional MRI in 
462 healthy twins 
• Estimate heritability of resting-state head-motion 
(HM), one of the largest confounders in fMRI studies 
• Evaluate HM confounding effect on heritability studies 
of resting-state functional connectivities (FC) 
• Head motion significantly heritable (h²=46% [0.27, 0.61] 
for the common factor between mean translation, mean 
rotation and maximum translation) 
• Some regions of the resting-state FC networks organised 
around Broca’s area (BA44 and BA45) may be heritable 
(BA44: h"=0.23 (sd=0.041), BA45: h"=0.26 (sd=0.061)). 
See discussion about limits of such result.  
• Heritability measured in resting-state language 
production networks is not attributable to HM 
(5) Head motion and 
Inattention/Hyperactivity 
share common genetic 
influences: implications 
for fMRI studies of 
ADHD 
• Estimate phenotypic and genetic correlations 
between resting-state head motion and ADHD scores 
• Discuss how to handle head motion in fMRI image 
processing and in analyses when it is associated with 
the outcome (e.g. ADHD) 
• Significant phenotypic correlation between HM and 
mother reported Inattention (r=0.17, p-value=7.4E-5) and 
Hyperactivity-Impulsivity (r=0.16, p-value=2.9E-4) 
• Significant genetic correlations: resp. rg=0.24 [0.02, 0.43], 
p-value=0.030 and rg=0.23 [0.07, 0.39], p-value=3.9E-3 
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• Image processing that include HM regression would 
result in a loss of power 
• Gross motion exclusion and frame censoring may create 
sample bias 
• Multivariate modelling in phenotypic and twin modelling 
can overcome these limitations 
(6) Evaluation of 
Regional Homogeneity 
processing options on 
test-retest correlation 
Evaluate the effect of RS-fMRI processing options on the 
3 months test-retest of voxel-wise Regional Homogeneity 
(ReHo). Processing options varied:  
• Physiological noise regression (Global signal 
regression and/or “CompCor”) 
• Head motion regression (“Rigid Body 6” or “Friston 
12” or “Friston 24”or voxel-wise motion) 
• Local smoothing (No smoothing or 1.5mm FWHM or 
4.5mm FWHM or 6mm FHWM or ReHo smoothing) 
• Number of voxels used in KCC (7 voxels or 19 or 27) 
• Greater smoothing and number of voxels increased ICC 
• CompCor and no global signal regression led to higher 
ICC 
• “Friston 12” and “Friston 24” led to marginally reduced 
ICC 
• Overall effect of processing options on ICC was modest 
(<5% difference in mean ICC) 
• Most reliable voxels are consistently reliable across all 
processing options 
• Mean voxel-wise ICC low (<0.3), across all processing 
options, which we attributed to short resting-state scan 
(5min 19s) 
(7) Collaborations with 
the ENIGMA-MDD 
consortium to propose 
robust endophenotypes 
for depression  
• Participate in the ENIGMA-MDD meta-analyses  
• Detail extraction of the MDD case-control sample, 
(not presented in the published manuscript) 
• Hippocampal reduction in MDD cases vs. controls* 
• Adult depression (age>21): thinning of cortical gray 
matter than controls in the orbitofrontal cortex (OFC), 
anterior and posterior cingulate, insula and temporal 
lobes (Cohen’s d effect sizes: − 0.10 to − 0.14)* 
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• Adolescent depression (age<21): reduced total surface 
area driven by reductions in frontal regions (medial OFC 
and superior frontal gyrus) and primary and higher-order 
visual, somatosensory and motor areas (d=−0.26 to − 
0.57)* 
(8) Lingual Gyrus 
surface area associated 
with anxiety-depression 
score in young adults: a 
genetically data driven 
approach 
• Parcellate cortical surface area and thickness maps 
into genetically homogenous regions  
• Evaluate phenotypic and genetic correlation with 
score of anxiety-depression to qualify as brain 
endophenotype 
• Replicate association(s) in an independent sample 
(HCP) 
• Surface area and thickness could be divided in 12 
regions per hemisphere 
• Cortical clustering matched previous initiative [70] despite 
differences in sample demographics  
• Surface area of an occipito-temporal cluster (right lingual, 
fusiform and parahippocampal gyrii) was phenotypically 
associated with anxiety-depression in QTIM (non-linear 
effect, r=-0.10, p-value=2.4E-5). Such association 
corresponded to a reduction of SA in participants with 
score above median 
• The reduction of SA was partially replicated in the HCP 
(reduction for 25%-95% quantiles of score, different 
anxiety-depression questionnaire, r=-0.04, p-value=3.2E-
3) 
• Post-hoc vertex-wise analysis pointed to a reduction of 
lingual gyrus 
• Genetic correlations did not reach significance, which we 
attributed to low statistical power (small effect sizes) 
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• Right lingual SA reduction may relate to reported visual 
memory and attention deficits in depression  
(9) GWAS and the 
genetics of brain 
phenotypes 
• Review GWAS method in the context of brain 
imaging consortium (e.g. ENIGMA, CHARGE) 
• Review GWAS literature on brain morphology 
• Compare statistical power of multivariate vs. 
univariate GWAS using real-case scenarios 
(subcortical volumes and hippocampus subfields) 
• Infer the relative genetic complexity of complex traits 
by comparing the effect size of genome-wide 
significant SNPs (complex traits considered: MDD, 
schizophrenia, Alzheimer’s disease, rheumatoid 
arthritis, ICV, hippocampal and putamen volumes) 
• A handful of variants have been found to influence ICV, 
putamen volume and hippocampal volume 
• In both GWAS scenarios considered a multivariate 
approach led to a significant boost of power compared to 
univariate GWAS. 
• Distribution of effect sizes (expressed in % of variance 
explained) were markedly different between complex 
traits consistent with brain phenotypes having a simpler 
genetic architecture than the disorders. This makes brain 
phenotypes promising endophenotypes for complex traits 
as a simpler genetic architecture suggests they would be 
closer to basic biological mechanisms. 
* Results of the meta-analyses [68, 385].  
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Detecting (more) brain endophenotypes 
Here, we identified the surface area of the right lingual gyrus as a candidate 
endophenotype for anxiety-depression (Chapter 8, Table 24). We found a reduction of 
surface area in participants with anxiety-depression SPHERE scores above median and 
observed a similar reduction using an independent sample of comparable age (Chapter 8, 
Table 24). However, we could not confirm the genetic relationship of this association, despite 
using large sample (N=834 and N=890), which we attributed to the modest effect sizes (post-
hoc statistical power<0.10, Chapter 8). In the following, we will discuss how the rest of the 
work summarised above (Table 24) can assist the search for brain endophenotypes by 
providing a reflection on comorbidities, statistical power, test-retest, heritability, disease 
heterogeneity, effect sizes and study design. 
Comorbidities of depression  
 Comorbidities between psychiatric disorders have been studied extensively since the 
90s’ [609] and we confirmed them in the BLTS cohort using lifetime DSM-IV and DSM-5 
diagnoses collected via the Composite International Diagnostic Interview (CIDI, Chapter 1). 
The comorbidity between depression and anxiety is mostly attributable to a common genetic 
predisposition (very high genetic correlations from twin studies [404]), which justifies using 
anxiety-depression scores in the search for endophenotypes of depression (e.g. Chapter 2 
and 8). In addition, recent evidence from twin and population samples confirmed the 
importance of comorbidity between depression and chronic fatigue (but also interestingly 
between fatigue and most of the DSM diagnoses) [610]. As for anxiety, the comorbidity was 
driven by the genetic correlation between depression and fatigue, while there was no 
evidence of causal relationships, necessary to specify hierarchies in the DSM [611]. This 
aligns with the phenotypic and genetic correlations between anxiety-depression and chronic 
fatigue scores that we report in Chapter 2 and would justify using the two dimensions of the 
SPHERE questionnaire in an analysis to identify endophenotypes. Indeed, we could expect 
an endophenotype for depression to also show a genetic correlation with the chronic fatigue 
SPHERE score. Thus, the chronic fatigue SPHERE scores could be used to confirm 
endophenotypes or to increase power via multivariate twin analyses [612]. We did not 
perform such analysis in Chapter 8 as we were greatly limited by the statistical power due 
to small effect sizes, even in the bivariate case [612].   
Investigating the genetic contribution to the comorbidity between MDD and other 
psychiatric disorders can require very large samples using twins, due to the low prevalence 
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of some of the disorders (see Chapter 1). However, recent methodological developments 
using GWAS (raw) data [47] or summary statistics [48, 49] have reported widespread 
genetic correlations between MDD and psychiatric traits (ADHD, BD, SCZ) [10, 11, 613], as 
well as with migraine or educational attainment [613]. 
These widespread comorbidities result in non-specific findings when looking for 
phenotypic markers of psychiatric diseases. For example the ENIGMA consortium reported 
hippocampal reduction for MDD (see Chapter 7), SCZ, BD and OCD [385, 389-391]. This 
lack of specificity can greatly impair the ability to predict a specific diagnosis from brain MRI 
images, thus limiting the usefulness of endophenotypes for prevention, early detection and 
treatment of specific mental health disorders. We can hypothesise that larger samples could 
lead to the identification of biomarkers of smaller effect that may reflect the specific genetic 
source of variance of the disorders.  
On the other hand, we can make use of the known comorbidity and shared genetics 
to boost statistical power to detect biomarkers that are common to several disorders. Such 
approach has been successfully used by the PGC-cross-disorder working group [614], 
which combined autism, ADHD, BD, MDD and SCZ cases to identify new variants 
associated with several diagnoses. The ENIGMA consortium will likely use a similar 
approach to identify more brain biomarkers common to these disorders [386].  
In addition, collecting extensive psychiatric assessment data (e.g. CIDI in Chapter 1) 
can provide a richer description of the population of interest (e.g. MDD with panic or with 
psychotic features), which may result in greater contrasts with controls, hence greater 
statistical power. However, the large number of comorbid combinations quickly results in 
small sample sizes, therefore it may be more profitable to consider a multivariate approach 
that uses the fact that mental health can be described by several dimensions (e.g. 
depressive, manic, psychotic, anxious, substance abuse), that present some level of 
correlation. We showed in Chapter 9 that a multivariate linear model would offer greater 
power than a univariate, for genetically correlated brain structural phenotypes. We can infer 
that such an approach would also be beneficial for the study of psychiatric diagnoses and it 
would be of interest to estimate such power increase. The main limitation to this is that most 
clinical samples that contribute to the PGC or ENIGMA datasets focus on a unique disorder 
and lack assessment of other psychiatric dimensions. Similarly, controls may not be 
screened for more than one disorder. In that regard, the UK biobank data represents great 
promises by combining large sample sizes and deep phenotyping.   
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Towards redefining the psychiatric diagnoses 
Comorbidities can be seen as a by-product of the diagnostic systems in psychiatry 
(e.g. DSM or International Classification of Diseases: ICD) that are composed of a myriad 
of diagnostic categories with few exclusionary hierarchies [615]. However, one can wonder 
about the nature of the psychiatric comorbidities: are psychopathologies discreet entities not 
currently well reflected by the diagnostic categories or are they dynamic and adaptive 
conditions leading to a wide range of symptomatic manifestation [616]? This interrogation 
strongly relates to the question of redefining psychiatric diagnoses into either more 
independent discreet entities (see for example neurological phenotypes [613]) or state of a 
progressive adaptative pathology. Such redefinition could simplify the study of the disorders 
(low comorbidities leading to specific findings), the treatment of patients (diagnoses and 
drugs would also be more specific) as well as the discovery of new therapeutics (fewer 
biological mechanisms, not overlapping across disorders/states). This redefinition is already 
happening within the DSM or ICD instruments as illustrated by the different versions that 
revise the diagnoses based on the most recent research, however many have criticised the 
slow pace of such approach (see [615] for example).   
 The first theory of comorbidities underlies the Research Domain Criteria (RDoC) 
initiative (https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml) that aims at 
breaking down normal and abnormal human behaviour into elementary constructs that can 
be aggregated into higher-level of functioning, thus providing a hierarchical framework that 
would have the potential to redefine the psychopathologies into independent constructs 
[617]. One potential limitation of the RDoC approach may lie in the choice of the basic 
constructs that may not be more independent than psychiatric constructs in term of genetics 
or environment. If this were the case, an RDoC-based redefinition of psychopathologies 
would not lead to less comorbidity. One way to overcome this problem would be to 
encourage early on the investigation of the genetic and environmental relationships between 
the RDoC domains and constructs. This would effectively consist of merging the 
endophenotype and RDoC approaches, by collecting extended multi-level phenotypes on 
twin samples, for instance. This could be doubly beneficial: encouraging RDoC research to 
detail the genetic contributions to reported associations and encourage more thorough 
investigation of endophenotypes using the exhaustive RDoC matrix (see NIH website cited 
above). As a side note: the BLTS (see Chapter 1) already represents a good example of 
such RDoC/endophenotype dataset as it collected twin data across many units of analysis: 
paradigms (e.g. fMRI, see Chapter 4-6, or IQ), self-reported measures (e.g. SPHERE, see 
Chapter 2 and 8 or CIDI, Chapter 1), behavioural assessments (e.g. mother reported 
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SWAN, see Chapter 5), measures of physiology, anatomy or circuits (e.g. MRI images, see 
Chapter 4-9), cells and molecules (via collection of blood sample) and genes (GWAS chips).  
 The second explanation for comorbidities implies that psychiatric conditions would 
lack predictability and symptom consistency due to the psychodynamic nature of the 
disorders [616]. In this framework, complexity and multiplicity of symptoms should be 
associated with greater severity and could be used to guide the redefinition of diagnoses 
[616]. A major limitation of this theory for depression is that several risk factors have been 
reliably identified, which suggest the disease is not completely unpredictable. Here for 
example (Chapter 3), we replicated the phenotypic and genetic associations between the 
depression score and self-reported stress levels. In addition, we showed that genetic 
predisposition as estimated from GWAS results (polygenic risk scores) also contributes to 
disease risk and even interacts positively with stress levels (Chapter 3). This confirms that 
depression can, to some extent, be predicted and its risk quantified, at least in adults. As for 
adolescents, who could be prone to exhibit more widespread and/or unstable symptoms due 
to greater brain plasticity during brain maturation [618, 619], we observed a significant 
stability of anxiety-depression scores between 12 and 28 years old (Chapter 2), which has 
also been reported in a Dutch sample [421]. These results suggest that the comorbidity of 
depression cannot be completely explained by the psychodynamic theory and that there 
should be discrete underlying disorders that make up affective disorders and psychotic 
symptoms (see comorbidities from Chapter 1). However, we cannot rule out some 
psychodynamic/neurodevelopmental components that would, for example, explain how 
some MDD cases can transition to BD, or some adolescents with psychotic features (7.1% 
in our sample, Chapter 1) later develop schizophrenia (prevalence of 1% in the general 
population). Longitudinal studies starting in adolescence would be needed to detail the 
temporal evolution of psychiatric symptoms, as well as their relationships with cognition and 
brain maturation. These studies would also be crucial to confirm the state-independence of 
the endophenotypes by confirming that the biomarkers precede the disease outcome.      
Heterogeneity of depression 
 Heterogeneity of depression is commonly accepted but there is still a lack of evidence 
characterising the subtypes. Some studies have described three genetic factors that explain 
the variety of symptomatic profiles [6], others have suggested that environmental risk factors 
(e.g. childhood trauma and stressful life events) could define sub-types of the disorder [7-9], 
or have proposed to break down MDD by sex to reflect differences in heritability and 
prevalence [5, 13, 447]. More recently, some studies have suggested differentiating cases 
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based on appetite/weight gain (atypical depression) or loss (typical) based on different 
patterns of association with BMI and SCZ [620]. Finally, some have attributed depression 
heterogeneity to misdiagnosis (BD for example [621]). 
 Understanding the heterogeneity is of great interest in the search of (brain) 
endophenotypes. Depression subtypes should represent more “pure” phenotypes, ideally 
independent of each other. This translates into more specific genetic and environmental 
components for each subtype, potentially differences in heritability, which in turn would yield 
greater correlations with some of the endophenotypes. Put another way, knowing the 
depression subtypes would lead to less noisy diagnoses and facilitate endophenotype 
identification.  
 Here, we contributed to this literature using PRS and self-reported stress measures 
in a large Australian adult twin sample (ATR, see Chapter 3). First, we replicated the findings 
that scores of depression, personal stressful life events (PSLE), network stressful life events 
and social support were heritable [7, 258] (Chapter 3). We also confirmed using twin models 
that depression and self-reported stress scores were phenotypically and genetically 
correlated [8, 9] (Chapter 3). Together with the results from a longitudinal study that reported 
that stressful life events can cause episodes of major depression (i.e. can precede episode) 
[622], this confirms that they are endophenotypes of depression. Thus, stresses define 
genetic sub-types of the disorders. It would be of interest to extend our research to more 
stress types (e.g. birth and post-partum depression, childhood trauma) but also to 
investigate the brain signature of such depression subtypes. Unfortunately the dataset used 
in Chapter 3 does not overlap with the QTIM sample, however questionnaires about PSLE 
have been included in the 19Up (Chapter 1).   
More interestingly, we used PRS in Chapter 3, to evaluate the interplay between 
genetic predisposition to MDD and self-reported stress measures. We identified a positive 
interaction between PRS and PSLE in a large sample comprising more than 5,000 
participants. This interaction fits with the reported bi-directional causation between stressful 
life event and MDD [622], but we cannot rule out other mechanisms of interaction (e.g. 
methylation). Intriguingly, we confirmed this interaction in females but did not observe it in 
males, which could be due to differences in power or could represent a true difference in the 
depression aetiology between sexes (Chapter 3).  
Overall, very large twin samples with in-depth phenotyping would be required to 
robustly identify or confirm subtypes of depression that should show differences in 
heritability, genetic sources of variance and therefore pattern of association with 
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endophenotypes. There is hope that new molecular methods applied to the UK biobank data 
could help breaking down more efficiently such heterogeneity.  
 
 Test-retest, heritability and statistical power to identify endophenotypes 
 We have highlighted several times in this thesis the importance of measuring and 
maximising test-retest reliability (Chapter 2, 4, 5 and 6), which is a measure of the signal to 
noise ratio in imaging (Chapter 4,5 and 6) or of the trait component of a self-reported 
phenotype (Chapter 2). As such, test-retest is important for a phenotypic analysis as it 
scales the effect size, assuming that there is no correlation between the noise (unreliable 
fraction of the phenotype variance) and the trait of interest (e.g. depression). Consequently, 
maximising the test-retest of a phenotype maximises the statistical power by ensuring that 
the effect sizes are not underestimated by the noise. In addition, it controls for false positive 
rate by reducing the chance of observing a spurious correlation driven by the unreliable 
sources of variances.  
 In Chapter 6 (see also Table 24), we showed that CompCor [365] associated to no 
GSR and simple HM regression (“Rigid-body 6” or voxel-wise regression) maximised test-
retest. However, the overall effect on ICC was small (which we attributed to short scan 
length) and would not have yielded great statistical power to identify ReHo endophenotypes 
of depression (Chapter 6). The test-retest of other fMRI metrics remains to be investigated 
in our sample but prior research has noted that ICC of ReHo was the highest compared to 
all other functional metrics considered (FC, intrinsic FC, degree centrality and eigenvector 
centrality) [22]. An option to circumvent low voxel-wise reliability is to average the signal 
over larger regions/volumes of the cortex. We confirmed this by showing that greater local 
smoothing or number of voxels in ReHo calculation increased the stability of the 
measurements (Chapter 6). However, ReHo aims at capturing the local correlation of BOLD 
signal, which conflicts with smoothing the brain maps or averaging over a very large number 
of voxels. Thus, other functional metrics that can be applied to larger cortical regions should 
be preferred in our sample.   
 For self-reported scores, we can argue that test-retest can also be maximised by 
investigating the item level properties of the questionnaire (see Chapter 2) even if we did 
not demonstrate it in the analysis. Indeed, differential item functioning (DIF) across age can 
suggest that participants may understand or interpret the questions differently in different 
occasions. Thus, ensuring a minimal level of age DIF may improve the score test-retest. In 
addition, items poorly correlated to the latent trait (e.g. showing non-monotonous IRSF or 
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flat IRSF) as well as guessed (left asymptote of IRSF not equal to 0, suggesting random 
choice of option) would contribute to lower test-retest by capturing noise instead of a truly 
changing state-like component. This further highlights the usefulness of IRT analyses over 
psychometric analyses that rely on meta-statistics such as Cronbach’s alpha or Mokken 
Scale analysis [184, 191, 192].  
 Test-retest is also directly related to heritability, often representing the upper bound 
of the estimate [67]. Thus, in presence of low ICC the heritability estimate becomes 
somewhat meaningless as it only represents the heritable fraction of the reliable variance. 
We provide a good example of such heritability estimates in Chapter 4: the FC voxel-wise 
heritability was around 20% but for a reliability between 0.4 and 0.8. We do not expect FC 
in the language production network to be so plastic that the FC would change drastically 
over a 3 months period, especially at a mean age of 22. Thus the low-moderate ICC likely 
reflects a limitation of the fMRI imaging duration, which we can reasonably assume in light 
of the estimated ReHo test-retest (Chapter 6). In absence of such data, we can only wonder 
what the heritability would be when estimated from a longer RS-fMRI scan in which all voxel-
wise ICC would be greater than 0.8. Overall, this limits the interpretation of our FC heritability 
analysis in Chapter 6 from which we can conclude that FC organised around the Broca’s 
areas may be heritable but we cannot determine the true heritability of such phenotypes. 
We should mention two more limitations of Chapter 6 that are relative to the significance of 
the heritability of the FC considered. The first one is that we selected voxels based on test-
retest and that creates a bias in the voxels included in the heritability analysis (“double-
dipping” [623]). Thus, we cannot conclude that the FC in the language production network 
are significantly heritable. However, this was not the aim of such analysis, rather we wanted 
to measure the effect of HM on the FC heritability. In that regard, the bias induced here 
would facilitate detecting a widespread genetic correlation of HM with FC across the Broca’s 
networks. Indeed, voxels showing higher test-retest would tend to mechanically show higher 
heritability, which translates into higher power to detect genetic correlations with HM [612]. 
Therefore, our approach helps to make the claim that HM should have a limited influence 
on heritability analyses of FC. The second limitation was not reported at the time of 
publication and concerns the method used to correct for multiple testing over the brain map 
[624]. Indeed, simulations suggest that spatial autocorrelation may not follow the required 
gaussian shape, which underlies using gaussian field theory to correct for multiple testing 
over the brain map. Permutation tests over the dataset should provide a better estimation of 
the null distribution and control more efficiently the false positive rate [624]. For these two 
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reasons we cannot ensure that the reported heritable regions of the Broca’s network really 
reach significance.  
 In summary, systematic investigation of test-retest should be encouraged in MRI 
studies, for which the effect of acquisition parameters, MRI scanner, image processing 
options and choice of functional metrics are still largely unknown. In addition, test-retest is 
also of interest when performing phenotypic and genetic analyses (i.e. twin models) as it 
can impact the observed phenotypic correlation, heritability and genetic correlations. 
Instruments and protocols that yield the highest test-retest should be preferred and imperfect 
test-retest should be taken into account when estimating the sample size needed to achieve 
an 80% power.      
 
Promises of brain endophenotypes 
 A recent set of publications (a special edition of Psychophysiology) criticised the 
search for brain endophenotypes using the argument that the 17 brain phenotypes studied 
were complex traits with no single SNPs explaining more than 1.4% of the variance (see 
[605] for discussion). Based on these results the authors concluded that brain phenotypes 
are not simpler genetically than clinical phenotypes and that brain endophenotypes will not 
assist gene discovery for clinical diagnoses [605]. Aside from the fairly provocative tone of 
the paper, which may explain some of the shortcuts in the conclusions (and the Donald 
Rumsfeld’s citation), we aimed at investigating the claim that brain phenotypes are indeed 
as complex as psychiatric disorders. We reviewed in Chapter 9 the most recent evidence 
from the largest imaging GWAS (ENIGMA and CHARGE consortia [76-78, 506]) and the 
most recent GWAS on a selection of clinical phenotypes: MDD [15], SCZ [79], Alzheimer’s 
disease [596] and Rheumatoid Arthritis (RA) [597, 625]. We showed that the effect sizes of 
the genome-wide significant SNPs were markedly greater for brain structural phenotypes 
(ICV, hippocampal and putamen volumes) than for clinical phenotypes. Such differences in 
effect size were consistent with brain phenotypes being complex traits, however less 
complex than the diagnoses. As a proof of concept we also noted a difference in genetic 
complexity between SCZ and RA, consistent with that reported before using an elaborate 
Bayesian modelling [592, 594]. We discussed the limitations of our approach at the end of 
Chapter 9 that arise mostly from fewer genome-wide significant SNPs reported for structural 
brain phenotypes. In addition, there are many imaging modalities that have never been 
studied in GWAS (e.g. DTI, RS-fMRI) and whose genetic complexity remains completely 
unknown. If the simpler genetic architecture is confirmed, GWAS of psychiatric 
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endophenotypes will prove very useful at breaking down the genetics of psychiatric traits, 
necessitating samples much smaller than what would be required to directly study the 
diagnoses. 
 In addition, the intrinsic multivariate nature of brain MRI phenotypes may facilitate the 
identification of variants influencing brain structure and functions. We detailed in chapter 9 
a method to calculate analytically the power of multivariate GWAS using path coefficients 
estimated from multivariate twin models. This method allowed us to calculate the power of 
real-case scenarios: multivariate GWAS of subcortical volumes and hippocampus subfields 
volumes. In both scenarios, the power of a multivariate GWAS was much greater than of a 
univariate approach (almost doubled for the analysis of hippocampus subfields, see 
Chapter 9). Thus, performing multivariate GWAS on brain phenotypes may lead to the 
identification of many more SNPs that generally influence subcortical or hippocampus 
subfields volumes. One limitation of the multivariate approach is that it would not identify 
which subcortical/subfield volumes drive the association, but this could be overcome by 
performing univariate replication analysis in order to precise the effect.  
 Our power calculator is very fast, relying on analytical calculations rather than 
simulations and does not make assumptions on the underlying genetic structure of the set 
of phenotypes included (Cholesky decomposition, see Chapter 9). Thus, it accommodates 
any set of phenotypes and is less biased than most simulated approaches, relying on 
estimates from twin models (real data) rather than arbitrary parameters, that can always be 
carefully chosen to demonstrate the superiority of one analysis type [571].  Many more 
multivariate scenarios would deserve to be investigated, for example thickness/surface area 
across anatomical cortical regions, or even voxel-wise measurements. To conclude, the 
multivariate nature of MRI images makes them great candidates for multivariate GWAS, 
especially compared to psychiatry in which multiple dimensions are not always collected 
and the overall number of dimension is limited.  
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Supplementary Document 1: Instruments and sections collected in each wave of the 19Up study 
 Total 
prevalence 
%(n) 
[95% CI] 
Prevalence 
Males 
%(n) 
[95% CI] 
Prevalence 
Females 
%(n) 
[95% CI] 
p-value 
males vs. 
females 
Prevalence 
NU2 
%(n) 
[95% CI] 
Prevalence 
NU3 
%(n) 
[95% CI] 
p-value 
NU2vs. 
NU3 
Affective Disorders        
MDD 16.8% (465)  
[15.4 18.2] 
13.6% (159) 
[11.7 15.7] 
19.1% (306) 
[17.2 21.1] 
1.6E-4 14.7% (98) 
[12.2 17.7] 
17.4% (367) 
[15.8 19.1] 
0.12 
Social anxiety 17.5% (486)  
[16.1 19] 
13.2% (154) 
[11.3 15.3] 
20.7% (332) 
[18.8 22.8] 
3.2E-07 16.2% (108) 
[13.6 19.3] 
17.9% (378) 
[16.3 19.7] 
0.35 
Panic Disorder (With agoraphobia) 0.9% (24)  
[0.57 1.3] 
0.3% (3)  
[0.1 0.8] 
1.3% (21) 
[0.8 2.0] 
5.9E-3✝▲ 1.1% (7)  
[0.5 2.3] 
0.8% (17) 
[0.5 1.3] 
0.72 
Panic Disorder (Without agoraphobia) 1.5% (42)  
[1.1 2.1] 
0.9% (10) 
[0.4 1.6] 
2.0% (32) 
[1.4 2.8] 
0.023▲ 1.7% (11)  
[0.9 3.0] 
1.5% (31) 
[1.0 2.1] 
0.88 
 Panic Attack 14.3% (397)  
[13.0 15.7] 
9.2% (107)  
[7.6 11.0] 
18.1% (290) 
[16.3 20.1] 
4.5E-11 15.6% (104) 
 [13.0 18.7] 
13.9% (293) 
[12.5 15.5] 
0.29 
Manic Episode 0.5% (14) 
 [0.3 0.9] 
0.7% (8)  
[0.3 1.4] 
0.4% (6)  
[0.2 0.9] 
0.39 0.6% (4) 
 [0.2 1.6] 
0.5% (10) 
[0.2 0.9] 
0.93✝ 
Substance Use        
Lifetime Use of any drug 57.8% (1604)  
[56.0 59.7] 
63.2% (740) 
[60.4 66] 
53.9% (864) 
[51.4 56.4] 
1.0E-06 62.3% (414) 
[58.4 65.9] 
56.5% (1190) 
 [54.3 58.6] 
9.4E-3▲ 
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Cannabis Abuse 11.6% (322)  
[10.5 12.9] 
17.0% (199) 
[14.9 19.3] 
7.7% (123) 
[6.44 9.11] 
5.6E-14 15.3% (102) 
[12.7 18.4] 
10.4% (220) 
[9.18 11.8] 
7.5E-4 
Cannabis Dependence 6.8% (189) 
 [5.9 7.8] 
9.8% (115)  
[8.2 11.7] 
4.6% (74) 
[3.7 5.8] 
1.1E-07 10.7% (71)  
[8.5 13.3] 
5.6% (118) 
[4.7 6.7] 
8.9E-06 
Alcohol Abuse 33.8% (938) 
 [32.1 35.6] 
40.2% (470) 
[37.4 43.1] 
29.2% (468) 
[27.0 31.5] 
2.1E-09 36.7% (244)  
[33.0 40.5] 
32.9% (694) 
[30.9 35] 
0.081 
Alcohol Dependence 28.0% (776) 
[26.3 29.7] 
35.4% (414) 
[32.7 38.2] 
22.6% (362) 
[20.6 24.7] 1.66E-13 
32.8% (218) 
[29.2 36.5] 
26.5% (558) 
[24.6 28.4] 0.0019 
Supplementary Document 2: Prevalence of DSM-IV diagnoses in the 19Up study 
Cells report prevalence%, (N) [95% CI] 
N.B. Analyses performed using a Chi Square test unless stated.  
▲: Would not survive multiple testing correction of 0.05/22 = 0.0022 
Significant p-value after multiple testing correction are highlighted in bold 
✝: Fisher’s Exact test used 
: Illicit drug or non-medical use of prescription drug. Participants are asked specifically about: Cocaine, Amphetamine type Stimulants, Inhalants, Sedatives or 
Sleeping Pills, Hallucinogens, Opioids, Party Drugs (Ecstasy, Ketamine, GHB), Over the counter/Prescription Pain killers and Analgesics for non-medical purposes, 
Over the counter/prescription Stimulants for non-medical purposes, or other. 
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MDD Cases - 32.5% 
[28.3 37] 
9.5%  
[7.0 
12.6] 
5.6%  
[3.8 8.2] 
34.8% 
[30.5 
39.4] 
30.1% 
[26 34.5] 
1.7% 
 [0.8 3.5] 
4.5%  
[2.9 6.9] 
29.5% 
[25.4 
33.9] 
0.0%  
[0.0 0.5] 
11%  
[8.3 
14.3] 
60.2% 
[55.6 
64.7] 
 Controls  14.5% 
[13.1 16] 
12.0%  
[10.8 
13.5] 
7.1%  
[6.1 8.2] 
33.6% 
[31.7 
35.6] 
27.6% 
[25.8 
29.4] 
0.7%  
[0.4 1.1] 
0.9%  
[0.6 1.4] 
11.3% 
[10.0 
12.6] 
0.6%  
[0.3 1.0] 
6.3%  
[5.3 7.4] 
57.4% 
[55.3 
59.4] 
 p-value  2.80E-20 0.13 0.29 0.65 0.29 0.056 2.10E-08 3.40E-24 0.15✝ 4.7E-4 0.28 
Social 
Anxiety 
Cases 31.1% 
[27.0 
35.4] 
- 15.2% 
[12.2 
18.8] 
9.3%  
[6.9 
12.3] 
36.8% 
[32.6 
41.3] 
34.2% 
[30.0 
38.6] 
2.1%  
[1.0 3.9] 
4.1%  
[2.6 6.4] 
30.5% 
[26.4 
34.8] 
1.6%  
[0.8 3.3] 
9.7%  
[7.3 12.7] 
62.1% 
[57.6 
66.4] 
 Controls 13.7% 
[12.4 
15.2] 
 10.8% 
[9.6 
12.2] 
6.3%  
[5.4 7.4] 
33.2% 
[31.3 
35.2] 
26.7% 
[24.9 
28.5] 
0.6%  
[0.3 1.1] 
1.0%  
[0.6 1.5] 
10.9% 
[9.7 
12.3] 
0.3%  
[0.1 0.6] 
6.5%  
[5.6 7.6] 
56.9% 
[54.9 59] 
 p-value 2.80E-20  0.0078 0.024 0.14 0.001 0.0043 6.90E-07 1.10E-28 3.8E-4 0.018 0.039 
Cannabis 
Abuse 
Cases 13.7% 
[10.2 18] 
23.0%  
[18.6 28] 
- 50.0% 
[44.6 
55.4] 
71.7% 
[66.4 
76.5] 
60.2% 
[54.7 
65.6] 
2.5%  
[1.2 5.0] 
0.6%  
[0.1 2.5] 
21.7% 
[17.4 
26.7] 
1.9%  
[0.8 4.2] 
12.4% 
[9.1 
16.6] 
98.1% 
[95.8 
99.2] 
 Controls 17.2% 
[15.7 
18.7] 
16.8% 
[15.4 
18.4] 
 1.1%  
[0.8 1.7] 
28.8% 
[27.1 
30.7] 
23.7% 
[22.1 
25.5] 
0.7%  
[0.4 1.1] 
1.6%  
[1.2 2.2] 
13.3% 
[12.0 
14.8] 
0.3%  
[0.2 0.7] 
6.4%  
[5.4 7.4] 
52.5% 
[50.6 
54.5] 
 p-value 0.13 0.0078  6.0E-233 2.2E-52 2.0E-42 0.0026 0.25 7.50E-05 0.0012 0.00011 2.80E-54 
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Cannabis
Depende
nce 
Cases 13.8% 
[9.3 
19.7] 
23.8% 
[18.1 
30.6] 
85.2% 
[79.1 
89.8] 
- 69.8% 
[62.7 
76.2] 
65.1% 
[57.8 
71.8] 
2.6%  
[1.0 6.4] 
0.5%  
[0.0 3.4] 
27.5% 
[21.4 
34.6] 
3.2%  
[1.3 7.1] 
17.5% 
[12.5 
23.8] 
97.9% 
[94.3 
99.3] 
 Controls 17%  
[15.6 
18.5] 
17.1% 
[15.6 
18.6] 
6.2%  
[5.3 7.2] 
 31.2% 
[29.4 33] 
25.3% 
[23.6 27] 
0.7%  
[0.5 1.2] 
1.6%  
[1.2 2.2] 
13.4% 
[12.1 
14.7] 
0.3%  
[0.1 0.6] 
6.3%  
[5.4 7.3] 
54.9% 
[53.0 
56.8] 
 p-value 0.29 0.024 6.0E-233  5.20E-27 1.50E-31 0.02 0.4 1.50E-07 1.30E-06 1.80E-08 1.80E-30 
Alcohol 
Abuse 
Cases 17.3% 
[14.9 
19.9] 
19.1% 
[16.6 
21.8] 
24.6% 
[21.9 
27.5] 
14.1% 
[11.9 
16.5] 
- 63.3% 
[60.1 
66.4] 
1.3%  
[0.7 2.3] 
1.8%  
[1.1 2.9] 
17.4% 
[15.0 
20.0] 
1.2%  
[0.6 2.2] 
8.0%  
[6.4 
10.0] 
82.3% 
[79.7 
84.7] 
 Controls 16.5% 
[14.9 
18.3] 
16.7% 
[15.1 
18.5] 
5.0%  
[4.0 6.1] 
3.1%  
[2.4 4.0] 
 9.9%  
[8.6 
11.4] 
0.7%  
[0.4 1.2] 
1.4%  
[0.9 2.0] 
12.8% 
[11.3 
14.4] 
0.2%  
[0.0 0.5] 
6.6%  
[5.5 7.9] 
45.3% 
[43.0 
47.7] 
 p-value 0.65 0.14 2.2E-52 5.2E-27  1.7E-192 0.14 0.45 0.0012 0.0011 0.2 2.8E-77 
Alcohol 
Depende
nce 
Cases 18%  
[15.4 
21.0] 
21.4% 
[18.6 
24.5] 
25%  
[22.0 
28.2] 
15.9% 
[13.4 
18.7] 
76.5% 
[73.4 
79.5] 
- 1.3%  
[0.7 2.4] 
1.9%  
[1.1 3.2] 
19.3% 
[16.6 
22.3] 
1.2%  
[0.6 2.3] 
7.9%  
[6.1 
10.0] 
83.1% 
[80.3 
85.6] 
 Controls 16.3% 
[14.7 
18.0] 
16%  
[14.5 
17.7] 
6.4%  
[5.4 7.6] 
3.3%  
[2.6 4.2] 
17.2% 
[15.6 
19.0] 
 0.7%  
[0.4 1.2] 
1.4%  
[0.9 2.0] 
12.4% 
[11.0 
13.9] 
0.3%  
[0.1 0.6] 
6.8%  
[5.7 8.0] 
48%  
[45.8 
50.2] 
 p-value 0.29 0.001 2.00E-42 1.50E-31 1.7E-192  0.2 0.34 3.50E-06 0.0062 0.35 4.90E-63 
Panic 
Disorder 
Cases 33.3% 
[16.4 
55.3] 
41.7% 
[22.8 
63.1] 
33.3% 
[16.4 
55.3] 
20.8% 
[7.9 
42.7] 
50%  
[31.4 
68.6] 
41.7% 
[22.8 
63.1] 
- NA  NA  4.2%  
[0.2 
23.1] 
4.2%  
[0.2 
23.1] 
75.0% 
[52.9 
89.4] 
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With 
Agora 
Controls 16.6% 
[15.3 
18.1] 
17.3% 
[15.9 
18.8] 
11.4% 
[10.3 
12.7] 
6.7%  
[5.8 7.7] 
33.7% 
[31.9 
35.5] 
27.9% 
[26.2 
29.6] 
 1.5%  
[1.1 2.1] 
13.6% 
[12.3 
14.9] 
0.5%  
[0.3 0.8] 
7.1%  
[6.2 8.1] 
57.7% 
[55.8 
59.5] 
p-value 0.056 0.0043 0.0026 0.02 0.14 0.2  NA▲ NA▲ 0.27 0.88 0.13 
Panic 
Disorder 
Without 
Agora 
Cases 50.0%  
[35.5 
64.5] 
47.6% 
[32.3 
63.4] 
4.8%  
[0.8 
17.4] 
2.4%  
[0.1 
14.1] 
40.5% 
[26.0 
56.7] 
35.7% 
[22.0 
52.0] 
0%  - 100%  0%  19.0% 
[9.1 
34.6] 
66.7% 
[50.4 80] 
Controls 16.3% 
[14.9 
17.7] 
17.1% 
[15.7 
18.5] 
11.7% 
[10.5 13] 
6.9%  
[6.0 7.9] 
33.7% 
[32.0 
35.5] 
27.9% 
[26.2 
29.6] 
0.9%  
[0.6 1.3] 
 13%  
[11.8 
14.3] 
0.5%  
[0.3 0.9] 
6.9%  
[6.0 7.9] 
57.7% 
[55.8 
59.6] 
p-value 2.10E-08 6.90E-07 0.25 0.4 0.45 0.34 NA  NA 1✝ 0.006 0.31 
Panic 
Attack 
Cases 34.5% 
[29.9 
39.4] 
37.3% 
[32.5 
42.3] 
17.6% 
[14.1 
21.8] 
13.1% 
[10 16.9] 
41.1% 
[36.2 
46.1] 
37.8% 
[33.0 
42.8] 
6.0%  
[4.0 9.0] 
10.6% 
[7.8 
14.1] 
- 2.3%  
[1.1 4.4] 
15.6% 
[12.3 
19.7] 
64.7% 
[59.8 
69.4] 
 Controls 13.8% 
[12.5 
15.3] 
14.2% 
[12.9 
15.7] 
10.6% 
[9.4 
11.9] 
5.8% 
[4.9 6.8] 
32.6% 
[30.7 
34.6] 
26.3% 
[24.6 
28.2] 
NA  NA  0.2%  
[0.1 0.5] 
5.6%  
[4.8 6.7] 
56.7% 
[54.7 
58.7] 
 p-value 3.40E-24 1.10E-28 7.50E-05 1.50E-07 0.0012 3.50E-06 NA▲ NA▲  6.70E-07 1.50E-12 0.0032 
Manic 
Episode 
Cases % [0 NA] 57.1% 
[29.6 
81.2] 
42.9% 
[18.8 
70.4] 
42.9% 
[18.8 
70.4] 
78.6% 
[48.8 
94.3] 
64.3% 
[35.6 86] 
7.1%  
[0.4 
35.8] 
0.0%  64.3% 
[35.6 
86.0] 
- 7.1%  
[0.4 
35.8] 
78.6% 
[48.8 
94.3] 
 Controls 16.9% 
[15.5 
18.3] 
17.3% 
[15.9 
18.8] 
11.5% 
[10.3 
12.7] 
6.6%  
[5.7 7.6] 
33.6% 
[31.8 
35.4] 
27.8% 
[26.1 
29.5] 
0.8%  
[0.5 1.3] 
1.5%  
[1.1 2.1] 
14.1% 
[12.8 
15.4] 
 7.1%  
[6.2 8.1] 
57.7% 
[55.9 
59.6] 
 p-value 0.19 0.00038 0.0012 1.30E-06 0.0011 0.0062 0.27 1✝ 6.70E-07  1 0.19 
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Psychoti
c 
Sympto
ms 
Cases 26.0% 
[20.1 
32.9] 
24.0% 
[18.3 
30.7] 
20.4% 
[15.1 
26.9] 
16.8% 
[12.0 
23.0] 
38.3% 
[31.5 
45.5] 
31.1% 
[24.8 
38.2] 
0.5%  
[0.0 3.2] 
4.1%  
[1.9 8.2] 
31.6% 
[25.3 
38.7] 
0.5%  
[0.0 3.2] 
- 65.3% 
[58.1 
71.9] 
 Controls 16.1% 
[14.7 
17.6] 
17%  
[15.6 
18.6] 
10.9% 
[9.8 
12.2] 
6.1%  
[5.2 7.1] 
33.5% 
[31.7 
35.4] 
27.7% 
[26.0 
29.5] 
0.9%  
[0.6 1.4] 
1.3%  
[0.9 1.9] 
13%  
[11.7 
14.4] 
0.5%  
[0.3 0.9] 
 57.3% 
[55.3 
59.2] 
 p-value 4.7E-4 0.018 1.1E-4 1.8E-08 0.2 0.35 0.88 0.006 1.5E-12 1  0.034 
Any 
Illegal 
Substan
ce Use* 
Cases 17.5% 
[15.6 
19.4] 
18.8% 
[17.0 
20.8] 
19.7% 
[17.8 
21.8] 
11.5% 
[10.0 
13.2] 
48.1% 
[45.7 
50.6] 
40.2% 
[37.8 
42.7] 
1.1%  
[0.7 1.8] 
1.7%  
[1.2 2.5] 
16.0%  
[14.3 
17.9] 
0.7%  
[0.4 1.3] 
8.0%  
[6.7 9.4] 
- 
Controls 15.8% 
[13.8 
18.1] 
15.7% 
[13.7 
18.0] 
0.5%  
[0.2 1.2] 
0.3%  
[0.1 0.9] 
14.2% 
[12.3 
16.4] 
11.2% 
[9.5 
13.2] 
0.5%  
[0.2 1.2] 
1.2%  
[0.7 2.1] 
12.0% 
[10.2 
14.0] 
0.3%  
[0.1 0.8] 
5.8%  
[4.6 7.4] 
 
p-value 0.28 0.039 2.80E-54 1.80E-30 2.80E-77 4.90E-63 0.13 0.31 0.0032 0.19 0.034  
Supplementary Document 3: Proportion of peolpe with one DSM-IV disorder (rows) who also have another disorder (columns) 
NB. Read rows first followed by columns, e.g. of participants with MDD 33.5% also had Social Anxiety. 
Significant p-values after multiple testing correction (Bonferroni corrected, significance threshold: 0.05/24=1.7E-3) appear in bold  
* Illicit drug or non-medical use of prescription drug. Include: Cocaine, Amphetamine type Stimulants, Inhalants, Sedatives or Sleeping Pills, Hallucinogens, Opioids, 
Party Drugs (Ecstasy, Ketamine, GHB), Over the counter/Prescription Pain killers and Analgesics for non-medical purposes, Over the counter/prescription 
Stimulants for non-medical purposes, or other 
✝: Fisher’s Exact test used 
▲: diagnoses and criteria whose definitions mutually exclude each other (e.g panic attack required for a diagnosis of panic disorder)
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 Phenotypic 
correlation  
[95% CI] 
Genetic 
correlation 
[95% CI] 
Environmental 
correlation 
[95% CI] 
TW1 0.88 [0.86, 0.89] 0.97 [0.94,1.00] 0.80 [0.76,0.83] 
TW2 0.90 [0.98,0.91] 0.97 [0.95,1.00] 0.84 [0.81,0.870.9] 
TM 0.92 [0.91,0.93] 0.98 [0.96,1.00] 0.88 [0.86,0.90] 
TA 0.91 [0.90,0.92] 0.97 [0.93,1.00] 0.88 [0.85,0.91] 
Supplementary Document 4: Phenotypic, genetic and environmental correlations 
between Fatigue and Somatisation subscales of the SPHERE-34 questionnaire 
Correlations were estimated in OpenMx, see main manuscript for sample sizes. 
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Supplementary Document 5: Treatment of missing values in SPHERE 
questionnaires 
We reported the sample missingness per individuals, twin pairs and items (Table 1). 
In addition, we compared the age, sex and SPHERE-34 sum scores between missing and 
non-missing groups to investigate whether data was missing (completely) at random 
(MCAR or MAR). MCAR or MAR (i.e. dependent on covariates such as age or sex but 
independent of the outcome variables) is necessary to ensure unbiased results after 
exclusion of missing values or imputation [626]. 
Overall, the number of missing values was fairly low in the studies. In TA, 
comprising the most missing observations, only 4% of individuals had one or more missing 
item, with 3 individuals (0.24%) having more than 5 items missing (Table 1). Missingness 
was not localised to one particular item as shown by the maximal percentage of missing 
observations across all 34 items (0.63%). Missingness was even rarer in TW1, TW2 
studies with no individual having more than 5 items missing. The TM study was even 
exempt from missing values.   
In order to study the pattern of missingness, we compared individuals with one or 
more item missing with individuals who fully completed the questionnaire. We compared 
the groups in term of age, sex, frequency, and the original SPHERE summed score 
(Fisher exact test and Mann-Whitney-Wilcoxon test). Two tests returned a p-value of 0.03, 
which can only be interpreted as a suggestive difference between groups as such result 
can be expected by chance, knowing that 21 tests were performed. At a young age (i.e. 
mean age 12), missingness could be associated with larger levels of somatic distress 
(median score 4 vs 2) and fatigue (median score 3 vs 2). This effect, if true, is specific to a 
class age as it was not observed in following studies at later age.  
In the following, we assumed missingness to be completely at random as it was not 
significantly associated with demographic variables or SPHERE scores. Thus, we can be 
more confident that the exclusion of the 70 individuals with missing values does not induce 
a selection bias in the analysis. In addition, the impact on power of such exclusion should 
be limited.  
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 TW1 TW2 TM TA 
N 
Mean age [range] (yrs) 
1,707 
12 [9-18] 
1,273 
14 [9-18] 
1,513 
16 [15-
22] 
1,264 
18  [11-
28] 
% (N) indiv with >0 missing 
value 
0.70% 
(12) 
0.63% (8) 0% 3.96% 
(50) 
% (N) indiv with >5 missing 
values 
0% 0% 0% 0.24% 
(3) 
maximal % (N) missingness per 
item 
0.12% 
(2) 
0.16% (2) 0% 0.63% 
(8) 
 
 
Test of 
predictors 
of 
missingness 
(p-values) 
Age 0.59 0.37 NA 0.86 
Sex 0.15 0.73 NA 0.11 
Depression-
Anxiety (SPHERE 
12) 
0.17 0.11 NA 0.16 
Chronic Fatigue 
(SPHERE 12) 
0.031 0.40 NA 0.84 
Depression-
Anxiety (SPHERE 
34) 
0.055 0.21 NA 0.11 
Somatic-Distress 
(SPHERE 34) 
0.053 0.93 NA 0.60 
Fatigue (SPHERE 
34) 
0.031 0.42 NA 0.93 
S5 Table 1: Missingness at each time point and investigation of MCAR and MAR 
hypotheses 
When testing sex ratio differences, Fisher exact test were used instead of chi-2 test to overcome 
the issue of small effectives. For the same reason, we preferred the Mann-Whitney-Wilcoxon test 
to the Student t-test to compare age and sum scores. Study TM does not have missing values as it 
was collected in the clinics with the research assistant making sure not question was omitted. 
Missingness rate is larger in study TA as data was collected at home. It is the only collection time 
point that was not conducted in the clinics. 
  
300 
 
 
 
Supplementary Document 6: Response Step Function of the 15 items proposed to 
measure chronic fatigue 
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Supplementary Document 7: Response Step Function of the 9 items proposed to 
measure chronic fatigue after exclusion of items not meeting IRT requirements 
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Supplementary Document 8: Sex DIF for the 14 items of the anxiety-depression 
scale (TA wave) 
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Supplementary Document 9: Sex DIF for the 14 items of the anxiety-depression 
subscale (TM wave) 
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Supplementary Document 10: Sex DIF for the 14 items of the anxiety-depression 
subscale (TW2 wave) 
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Supplementary Document 11: Sex DIF for the 14 items of the anxiety-depression 
subscale (TW1 wave) 
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Supplementary Document 12: DIF between studies TM and TA (anxiety-depression 
subscale) 
  
307 
 
 
Supplementary Document 13: DIF between studies TW2 and TA (anxiety-depression 
subscale) 
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Supplementary Document 14: DIF between studies TW1 and TA (anxiety-depression 
subscale) 
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Supplementary Document 15: Sex DIF for the 11 items of the chronic fatigue 
subscale (TA wave) 
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Supplementary Document 16: Sex DIF for the 11 items of the chronic fatigue 
subscale (TM wave) 
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Supplementary Document 17: Sex DIF for the 11 items of the chronic fatigue 
subscale (TW2 wave) 
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Supplementary Document 18: Sex DIF for the 11 items of the chronic fatigue 
subscale (TW1 wave) 
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Supplementary Document 19: DIF between studies TM and TA (chronic fatigue 
subscale) 
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Supplementary Document 20: DIF between studies TW2 and TA (chronic fatigue 
scale) 
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Supplementary Document 21: DIF between studies TW1 and TA (chronic fatigue 
subscale) 
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Supplementary Document 22: SPHERE-21 for population samples 
 
Please indicate if over the past few weeks you have been troubled by any of the following symptoms. 
Select the appropriate response to indicate sometimes/never, often, or most of the time. 
  
  Sometimes/Neve
r 
Often Most of the time 
1. Feeling irritable or cranky? ¡ ¡ ¡ 
2. Poor Memory? ¡ ¡ ¡ 
3. Feeling nervous or tense? ¡ ¡ ¡ 
4. Waking up tired? ¡ ¡ ¡ 
5. Rapidly changing moods? ¡ ¡ ¡ 
6. Feeling unhappy and depressed? ¡ ¡ ¡ 
7. Back pain? ¡ ¡ ¡ 
8. Prolonged tiredness after activity? ¡ ¡ ¡ 
9. Feeling constantly under strain? ¡ ¡ ¡ 
10. Weak muscles? ¡ ¡ ¡ 
11. Feeling frustrated? ¡ ¡ ¡ 
12. Poor sleep? ¡ ¡ ¡ 
13. Getting annoyed easily? ¡ ¡ ¡ 
14. Everything getting on top of you? ¡ ¡ ¡ 
15. Dizziness? ¡ ¡ ¡ 
16. Feeling tired after rest or 
relaxation? 
¡ ¡ ¡ 
17. Poor concentration? ¡ ¡ ¡ 
18. Tired muscles after activity? ¡ ¡ ¡ 
19. Feeling lost for words? ¡ ¡ ¡ 
20. Losing confidence? ¡ ¡ ¡ 
21. Being unable to overcome 
difficulties? 
¡ ¡ ¡ 
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Supplementary Document 23: Summary of Genetic Analyses 
S23 Table 1: Sampling homogeneity, covariate significance and twin pair correlations  
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 score Age Sex TW1 TW2 TM Omnibus test  
(20 df) 
H1c H2c H3c H4c rMZ rDZ 
  p-value p-value p-
value 
p-
value 
p-
value 
χ2 p-value p-value p-value p-value p-value   
<13 years old               
Anxiety-
depression 
IRT 0.86 4.8E-4 0.30 0.16 NA 29.3 0.082 0.21 0.33 9.4E-3 2.3E-14 0.43 0.22 
 Sum score 0.47 2.1E-4 0.74 0.32 NA 68.5 3.2E-7 1.8E-3 0.026 0.027 2.2E-20 0.46 0.28 
Chronic Fatigue IRT 0.58 1.2E-6 0.39 0.48 NA 26.8 0.14 0.16 0.19 0.032 2.4E-15 0.42 0.25 
 Sum score 0.55 5.4E-6 0.88 0.92 NA 47.8 4.5E-4 1.2E-3 0.02 0.027 2.6E-16 0.43 0.27 
[13, 15[               
Anxiety-
depression 
IRT 0.78 0.78 0.31 0.91 NA 13.5 0.85 0.69 0.81 0.78 1.3E-17 0.38 0.32 
 Sum score 0.32 0.96 0.99 0.049 NA 36.3 0.014 0.15 0.42 0.12 4.1E-12 0.34 0.24 
Chronic Fatigue IRT 0.22 0.019 0.11 0.52 NA 26.6 0.15 0.55 0.59 0.27 3.0E-21 0.53 0.29 
 Sum score 0.27 0.052 0.43 0.53 NA 36.6 0.013 6.7E-3 0.44 0.041 1.4E-18 0.48 0.25 
[15, 17[               
Anxiety-
depression 
IRT 0.33 5.4E-7 0.25 0.071 0.91 16.5 0.68 0.59 0.62 0.35 4.5E-10 0.28 0.20 
 Sum score 0.12 2.4E-10 0.77 0.32 0.21 53.9 5.9E-5 0.32 0.77 0.40 3.6E-7 0.24 0.15 
Chronic Fatigue IRT 0.08 0.017 0.12 0.16 0.19 13.6 0.85 0.25 0.91 0.045 1.10E-10 0.38 0.15 
 Sum score 0.04 0.038 0.34 0.41 0.059 18.0 0.59 0.63 0.89 0.016 4.6E-9 0.39 0.13 
>=17               
Anxiety-
depression 
IRT 0.06 5.1E-4 0.22 NA 0.53 19.7 0.48 0.95 0.81 0.022 4.6E-4 0.39 0.18 
 Sum score 0.049 1.7E-5 0.17 NA 0.15 48.8 3.3E-4 0.51 0.37 0.067 0.17 0.29 003 
Chronic Fatigue IRT 1.2E-3 2.0E-3 0.77 NA 0.11 27.5 0.12 0.58 0.97 0.042 4.4E-3 0.27 0.07 
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P-values correspond to tests of likelihood ratio calculated in OpenMx. χ2 is the test statistic of the omnibus test (saturated model vs. reduced model with all means 
and variances equals across twin zygosity groups and siblings). rMZ and rDZ and the twin pair correlations for the MZ and DZ groups.  H1c and H2c test equality of 
covariances that indicate sex specific heritability (scalar and non-scalar sex limitation), H3c is a test of familial aggregation and H4c a test of significance of the twin 
pair covariance. Notations correspond to those used in [200]. Nominally significant (p-value<0.05) tests are highlighted in bold. 
 
  
 
 
Sum score 2.0E-3 0.021 0.17 NA 0.52 36.1 0.015 0.18 0.44 0.01 0.1 0.26 0.01 
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S23 Table 2: Heritability of Anxiety-Depression IRT score across age groups 
 Model† Parameter estimates Model fit 
  A C/D E df Δdf -2LL Δ-2LL AIC P-value 
<13 
ADE 0.33 [0.058,0.49] 0.081 
[0.00,0.41] 
0.59 [0.5,0.68] 7  5217.8  2467.8 NA 
AE 0.41 [0.32,0.49]  0.59 
[0.51,0.68] 
6 1 5218 0.2 2466 0.65 
E    5 2 5284.4 66.6 2530.4 3.50E-
15 ACE 0.36 [0.15,0.49] 0.035 
[0.00,0.23] 
0.6 [0.51,0.71] 7  5217.9  2467.9  
[13-15[ 
ACE 0.19 [0.00,0.43] 0.19 [0.00,0.35] 0.62 
[0.53,0.74] 
7  5193  2467 NA 
AE 0.42 [0.33,0.5]  0.58 [0.5,0.67] 6 1 5196.9 3.9 2468.9 0.047 
CE  0.31 [0.24,0.37] 0.69 
[0.63,0.76] 
6 1 5195.1 2.1 2467.1 0.15 
E    5 2 5268.5 75.5 2538.5 4.10E-
17 ADE 0.42 [0.28,0.5] 0.00 [0.00,0.13] 0.58 [0.5,0.67] 7  5196.9  2470.9  
[15-17[ 
ACE 0.13 [0.00,0.36] 0.12 [0.00,0.27] 0.74 
[0.64,0.85] 
7  5732.7  2740.7 NA 
AE 0.29 [0.2,0.38]  0.71 [0.62,0.8] 6 1 5734.2 1.5 2740.2 0.22 
CE  0.21 [0.14,0.27] 0.79 
[0.73,0.86] 
6 1 5733.6 0.9 2739.6 0.34 
E    5 2 5771 38.3 2775 5.00E-
09 ADE 0.29 [0.16,0.38] 0.00 [0.00,0.29] 0.71 [0.62,0.8] 7  5734.2  2742.2  
17+ 
ADE 0.17 [0.00,0.49] 0.22 [0.00,0.51] 0.6 [0.46,0.77] 8  3244.3  1526.3 NA 
AE 0.37 [0.21,0.51]  0.63 [0.49,0.79] 7 1 3245.3 1 1525.3 0.32 
E    6 2 3264.1 19.8 1542.1 5.10E-05 
ACE 0.37 [0.09,0.51] 0.00 [0.00,0.17] 0.63 [0.49,0.79] 8  3245.3  1527.3  
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S23 Table 3: Heritability of Anxiety-Depression sum score across age groups 
 Model† Parameter estimates Model fit 
  A C/D E df Δdf -2LL Δ-2LL AIC P-value 
<13 
ACE 0.30 [0.053,0.52] 0.14 [0.00,0.32] 0.56 
[0.47,0.66] 
7  7914  5164.0 NA 
AE 0.47 [0.38,0.55]  0.53 
[0.45,0.62] 
6 1 7916 2 5164.0 0.16 
CE  0.34 [0.27,0.41] 0.66 
[0.59,0.73] 
6 1 7919.6 5.6 5167.6 0.018 
E    5 2 8006.8 92.8 5252.8 7.20E-
21 ADE 0.47 [0.38,0.55] 0.00 [NA,0.27] 0.53 
[0.45,0.62] 
7  7916  5166.0  
[13-15[ 
ACE 0.32 [0.025,0.48] 0.053 
[0.00,0.25] 
0.63 
[0.52,0.76] 
7  7789.6  5063.6 NA 
AE 0.39 [0.29,0.48]  0.61 
[0.52,0.71] 
6 1 7789.9 0.3 5061.9 0.58 
CE  0.25 [0.18,0.32] 0.75 
[0.68,0.82] 
6 1 7794.1 4.5 5066.1 0.034 
E    5 2 7841.7 52.1 5111.7 5.00E-
12 ADE 0.39 [0.15,0.48] 0.00 [0.00,0.25] 0.61 
[0.52,0.71] 
7  7789.9  5063.9  
[15-17[ 
ACE 0.18 [0.00,0.34] 0.052 
[0.00,0.22] 
0.77 
[0.66,0.89] 
7  8831.4  5839.4 NA 
AE 0.25 [0.16,0.35]  0.75 
[0.65,0.84] 
6 1 8831.7 0.3 5837.7 0.6 
CE  0.17 [0.1,0.23] 0.83 [0.77,0.9] 6 1 8833 1.6 5839.0 0.21 
E    5 2 8857.4 26 5861.4 2.30E-
06 ADE 0.25 [0.12,0.35] 0.00 [0.00,0.24] 0.75 [0.65,0.84] 7  8831.7  5839.7  
17+ 
ADE 0.053 [0.00,0.34] 0.15 [0.00,0.36] 0.79 [0.62,0.97] 8  5097.9  3379.9 NA 
AE 0.19 [0.022,0.36]  0.81 [0.64,0.98] 7 1 5098.6 0.7 3378.6 0.39 
E    6 2 5103.5 5.6 3381.5 0.06 
ACE 0.19 [0.022,0.36] 0.00 [0.00,0.14] 0.81 [0.64,0.98] 8  5098.6  3380.6  
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S23 Table 4: Heritability of Chronic-Fatigue IRT score across age groups 
 Model† Parameter estimates Model fit 
  A C/D E df Δdf -2LL Δ-2LL AIC P-value 
<13 
ACE 0.37 [0.11,0.51] 0.046 
[0.00,0.23] 
0.59 
[0.49,0.69] 
7  5111.3  2361.3 NA 
AE 0.42 [0.33,0.51]  0.58 
[0.49,0.67] 
6 1 5111.5 0.2 2359.5 0.64 
CE  0.29 [0.22,0.36] 0.71 
[0.64,0.78] 
6 1 5118.9 7.6 2366.9 0.0058 
E    5 2 5181.7 70.4 2427.7 5.10E-
16 ADE 0.42 [0.26,0.51] 0.00 [0.00,0.24] 0.58 
[0.49,0.67] 
7  5111.5  2361.5  
[13-15[ 
ACE 0.49 [0.26,0.59] 0.021 
[0.00,0.19] 
0.49 
[0.41,0.59] 
7  4900.5  2174.5 NA 
AE 0.51 [0.43,0.59]  0.49 
[0.41,0.57] 
6 1 4900.6 0.1 2172.6 0.81 
CE  0.33 [0.27,0.4] 0.67 [0.6,0.73] 6 1 4917.2 16.7 2189.2 4.50E-
05 E    5 2 5007.7 107 2277.7 5.30E-
24 ADE 0.51 [0.43,0.59] 0.00 [0.00,0.1] 0.49 
[0.41,0.57] 
7  4900.6  2174.6  
[15-17[ 
ACE 0.35 [0.15,0.44] 0.00 [0.00,0.13] 0.65 
[0.56,0.75] 
7  5322.7  2330.7 NA 
AE 0.35 [0.25,0.44]  0.65 
[0.56,0.75] 
6 1 5322.7 0 2328.7 1 
CE  0.22 [0.15,0.28] 0.78 
[0.72,0.85] 
6 1 5332.4 9.7 2338.4 0.0018 
E    5 2 5372.4 49.7 2376.4 1.60E-
11 ADE 0.35 [0.11,0.44] 0.00 [0.00,0.25] 0.65 [0.56,0.75] 7  5322.7  2330.7  
17+ 
ADE 0.00 [0.00,0.36] 0.32 [0.00,0.46] 0.68 [0.54,0.85] 8  3031.3  1313.3 NA 
AE 0.27 [0.11,0.41]  0.73 [0.59,0.89] 7 1 3033.6 2.3 1313.6 0.13 
E    6 2 3044.2 12.9 1322.2 0.0015 
ACE 0.27 [0.00,0.41] 0.00 [0.00,0.23] 0.73 [0.59,0.89] 8  3033.6  1315.6  
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S23 Table 5: Heritability of Chronic-Fatigue sum score across age groups 
 Model† Parameter estimates Model fit 
  A C/D E df Δdf -2LL Δ-2LL AIC P-value 
<13 
ACE 0.40 [0.15,0.53] 0.039 
[0.00,0.23] 
0.56 
[0.47,0.66] 
7  7103.3  4353.3 NA 
AE 0.45 [0.36,0.53]  0.55 
[0.47,0.64] 
6 1 7103.4 0.1 4351.4 0.69 
CE  0.31 [0.24,0.37] 0.69 
[0.63,0.76] 
6 1 7112.3 9 4360.3 0.0026 
E    5 2 7179.9 76.6 4425.9 2.40E-
17 ADE 0.45 [0.29,0.53] 0.00 [0.00,0.23] 0.55 
[0.47,0.64] 
7  7103.4  4353.4  
[13-15[ 
ACE 0.46 [0.21,0.57] 0.021 [0.00,0.2] 0.52 
[0.43,0.63] 
7  7106.5  4380.5 NA 
AE 0.49 [0.4,0.57]  0.51 [0.43,0.6] 6 1 7106.6 0.1 4378.6 0.81 
CE  0.31 [0.24,0.37] 0.69 
[0.63,0.76] 
6 1 7118.9 12.4 4390.9 0.00044 
E    5 2 7196.3 89.8 4466.3 3.20E-
20 ADE 0.49 [0.29,0.57] 0.00 [0.00,0.2] 0.51 [0.43,0.6] 7  7106.6  4380.6  
[15-17[ 
ADE 0.33 [0.076,0.44] 0.023 
[0.00,0.28] 
0.65 
[0.56,0.75] 
7  7963.2  4971.2 NA 
AE 0.35 [0.25,0.44]  0.65 
[0.56,0.75] 
6 1 7963.2 0 4969.2 0.87 
E    5 2 8009 45.8 5013 1.10E-
10 ACE 0.35 [0.19,0.44] 0.00 [0.00,0.099] 0.65 [0.56,0.75] 7  7963.2  4971.2  
17+ 
ADE 0.00 [0.00,0.24] 0.24 [0.048,0.39] 0.76 [0.61,0.93] 8  4526.4  2808.4 NA 
AE 0.18 [0.015,0.35]  0.82 [0.65,0.99] 7 1 4529.9 3.5 2809.9 0.062 
E    6 2 4534.5 8.1 2812.5 0.018 
ACE 0.18 [0.00,0.35] 0.00 [0.00,0.17] 0.82 [0.65,0.99] 8  4529.9  2811.9  
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S23 Table 6: Phenotypic, genetic and environmental correlations between Anxiety-depression and Chronic-fatigue IRT scores 
 Phenotypic correlation Genetic correlation Environmental correlation 
 r [95% CI] p-value  
(H0: r=0) 
p-value  
(H0: r=1) 
r [95% CI] p-value 
(H0: r=0) 
p-value  
(H0: r=1) 
r [95% CI] p-value 
(H0: r=0) 
p-value 
(H0: r=1) 
<13 0.62 
[0.58,0.65] 
2.8E-128 2.1E-20 0.88 
[0.77,0.98] 
8.2E-18 0.17 0.44 
[0.36,0.52] 
1.7E-23 2.3E-12 
[13,15[ 0.67 
[0.64,0.70] 
6.1E-149 1.5E-21 0.85 
[0.77,0.92] 
1.4E-20 0.15 0.52 
[0.43,0.59] 
2.4E-28 4.1E-14 
[15,17[ 0.68 
[0.65,0.70] 
9.9E-176 1.4E-19 0.88 
[0.77,0.97] 
8.1E-11 7.0E-4 0.58 
[0.51,0.64] 
2.3E-52 2.6E-8 
>=17 0.63 
[0.57,0.68] 
1.8E-65 8.6E-17 1.00 
[0.88,1.00] 
5.2E-7 0.017 0.43 
[0.31,0.54] 
8.0E-11 1.5E-6 
The p-values correspond to a likelihood ratio test with 1 df for tests on genetic and environmental correlations, 2 df for phenotypic correlations. The 
null hypothesis is indicated in brackets. Significant tests after Bonferroni correction (16 tests, significance threshold of 0.003) appear in bold. 
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S23 Table 7: Phenotypic, genetic and environmental correlations between Anxiety-depression and Chronic-fatigue sum scores 
 Phenotypic correlation Genetic correlation Environmental correlation 
 r [95% CI] p-value  
(H0: r=0) 
p-value  
(H0: r=1) 
r [95% CI] p-value 
(H0: r=0) 
p-value  
(H0: r=1) 
r [95% CI] p-value 
(H0: r=0) 
p-value 
(H0: r=1) 
<13 0.73 
[0.71,0.76] 
5.1E-207 <1.0E-300 0.87 
[0.79,0.93] 
1.9E-19 7.7E-8 0.63 
[0.56,0.69] 
1.9E-53 7.8E-164 
[13,15[ 0.70 
[0.67,0.73] 
9.5E-174 3.2E-31 0.83 
[0.74,0.90] 
3.9E-14 2.6E-6 0.61 
[0.54,0.68] 
2.0E-41 1.1E-4 
[15,17[ 0.69 
[0.66,0.72] 
2.1E-191 2.1E-41 0.76 
[0.61,0.87] 
1.0E-6 0.020 0.67 
[0.61,0.72] 
4.2E-66 4.1E-13 
>=17 0.66 
[0.62,0.70] 
2.6E-75 2.2E-11 1.00 
[0.92,1.00] 
4.0E-4 0.042 0.53 
[0.43,0.62] 
1.6E-18 0.013 
The p-values correspond to a likelihood ratio test with 1 df for tests on genetic and environmental correlations, 2 df for phenotypic correlations. The 
null hypothesis is indicated in brackets. Significant tests after Bonferroni correction (16 tests, significance threshold of 0.003) appear in bold. 
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S23 Table 8: Phenotypic, genetic and environmental correlations between Anxiety-depression and Chronic-fatigue IRT scores 
after removing items in common from the anxiety-depression scale 
 Phenotypic correlation Genetic correlation Environmental correlation 
 r [95% CI] p-value  
(H0: r=0) 
p-value  
(H0: r=1) 
r [95% CI] p-value 
(H0: r=0) 
p-value  
(H0: r=1) 
r [95% CI] p-value 
(H0: r=0) 
p-value 
(H0: r=1) 
<13 0.55 
[0.51,0.58] 
8.9E-94 2.8E-25 0.83 
[0.71,0.95] 
1.4E-6 0.057 0.36 
[0.27,0.45] 
1.1E-13 9.4E-17 
[13,15[ 0.57 
[0.53,0.61] 
5.2E-100 5.7E-28 0.87 
[0.77,0.99] 
1.5E-19 0.40 0.36 
[0.26,0.45] 
2.2E-13 2.0E-22 
[15,17[ 0.60 
[0.56,0.63] 
3.8E-127 8.1E-25 0.91 
[0.75,1.00] 
7.7E-10 4.7E-3 0.48 
[0.40,0.55] 
9.2E-34 2.6E-16 
>=17 0.56 
[0.50,0.62] 
8.1E-49 3.8E-22 0.97 
[0.75,1.00] 
1.4E-6 4.7E-3 0.35 
[0.20,0.49] 
2.0E-6 1.6E-7 
The p-values correspond to a likelihood ratio test with 1 df for tests on genetic and environmental correlations, 2 df for phenotypic correlations. The 
null hypothesis is indicated in brackets. Significant tests after Bonferroni correction (16 tests, significance threshold of 0.003) appear in bold. 
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Supplementary Document 24: Risk of MDD, social anxiety and substance 
dependence increases with anxiety-depression sum scores 
  
328 
 
 
Supplementary Document 25: Risk of MDD, social anxiety and substance 
dependence increases with chronic-fatigue sum scores 
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Supplementary Document 26:  Summary of Item Response Theory (IRT) Analysis  
 
 
 
S26 Figure 1: Item Response Step Function for each option of each item included in 
the depression score 
All items were 4 points likert scales (coding 0: not at all, 1: a little, 2: a lot, 3: unbearably)  
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S26 Figure 1: IRSF of the PSLE scale 
All items were yes (1), no (0) questions 
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S26 Figure 2: IRSF of the NSLE scale 
All items were yes (1), no (0) questions 
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S26 Figure 3: IRSF of the SS scale 
All items were 4 points likert scales (coding 0: not at all, 1: a little, 2: quite a bit, 3: a great deal)  
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Supplementary Document 27:  Details of phenotype and genotype data collection 
 
Timeline of the phenotypic data collection. Health and Lifestyle Questionnaire, waves 1, 2 and 3 (HLQ1, 
HLQ2, HLQ3), and follow-up clinical assessment of lifetime major depressive disorder as per DSM-IV criteria 
(DSM). 
 
 
 
Supplementary Document 28: Number of subjects per cohort contributing to PRS 
calculation 
Number of subjects per cohort contributing to PRS calculation used in our analyses as of July 
2016.  
 
Dataset N cases N controls 
GERA 7,162 38,307 
deCODE 1,980 9,536 
Generation Scotland 997 6,358 
iPSYCH 16,242 15,847 
UK Biobank 8,248 16,089 
PGC-MDD core 14,895 23,937 
Total 49,524 110,074 
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Supplementary Document 29: Number of SNPs used in the PRS calculation after 
clumping 
p-value thresholds PGC MDD 
(2013 publication) 
PGC MDD 
(July, 9th 2016 update) 
p<5E-8 0 5 
p<1E-5 11 77 
p<1E-3 733 2,044 
p<0.01 5,018 11,992 
p<0.05 17,699 40,916 
p<0.1 29,840 68,444 
p<0.5 87,685 204,038 
p<1 119,734 280,416 
 
 
 
Supplementary Document 30:  Histograms of the IRT scores and PRS 
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Histograms of the IRT scores for depression, personal stressful life events (PSLE), network stressful life 
events (NSLE), social support (SS) and polygenic risk scores for major depressive disorder (PRS MDD, July 
2016 GWAS). There were no by sex differences in the distributions of the PRS.
336 
 
Supplementary Document 31: Variance of the depression score explained by the 
interactions between personal stressful life events (PSLE) network stressful life 
events (NSLE), social support (SS) and polygenic risk scores for major depressive 
disorder 
 
 
 
Variance of the depression score explained by the interactions between personal stressful life events (PSLE) 
network stressful life events (NSLE), social support (SS) and polygenic risk scores for major depressive 
disorder (PRS MDD, July 2016 GWAS). 
We focused on the association with the PRS comprising all haplotypes but the other associations are also 
reported for completeness. Blue bars indicate negative correlations and red bars indicate positive correlation 
with the depression score. 
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Supplementary Document 32: Jinks-Fulker plot of absolute MZ pair differences 
(1,110 MZ pairs) on corresponding pair sums for IRT depression scores 
 
 
 
 
 
 
 
Jinks-Fulker plot ([627], p. 313) of absolute MZ pair differences (1,110 MZ pairs) on corresponding pair sums 
for IRT depression scores. The significant linear (p-value = 3.24E-12) plus quadratic regression (p-value = 
0.0495) indicates heteroscedasticity, which may generate scale dependent GxE interaction. However, while 
significant, the effect is not numerically large and the interaction is almost significant (p-value = 0.059) in the 
logistic regression analysis of the less powerful binary DSM-IV MDD diagnosis.  
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Supplementary Document 33: Twin heritability, phenotypic, genetic and 
environmental correlations of depression score and stressors. 
 
We used OpenMx [197] to calculate the heritability and correlations (likelihood-ratio 
test, using a kinship matrix to account for familial relatedness) of the depression score and 
the stressors. Heritability was significant for all traits (p-value<2.1E-25), correcting for age, 
sex, age2, sex*age, sex*age2, and wave. AE models showed the best fit to the data and 
shared environment could not explain the association (p-value<1.7E-3).   
 
 
 
S33 Figure 1: Twin heritability of depression and self-reported stress levels 
(diagonal) and phenotypic correlations between measurements (above diagonal). 
Coloured squares indicate significant association (p-value<0.001). 
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S33 Figure 2: Genetic (above diagonal) and environmental correlations (below 
diagonal). 
Coloured squares indicate significant correlations (p-value<0.001). 
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Supplementary Document 34: Relationship between MDD-PRS and stress scores 
 
 
 
 
Association between MDD-PRS (July 2016 release) and self reported measures of stress (PSLE, NSLE, 
SS). Red bars indicate a positive correlation; blue bars a negative correlation between PRS and stress 
scores. 
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Metric MR  MT*  MAXT  HM-PC1† Power et al. 
(FD) 
Jenkinson et 
al. 
Definition 
Independent of 
centre of rotation 
X     X  
No hypothesis on 
brain radius 
X X X X  Radius=50mm Radius=80mm 
Paper of reference 
Van Dijk et 
al. 
Van Dijk et 
al. 
Van Dijk et 
al. 
 Power et al. Jenkinson et al. 
Performance 
against 
Jenkinson et 
al. metric 
rPearson 0.75‡ 0.97‡ 0.66‡ 0.92 0.99 1 
τKendall 0.56 0.85 0.58 0.80 0.91 1 
Properties 
Mean (sd) -7.32 (0.32) -2.83 (0.35) -1.54 (0.65) 0.00 (1.50) 0.14 (0.047) 0.076 (0.027) 
Repeatability₫ 
(ICC) 
0.53  
[0.24, 0.74] 
0.59  
[0.32,0.77] 
0.53  
[0.24,0.73] 
0.66  
[0.42,0.82] 
0.60 
[0.33, 0.78] 
0.61 
[0.34,0.79] 
Heritability (h2) 
0.27  
[0.10,0.42] 
0.54  
[0.39,0.65] 
0.34  
[0.19,0.48] 
0.42  
[0.25,0.56] 
0.45  
[0.28,0.59] 
0.49  
[0.32,0.62] 
Contribution of 
translation 
 100%  
40% 
(MT: 25%, 
 MAXT: 15%) 
64% 73% 
Supplementary Document 35: Comparison of the different HM metrics 
MT, HM-PC1and Power et al. metrics can be considered almost equivalent to Jenkinson et al. metric. Their main differences lie in the hypotheses that they make: 
MT, HM-PC1and Power et al. are dependent on the centre of rotation, which may limit the comparability of motion estimates across studies and complicate the gross 
motion exclusion (when calculating the maximal rotation allowed around each axis). On the other hand, Power et al. and Jenkinson et al. metrics use a hypothesis 
on brain size that may have to be adapted to the age and sex of the sample. Empirical contribution of translation was calculated for each metric as E(translation / 
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(rotation + translation)) to illustrate the different contributions of rotation and translation in different metrics over the same sample. Correlation with Jenkinson et al. 
metric was decreasing as the weight furthered from Jenkinson et al. value (64%). In addition, heritability being lower for MR and MAXT, the importance given to 
these aspects of movement in HM-PC1 can explain its slightly lower heritability estimate. All metrics were calculated using R 3.1.0 from the SPM output files 
containing the rigid body parameters.   
 * The calculation of MT, as described in Van Dijk et al. paper (see Yan et al., 2013 for a formula) yielded to very different results. They defined the translation 
between 2 frames as the difference between the frame distances to the origin. Thus, their mean translation derived from absolute motion while we considered 
relative motion (see section 2.3). We computed  Van Dijk et al. mean translation and found similar performance against a metric of reference to that previously 
reported (Yan et al. 2013): rPearson=0.75 and τKendall=0.54.  
‡ The Pearson correlation was calculated on non-log transformed MR MT and MAXT. Indeed, the log-transformation made the relations with Jenkinson et al. metric 
no longer linear. Kendall Tau is based on the ranks in the distribution and is therefore unchanged by log-transformation (monotonous function). 
† HM-PC1was defined as the first principal component of a PCA on (log-transformed) MR, MT and MAXT, and differs from the other composite metrics in the way 
that it contains a measure of extreme movements. We investigated the correlation between Jenkinson et al. metric and a 1st principal components calculated only on 
MR and MT. As anticipated, the correlations were even stronger (rPearson =0.94 and τKendall=0.85). 
₫To ensure comparability of the ICC across metrics, the estimates reported in the table are for log-transformed Power and Jenkinson et al. metrics. Un-log-
transformed metrics exhibited uniformly lower ICC. Outliers previously identified in MR ICC calculation were also pruned for HM-PC1, Jenkinson and Power et al. In 
the overall sample ICCJenkinson= 0.54 [0.25, 0.74]; ICCPower=0.53[0.24,0.73]; ICCHM-PC1=0.65 [0.40, 0.80].  
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Supplementary Document 36: Correlations between the different HM metrics 
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Variable Size 
(voxels) 
Brain region (BA) Statistics MNI coordinates 
Age   β sd max|β| xMax yMax zMax 
 195 Left IPC (hIP1-3) 0.013 0.0035 0.022 -39 -39 42 
 67 Left SMA (BA6) -0.014 0.0027 -0.019 -3 12 57 
 52 Left MTC -0.0099 0.0018 -0.014 -66 -51 -3 
Sex  
104 
 
Left IPC (PGa, hIP3) 
 
-0.072 
 
0.014 
 
-0.11 
 
-27 
 
-63 
 
42 
h2   ℎ# sd maxh2 xMax yMax zMax 
 242 Left IPC (hIP1-3) 0.27 0.070 0.47 -57 -36 51 
 126 Left SMA (BA6) 0.23 0.052 0.38 3 9 60 
 83 Right IPC (hIP1-2, PF) 0.25 0.043 0.35 -39 -45 36 
Supplementary Document 37: Regions of BA45's network significant for age and heritability 
Description of the brain regions showing a significant age effect or heritability (size≥47 voxels). IPC: Inferior Parietal Cortex, SMA: Supplementary Motor Area, MTC 
(Middle Temporal Cortex), IFC: Inferior Frontal Cortex. Age effect was consistent on adults (after exclusion of the 16 years old) in left IPC ($	=0.014 (sd=0.0057), 
max=0.028) and SMA ($=-0.013 (sd=0.0048), max=-0.023) despite a greater variability. The effect was partially driven by the 16 years old observations on MTC ($=-
0.0056 (sd=0.0053), max=-0.021 for the  adults only). Percentage of variation per year of age revealed a moderate to strong effect on FC: left IPC (median=3%, 
range=[2-6]), left SMA (4%, [2-5]), left MTC (3%, [2-4]). 
The variation in FC corresponding to the sex effect was much more important in the IPC (median=20%, range=[13-32]), indicating a reduced FC in the female group.  
We identified 3 regions of significant age effect on FC: left IPC (k=195 voxels, $	=0.013 (sd=0.0035)), SMA (k=67,  $	=-0.014 (0.0027) ), MTC (k=52, $	=-0.0099 
(0.0018) ). However, when we excluded the 16 years old (16% of the sample) from the analysis, only the left IPC ($	=0.014 (sd=0.0057) ) and SMA ($=-0.013 
(sd=0.0048) )  showed a robust age effect. Age effect on MTC connectivity ($=-0.0056 (sd=0.0053) after excluding the 16 years old) was less consistent, revealing 
similar amount of age effect circumscribed to a less extended region. The age effect was moderate to strong with a median variation of FC of 3% (range 2-6%) per 
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year of age. 
We identified one significant cluster of sex effect in the left IPC indicating a median reduced FC of 20% in females compared to the males.
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Supplementary Document 38: Age and Sex effect in BA45’s network 
A) Effect of age on BA45’s FC with beta maps and corresponding –log(p-values) map (in purple) 
B) Effect of sex on BA45’s FC with beta maps and corresponding –log(p-values) map (in purple)  
The negative betas are shown in cold colours (with strongest effect corresponding to green), positive betas 
are plotted with warm colours (the strongest effect being white). Therefore, all the colorbars rank 
effect/significance from low to high (i.e. left to right). Effect size and significance are plotted voxel-wise.  
Age and sex effects are projected onto brain maps after averaging the signal (using 12 voxels depth 
resolution) using MRIcron (Rorden and Brett, 2000). We plotted the top 80% of voxels for age and sex  effect 
to facilitate the reading of the image. No thresholding was applied on the p-values maps and significance of 
all the voxels considered is presented. 
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Variable Size (voxels) Brain region (BA) Statistics MNI coordinates 
Age   β sd max|β| xMax yMax zMax 
 165 Left/Right OC (BA17, 18, 7M) 0.011 0.0028 0.019 -9 -78 33 
 133 Left IPC (PF, PFcm, PFt) 0.015 0.0038 0.022 -63 -33 30 
 96 Left IPC (PFm, PGa) -0.012 0.0020 -0.016 -60 -54 33 
 84 Left SMA (BA6) -0.011 0.0030 -0.020 -3 12 57 
 80 Right IPC (PF, PFt) 0.012 0.0026 0.019 63 -27 42 
 78 Left MFC  -0.011 0.0020 -0.016 -18 51 36 
HM-PC1   β sd max|β| xMax yMax zMax 
 98 Right SPC  0.025 0.0069 -0.045 -9 -54 30 
Sex         
 166 Left SMA (BA6) 0.068 0.014 0.11 0 12 48 
 68 Left IPC (PF, PFt) -0.071 0.014 -0.10 -63 -30 -36 
 64 Left MFC  0.067 0.012 0.094 -21 45 30 
h2   ℎ# sd maxh2 xMax yMax zMax 
 123 Left SMA (BA6) 0.23 0.043 0.35 0 15 54 
 90 Left IPC (PF, PFcm, PFt) 0.23 0.036 0.34 -63 -42 30 
 69 Left IPC (PFm, PGa) 0.23 0.042 0.39 -57 -57 39 
 62 Left/Right OC (BA17, 18) 0.21 0.045 0.37 0 -72 24 
Supplementary Document 39: Regions of BA44’s network significant for age, head motion or heritability 
Description of the brain regions showing a significant age, HM effect (HM-PC1: first principal component of HM) or heritability (size≥58 voxels). OC: Occipital cortex, 
IPC: Inferior Parietal Cortex, SMA: Supplementary Motor Area, SPC: Superior Parietal Cortex, MFC (Middle Frontal Cortex). Age effect was increased in all areas 
after exclusion of the 16 years old: OC ($=0.016 (sd=0.0037), max=0.025), left IPC ($=0.022 (sd=0.0059), max=0.032) and ($=-0.016 (sd=0.0045), max=-0.025), left 
348 
 
SMA ($=-0.015 (sd=0.0042), max=0.025). right IPC ($=0.017 (sd=0.0048), max=0.028) and left MFC ($=-0.013 (sd=0.0025), max=-0.019). Percentage of variation 
per year of age revealed a moderate to strong effect on FC: OC(median=3%, range [2-6]), left IPC (4%, [2-6]) and (3%, [2-4]), left SMA (3%, [2-5]), right IPC (4%, [2-
6]) and left MTC (3%, [2-4]). The FC differences between sexes were important with a median increase of left SMA FC in girls (N=166, median percent change =19%, 
range=[13-32] and N=64, median percent change =17%, range=[13-28]) and a median decrease in left IPC FC (N=68, median percent change= 19%, range=[14-30]). 
In BA44’s network, 5 regions showed a significant effect of age on FC: left and right OC (k=165, $	=0.011 (sd=0.0019) ), left IPC (k=133, $	=0.015 (0.0038)  and k=96, $	=-0.012 (0.0020) ), left SMA (k=84, $	=-0.011 (0.0030) ), right IPC (k=80, $	=0.012 (0.0026) ) and left MFC (k=78, $	=-0.011 (0.0020) ). These results were impacted 
by the high proportion of 16 years old in the sample, with the exclusion of the underage yielding to higher estimates and larger significant areas (see inline 
Supplementary Table 2). The effect of age on FC was moderate to strong: median variation of 3% per year of age (range 1-6%) (see inline Supplementary Table 2). 
The finding of a localised moderate to strong significant age effect on the networks’ FCs, could correspond to early adulthood brain maturation, given the age range 
of our sample. This is consistent with the literature on RS-FCs maturation, which describes an evolution from diffuse to local correlations (over-connectivity followed 
by pruning) with a strengthening of long range FC [628]. We observed localised diminution of FC among the network (FC pruning) and some increase in long range 
FC with IPC, especially at adult age, also coherent with the observation of latest development of anterior–posterior connectivity [628, 629]. 
Three clusters passed the significance threshold for sex effect. The females exhibited greater FC in the left SMA than males (median percent change =19%, range=[13-
32] and  median percent change =17%, range=[13-28]) but reduced FC in the left IPC (median percent change=19%, range=[14-30]). 
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Supplementary Document 40: Age and Sex effect in BA44’s network 
A) Effect of age on BA44’s FC with beta maps and corresponding –log(p-values) map (in purple) 
B) Effect of sex on BA44’s FC with beta maps and corresponding –log(p-values) map (in purple)  
The negative betas are shown in cold colours (with strongest effect corresponding to green), positive betas 
are plotted with warm colours (the strongest effect being white). Therefore, all the colorbars rank 
effect/significance from low to high (i.e. left to right). Effect size and significance are plotted voxel-wise.  
Age and sex effects are projected onto brain maps after averaging the signal (using 12 voxels depth 
resolution) using MRIcron (Rorden and Brett, 2000). We plotted the top 80% of voxels for age and sex effect 
to facilitate the reading of the image. No thresholding was applied on the p-values maps and significance of 
all the voxels considered is presented.
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Supplementary Document 41: SWAN samples wave and design description 
Twins were on average, 22 years old at mother SWAN report, and 26 years old at 
self SWAN report, with large age differences within and between waves (S10 Figures 1-3). 
Mother scoring largely (98%) came from an online instrument (wave 2) and only 12 
individuals (2%) were assessed when the mother was attending the clinic (at a younger 
mean twin age of 14: wave1) (S10 Table 1 and S10 Figure 2). Wave 1 was prospective 
while for wave 2, 65% of twins were older than 20 at the time of mother report, and were 
thus scored about their current symptoms (prospective design), with the remaining 35% 
rated retrospectively (“how was he/she in primary school?”). Self report ratings were 
collected using an online questionnaire (wave 3: 77%) or telephone interview (wave 2: 22%) 
at mean age 26 (sd=2.4) and 25 (sd=3.6) respectively, where participants were asked about 
their current status. The remaining 1% (wave 1) of the self-reported SWAN scores were 
collected by telephone, at mean age 22 (sd=2.1) and focused on symptoms at primary 
school (S10 Table 1 and S10 Figure 3).   
 
 
S41 Figure 1: Age at resting-state functional MRI in the final sample 
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S41 Figure 2: Age at mother report in the final sample, broken down by wave 
Wave 1 corresponds to mother report acquired during the clinical visits of the twins at age 14. Wave 2 was 
collected using an online questionnaire several years after the clinical visits. If the twins were older than 20 
years old when mothers were contacted, they were asked to rate current symptoms (prospective design). If 
twins were not 20, mothers were instructed to “think back to when he/she was in primary school” (retrospective 
design).  
 
S41 Figure 3: Age at self-report in the final sample, broken down by wave 
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The first 2 waves of self report SWAN scores were acquired from computer assisted telephone interviews 
between February and December 2009 (wave 1) and between December 2009 and November 2011 (wave 2). 
The third wave started in August 2012 using an online questionnaire, recruitment is still ongoing. Wave 1 was 
retrospective (“think back when you were in primary school”) while the 2 following were prospective. 
 
 
 
 Wave1  Wave2 Wave3 Total 
N (%) 38 (2%) 661 (29%) 1,546 (69%) 2,246 
Design Retrospective Prospective Prospective  
Acquisition 
method 
Telephone 
interview 
Telephone 
interview 
Online 
questionnaire 
 
Age (sd) 23.6 (3.1) 27.2 (3.0) 26.2 (4.2) 26.4 (3.9) 
Females (%) 20 (53%) 380 (57%) 906 (59%) 1306 (58%) 
Inattention (sd) -0.67 (0.58) -0.46 (0.68) -0.43 (0.59) -0.44 (0.62) 
Hyperactivity/ 
Impulsivity (sd) 
 
-0.53 (0.71) 
 
-0.52 (0.69) 
 
-0.43 (0.62) 
 
-0.46 (0.64) 
S41 Table 1: Description of the full sample of Self Reported SWAN scores: N=2,246 
Self reported scores were acquired in 3 overlapping waves: N=373, N=707 and N=1,546 (ongoing wave). 
SWAN questions were retrospective in wave 1 (“think back when you were in primary school”) while they were 
not in the 2 following (“compare yourself to other people of the same age”). Waves 1 and 2 were acquired over 
the telephone, wave 3 using an online questionnaire. When several observations were available for one 
individual we kept the scores acquired in wave 3 (ongoing), than wave 2 and wave 1. This resulted in a total 
sample of 2,246 individuals 
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Supplementary Document 42:  Characteristics of individuals with “gross motion” 
Sex and wave frequencies were comparable between individuals included in the final 
sample and those excluded for gross motion (S11 Table 1). However, the excluded 
observations (i.e. 8 individuals) corresponded to significantly younger twins at mother report 
(mean age 19 vs. 22, p-value=0.015) and RS-fMRI scan (mean age 19 vs. 22, p-
value=0.025). Self reported inattention was significantly lower (p-value=0.028) in the gross 
motion group, even if only 4 individuals composed this group, which limits the confidence in 
the test result. All other differences did not reach significance. Overall, the individuals 
excluded for gross motion had higher scores for ADHD (by about 0.5*SD), but larger 
samples sizes are required to confirm such difference and the significant results reported 
above. Here, it is unlikely that gross motion exclusion would bias our results. 
Here, we excluded participants exhibiting 3mm translation or 2 degreees rotation 
between 2 consecutive frames. This leads to fewer exclusions for gross motion than in 
Chapter 4 (where we used the frame absolute displacement i.e. displacement from the first 
volume), while ensuring that the movement during a frame acquisition does not exceed the 
voxel size. 
 
 Excluded for 
gross motion 
(N=8) 
Included  
(N=857) 
p-value† 
 Mean (sd) or Frequency (%)  
Age (at RS-fMRI) 19.2 (2.3) 22.0 (3.2) 0.015 
Sex (female) 6 (75%) 545 (64%) 0.72 
Mother reported data  N=8 N=627   
Twin Age (at questionnaire) 19.4  (2.2) 22.1 (3.8) 0.025 
Wave  
            “online” 
 
8 (100%) 
 
615 (98%) 
 
 
            “in clinic” 0 12 (2%) 1 
Inattention  -0.56 (0.96) -1.04 (1.14) 0.19 
Hyperactivity/ Impulsivity  -0.69 (0.79) -1.06 (1.10) 0.38 
Self reported data N=4 N=725  
Twin Age (at questionnaire) 23.0 (1.6) 25.1 (3.4) 0.15 
Wave    
           “telephone retrospective” 0 9 (1%)  
           “telephone prospective” 1 (25%) 159 (22%)  
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           “online prospective” 3 (75%) 557 (77%) 0.54 
Inattention 0.00 (0.09) -0.51 (0.59) 0.028 
Hyperactivity/ Impulsivity -0.14 (0.36) -0.50 (0.62) 0.17 
S42 Table 1: Description of the final twin sample and comparison with individuals 
excluded for gross motion 
† We used a Fisher exact test instead of χ2 test to overcome the issue of small sample sizes. We used the 
Mann–Whitney–Wilcoxon test instead of the t-test because of the greater robustness of its test statistic to 
individual observations.  
In addition, our sample contains related family members (within and across groups to compare), thus the 
variance of heritable traits could be underestimated, leading to a lowering bias on the p-values. To limit the 
inflation of true positives, we calculated the p-values after excluding related individuals. For the testing, the 2 
groups reduced to: N=8 individuals with gross motion, N=523 independent included individuals (373 with 
mother reported score, 446 with self reported). Mean, sd and frequencies reported in the table correspond to 
the whole sample (includes related individuals).  
 
 
S42 Figure 1: Self reported SWAN scores for individuals with gross motion during 
RS-fMRI 
Two individuals scored 0 for Inattention and Hyperactivity/Impulsivity, which explains that there are only 3 
vertical bars.  
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S42 Figure 2: Mother reported SWAN scores of individuals with gross motion 
 Mother Reported Scores Self Reported Scores Head Motion 
 Inattention Hyperactivity / 
Impulsivity 
Inattention Hyperactivity / 
Impulsivity 
 Β (sd) p-
value 
Β (sd) p-
value 
Β (sd) p-
value 
Β (sd) p-
value 
Β 
(sd) 
p-value 
Covariates effect and significance 
Age (RS-fMRI) -0.051 
(0.044) 0.25 
-0.022 
(0.046) 0.63 
-0.007 
(0.020) 0.72 
0.006 
(0.021) 0.77 
-0.014 
(0.004) 
 
4.0E-4 
Age  (at 
questionnaire) 
0.047 
(0.044) 0.28 
0.029 
(0.046) 0.53 
0.010 
(0.018) 0.59 
0.0003 
(0.019) 0.98 
  
NA 
Sex : F vs M -0.56 
(0.10) 2.0E-8 
-0.33 
(0.09) 2.9E-4 
-0.18 
(0.05) 
4.7E-
4 
-0.20 
(0.05) 
1.5E-
4 
-0.081 
(0.025) 
 
1.4E-3 
Wave:            
   2nd (vs 1st) 0.48 
(0.40) 0.23 
0.53 
(0.44) 0.22 
0.19 
(0.20) 0.34 
-0.16 
(0.21) 0.45 
  
NA 
   3rd (vs 1st)  
 
 
 
0.08 
(0.19) 0.68 
-0.33 
(0.21) 0.11 
  
NA 
Design: 
Retrospective 
vs Prospective 
 
0.047 
(0.17) 0.78 
 
0.20 
(0.17) 0.25 
 
NA₫ 
 
NA₫ 
  
 
NA 
Number of 
siblings 
-0.022 
(0.050) 0.66 
-0.016 
(0.052) 0.77 
0.015 
(0.023) 0.50 
-0.004 
(0.002) 0.86 
  
NA 
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Zygosity Groups Homogeneity 
Mean Differences 
“Birth order”   0.35  0.055  0.14  0.43  0.29 
“Same sex 
pairs”  
 
0.83 
 
0.68 
 
0.75 
 
0.72 
 
0.84 
“Same-sex vs 
opposite-sex 
pairs”  
 
0.28 
 
0.11 
 
0.27 
 
0.85 
 
0.48 
“Sex groups”   1.0  1.0  1.0  1.0  1.0 
Variance Differences  
“Birth order”   0.13  0.11  0.87  0.49  0.93 
“Same sex 
pairs”  
 
0.12 
 
0.40 
 
0.024 
 
0.11 
 
0.76 
“Same-sex vs 
opposite-sex 
pairs”  
 
0.62 
 
0.67 
 
0.71 
 
0.81 
 
2.1E-4 
“Sex groups”   0.25  0.64  0.33  0.18  0.72 
Covariance Difference 
“Quantitative 
sex-limitation”  
 
0.21 
 
5.8E-6 
 
0.24 
 
0.59 
 
0.25 
“Qualitative  
sex-limitation”  
 
0.44 
 
NA 
 
0.62 
 
0.48 
 
0.67 
“Presence of 
genetic factors”  
 
1.7E-10 
 
NA 
 
3.2E-5 
  
0.015 
 
2.2E-4 
“Familial 
aggregation”  
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
Supplementary Document 43: Results of saturated models for Head Motion, mother 
and self reported SWAN scores 
₫ In self report the design is constant within waves, thus score differences caused by design are captured in 
the wave effect.  This testing ensures that the mean, variances and covariances are homogeneous across 
sex, birth order and zygosity allowing reducing the model to 2 groups of twins: MZ and DZ.  We also tested 
the effect of age, sex, wave, design and number of siblings by including them in the model. For of self-reported 
Inattention, the variance difference between females DZ (σ2=0.39) and MZ (σ2=0.27, p-value=0.025) 
appeared driven by one extreme value (inattention score of 2) in the DZ group (p-value=0.09 when individual 
removed). In addition, HM variance was significantly different between females from same sex pairs (σ2=0.10) 
and females from opposite sex pairs (σ2=0.17, p-value=2.1E-4). Most of the difference was driven by more 
females from opposite-sex pairs exhibiting high HM, similar to their male co-twin (S6 Fig.). The difference could 
be partially attributed to greater age variability (σ2=12.5) compared to the female same sex pair groups 
(σ2=9.8) but cannot be accounted for by the presence of siblings in the DZ groups (HM variance unchanged 
after exclusion) nor by a greater resemblance to the male co-twin (similar twin pair correlation as female same-
sex group). Finally, we did not model the effect of time difference between scoring and scanning explicitely, 
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but by including both age at questionnaire and age at scan as covariates, we implicitely model the effect of 
interval time as our model: “SWANscore = b1*AgeQuestionnaire + b2* AgeScan + … + e” is equivalent to: 
“SWANscore = b1 * (AgeQuestionnaire – AgeScan) + (b1+b2)*AgeScan + … + e” 
 
The Null hypotheses associated with the tests performed are: 
“Birth order”: Mean/Variance is equal between first and last born twin 
“Same sex pairs”: Mean/Variance is equal between female MZ and DZ (same sex) pairs AND 
Mean/Variance is equal between male MZ and DZ (same sex) pairs  
“Same-sex vs opposite-sex pairs”: Mean is equal across all zygosity groups (same sex and 
opposite sex) for females AND Mean is equal across all zygosity groups (same sex and opposite 
sex) for males  
“Sex groups”: Mean/Variance is equal across sexes  
“Quantitative sex-limitation”: Pair covariance equal within same sex zygosity groups  
“Qualitative sex limitation”: Pair covariance equal within zygosity groups  
“Presence of genetic factors”: Pair covariance equal across zygosity groups  
“Familial aggregation”: Pair covariance is null  
“Covariate”: Covariate effect is null 
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Supplementary Document 44: Boxplot of the head motion distribution per sex and 
zygosity groups 
FMZ: females monozygotic group, MMZ: male monozygotic, FDZ: females from same sex dizygotic pairs, 
MDZ: males from same sex dizygotic pairs, FOSDZ: females from opposite sex DZ pairs, MOSDZ: males 
from opposite-sex DZ pairs.  
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Supplementary Document 45: Heritability of HM and ADHD  
We reported summary of univariate models for HM and the SWAN scores in 
Supplementary Table 4. Best models are the simplest (i.e. with the fewest parameters) without 
significant reduction in fit compared to the full (ACE or ADE) model, they appear in bold (S4). ACE 
and ADE models are not nested but can be compared using the Akaike Information Criteria (AIC) 
[630].   
Heritability of mother reported scores has already been reported for the full sample [337]. 
Here, our final sample comprised 19% of the mother scorings but however yielded identical results. 
For Inattention, we measured the additive component to be between 0 and 43% (0-35% in [337]) 
and the dominant between 32 and 83% (37-74% in [337]). For Hyperactivity-Impulsivity we found 
the additive sources to explain between 88 and 94% of the variance in females (79-94% in [337]). 
The A component was only explaining 63 to 87% in males (72-85% in [337]). The general sex 
limitation model outperformed standard ACE fit (p-value=5.1E-6), confirming tests from the 
hypothesis testing (supplementary Table 3). Genetic correlation (rg=1) between males and females 
suggested that genes influencing Hyperactivity-Impulsivity are the same, even if they explain 
different proportion of variance within sexes. Similar heritability estimates have also been reported 
in an independent sample using the SWAN instrument [351].  
In heritability of self reported scores, our sample only overlaps partially with Ebejer et al., 
[337] due to ongoing recruitment (see Material and Methods). In addition they modeled the 
negative contrast effects by including siblings of twin pairs in the analysis [337], who were not 
imaged. Such contrast often results in underestimation of MZ and DZ correlations, which may 
spuriously suggest (or bias upward) dominance estimates. In addition it can lead to an 
overestimation of variance [44, 347] that reduces power and can even bias heritability estimates 
(when more pronounced in MZ or DZ group). Controlling the scores for the number of siblings as 
previously suggested [350] had no effect on the rater’s effect (S16 Table 1). Therefore, we could 
expect our results to show wider confidence intervals (power reduction caused by negative 
contrast and smaller sample size) with larger dominant sources of variance than Ebejer’s [337]. 
However, we observed very comparable results for both Inattention and Hyperactivity-Impulsivity: 
small estimates of additive genetic sources of variance with large CI (that include 0), medium 
estimates of dominant sources of variance with again large CI, though largely overlapping across 
studies (Supplementary Table 4) [337]. Both studies lack power to detect small additive genetics 
and dominant effect, which is caused by limited sample size (here) or report of estimates for males 
and females [337] which eliminated the increased precision in estimation that a larger study had. 
The agreement of results (largely overlapping CIs) was also enhanced by the contrast effect being 
small [337]. Heritability reported in an independent sample also found self-report to be less 
heritable (of about 20%). This difference might be greater in our sample, even if the absence of 
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distinction between heritability of self and parental report [351] makes a detailed comparison 
impossible. 
Finally, heritability of HM was consistent with estimates previously calculated on a subset of 
462 twins [262]. The addition of 67 extra twin pairs led to slightly more precise estimate: h2HM =0.40 
[0.26,0.53] (against h2HM=0.49 [0.32,0.62] previously).  
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 Variable Model† Parameter estimates   Model fit 
  A C/D E    
df 
Δdf -2LL Δ-2LL AIC P-value 
Mother reported 
Inattention 
ADE 0.00 [0.00,0.43] 0.77 [0.32,0.83] 0.23 [0.17,0.32] 621  1837.6   595.6  
AE 0.73 [0.62,0.81]  0.27 [0.19,0.38] 622 1 1847.7 10.2 635.8 1.4E-3 
E    623 2 1909.5 71.9 695.4 2.4E-16 
 ACE 0.73 [0.61,0.81] 0.00 [0.00,0.07] 0.27 [0.19,0.38] 621  1847.7  605.7  
 
Mother reported 
Hyperactivity 
Impulsivity  
ACE  f 0.71 [0.46,0.94] 0.21 [0.00,0.46] 0.08 [0.06,0.12]       
          m 0.72 [0.32,0.86] 0.05 [0.00,0.37] 0.23 [0.13,0.43] 619  1686.1  448.1  
ACE     0.80 [0.58,0.90] 0.07 [0.00,0.28] 0.13 [0.10,0.18] 622 3 1713.4 27.3 469.4 5.1E-6 
AE     f         0.92 [0.88,0.94]  0.08 [0.06,0.12]       
          m 0.79 [0.63,0.87]  0.21 [0.13,0.37] 621 2 1687.9 1.75 445.9 0.42 
CE    f  0.74 [0.65,0.80] 0.26 [0.20,0.35]       
         m  0.41 [0.22,0.58] 0.59 [0.42,0.78] 621 2 1737.5 51.4 495.5 6.8E-12 
E    623 4 1870.1 184.0 624.1 1.0E-38 
 ADE  f 0.92 [0.58,0.94] 0.00 [0.00,0.34] 0.08 [0.06,0.12]       
           m 0.77 [0.21,0.87] 0.00 [0.00,0.58] 0.23 [0.13,0.40] 619  1687.9  449.9  
 
Self reported 
Inattention 
ADE 0.00 [0.00,0.22] 0.45 [0.16,0.60] 0.55[0.40,0.75] 719  1274.0  -164.0  
AE 0.31 [0.11,0.48]  0.69 [0.52,0.89] 720 1 1280.8 6.8 -159.2 9.3E-3 
E    721 2 1290.2 16.2 -151.8 3.0E-4 
ACE 0.31 [0.10,0.48] 0.00 
[0.00,0.095] 
0.69 [0.52,0.89] 719  1280.8  -157.2  
Self reported 
Hyperactivity 
Impulsivity 
ADE 0.00 [0.00,0.27] 0.28 [0.00,0.43] 0.74 [0.57,0.95] 719  1345.5  -92.5  
AE 0.17 [0.00,0.34]  0.83 [0.66,1.00] 720 1 1347.9 2.4 -92.1 0.12 
E    721 2 1351.5 6.0 -90.5 0.050 
ACE 0.17 [0.00,0.34] 0.00 [0.00,0.14] 0.83 [0.66,1.00] 719  1347.9  -90.1  
Head Motion ADE 0.07[0.00,0.50] 0.38 [0.00,0.57] 0.55 [0.43,0.71] 850  566.7  -1133.3  
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AE 0.40 [0.26,0.53]  0.60 [0.47,0.74] 851 1 568.3 1.60 -1133.7 0.21 
E    852 2 593.8 27.12 -1110.2 8.0E-7 
 ACE 0.40 [0.16,0.53] 0.00 [0.00,0.16] 0.60 [0.47,0.74] 850  568.3  -1124.7  
S45 Table 1: Heritability of SWAN scores and HM 
† The models used on the SWAN scores are 2 groups (MZ and DZ) ACE or ADE models for, except for MR Hyperactivity/ Impulsivity where a general sex limitation 
model was used. As a result, we estimated 7 parameters instead of 3: sex specific A, C/D and E and genetic correlation between sexes. The genetic correlation was 
exactly 1 in the models leaving the fit unchanged when set to constant. We concluded that the same genetic sources of variance influence mother reported hyperactivity-
Impulsivity for males and females, with however differences in intensity. 
Head motion twin model included age at scan as covariate and allowed the variance to vary between same sex and opposite sex zygosity groups.   
Best univariate models were AE models for Hyperactivity-Impulsivity (self and mother report), as well as for motion. For the two Inattention scores, ADE models had 
a significant better fit to the data than AE as the heritability of the trait appears to come mostly from dominant sources of variance (as suggested by large significant D 
and smaller A) 
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Authors Phenotype Discovery sample size Replication sample Samples Ethnicity Genome –wide 
significant 
association† 
Replication† 
Potkin, Turner [487] BOLD signal 
in the dorsolateral prefrontal cortex 
during the probe condition 
for a memory load of 3 items 
FBIRN: 138 (64 SCZ, 74 HC) NA Mostly European 
(80%) 
no NA 
Baranzini, 
Srinivasan [482] 
Glutamate level 382 MS NA European no NA 
Liu, Akula [483] Amygdala activation during face 
recognition paradigm 
68 (39 BD, 29 HC) NA Mostly European 
(84%) 
no no 
Liu, Cannon [484] Brain serotonin transporter  5-HTT 
levels in thalamus 
55 (22HC, 16 BD, 17 MDD) 51 Mix / European no no 
Brown, Jensen [485] Hyperactivated cortical regions during 
face recognition paradigm 
Negative faces:246 (108HC, 138 
cases) 
Positive faces: 284 (124 HC, 160 
cases) 
85 (non independent 
sample) 
European / North 
American Caucasian 
no Subject to caution ₫ 
Ousdal, Anand 
Brown [486] 
Amygdala activation during face 
paradigm 
TOP: 224 (97 HC, 51 SCZ, 64 BD, 
12 other) 
DNS:100 HC European / Mixed 
(50% European) 
3 SNP is high LD no 
Supplementary Document 46: GWAS on functional MRI and Magnetic Resonance Spectroscopy (MRS) phenotypes  
₫ This study was greatly underpowered and suffers methodological limitations. The prior hypothesis (derived from the discovery analysis) contained a high rate of false positive (false discovery rate=0.5). 
Non-independence of the “replication sample” does not add much confidence in the final results being true positive.  
AD Alzheimer’s disease; BD bipolar disorder; CSF cerebral spinal fluid; GM grey matter; HC healthy controls; MD major depressive disorder; MCI: mild cognitive impairment, MS: multiple sclerosis cases; 
P&AD psychotic and affective disorder cases; SCZ schizophrenic cases; WMHI white matter hyperintensities.  
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Supplementary Document 47: Factor level power in multivariate GWAS 
 The plots below show the power for each factor of the multivariate modelling. The curves are more dispersed for hippocampus subfields, than for subcortical 
volumes. However, taking the mean power or weighted mean (using % variance explained by each factor as weights) resulted in very similar power. This says that 
the genetic factors all explain a comparable amount of variance (confirmed by the paths coefficients). Overall, the power for each multivariate factor is still greater 
than the univariate one, highlighting the interest of multivariate modelling to separate signal from noise.  
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S47 Figure 1:Power of each genetic factor (from a Cholesky decomposition) for a multivariate GWAS on subcortical volumes 
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S47 Figure 2: Power of each genetic factor (from a Cholesky decomposition) for a multivariate GWAS hippocampus subfield 
volumes 
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Supplementary Document 48: SNPs identified using GWAS and their corresponding 
effect sizes expressed in % of variance explained  
 
Phenotype SNP Ch
r 
Minor 
allele 
/ 
Other 
MAF p-valuea % 
Variance 
Explaine
d R2 c 
Combin
ed 
Sample 
Sizea 
 
Hippocampal 
volume a 
rs61921502 12 G/T 0.16 6.87 × 10-11 0.24 26,814  
rs77956314 12 C/T 0.08 2.06 ×10-25 
 
0.32 26,814  
rs11979341 7 G/C 0.32 
 
1.42 × 10-11 
 
0.14 24,484  
rs7020341 9 G/C 0.64 
 
3.04 × 10-11 
 
0.13 26,700  
rs2268894 2 C/T 0.46 
 
5.89 × 10-11 
 
0.13 26,814  
rs2289881 5 G/T 0.65 
 
2.73 × 10-08 
 
0.092 26,814  
Intracranial 
volume a 
rs17689882 17 A/G 0.16 7.72 × 10-09 0.10 12,822  
 rs199525 17 G/T 0.20 3.80 × 10-21 
 
0.27 26,577  
 rs11759026 
 
6 G/A 0.24 2.20 × 10-20 
 
0.26 26,577  
 rs2022464 
 
6 C/A 0.70 3.70 × 10-11 
 
4.14 26,577  
 rs11191683 
 
10 G/T 0.67 
 
1.10 × 10-10 
 
0.13 26,577  
 rs9811910 
 
3 G/C 0.92 
 
2.00 × 10-09 
 
0.11 26,577  
 rs13807433
5 
 
12 G/A 0.41 6.20 × 10-09 
 
0.10 26,577  
 rs2195243 
 
12 G/C 0.78 1.50 × 10-08 
 
0.099 26,577  
Putamen 
Volume a 
rs945270 14 G/C 0.42 1.08 × 10-33 0.32 28,275  
 rs62097986 18 A/C 0.44 1.01 × 10-13 0.18 28,036  
 rs6087771 20 C/T 0.29 1.28 × 10-12 0.16 25,540  
 rs6083250 11 G/A 0.37 3.94 × 10-11 0.14 26,258  
Schizophrenia a rs4648845 
 
1 C/T 0.47 
 
8.70 × 10-10 
 
0.020 150,064  
 rs1498232 
 
1 C/T 0.66 
 
2.86 × 10-09 
 
0.020 150,064  
 rs11210892 
 
1 G/A 0.33 
 
3.39 × 10-10 
 
0.015 150,064  
 rs12129573 
 
1 C/A 0.64 
 
2.03 × 10-12 
 
0.015 150,064  
 rs76869799 
 
1 G/C 0.04 
 
2.64 × 10-08 
 
0.064 150,064  
 rs1702294 
 
1 C/T 0.81 3.36 × 10-19 
 
0.015 150,064  
 rs14050593
8 
 
1 C/T 0.84 
 
4.49 × 10-10 
 
0.017 150,064  
 rs6670165 
 
1 C/T 0.81 
 
4.45 × 10-08 
 
0.019 150,064  
 rs7523273 
 
1 G/A 0.31 
 
4.47 × 10-08 
 
0.018 150,064  
 rs10803138 
 
1 G/A 0.76 
 
2.03 × 10-08 
 
0.014 150,064  
 rs77149735 
 
1 G/A 0.98 
 
3.73 × 10-09 
 
0.025 150,064  
 rs14403 
 
1 C/T 0.78 4.42 × 10-08 
 
0.014 150,064  
 rs11682175 
 
2 C/T 0.46 
 
1.47 × 10-11 
 
0.017 150,064  
 rs75575209 
 
2 T/A 0.09 
 
3.95 × 10-08 
 
0.016 150,064  
 rs3768644 
 
2 G/A 0.90 
 
7.39 × 10-09 
 
0.015 150,064  
 rs2909457 
 
2 G/A 0.41 
 
4.62 × 10-08 
 
0.016 150,064  
 rs11693094 
 
2 C/T 0.55 
 
1.53 × 10-12 
 
0.016 150,064  
 rs59979824 
 
2 C/A 0.67 8.41 × 10-12 
 
0.021 150,064  
 rs6434928 
 
2 G/A 0.84 
 
2.06 × 10-11 
 
0.030 150,064  
 rs67044641 
 
2 G/A 0.19 
 
8.33 × 10-09 
 
0.017 150,064  
 rs11685299 
 
2 C/A 0.70 
 
1.12 × 10-08 
 
0.024 150,064  
 rs6704768 
 
2 G/A 0.45 
 
2.32 × 10-12 
 
0.022 150,064  
 rs17194490 
 
3 G/T 0.84 
 
2.96 × 10-11 
 
0.038 150,064  
 rs4330281 
 
3 C/T 0.52 
 
4.64 × 10-09 
 
0.015 150,064  
 rs75968099 
 
3 C/T 0.67 
 
1.05 × 10-13 
 
0.017 150,064  
 rs2535627 
 
3 C/T 0.47 
 
4.26 × 10-11 
 
0.017 150,064  
 rs832187 
 
3 C/T 0.39 
 
1.43 × 10-08 
 
0.014 150,064  
 rs7432375 
 
3 G/A 0.56 
 
7.26 × 10-11 
 
0.021 150,064  
 rs9841616 
 
3 T/C 0.84 
 
2.35 × 10-08 
 
0.016 150,064  
 rs215411 
 
4 T/A 0.68 
 
3.06 × 10-08 
 
0.023 150,064  
 rs35518360 
 
4 T/A 0.08 
 
7.89 × 10-15 
 
0.024 150,064  
 rs10520163 
 
4 C/T 0.52 
 
1.47 × 10-09 
 
0.021 150,064  
 rs1106568 
 
4 G/A 0.24 
 
9.47 × 10-09 
 
0.036 150,064  
 rs1501357 
 
5 C/T 0.20 
 
5.05 × 10-09 
 
0.015 150,064  
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 rs4391122 
 
5 G/A 0.48 
 
1.10 × 10-14 
 
0.014 150,064  
 rs16867576 
 
5 G/A 0.12 
 
4.61 × 10-09 
 
0.018 150,064  
 rs4388249 
 
5 C/T 0.79 
 
3.05 × 10-08 
 
0.015 150,064  
 rs10043984 
 
5 C/T 0.75 
 
1.09 × 10-08 
 
0.024 150,064  
 rs3849046 
 
5 C/T 0.47 
 
4.67 × 10-09 
 
0.014 150,064  
 rs79212538 
 
5 G/T 0.95 
 
7.00 × 10-09 
 
0.018 150,064  
 rs11129493
0 
5 G/A 0.22 1.06 × 10-10 0.028 150,064  
 rs2973155 5 C/T 0.63 1.11 × 10-11 0.016 150,064  
 rs12522290 5 G/C 0.17 1.99 × 10-08 0.016 150,064  
 rs11740474 5 T/A 0.38 3.15 × 10-08 0.016 150,064  
 rs11532926
5 
6 G/A 0.15 3.48 × 10-31 0.026 150,064  
 rs1339227 6 C/T 0.64 2.69 × 10-08 0.017 150,064  
 rs11707456
0 
6 C/T 0.95 1.64 × 10-09 0.019 150,064  
 rs12704290 7 G/A 0.88 3.33× 10-10 0.015 150,064  
 rs6466055 7 C/T 0.66 1.13× 10-09 0.026 150,064  
 rs211829 7 C/T 0.37 3.71 × 10-08 0.014 150,064  
 rs13240464 7 C/T 0.35 3.03 × 10-13 0.022 150,064  
 rs7801375 7 G/A 0.85 4.42 × 10-08 0.027 150,064  
 rs3735025 7 C/T 0.35 3.28 × 10-09 0.015 150,064  
 rs10503253 8 C/A 0.78 1.06 × 10-08 0.018 150,064  
 rs73229090 8 C/A 0.89 2.10 × 10-08 0.021 150,064  
 rs6984242 8 G/A 0.40 5.97 × 10-09 0.015 150,064  
 rs7819570 8 G/T 0.82 1.22 × 10-08 0.015 150,064  
 rs36068923 8 G/A 0.20 2.61 × 10-11 0.019 150,064  
 rs4129585 8 C/A 0.57 1.74 × 10-15 0.015 150,064  
 rs11139497 9 T/A 0.66 3.61 × 10-09 0.015 150,064  
 rs7893279 10 G/T 0.10 1.97 × 10-12 0.023 150,064  
 rs7907645 10 G/T 0.11 1.27 × 10-11 0.022 150,064  
 rs11191419 10 T/A 0.65 6.20 × 10-19 0.015 150,064  
 rs55833108 10 G/T 0.80 2.23 × 10-08 0.019 150,064  
 rs11027857 11 G/A 0.50 2.55 × 10-09 0.016 150,064  
 rs9420 11 G/A 0.69 2.24 × 10-09 0.014 150,064  
 rs12421382 11 C/T 0.67 3.70 × 10-08 0.022 150,064  
 rs2514218 11 C/T 0.69 2.75 × 10-11 0.014 150,064  
 rs77502336 11 G/C 0.67 7.54 × 10-09 0.021 150,064  
 rs55661361 11 G/A 0.67 2.80 × 10-12 0.015 150,064  
 rs10791097 11 G/T 0.54 1.09 × 10-12 0.017 150,064  
 rs75059851 11 G/A 0.20 3.87 × 10-11 0.015 150,064  
 rs2007044 12 G/A 0.38 3.22 × 10-18 0.024 150,064  
 rs2239063 12 C/A 0.28 1.93 × 10-08 0.019 150,064  
 rs679087 12 C/A 0.67 3.91 × 10-08 0.0198 150,064  
 rs324017 12 C/A 0.70 1.30 × 10-09 0.0198 150,064  
 rs12826178 12 G/T 0.93 2.13 × 10-08 0.015 150,064  
 rs4240748 12 G/C 0.64 2.02 × 10-12 0.015 150,064  
 rs10860964 12 C/T 0.35 4.84 × 10-08 0.064 150,064  
 rs4766428 12 G/C 0.52 1.40 × 10-09 0.015 150,064  
 rs2851447 12 G/C 0.26 1.86 × 10-14 0.017 150,064  
 rs2068012 14 C/T 0.23 1.14 × 10-08 0.019 150,064  
 rs2332700 14 G/C 0.75 4.86 × 10-09 
 
0.018 150,064  
 rs2693698 14 G/A 0.58 4.80 × 10-09 0.014 150,064  
 rs12887734 14 G/T 0.71 1.36 × 10-13 0.025 150,064  
 rs56205728 15 G/A 0.72 4.18 × 10-09 0.014 150,064  
 rs12903146 15 G/A 0.47 3.38 × 10-10 0.017 150,064  
 rs12148337 15 C/T 0.53 1.79 × 10-08 0.016 150,064  
 rs8042374 15 G/A 0.27 2.44 × 10-13 0.015 150,064  
 rs19006594
4 
15 G/A 0.74 4.71 × 10-08 0.016 150,064  
 rs950169 15 C/T 0.75 1.62 × 10-11 0.016 150,064  
 rs4702 15 G/A 0.44 8.30 × 10-14 0.021 150,064  
 rs9922678 16 G/A 0.72 1.28 × 10-08 0.0302 150,064  
 rs7405404 16 C/T 0.77 1.01 × 10-09 0.017 150,064  
 rs12691307 16 G/A 0.49 4.55 × 10-11 0.024 150,064  
 rs12325245 16 T/A 0.14 1.87 × 10-08 0.022 150,064  
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 rs8044995 16 G/A 0.84 1.51 × 10-08 0.038 150,064  
 rs4523957 17 G/T 0.37 2.86 × 10-08 0.015 150,064  
 rs8082590 17 G/A 0.39 1.77 × 10-08 0.016 150,064  
 rs78322266 18 G/T 0.97 1.32 × 10-08 0.017 150,064  
 rs9636107 18 G/A 0.50 3.34 × 10-08 0.014 150,064  
 rs72934570 18 C/T 0.92 1.97 × 10-11 0.021 150,064  
 rs715170 18 C/T 0.73 1.27 × 10-08 0.016 150,064  
 rs2905426 19 G/T 0.38 3.63 × 10-10 0.023 150,064  
 rs2053079 19 G/A 0.23 4.49 × 10-09 0.024 150,064  
 rs56873913 19 G/T 0.23 4.69 × 10-08 0.021 150,064  
 rs6065094 20 G/A 0.68 1.46 × 10-11 0.036 150,064  
 rs7267348 20 C/T 0.25 4.56 × 10-08 0.015 150,064  
 rs9607782 22 T/A 0.76 2.07 × 10-11 0.014 150,064  
 rs1023500 22 C/T 0.19 3.43 × 10-08 0.018 150,064  
 rs6002655 22 C/T 0.55 1.71 × 10-09 0.015 150,064  
 rs12845396 X T/A 0.25 2.21 × 10-08 0.024 150,064  
 rs1378559 X C/T 0.17 1.61 × 10-12 0.014 150,064  
 rs5937157 X G/T 0.25 1.98 × 10-10 0.018 150,064  
 rs11400214
0 
6 G/A 0.24 9.14 × 10-14 0.075 39,838  
 rs7085104 10 G/A 0.36 3.68× 10-13 0.071 39,838  
 rs6461049 7 C/T 0.43 5.93 × 10-13 0.070 39,838  
 rs1198588 1 T/A 0.79 1.72 × 10-12 0.067 39,838  
 rs1006737 12 G/A 0.67 5.22 × 10-12 0.064 39,838  
 rs17691888 10 G/A 0.89 1.27 × 10-10 0.056 39,838  
 rs4129585 8 C/A 0.56 2.19 × 10-10 0.054 39,838  
 rs10789369 1 G/A 0.62 3.64 × 10-10 0.053 39,838  
 rs7940866 11 T/A 0.49 1.83 × 10-09 0.049 39,838  
 rs17504622 5 C/T 0.95 2.65 × 10-09 0.048 39,838  
 rs2905424 19 C/T 0.65 3.44 × 10-09 0.047 39,838  
 rs2373000 2 C/T 0.60 6.78 × 10-09 0.045 39,838  
 rs6878284 5 C/T 0.36 9.03 × 10-09 0.045 39,838  
 rs4687552 3 C/T 0.36 1.16 × 10-08 0.044 39,838  
 rs12991836 2 C/A 0.35 1.19 × 10-08 0.044 39,838  
 rs2949006 2 G/A 0.81 1.21 × 10-08 0.044 39,838  
 rs4801131 18 C/T 0.58 1.22 × 10-08 0.044 39,838  
 rs778371 2 G/A 0.28 1.51 × 10-08 0.043 39,838  
 rs14403 1 C/T 0.77 1.80 × 10-08 0.043 39,838  
 rs11532322 12 G/A 0.68 2.28 × 10-08 0.042 39,838  
 rs1538774 1 G/C 0.74 2.53 × 10-08 0.042 39,838  
 rs11995572 8 G/T 0.87 3.33 × 10-08 0.041 39,838  
 rs171748 5 G/A 0.53 3.78 × 10-08 0.041 39,838  
 rs2910032 5 C/T 0.47 4.12 × 10-08 0.041 39,838  
 rs4380187 2 C/A 0.47 5.66 × 10-08 0.040 39,838  
 rs4523957 17 G/T 0.38 5.69 × 10-08 0.040 39,838  
 rs6550435 3 G/T 0.34 5.86 × 10-08 0.040 39,838  
Depressionb rs2922240 1 C/T 0.62 2.80 × 10-06 
 
 
0.068 10,640  
 rs3766688 1 C/T 0.61 1.83 × 10-06 
 
 
0.071 10,640  
 rs57047840 1 G/A 0.72 4.64 × 10-05 
 
0.051 10,640  
 rs55713588 5 G/A 0.90 6.04 × 10-07 
 
0.077 10,640  
 rs55800092 6 T/C 0.85 1.35 × 10-06 
 
0.072 10,640  
 rs12415800 10 A/G 0.55 1.92 × 10-08 
 
0.10 10,640  
 rs35936514 10 T/C 0.74 1.27 × 10-08 
 
0.098 10,640  
 rs61967003 13 T/C 0.98 6.70 × 10-06 
 
0.063 10,640  
 rs17827252 14 G/C 0.54 1.44 × 10-05 
 
0.058 10,640  
 rs11880240 19 G/C 0.93 8.02 × 10-06 
 
0.062 10,640  
 rs1921918 X G/A 0.28 3.22 × 10-05 
 
0.054 10,640  
 rs11573525 X T/C 0.74 5.86 × 10-06 
 
0.064 10,640  
Rheumatoid 
Arthritis 
rs3890745 
 
 
1 A/T 
 
 
0.32 
 
 
3.60 × 10-06 
 
0.060 
 
 
25,708  
 rs2476601 
 
 
1 A/G 
 
 
0.10 
 
 
9.10 × 10-71 
 
2.02 
 
 
25,708  
 rs11586238 
 
 
1 G/C 
 
 
0.24 
 
 
1.00 × 10-05 
 
0.055 
 
 
25,708  
 rs12746613 
 
 
1 T/C 
 
 
0.12 
 
 
4.00 × 10-04 
 
0.035 
 
 
25,708  
 rs10919563 
 
 
1 A/G 
 
 
0.13 
 
 
2.00 × 10-04 
 
0.039 
 
 
25,708  
370 
 
 
 
a Sample size of combined discovery and replication samples (when available). 
b GWAS meta-analysis results for previously known SNPs associated with rheumatoid 
arthritis risk among European populations.  
 rs13031237 
 
 
2 T/G 
 
 
0.37 
 
 
7.90 × 10-07 
 
 
0.068 
 
 
25,708  
 rs10865035 
 
 
2 A/G 
 
 
0.47 
 
 
2.00 × 10-06 
 
 
0.064 
 
 
25,708  
 rs7574865 
 
 
2 T/G 
 
 
0.22 
 
 
2.90 × 10-07 
 
 
0.074 
 
 
25,708  
 rs1980422 
 
 
2 C/T 
 
 
0.24 
 
 
5.20 × 10-05 
 
0.046 
 
 
25,708  
 rs3087243 
 
 
2 A/G 
 
 
0.44 
 
 
1.20 × 10-08 
 
 
0.092 
 
 
25,708  
 rs6822844 
 
 
4 T/G 
 
 
0.18 
 
 
7.00 × 10-04 
 
 
0.032 
 
 
25,708  
 rs6910071 
 
 
6 G/A 
 
 
0.22 
 
 
1.00 × 10-299 
 
22.98 
 
 
25,708  
 rs548234 
 
 
6 C/T 
 
 
0.33 
 
 
9.70 × 10-05 
 
0.043 
 
 
25,708  
 rs10499194 
 
 
6 T/C 
 
 
0.27 
 
 
7.00 × 10-04 
 
0.032 
 
 
25,708  
 rs6920220 
 
 
6 A/G 
 
 
0.22 
 
 
8.90 × 10-13 
 
0.14 
 
 
25,708  
 rs5029937 
 
 
6 T/G 
 
 
0.04 
 
 
7.50 × 10-08 
 
0.082 
 
 
25,708  
 rs394581 
 
 
6 C/T 
 
 
0.30 
 
 
6.00 × 10-04 
 
0.033 
 
 
25,708  
 rs2736340 
 
 
8 T/C 
 
 
0.25 
 
 
1.50 × 10-05 
 
0.053 
 
 
 
 
25,708  
 rs2812378 
 
 
9 G/A 
 
 
0.34 
 
 
1.00 × 10-04 
 
0.043 
 
 
25,708  
 rs3761847 9 G/A 
 
0.43 
 
 
2.10 × 10-07 
 
0.076 
 
 
25,708  
 rs2104286 
 
 
10 C/T 
 
 
0.27 
 
 
0.002 
 
 
0.027 25,708  
 rs4750316 
 
 
10 C/G 
 
 
0.19 
 
 
2.00 × 10-06 
 
0.064 
 
 
25,708  
 rs540386 
 
 
11 C/T 
 
 
0.14 
 
 
0.003 
 
 
0.025 
 
 
25,708  
 rs1678542 
 
 
12 G/C 
 
 
0.38 
 
 
0.002 
 
 
0.027 
 
 
25,708  
 rs4810485 
 
 
20 T/G 
 
 
0.25 
 
 
2.80 × 10-09 
 
0.099 
 
 
25,708  
 rs3218253 
 
 
22 A/G 
 
 
0.26 
 
 
0.002 
 
 
0.027 
 
 
25,708  
Alzheimer’s 
Disease 
rs6656401 1 G/A 0.20 5.70 × 10-24 0.11 74,046  
 rs6733839 2 C/T 0.41 6.90 × 10-44 0.32 74,046  
 rs10948363 6 A/G 0.27 5.20 × 10-11 0.046 74,046  
 rs11771145 7 A/G 0.34 1.10 × 10-13 0.059 74,046  
 rs9331896 8 T/C 0.38 2.80 × 10-25 0.12 74,046  
 rs983392 11 A/G 0.40 6.10 × 10-16 0.071 74,046  
 rs10792283
2 
11 G/A 0.36 9.30 × 10-26 0.11 74,046  
 rs4147929 19 G/A 0.19 1.10 × 10-15 0.069 74,046  
 rs3865444 19 C/A 0.31 3.00 × 10-06 0.023 74,046  
 rs9271192 6 A/C 0.28 2.90 × 10-12 0.053 74,046  
 rs28834970 8 T/C 0.37 7.40 × 10-14 0.062 74,046  
 rs11218343 11 T/C 0.04 9.70 × 10-15 0.065 74,046  
 rs10498633 14 G/T 0.22 5.50 × 10-09 0.037 74,046  
 rs8093731 18 C/T 0.02 1.00 × 10-04 0.016 74,046  
 rs35349669 2 C/T 0.49 3.20 × 10-08 0.033 74,046  
 rs190982 5 A/G 0.408 3.20 × 10-08 0.033 74,046  
 rs2718058 7 A/G 0.373 4.80 × 10-09 0.037 74,046  
 rs1476679 7 T/C 0.287 5.60 × 10-10 0.041 74,046  
 rs10838725 11 T/C 0.316 1.10 × 10-08 0.035 74,046  
 rs17125944 14 T/C 0.092 7.90 × 10-09 0.036 74,046  
 rs7274581 
 
20 T/C 0.083 2.50 × 10-08 0.033 74,046 
 
 
c Percentage variance explained was based on the combined discovery and replication samples 
using the following equation (X/((n-k-1)+X) where X is the chi-square statistic calculated from the 
p-value. 
 
 
 
